0001104506-23-000012.txt : 20230504 0001104506-23-000012.hdr.sgml : 20230504 20230504073041 ACCESSION NUMBER: 0001104506-23-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 23886486 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 10-Q 1 insm-20230331.htm 10-Q insm-20230331
0001104506false--12-312023Q1http://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Memberhttp://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member25.53840.025538430.76920.030769200011045062023-01-012023-03-3100011045062023-05-01xbrli:shares00011045062023-03-31iso4217:USD00011045062022-12-31iso4217:USDxbrli:shares00011045062022-01-012022-03-310001104506us-gaap:CommonStockMember2021-12-310001104506us-gaap:AdditionalPaidInCapitalMember2021-12-310001104506us-gaap:RetainedEarningsMember2021-12-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100011045062021-12-3100011045062021-01-012021-12-310001104506us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001104506us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001104506srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001104506us-gaap:RetainedEarningsMember2022-01-012022-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001104506us-gaap:CommonStockMember2022-01-012022-03-310001104506us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001104506us-gaap:CommonStockMember2022-03-310001104506us-gaap:AdditionalPaidInCapitalMember2022-03-310001104506us-gaap:RetainedEarningsMember2022-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100011045062022-03-310001104506us-gaap:CommonStockMember2022-12-310001104506us-gaap:AdditionalPaidInCapitalMember2022-12-310001104506us-gaap:RetainedEarningsMember2022-12-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001104506us-gaap:RetainedEarningsMember2023-01-012023-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001104506us-gaap:CommonStockMember2023-01-012023-03-310001104506us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001104506us-gaap:CommonStockMember2023-03-310001104506us-gaap:AdditionalPaidInCapitalMember2023-03-310001104506us-gaap:RetainedEarningsMember2023-03-310001104506us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001104506us-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMemberinsm:CustomerAMember2023-01-012023-03-31xbrli:pure0001104506us-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMemberinsm:CustomerAMember2022-01-012022-03-310001104506us-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMemberinsm:CustomerBMember2023-01-012023-03-310001104506us-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMemberinsm:CustomerBMember2022-01-012022-03-310001104506us-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMemberinsm:CustomerCMember2023-01-012023-03-310001104506us-gaap:SalesRevenueProductLineMemberus-gaap:CustomerConcentrationRiskMemberinsm:CustomerCMember2022-01-012022-03-31insm:reportingUnit0001104506us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001104506us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001104506us-gaap:PerformanceSharesMember2023-01-012023-03-310001104506us-gaap:PerformanceSharesMember2022-01-012022-03-310001104506us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001104506us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001104506us-gaap:PerformanceSharesMember2023-01-012023-03-310001104506us-gaap:PerformanceSharesMember2022-01-012022-03-310001104506us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-03-310001104506us-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-03-310001104506us-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-01-010001104506us-gaap:AccountingStandardsUpdate202006Member2022-01-010001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-03-310001104506us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001104506us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-03-310001104506us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001104506us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001104506us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001104506us-gaap:ShareBasedCompensationAwardTrancheTwoMemberinsm:MotusBiosciencesIncMember2021-08-012021-08-310001104506us-gaap:ShareBasedCompensationAwardTrancheOneMemberinsm:MotusBiosciencesIncMember2021-08-012021-08-310001104506us-gaap:ShareBasedCompensationAwardTrancheThreeMemberinsm:MotusBiosciencesIncMember2021-08-012021-08-310001104506insm:MotusBiosciencesIncMember2022-07-012022-09-300001104506insm:AccruedLiabilitiesCurrentMember2023-03-310001104506us-gaap:OtherNoncurrentLiabilitiesMember2023-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:MeasurementInputSharePriceMember2023-03-310001104506insm:MotusBiosciencesIncMember2021-08-042021-08-040001104506insm:AlgaeneXIncMember2021-08-012021-08-310001104506insm:MeasurementInputProbabilityOfSuccessMember2023-03-310001104506insm:MotusBiosciencesIncMember2023-03-31insm:numberOfSales0001104506us-gaap:FairValueInputsLevel3Memberinsm:MotusBiosciencesIncMember2023-03-310001104506us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberinsm:MotusBiosciencesIncMember2023-03-310001104506insm:DevelopmentAndRegulatoryMilestonesMember2023-03-310001104506insm:DevelopmentAndRegulatoryMilestonesMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Memberinsm:MeasurementInputProbabilityOfSuccessMember2023-03-310001104506insm:DevelopmentAndRegulatoryMilestonesMemberus-gaap:FairValueInputsLevel3Memberinsm:MeasurementInputProbabilityOfSuccessMembersrt:MaximumMember2023-03-310001104506insm:PriorityReviewVoucherMilestoneMember2023-03-310001104506us-gaap:FairValueInputsLevel3Memberinsm:MeasurementInputProbabilityOfSuccessMemberinsm:PriorityReviewVoucherMilestoneMember2023-03-310001104506us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberinsm:PriorityReviewVoucherMilestoneMember2023-03-310001104506us-gaap:FairValueInputsLevel2Member2021-12-310001104506us-gaap:FairValueInputsLevel3Member2021-12-310001104506us-gaap:FairValueInputsLevel2Member2022-01-012022-03-310001104506us-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001104506us-gaap:FairValueInputsLevel2Member2022-03-310001104506us-gaap:FairValueInputsLevel3Member2022-03-310001104506us-gaap:FairValueInputsLevel2Member2022-12-310001104506us-gaap:FairValueInputsLevel3Member2022-12-310001104506us-gaap:FairValueInputsLevel2Member2023-01-012023-03-310001104506us-gaap:FairValueInputsLevel3Member2023-01-012023-03-310001104506us-gaap:FairValueInputsLevel2Member2023-03-310001104506us-gaap:FairValueInputsLevel3Member2023-03-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2023-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member2023-03-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2023-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2023-03-310001104506country:US2023-01-012023-03-310001104506country:US2022-01-012022-03-310001104506country:JP2023-01-012023-03-310001104506country:JP2022-01-012022-03-310001104506insm:EuropeAndTheRestOfTheWorldMember2023-01-012023-03-310001104506insm:EuropeAndTheRestOfTheWorldMember2022-01-012022-03-310001104506insm:AcquiredResearchAndDevelopmentMember2022-12-310001104506insm:AcquiredResearchAndDevelopmentMember2023-01-012023-03-310001104506insm:AcquiredResearchAndDevelopmentMember2023-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2022-12-310001104506us-gaap:InProcessResearchAndDevelopmentMember2023-01-012023-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2023-03-310001104506us-gaap:LicensingAgreementsMember2022-12-310001104506us-gaap:LicensingAgreementsMember2023-01-012023-03-310001104506us-gaap:LicensingAgreementsMember2023-03-310001104506insm:AcquiredResearchAndDevelopmentMember2021-12-310001104506insm:AcquiredResearchAndDevelopmentMember2022-01-012022-03-310001104506insm:AcquiredResearchAndDevelopmentMember2022-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2021-12-310001104506us-gaap:InProcessResearchAndDevelopmentMember2022-01-012022-03-310001104506us-gaap:InProcessResearchAndDevelopmentMember2022-03-310001104506us-gaap:LicensingAgreementsMember2021-12-310001104506us-gaap:LicensingAgreementsMember2022-01-012022-03-310001104506us-gaap:LicensingAgreementsMember2022-03-310001104506us-gaap:EquipmentMember2023-01-012023-03-310001104506us-gaap:EquipmentMember2023-03-310001104506us-gaap:EquipmentMember2022-12-310001104506us-gaap:FurnitureAndFixturesMember2023-01-012023-03-310001104506us-gaap:FurnitureAndFixturesMember2023-03-310001104506us-gaap:FurnitureAndFixturesMember2022-12-310001104506insm:ComputerHardwareAndSoftwareMembersrt:MinimumMember2023-01-012023-03-310001104506insm:ComputerHardwareAndSoftwareMembersrt:MaximumMember2023-01-012023-03-310001104506insm:ComputerHardwareAndSoftwareMember2023-03-310001104506insm:ComputerHardwareAndSoftwareMember2022-12-310001104506us-gaap:OfficeEquipmentMember2023-01-012023-03-310001104506us-gaap:OfficeEquipmentMember2023-03-310001104506us-gaap:OfficeEquipmentMember2022-12-310001104506insm:ManufacturingEquipmentMember2023-01-012023-03-310001104506insm:ManufacturingEquipmentMember2023-03-310001104506insm:ManufacturingEquipmentMember2022-12-310001104506us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2023-01-012023-03-310001104506us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2023-01-012023-03-310001104506us-gaap:LeaseholdImprovementsMember2023-03-310001104506us-gaap:LeaseholdImprovementsMember2022-12-310001104506us-gaap:ConstructionInProgressMember2023-03-310001104506us-gaap:ConstructionInProgressMember2022-12-310001104506srt:MinimumMember2023-01-012023-03-310001104506srt:MaximumMember2023-01-012023-03-3100011045062022-01-012022-12-310001104506us-gaap:ConvertibleNotesPayableMember2023-03-310001104506us-gaap:ConvertibleNotesPayableMember2022-12-310001104506insm:TermLoanMember2023-03-310001104506insm:TermLoanMember2022-12-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2018-01-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2018-01-012018-01-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2021-05-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2018-01-012018-01-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member2018-01-012018-01-310001104506insm:DebtInstrumentConversionTermOneMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2018-01-012018-01-31insm:day0001104506insm:DebtInstrumentConversionTermOneMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506insm:DebtInstrumentConversionTermTwoMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506insm:DebtInstrumentConversionTermTwoMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2018-01-012018-01-310001104506insm:DebtInstrumentConversionTermThreeMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2018-01-012018-01-310001104506insm:DebtInstrumentConversionTermThreeMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506insm:DebtInstrumentConversionTermFourMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2018-01-012018-01-310001104506insm:DebtInstrumentConversionTermFourMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2021-05-012021-05-310001104506us-gaap:ConvertibleNotesPayableMember2018-01-310001104506us-gaap:ConvertibleNotesPayableMember2021-05-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Memberus-gaap:ConvertibleNotesPayableMember2023-01-012023-03-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Memberus-gaap:ConvertibleNotesPayableMember2023-01-012023-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberinsm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member2023-03-310001104506us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberinsm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2023-03-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2022-10-310001104506insm:SecuredOvernightFinancingRateSOFRMemberus-gaap:SecuredDebtMemberinsm:TermLoanMember2022-10-012022-10-310001104506insm:SecuredOvernightFinancingRateSOFRMemberinsm:VariableRateComponentTwoMemberus-gaap:SecuredDebtMemberinsm:TermLoanMember2022-10-012022-10-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2022-10-012022-10-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2023-03-310001104506us-gaap:SecuredDebtMemberinsm:TermLoanMember2022-12-310001104506us-gaap:ConvertibleDebtMember2023-01-012023-03-310001104506us-gaap:ConvertibleDebtMember2022-01-012022-03-310001104506insm:TermLoanMember2023-01-012023-03-310001104506insm:TermLoanMember2022-01-012022-03-310001104506us-gaap:RoyaltyAgreementsMember2023-01-012023-03-310001104506us-gaap:RoyaltyAgreementsMember2022-01-012022-03-310001104506insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member2021-05-012021-05-310001104506insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member2021-05-012021-05-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2022-10-012022-10-310001104506us-gaap:SubsequentEventMemberinsm:ARIKAYCEGlobalNetSalesMemberus-gaap:RoyaltyAgreementsMember2025-09-010001104506insm:ARIKAYCEGlobalNetSalesMemberus-gaap:RoyaltyAgreementsMember2022-10-310001104506insm:BrensocatibGlobalNetSalesMemberus-gaap:SubsequentEventMemberus-gaap:RoyaltyAgreementsMember2025-09-010001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2022-10-310001104506us-gaap:RoyaltyAgreementsMember2022-10-310001104506us-gaap:RoyaltyAgreementsMembersrt:MaximumMember2022-10-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2022-12-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2023-01-012023-03-310001104506us-gaap:SecuredDebtMemberus-gaap:RoyaltyAgreementsMember2023-03-310001104506us-gaap:EmployeeStockOptionMember2023-03-310001104506us-gaap:RestrictedStockUnitsRSUMember2023-03-310001104506us-gaap:PerformanceSharesMember2023-03-310001104506us-gaap:ConvertibleNotesPayableMember2023-03-310001104506insm:MotusBiosciencesIncMember2021-07-012021-09-300001104506insm:VertuisBioIncMember2023-01-310001104506insm:VertuisBioIncMember2023-01-012023-01-310001104506insm:VertuisBioIncMember2023-03-310001104506insm:PublicStockOfferingMember2022-10-012022-10-3100011045062022-10-3100011045062022-10-012022-10-310001104506insm:PublicStockOfferingMember2021-04-012021-06-300001104506us-gaap:OverAllotmentOptionMember2021-04-012021-06-3000011045062021-06-3000011045062021-04-012021-06-300001104506insm:AtTheMarketAgreementMember2021-01-012021-03-310001104506insm:AtTheMarketAgreementMember2023-03-310001104506insm:AtTheMarketAgreementMember2022-07-012022-09-300001104506insm:A2019IncentivePlanThirdAmendmentMember2019-05-160001104506insm:A2019IncentivePlanThirdAmendmentMember2020-05-122020-05-120001104506insm:A2019IncentivePlanSecondAmendmentMember2021-05-122021-05-120001104506insm:A2019IncentivePlanThirdAmendmentMember2022-05-112022-05-110001104506insm:AmendedAndRestatedPlanMember2022-05-112022-05-110001104506insm:A2019IncentivePlanThirdAmendmentMember2023-03-310001104506insm:EmployeeStockPurchasePlan2018Member2018-05-150001104506insm:EmployeeStockPurchasePlan2018Member2018-05-152018-05-150001104506us-gaap:ResearchAndDevelopmentExpenseMemberinsm:StockOptionsAndRestrictedStockUnitsMember2023-01-012023-03-310001104506us-gaap:ResearchAndDevelopmentExpenseMemberinsm:StockOptionsAndRestrictedStockUnitsMember2022-01-012022-03-310001104506us-gaap:GeneralAndAdministrativeExpenseMemberinsm:StockOptionsAndRestrictedStockUnitsMember2023-01-012023-03-310001104506us-gaap:GeneralAndAdministrativeExpenseMemberinsm:StockOptionsAndRestrictedStockUnitsMember2022-01-012022-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMember2023-01-012023-03-310001104506insm:StockOptionsAndRestrictedStockUnitsMember2022-01-012022-03-310001104506insm:MilestoneEvent1Memberinsm:VertuisBioIncMember2023-01-310001104506insm:MilestoneEvent2Memberinsm:VertuisBioIncMember2023-01-310001104506insm:MilestoneEvent3Memberinsm:VertuisBioIncMember2023-01-310001104506us-gaap:CommonStockMemberinsm:VertuisBioIncMember2023-01-012023-01-310001104506insm:MotusBiosciencesIncMember2021-08-040001104506insm:AlgaeneXIncMember2021-08-310001104506insm:MotusBiosciencesIncMember2021-08-3100011045062021-05-242021-05-24insm:days0001104506insm:MotusBiosciencesIncAndAlgaeneXIncMember2021-08-012021-08-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to
Commission File Number 000-30739
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
Virginia54-1972729
(State or other jurisdiction of incorporation or organization)(I.R.S. employer identification no.)
700 US Highway 202/206,
 
Bridgewater, New Jersey
08807
(Address of principal executive offices)(Zip Code)
(908) 977-9900
(Registrant’s telephone number including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section12(b) of the Act:
Title of each classTrading symbolsName of each exchange on which registered
Common stock, par value $0.01 per shareINSMNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o
Smaller reporting company ☐
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
As of May 1, 2023, there were 136,432,799 shares of the registrant’s common stock outstanding.



INSMED INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2023
 
INDEX
 
 
 
 
 
 
Unless the context otherwise indicates, references in this Form 10-Q to “Insmed Incorporated” refers to Insmed Incorporated, a Virginia corporation, and the “Company,” “Insmed,” “we,” “us” and “our” refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, ARIKARES and ARIKAYCE are trademarks of Insmed Incorporated. This Form 10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form 10-Q is the property of its owner.

2

PART I.  FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
INSMED INCORPORATED
Consolidated Balance Sheets
(in thousands, except par value and share data)
As ofAs of
March 31, 2023December 31, 2022
 (unaudited) 
Assets  
Current assets:  
Cash and cash equivalents$968,907 $1,074,036 
Marketable securities29,774 74,244 
Accounts receivable30,523 29,713 
Inventory71,317 69,922 
Prepaid expenses and other current assets28,542 25,468 
Total current assets1,129,063 1,273,383 
Fixed assets, net59,556 56,491 
Finance lease right-of-use assets23,019 23,697 
Operating lease right-of-use assets21,154 21,894 
Intangibles, net67,493 68,756 
Goodwill136,110 136,110 
Other assets81,322 76,104 
Total assets$1,517,717 $1,656,435 
Liabilities and shareholders’ equity  
Current liabilities:  
Accounts payable and accrued liabilities$179,005 $182,117 
Finance lease liabilities2,158 1,217 
Operating lease liabilities6,821 6,909 
Total current liabilities187,984 190,243 
Debt, long-term1,132,188 1,125,250 
Royalty financing agreement150,173 148,015 
Contingent consideration38,600 51,100 
Finance lease liabilities, long-term29,015 29,636 
Operating lease liabilities, long-term14,534 14,853 
Other long-term liabilities9,876 9,387 
Total liabilities1,562,370 1,568,484 
Shareholders’ equity:  
Common stock, $0.01 par value; 500,000,000 authorized shares, 136,429,216 and 135,653,731 issued and outstanding shares at March 31, 2023 and December 31, 2022, respectively
1,364 1,357 
Additional paid-in capital2,809,242 2,782,416 
Accumulated deficit(2,856,342)(2,696,578)
Accumulated other comprehensive income1,083 756 
Total shareholders’ (deficit) equity(44,653)87,951 
Total liabilities and shareholders’ equity$1,517,717 $1,656,435 
See accompanying notes to consolidated financial statements
3

INSMED INCORPORATED
Consolidated Statements of Comprehensive Loss (unaudited)
(in thousands, except per share data)
 Three Months Ended March 31,
 20232022
Product revenues, net$65,214 $53,107 
Operating expenses:  
Cost of product revenues (excluding amortization of intangible assets)13,830 12,191 
Research and development127,865 84,356 
Selling, general and administrative79,914 56,748 
Amortization of intangible assets1,263 1,263 
Change in fair value of deferred and contingent consideration liabilities(9,500)(11,618)
Total operating expenses213,372 142,940 
Operating loss(148,158)(89,833)
Investment income10,524 137 
Interest expense(20,003)(3,291)
Change in fair value of interest rate swap(1,533)— 
Other expense, net(111)(1,249)
Loss before income taxes(159,281)(94,236)
Provision for income taxes483 385 
Net loss$(159,764)$(94,621)
Basic and diluted net loss per share$(1.17)$(0.80)
Weighted average basic and diluted common shares outstanding
136,355 118,929 
Net loss$(159,764)$(94,621)
Other comprehensive income (loss):  
Foreign currency translation loss(171)(494)
Unrealized gain (loss) on marketable securities498 (704)
Total comprehensive loss$(159,437)$(95,819)
    
See accompanying notes to consolidated financial statements

4

INSMED INCORPORATED
Consolidated Statements of Shareholders' Equity (unaudited)
(in thousands)
 Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Other
Comprehensive
Income (Loss)		Total
SharesAmount
Balance at December 31, 2021118,738 $1,187 $2,673,556 $(2,265,243)$968 $410,468 
Cumulative impact of ASU adoption 2020-06
(264,609)50,199 (214,410)
Comprehensive loss:
Net loss(94,621)(94,621)
Other comprehensive loss(1,198)(1,198)
Exercise of stock options and ESPP shares450 4 6,812 6,816 
Issuance of common stock for vesting of RSUs158 2 2 
Stock compensation expense12,823 12,823 
Balance at March 31, 2022119,346 $1,193 $2,428,582 $(2,309,665)$(230)$119,880 
Balance at December 31, 2022135,654 $1,357 $2,782,416 $(2,696,578)$756 $87,951 
Comprehensive loss:
Net loss(159,764)(159,764)
Other comprehensive income327 327 
Exercise of stock options and ESPP shares82 1 1,138 1,139 
Issuance of common stock for vesting of RSUs193 1 1 
Issuance of common stock for asset acquisition 500 5 9,245 9,250 
Stock compensation expense16,443 16,443 
Balance at March 31, 2023136,429 $1,364 $2,809,242 $(2,856,342)$1,083 $(44,653)
See accompanying notes to consolidated financial statements
5

INSMED INCORPORATED
Consolidated Statements of Cash Flows (unaudited)
(in thousands)
 Three Months Ended March 31,
 20232022
Operating activities  
Net loss$(159,764)$(94,621)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation1,248 1,286 
Amortization of intangible assets1,263 1,263 
Stock-based compensation expense16,443 12,823 
Amortization of debt issuance costs1,724 822 
Paid-in-kind interest capitalized5,456 — 
Royalty financing non-cash interest expense2,615 — 
Finance lease amortization expense678 729 
Non-cash operating lease expense2,491 2,369 
Change in fair value of deferred and contingent consideration liabilities(9,500)(11,618)
Change in fair value of interest rate swap1,533 — 
Vertuis acquisition10,250 — 
Changes in operating assets and liabilities:  
Accounts receivable(860)(1,798)
Inventory(1,187)2,240 
Prepaid expenses and other current assets(3,199)(2,752)
Other assets(5,231)(6,289)
Accounts payable and accrued liabilities(8,841)13,363 
Other liabilities(1,422)(22,978)
Net cash used in operating activities(146,303)(105,161)
Investing activities  
Purchase of fixed assets(3,398)(1,701)
Purchase of marketable securities— (99,706)
Maturities of marketable securities45,000 — 
Net cash provided by (used in) investing activities41,602 (101,407)
Financing activities  
Proceeds from exercise of stock options and ESPP1,139 6,818 
Payments of finance lease principal(320)(359)
Payment of debt issuance costs(1,218)— 
Net cash (used in) provided by financing activities(399)6,459 
Effect of exchange rates on cash and cash equivalents(29)(969)
Net decrease in cash and cash equivalents(105,129)(201,078)
Cash and cash equivalents at beginning of period1,074,036 716,782 
Cash and cash equivalents at end of period$968,907 $515,704 
Supplemental disclosures of cash flow information:  
Cash paid for interest$11,589 $2,375 
Cash paid for income taxes$1,004 $635 
See accompanying notes to consolidated financial statements
6
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. The Company and Basis of Presentation
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib, treprostinil palmitil inhalation powder (TPIP) and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company is also advancing its early-stage research programs encompassing a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, and protein manufacturing.
The Company was incorporated in the Commonwealth of Virginia on November 29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan.
The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
     The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.
     The Company had $968.9 million in cash and cash equivalents and $29.8 million of marketable securities as of March 31, 2023 and reported a net loss of $159.8 million for the three months ended March 31, 2023. The Company has funded its operations through public offerings of equity securities, debt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.
The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company’s commercial, regulatory and development activities. Any future financing will also be contingent upon market conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.
7
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
2. Summary of Significant Accounting Policies
The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2022:
Use of Estimates - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.
Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.
The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.
March 31,
20232022
Customer A36%36%
Customer B36%32%
Customer C17%17%
The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.
Inventory and Cost of Product Revenues (excluding amortization of intangible assets) - Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. See Note 5 - Inventory for further details. Inventory used for clinical development purposes is expensed to R&D expense when consumed.
Acquisitions - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create
8
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with Accounting Standards Codification (ASC) 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. See Note 16 - Acquisitions for further information.
Indefinite-lived intangible assets - Indefinite-lived intangible assets consist of IPR&D. IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1. See Note 6 - Intangibles, Net and Goodwill for further details.
Finite-lived Intangible Assets - Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See Note 6 - Intangibles, Net and Goodwill for further details.
9
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
Impairment Assessment - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.
Goodwill - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2023. See Note 6 - Intangibles, Net and Goodwill for further details.
Leases - A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.
Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See Note 9 - Leases for further details.
Foreign Currency - The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' (deficit) equity, as a component of accumulated other comprehensive income.
The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.
Debt Issuance Costs - Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Synthetic Royalty Financing Agreement - In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty & Credit Opportunities IV, LP (OrbiMed). The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See Note - 11 Royalty Financing Agreement for further details.
10
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
Derivatives - In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.
Net Loss Per Share - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.
The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2023 and 2022:
 
 Three Months Ended March 31,
 20232022
 
Numerator:  
Net loss$(159,764)$(94,621)
Denominator:  
Weighted average common shares used in calculation of basic net loss per share:136,355 118,929 
Effect of dilutive securities:  
Common stock options— — 
RS and RSUs— — 
PSUs— — 
Convertible debt securities— — 
Weighted average common shares outstanding used in calculation of diluted net loss per share136,355 118,929 
Net loss per share:  
Basic and diluted$(1.17)$(0.80)
The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2023 and 2022, respectively, as their effect would have been anti-dilutive (in thousands):
 
March 31,
 20232022
Common stock options19,156 15,282 
Unvested restricted stock and RSUs2,058 1,163 
PSUs671 679 
Convertible debt securities23,438 23,438 
Recently Adopted Accounting Pronouncements - In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt — Accounting for Convertible Instruments, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 is effective for fiscal years beginning
11
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
 2. Summary of Significant Accounting Policies (Continued)
after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by approximately $221.9 million, increasing issuance costs classified to debt by $6.1 million, decreasing the deferred tax liability by $1.4 million, and increasing retained earnings by $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.

3. Fair Value Measurements
The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:
•Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
•Level 2 — Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
•Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
March 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$968.9 $968.9 $— $— 
Marketable securities$29.8 $29.8 $— $— 
Collateral for interest rate swap$5.0 $5.0 $— $— 
Liabilities
Interest rate swap$3.1 $— $3.1 $— 
Deferred consideration$6.2 $— $6.2 $— 
Contingent consideration$49.8 $— $— $49.8 
12
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Fair Value Measurements (Continued)
December 31, 2022
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$1,074.0 $1,074.0 $— $— 
Marketable securities$74.2 $74.2 $— $— 
Collateral for interest rate swap$5.0 $5.0 $— $— 
Liabilities
Interest rate swap$1.5 $— $1.5 $— 
Deferred consideration$7.4 $— $7.4 $— 
Contingent consideration$58.1 $— $— $58.1 
The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of March 31, 2023 and December 31, 2022. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March 31, 2023.
As of March 31, 2023, the Company held $29.8 million of current available-for-sale securities, net of an unrealized loss of $0.2 million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.
The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the three months ended March 31, 2023.
Deferred Consideration
The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022, the Company fulfilled the payment due on the first anniversary of the closing date by issuing 171,427 shares of the Company's common stock, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.
The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within 12 months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2023, the fair value of deferred consideration included in accounts payable and accrued liabilities was $3.1 million. Deferred consideration expected to be settled in more than 12 months is classified as a non-current liability within other long-term liabilities. As of March 31, 2023, the fair value of deferred consideration included in other long-term liabilities was $3.1 million.
The following observable input was used in the valuation of the deferred consideration as of March 31, 2023:
13
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Fair Value Measurements (Continued)
Fair Value as of March 31, 2023 (in millions)
Observable InputInput Value
Deferred consideration
$6.2
Insmed share price as of March 31, 2023
$17.05
Contingent Consideration
The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 16). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At March 31, 2023, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.
If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash.
The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of March 31, 2023, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.
The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within 12 months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2023, the fair value of contingent consideration included in accounts payable and accrued liabilities was $11.2 million. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of March 31, 2023, the fair value of non-current contingent consideration was $38.6 million.
Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability in the consolidated balance sheet. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.
The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2023:

Fair Value as of March 31, 2023 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$41.2Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$6.2Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
12.3%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2023 and 2022 (in thousands):
14
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Fair Value Measurements (Continued)
Deferred Consideration (Level 2 Liabilities)Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2021$14,931 $75,668 
Additions— — 
Change in Fair Value(2,070)(9,548)
Payments— — 
Balance as of March 31, 2022$12,861 $66,120 
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value(1,200)(8,300)
Payments— — 
Balance as of March 31, 2023$6,200 $49,800 
Convertible Notes
The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility, and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.
The estimated fair value of the liability component of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2023 was $446.5 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.
The estimated fair value of the liability component of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2023 was $202.3 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. See Note 10 - Debt for further details on the Company's convertible notes.

4. Product Revenues, Net
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.
Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.
The following table presents a summary of the Company's product revenues, net, by geographic location for the three months ended March 31, 2023 and 2022 (in thousands):
15
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
4. Product Revenues, Net (Continued)
Three Months Ended March 31,
20232022
US$49,067 $40,782 
Japan13,156 10,676 
Europe and rest of world2,991 1,649 
  Total product revenues, net$65,214 $53,107 
Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.
Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.
Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.
If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.
16
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
4. Product Revenues, Net (Continued)
The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.
5. Inventory
As of March 31, 2023 and December 31, 2022, the Company's inventory balance consists of the following (in thousands):
March 31, 2023December 31, 2022
Raw materials$24,553 $27,245 
Work-in-process20,166 22,460 
Finished goods26,598 20,217 
$71,317 $69,922 
The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.
6. Intangibles, Net and Goodwill
 Intangibles, Net
Finite-lived Intangible Assets
As of March 31, 2023, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D and the milestones paid to PARI for the license to use Lamira for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestones intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.
Indefinite-lived Intangible Assets
As of March 31, 2023, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition (Note 16). Indefinite-lived intangible assets are not amortized.
A rollforward of the Company's intangible assets for the three months ended March 31, 2023 and March 31, 2022 is as follows (in thousands):
Intangible AssetDecember 31, 2022AdditionsAmortization
March 31, 2023
Acquired ARIKAYCE R&D$37,588 $— $(1,212)$36,376 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (51)1,517 
$68,756 $— $(1,263)$67,493 
Intangible AssetDecember 31, 2021AdditionsAmortization
March 31, 2022
Acquired ARIKAYCE R&D$42,439 $— $(1,212)$41,227 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,770 — (51)1,719 
$73,809 $— $(1,263)$72,546 
Goodwill
The Company's goodwill balance of $136.1 million as of March 31, 2023 and December 31, 2022, resulted from the August 2021 Business Acquisition. See Note 16 - Acquisitions for further details. 
17
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
7. Fixed Assets, Net
Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):
Estimated
Useful Life (years)		As of
Asset DescriptionMarch 31, 2023December 31, 2022
Lab equipment7$18,982 $16,403 
Furniture and fixtures76,428 6,428 
Computer hardware and software
3-5
5,695 5,227 
Office equipment789 89 
Manufacturing equipment71,336 1,203 
Leasehold improvements
2-10
37,042 37,057 
Construction in progress—30,662 29,529 
100,234 95,936 
Less: accumulated depreciation(40,678)(39,445)
$59,556 $56,491 

8. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
As of
March 31, 2023December 31, 2022
Accounts payable and other accrued operating expenses$56,670 $50,461 
Accrued clinical trial expenses26,607 36,456 
Accrued professional fees18,242 14,403 
Accrued technical operation expenses6,734 3,345 
Accrued compensation and employee related costs18,867 32,040 
Accrued royalty and milestones payable6,165 4,710 
Accrued interest payable2,270 6,340 
Royalty revenue payable2,608 2,149 
Accrued sales allowances and related costs11,762 6,974 
Accrued France ATU reimbursement payable12,945 12,943 
Deferred and contingent consideration from Business Acquisition14,300 10,700 
Other accrued liabilities1,835 1,596 
$179,005 $182,117 
9. Leases
The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease
18
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
9. Leases (Continued)
and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.
The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.
The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $0.1 million and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20232022
Finance right-of-use assets obtained in exchange for lease obligations$— $9,287 
Operating right-of-use assets obtained in exchange for lease obligations$1,751 $341 
In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $42.5 million and $40.7 million incurred by the Company under these additional agreements have been classified within other assets in the Company's consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.
10. Debt
Debt, long-term consists of the following commitments as of March 31, 2023 and December 31, 2022 (in thousands):
As of
March 31, 2023December 31, 2022
Convertible notes$786,443 $785,621 
Term Loan345,745 339,629 
Debt, long-term$1,132,188 $1,125,250 
Convertible Notes
In May 2021, the Company completed an underwritten public offering of the 2028 Convertible Notes, in which the Company sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7 million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased.
19
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Debt (Continued)
In January 2018, the Company completed an underwritten public offering of the 2025 Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased.
A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.
On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.
Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a) the second business day immediately preceding the related redemption date or (b) if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes.
20
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Debt (Continued)
Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources that utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity’s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9 million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6 million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4 million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December 31, 2021, prior to the adoption of ASU 2020-06. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 1.79 years and 5.17 years, respectively.
The $563.3 million carrying value of the 2028 Convertible Notes as of March 31, 2023 excludes $11.7 million of unamortized debt issuance costs. The $223.2 million carrying value of the 2025 Convertible Notes as of March 31, 2023 excludes $1.8 million of unamortized debt issuance costs. The following table presents the carrying value of the Company's debt balance (in thousands):
 
As of
March 31, 2023December 31, 2022
Face value of outstanding convertible notes$800,000 $800,000 
Debt issuance costs, unamortized(13,557)(14,379)
Debt, long-term$786,443 $785,621 
Secured Senior Term Loan
In October 2022, the Company entered into a $350 million senior secured term loan agreement with Pharmakon Advisors LP, manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. During the three months ended March 31, 2023, paid-in-kind interest capitalized was $5.5 million. Net proceeds from the Term Loan, after deducting the lenders fees and deal expenses of $15.2 million, were $334.8 million.
The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2023 (in thousands):
21
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Debt (Continued)
As of
March 31, 2023December 31, 2022
Original Term Loan balance$350,000 $350,000 
Paid-in-kind interest capitalized9,621 4,165 
Term Loan issuance costs, unamortized(13,876)(14,536)
Term Loan$345,745 $339,629 
As of March 31, 2023, future principal repayments of debt for each of the years through maturity were as follows (in thousands):
 
Year Ending December 31: 
2023$— 
2024— 
2025225,000 
2026179,811 
2027179,810 
2028 and thereafter575,000 
 $1,159,621 
Interest Expense
Interest expense related to debt and finance leases for the three months ended March 31, 2023 and 2022 is as follows (in thousands):
Three Months Ended March 31,
20232022
Convertible debt contractual interest expense$2,063 $2,063 
Term Loan contractual interest expense10,911 — 
Royalty Financing Agreement non-cash interest expense4,764 — 
Amortization of debt issuance costs1,724 822 
Swap interest income(73)— 
   Total debt interest expense19,389 2,885 
Finance lease interest expense614 406 
   Total interest expense$20,003 $3,291 
11. Royalty Financing Agreement
In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by us to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders fees and deal expenses of $3.8 million were, $146.2 million.
The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective
22
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
11. Royalty Financing Agreement (Continued)
interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be 12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. 
The following table presents a rollforward of the carrying value of the Company’s Royalty Financing Agreement balance for the three months ended March 31, 2023 (in thousands):

 Royalty financing agreement - beginning balance $148,015 
      Royalty revenue payments 2,017 
      Royalty revenue payable (2,608)
      Amortization of issuance costs134 
      Non-cash interest expense 2,615 
 Liability related to the sale of future royalties - ending balance $150,173 
Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss. Royalty revenue payable is recorded within accounts payable and accrued liabilities on the consolidated balance sheet.
12. Shareholders' Equity
Common Stock — As of March 31, 2023, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 136,429,216 shares of common stock issued and outstanding. In addition, as of March 31, 2023, the Company had reserved 19,155,595 shares of common stock for issuance upon the exercise of outstanding stock options, 2,057,694 shares of common stock for issuance upon the vesting of RSUs and 671,112 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430 shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved 9,406,112 shares of the Company’s common stock, subject to certain closing-related reductions. The shares of the Company’s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first anniversary of the closing date of the acquisition, and will also be issued upon the second and third anniversaries of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company’s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.
Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (Note 16) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition.
In connection with the Company’s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved 550,000 shares of the Company’s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. An additional $1 million of shares of common stock will be issued to Vertuis’ former stockholders on July 1, 2024, based on the share price on June 28, 2024. See Note 16 - Acquisitions for further details.
In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.
In the second quarter of 2021, the Company completed an underwritten public offering of 11,500,000 shares of the Company's common stock, including 1,500,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, at a public offering price of $25.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $17.5 million, were $270.1 million.
In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as SVB Securities LLC) (SVB Securities), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an “at the market” equity offering program (the ATM program), under which SVB Securities acts as sales agent. During the third quarter of 2022, the Company issued and sold an aggregate of 1,289,995 shares of common stock through the ATM program at a weighted-average public offering price of $26.68 per share and received net
23
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
12. Shareholders' Equity (Continued)
proceeds of $33.4 million. As of March 31, 2023, an aggregate of $215.6 million of shares of common stock remain available to be issued and sold under the ATM program.
Preferred Stock — As of March 31, 2023, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.
13. Stock-Based Compensation
The Company's current equity compensation plan, the Insmed Incorporated 2019 Incentive Plan (as amended, the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders in May 2019. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. On May 16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the Company's 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. On May 12, 2021, at the Company's 2021 Annual Meeting of Shareholders, the Company's shareholders approved the second amendment to the 2019 Incentive Plan providing for the issuance of an additional 2,750,000 shares under the plan. On May 11, 2022, at the Company's 2022 Annual Meeting of Shareholders, the Company's shareholders approved the third amendment to the 2019 Incentive Plan, providing for the issuance of an additional 3,000,000 shares under the plan. The Company has submitted a proposal to its shareholders to approve an Amended and Restated 2019 Incentive Plan at the 2023 Annual Meeting of Shareholders (the Amended and Restated Plan). The Amended and Restated Plan, if approved, will provide for the issuance of an additional 10,500,000 shares under the plan. As of March 31, 2023, 245,789 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the three months ended March 31, 2023, the Company granted inducement stock options covering 484,390 shares of the Company's common stock to new employees.
On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i) 1,000,000 shares of common stock, plus (ii) commencing on January 1, 2019 and ending on December 31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C) an amount determined by the administrator.
Stock Options — As of March 31, 2023, there was $116.5 million of unrecognized compensation expense related to unvested stock options.
As of March 31, 2023, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria.
Restricted Stock Units — As of March 31, 2023, there was $35.3 million of unrecognized compensation expense related to unvested RSU awards.
Performance Stock Units — As of March 31, 2023, there were 268,442 PSUs outstanding with an unrecognized compensation expense of $10.5 million of unrecognized compensation expense related to unvested PSU awards, which assumes a payout of 100% of the target.
The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2023 and 2022, respectively (in millions): 
24
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
13. Stock-Based Compensation (Continued)
 Three Months Ended March 31,
 20232022
Research and development$7.9 $5.6 
Selling, general and administrative8.5 7.2 
Total$16.4 $12.8 
There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three months ended March 31, 2023 or March 31, 2022, as the performance conditions associated with the PSU awards were not probable as of either date.
14. Income Taxes
The Company recorded a provision for income taxes of $0.5 million and $0.4 million for the three months ended March 31, 2023 and 2022, respectively. The provisions recorded for the three months ended March 31, 2023 and 2022 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.
The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company’s federal tax returns for the years ended 2019 and later, generally open for certain states for the years 2018 and later, and generally open for international jurisdictions for the years 2017 and later. The Company has incurred net operating losses since inception, except for the year ended December 31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of March 31, 2023 and December 31, 2022, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US. However, given the Company’s valuation allowance position, these reserves do not have an impact on the balance sheet as of March 31, 2023 and December 31, 2022 or the consolidated statements of comprehensive loss for the three months ended March 31, 2023 and 2022. The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.
15. Commitments and Contingencies
Rent expense charged to operations was $2.2 million and $2.0 million for the three months ended March 31, 2023 and 2022, respectively.
Legal Proceedings
From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.
16. Acquisitions
Asset Acquisition
In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to Vertuis’ former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 with an aggregate value of $1.0 million, based on the share price on June 28, 2024, and pay to the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions.
The shares of the Company’s common stock issuable to the Vertuis equityholders are being issued pursuant to Section 4(a)(2) of the Securities Act of 1933.
25
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
16. Acquisitions (Continued)
The following table summarizes the purchase price (in millions).
Shares of Insmed common stock issued on closing$9.25 
Shares of Insmed common stock issuable on July 1, 20241.00 
  Total purchase price$10.25 
The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.
Business Combination
On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company’s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company’s common stock, following certain closing-related reductions, to Motus’s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35 million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022, the Company fulfilled the payment due on the first anniversary of the closing date by issuing 171,427 shares of the Company's common stock, after certain reductions.
At the closing of the Company’s acquisition of AlgaeneX, the Company paid $1.5 million in cash to AlgaeneX’s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company’s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX’s manufacturing technology, in each case, subject to certain reductions.
The shares of the Company’s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.
The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.
Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5 million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.
The fair value of IPR&D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&D assets will be determined based on the
26
INSMED INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
16. Acquisitions (Continued)
anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.
27
ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.
                  Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:
•failure to successfully commercialize ARIKAYCE, our only approved product, in the United States (US), Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain US, European or Japanese approval for ARIKAYCE;
•uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;
•our inability to obtain full approval of ARIKAYCE from the US Food and Drug Administration (FDA), including the risk that we will not successfully or in a timely manner complete the study to validate a patient reported outcome (PRO) tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;
•inability of us, PARI Pharma GmbH (PARI) or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira® Nebulizer System (Lamira);
•our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;
•development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, TPIP or our other product candidates;
•inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;
•the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon Advisors, LP and our royalty financing with OrbiMed Royalty & Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements;
•our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;
•failure to obtain regulatory approval to expand ARIKAYCE’s indication to a broader patient population;
•risk that brensocatib or TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies, including, for brensocatib, the ASPEN study;
•risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication;
•failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products;
•failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;
•risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;
•failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the US, Europe or Japan, or for our product candidates in the US, Europe, Japan or other markets, including separate regulatory approval for Lamira in each market and for each usage;
28
•failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us;
•our inability to attract and retain key personnel or to effectively manage our growth;
•our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management’s time and attention devoted to integration activities;
•risks that our acquired technologies, products and product candidates are not commercially successful;
•our inability to adapt to our highly competitive and changing environment;
•risk that we are unable to maintain our significant customers;
•risk that government healthcare reform materially increases our costs and damages our financial condition;
•business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;
•impact of the COVID-19 pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers;
•deterioration in general economic conditions in the US, Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners;
•our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;
•restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;
•the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;
•risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;
•our limited experience operating internationally;
•changes in laws and regulations applicable to our business, including any pricing reform, and failure to comply with such laws and regulations;
•our history of operating losses, and the possibility that we never achieve or maintain profitability;
•goodwill impairment charges affecting our results of operations and financial condition;
•inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and
•delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.
We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Quarterly Report on Form 10-Q and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q and included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2022.
OVERVIEW
      We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, is approved in the US as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the
29
treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the EC approved ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
Our clinical-stage pipeline includes brensocatib, TPIP and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we are developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including CRSsNP. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for PH-ILD and PAH. Our early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, and protein manufacturing.
The information below summarizes the anticipated near-term milestones for ARIKAYCE and our product candidates.
ARIKAYCE
•We will continue to advance the ARISE and ENCORE trials, our post-marketing confirmatory, MAC lung disease clinical trial program for ARIKAYCE.
•We anticipate sharing topline efficacy and safety data from ARISE in the third quarter of 2023.
•We anticipate completing enrollment in ENCORE by the end of 2023.
Brensocatib
•In the first quarter of 2023, we completed enrollment of the Phase 3 ASPEN trial in adult patients, and we anticipate sharing topline data in the second quarter of 2024.
•We plan to explore the potential of brensocatib in additional neutrophil-mediated diseases, including advancing CRSsNP into Phase 2 development in the fourth quarter of 2023.
•We are advancing commercial readiness activities in 2023 in preparation for a launch of brensocatib for patients with bronchiectasis, if approved.
TPIP
•We will continue to advance our Phase 2 studies in both PH-ILD and PAH.
•We anticipate sharing interim, blinded dose titration and safety and tolerability data from both the PH-ILD and PAH studies in the second half of 2023, pending the rate of enrollment.
•We anticipate sharing topline results from the PH-ILD study in the first half of 2024.
Early-Stage Research
•We remain on track to initiate our first clinical trial in gene therapy in the second half of 2023.
•We anticipate sharing preclinical data in musculoskeletal and ocular indications in the first half of 2023.
•We anticipate sharing clinical data from the first trial in a musculoskeletal disease in the first half of 2024.
To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases.
30
Our Strategy
Our strategy focuses on the needs of patients with rare diseases. Our first product ARIKAYCE, is approved in the US as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe or Japan. We believe that ARIKAYCE has the potential to prove beneficial in other patients with MAC. Our product candidates are brensocatib, our Phase 3 product candidate which we are developing for patients with bronchiectasis, CF and other neutrophil-mediated diseases, and TPIP, our product candidate that may offer a differentiated product profile for patients with PH-ILD and PAH. We are also advancing our early-stage research programs encompassing a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, and protein manufacturing.
Our key priorities are as follows:
•Continue to provide ARIKAYCE to appropriate patients by leveraging and expanding our reliable revenue stream;
•Produce topline clinical data readouts in the near and long term;
•Advance commercial readiness activities to serve significantly more patients with serious and rare diseases; and
•Control spending, prudently deploying capital to support the best return-generating opportunities.
ARIKAYCE for Patients with MAC Lung Disease
ARIKAYCE is our first approved product. ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. In October 2020, ARIKAYCE received approval in Europe for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, ARIKAYCE received approval in Japan for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function. Unlike amikacin solution for intravenous administration, our proprietary Pulmovance™ technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. This technology also prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung and sites of MAC infection via the use of our Pulmovance technology distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily using Lamira, an inhalation device developed and manufactured by PARI. Lamira is a portable nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and was designed specifically for ARIKAYCE delivery.
The FDA has designated ARIKAYCE as an orphan drug and a Qualified Infectious Disease Product (QIDP) for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation provides an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years of exclusivity in the indication for which ARIKAYCE was approved.
ARIKAYCE also has been included in the international treatment guidelines for NTM lung disease. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA), strongly recommend the use of ARIKAYCE for MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options who have failed to convert to a negative sputum culture after at least six months of treatment.
In October 2020, the FDA approved a supplemental new drug application for ARIKAYCE, adding important efficacy data regarding the durability and sustainability of culture conversion to the ARIKAYCE label. The data, which are from the Phase 3 CONVERT study of ARIKAYCE, demonstrate that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.
Accelerated Approval
In March 2018, we submitted a new drug application (NDA) for ARIKAYCE to the FDA to request accelerated approval. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. In September 2018, the FDA granted accelerated approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of refractory MAC lung disease
31
as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options via the accelerated approval pathway. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs. As required for drugs approved under the LPAD pathway, labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.
As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial. In December 2020, we commenced the post-marketing confirmatory MAC lung disease clinical trial program for ARIKAYCE in patients with MAC lung disease. The MAC lung disease trial program consists of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung infection who have not started antibiotics using the PRO tool validated in the ARISE trial. We are running these global studies in parallel and approximately 200 sites are expected to be initiated for these clinical trials. We have completed enrollment in the ARISE trial and anticipate completing enrollment in ENCORE by the end of 2023. The MAC lung disease clinical program is intended to fulfill the FDA’s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCE.
Regulatory Pathway Outside of the US
In October 2020, the EC granted marketing authorization for ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. ARIKAYCE is now available commercially for patients in several of the major European Union (EU) countries. In October 2022, we secured reimbursement approval for ARIKAYCE in England, at which point ARIKAYCE became reimbursed across all UK nations. In September 2022, patient supply of ARIKAYCE in Germany was enabled by import from other EU countries. We have worked with the German National Association of Statutory Health Insurance Funds (GKV-SV) towards an agreement on the price of ARIKAYCE that would allow us to better serve the needs of patients in Germany; however, to date, we have been unable to reach an agreement. We are working to ensure an uninterrupted supply of ARIKAYCE for patients in Germany and to provide physicians and pharmacists the information they need to obtain ARIKAYCE for their patients through the importation pathway. Discussions remain ongoing with the GKV-SV with the goal of reaching an agreement and re-initiating direct access to ARIKAYCE. In January 2023, we agreed upon reimbursement terms with the French authorities. To date, we have been unable to reach an acceptable agreement of a nationally reimbursed price with the Italian Medicines Agency (AIFA). ARIKAYCE remains commercially available for physicians to prescribe in Italy under Class C, where we set the price and funding is agreed locally. We anticipate recommencing negotiations for national reimbursement in 2023 with the newly constituted AIFA.
In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. In July 2021, we launched ARIKAYCE in Japan.
The CONVERT Study and 312 Study
Accelerated approval of ARIKAYCE was supported by preliminary data from the CONVERT study, a global Phase 3 study evaluating the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. Patients who achieved sputum culture conversion by Month 6 continued in the CONVERT study for an additional 12 months of treatment following the first monthly negative sputum culture in order to assess the durability of culture conversion, as defined by patients that have completed treatment and continued in the CONVERT study off all therapy for three months. In May 2019, we presented at the American Thoracic Society meeting that 41/65 (63.1%) of patients on ARIKAYCE plus GBT who had achieved culture conversion by Month 6 had maintained durable culture conversion for three months off all therapy compared to 0/10 (0%) on GBT only (p<0.0002). Safety data for these patients were consistent with safety data previously reported for patients by Month 6 of the CONVERT study.
Patients who did not culture convert by Month 6 may have been eligible to enroll in the 312 study, an open-label extension study for these non-converting patients who completed six months of treatment in the CONVERT study. The primary objective of the 312 study was to evaluate the long-term safety and tolerability of ARIKAYCE in combination with a standard multi-drug regimen. The secondary objectives of the 312 study included evaluating the proportion of subjects achieving culture conversion (defined in the same way as the CONVERT study) by Month 6 and the proportion of subjects achieving culture conversion by Month 12, which was the end of treatment. We previously reported interim data as of December 2017 for patients in the 312 study, with 28.4% of patients who received GBT only in the CONVERT study (19/67) and 12.3% of patients who had received ARIKAYCE plus GBT in the CONVERT study (7/57) achieving culture conversion by Month 6 of the 312 study. The 312 study has concluded and final efficacy data regarding culture conversion were consistent with these interim data. We have analyzed the safety and efficacy data from the 312 study, and we did not observe any new safety signals.
32
Further Research and Lifecycle Management
We are currently exploring and supporting research and lifecycle management programs for ARIKAYCE beyond treatment of refractory MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. As noted above, we will continue to advance the post-marketing confirmatory, MAC lung disease clinical trial program for ARIKAYCE, through the ARISE and ENCORE trials, which are intended to fulfill the FDA's post-marketing requirement to allow for the full approval of ARIKAYCE in the US, as well as to support the use of ARIKAYCE as a treatment for patients with MAC lung infection.
The ARISE trial is a randomized, double-blind, placebo-controlled Phase 3b study in adult patients with newly diagnosed or recurrent MAC lung infections that aims to generate evidence demonstrating the domain specification, reliability, validity, and responsiveness of PRO-based scores, including a respiratory symptom score. Patients were randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for six months. Patients will then discontinue all study treatments and remain in the trial for one month for the continued assessment of PRO endpoints. In the fourth quarter of 2022, we completed enrollment in the ARISE trial. We anticipate sharing topline efficacy and safety data from ARISE in the third quarter of 2023.
The ENCORE trial is a randomized, double-blind, placebo-controlled Phase 3b study to evaluate the efficacy and safety of an ARIKAYCE-based regimen in patients with newly diagnosed or recurrent MAC lung infection who have not started antibiotics. Patients will be randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for 12 months. Patients will then discontinue all study treatments and remain in the trial for three months for the assessment of durability of culture conversion. The primary endpoint is change from baseline to Month 13 in respiratory symptom score. The key secondary endpoint is the proportion of subjects achieving durable culture conversion at Month 15. The study is currently enrolling patients, and is expected to enroll approximately 250 patients. We anticipate completing enrollment for ENCORE by the end of 2023.
Subsequent lifecycle management studies could also potentially enable us to reach more patients. These initiatives include investigator-initiated studies, which are clinical studies initiated and sponsored by physicians or research institutions with funding from us and may also include new clinical studies sponsored by us.
Product Pipeline
Brensocatib
Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs) in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the NSPs (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.
Based on the positive results of the WILLOW study discussed below, in December 2020 we commenced our Phase 3 trial, ASPEN, which will investigate brensocatib in bronchiectasis. ASPEN is a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in adult patients with bronchiectasis. Patients with bronchiectasis due to CF may not be enrolled in the study. Patients will be randomized to receive brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period. Secondary endpoints include time to first pulmonary exacerbation, percentage of subjects who remain pulmonary exacerbation-free, change from baseline in post-bronchodilator FEV1, rate of severe pulmonary exacerbations, change from baseline in the Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score, and incidence and severity of treatment-emergent adverse events (AEs). This study completed enrollment of adult patients in the first quarter of 2023. The study enrolled more than 1,700 adult patients at approximately 460 sites in 40 countries. We anticipate sharing topline data in the second quarter of 2024.
In March 2020, AstraZeneca exercised its first option pursuant to our October 2016 license agreement under which AstraZeneca can advance clinical development of brensocatib in the indications of chronic obstructive pulmonary disease (COPD) or asthma. Under the terms of the agreement, upon exercise of this option, AstraZeneca is solely responsible for all aspects of the development of brensocatib up to and including Phase 2b clinical trials in COPD or asthma. The agreement also includes a second and final option which, if exercised, would permit AstraZeneca to further develop brensocatib beyond Phase 2b clinical trials upon reaching agreement on commercial terms satisfactory to each party for the further development and commercialization of brensocatib in COPD or asthma. We retain full development and commercialization rights for brensocatib in all other indications and geographies.
In June 2020, the FDA granted breakthrough therapy designation for brensocatib for the treatment of adult patients
33
with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbations. The FDA's breakthrough therapy designation is designed to expedite the development and review of therapies that are intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. The benefits of breakthrough therapy designation include more frequent communication and meetings with FDA, eligibility for rolling and priority review, intensive guidance on an efficient drug development program, and organizational commitment from the FDA involving senior managers. In November 2020, brensocatib was granted access to the PRIME scheme from the European Medicines Agency (EMA) for patients with NCFBE.
In October 2021, the EMA’s Paediatric Committee approved the brensocatib Pediatric Investigational Plan for the treatment of patients with NCFBE. Subsequently, the ASPEN trial will now include 40 adolescent patients between ages 12 to 17, which will fulfill the pediatric study requirements to support marketing applications in this patient population in the US, Europe and Japan.
The WILLOW Study
The WILLOW study was a randomized, double-blind, placebo-controlled, parallel-group, multi-center, multi-national, Phase 2 study to assess the efficacy, safety and tolerability, and pharmacokinetics of brensocatib administered once daily for 24 weeks in patients with NCFBE. The WILLOW study was conducted at 116 sites and enrolled 256 adult patients diagnosed with NCFBE who had at least two documented pulmonary exacerbations in the 12 months prior to screening. Patients were randomized 1:1:1 to receive either 10 mg or 25 mg of brensocatib or matching placebo. The primary efficacy endpoint was the time to first pulmonary exacerbation over the 24-week treatment period in the brensocatib arms compared to the placebo arm.
WILLOW Efficacy Data
We announced topline data for the WILLOW study in February 2020 and full data for the WILLOW study in June 2020. In September 2020, final results from the WILLOW study were published online in the New England Journal of Medicine. The data demonstrate that the WILLOW study met its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period for both the 10 mg and 25 mg dosage groups of brensocatib compared to placebo (p=0.027, p=0.044, respectively). The risk of exacerbation at any time during the trial was reduced by 42% for the 10 mg group versus placebo (HR 0.58, p=0.029) and by 38% for the 25 mg group versus placebo (HR 0.62, p=0.046). In addition, treatment with brensocatib 10 mg resulted in a significant reduction in the rate of pulmonary exacerbations, a key secondary endpoint, versus placebo. Specifically, patients treated with brensocatib experienced a 36% reduction in the 10 mg arm (p=0.041) and a 25% reduction in the 25 mg arm (p=0.167) versus placebo. Change in concentration of active NE in sputum versus placebo from baseline to the end of the treatment period was also statistically significant (p=0.034 for 10 mg, p=0.021 for 25 mg).
WILLOW Safety and Tolerability Data
Brensocatib was generally well-tolerated in the study. Rates of AEs leading to discontinuation in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg were 10.6%, 7.4%, and 6.7%, respectively. The most common AEs in patients treated with brensocatib were cough, headache, sputum increase, dyspnea, fatigue, and upper respiratory tract infection. Rates of adverse events of special interest (AESIs) in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg, respectively, were as follows: rates of skin events (including hyperkeratosis) were 11.8%, 14.8%, and 23.6%; rates of dental events were 3.5%, 16.0%, and 10.1%; and rates of infections that were considered AESIs were 17.6%, 13.6%, and 16.9%.
Further Research and Development
In August 2019, we received notice from the FDA that we were awarded a development grant of $1.8 million for specific work to be performed on a PRO tool. The grant funding is for the development of a novel PRO tool for use in clinical trials to measure symptoms in patients with NCFBE with and without NTM lung infection.
In January 2023, we reported topline data from the Phase 2, multiple-dose, pharmacokinetic/pharmacodynamic study of brensocatib in patients with CF. This Phase 2 study included both patients who were on background CFTR modulator drugs and patients who were not on CFTR modulator drugs. The study duration was approximately one month and dosed CF patients to placebo, 10 mg, 25 mg, and 40 mg of brensocatib. A clear dose-dependent and exposure-dependent inhibition of blood NSPs was observed in patients treated with brensocatib across all doses in this study, consistent with the mechanism of action of brensocatib. Safety and tolerability were consistent with what was observed during the Phase 2 WILLOW study, with no significant drug-related findings. We concluded that an additional cohort evaluating a 65 mg dose of brensocatib is not needed in this patient population. We believe that we can use the data from this Phase 2 study, in addition to the clinical work done for the WILLOW and ASPEN studies, to help inform the safety and efficacy of brensocatib for CF patients.
We also plan to explore the potential of brensocatib in additional neutrophil-mediated diseases, including CRSsNP. CRSsNP currently has no approved therapies and many patients do not respond to corticosteroids or endoscopic sinus surgery. We anticipate moving brensocatib into Phase 2 development for CRSsNP in the fourth quarter of 2023.
Market Opportunity for Brensocatib in Bronchiectasis
34
Bronchiectasis is a severe, chronic pulmonary disorder in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. Based on information from external sources, including market research funded by us and third parties, and internal analyses and calculations, we estimate the potential addressable market at launch in the US, the European 5 and Japan will be as follows (approximately):
Potential MarketEstimated Number of Patients Diagnosed with Bronchiectasis
United States450,000
European 5400,000
Japan150,000
Today, there are no approved therapies in the US, Europe, or Japan for the treatment of patients with bronchiectasis.
Treprostinil Palmitil Inhalation Powder
TPIP is an investigational inhaled formulation of a treprostinil prodrug that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that TPIP prolongs duration of effect and may provide patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day. Reducing dose frequency has the potential to ease patient burden and improve compliance. Additionally, we believe that TPIP may be associated with fewer side effects, including severity and/or frequency of cough, headache, throat irritation, nausea, flushing and dizziness that are associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe TPIP may offer a differentiated product profile for PH-ILD and PAH.
In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. The objective of this first-in-human single ascending dose and multiple ascending dose study was to assess the pharmacokinetics and tolerability profile of TPIP. Data from the study demonstrated that TPIP was generally well tolerated, with a pharmacokinetic profile that supports continued development with once-daily dosing. The most common AEs across all cohorts in the study were cough, dizziness, headache, and nausea. Most AEs were mild in severity and consistent in nature with those typically seen with other inhaled prostanoid therapies. There were few moderate AEs and no severe or serious AEs. Subjects in the multiple dose panel that incorporated an up-titration approach beginning at 112.5 µg once-daily and progressing to 225 µg once-daily reported fewer AEs compared to the panel dosed with 225 µg once-daily from the first dose.
Overall pharmacokinetic results demonstrated that treprostinil exposure (AUC and Cmax) was dose-proportional, with low to moderate inter-subject variability. Treprostinil was detected in the plasma at 24 hours at all doses and throughout the 48-hour sampling period for the two highest doses. Compared with currently available inhaled treprostinil therapy, TPIP showed substantially lower Cmax and longer half-life. Data from this study were presented in an oral session at the European Society of Cardiology Congress in August 2021.
We are advancing the development of TPIP with two ongoing Phase 2 studies. The first study is designed to assess the safety and tolerability of TPIP in patients with PH-ILD over a 16-week treatment period using an up-titration, once-daily dosing schedule. The second study is designed to investigate the effect of TPIP in patients with PAH on changes in PVR and six-minute walk distance over a 16-week treatment period and will also employ an up-titration, once-daily dosing schedule. A third study, which was a Phase 2a study designed to study the immediate impact of a single dose of TPIP in PAH patients over a 24-hour period was discontinued primarily due to hospital and intensive care unit restrictions during the COVID-19 pandemic that were necessary to conduct the study. One patient was dosed in this study at 112.5 micrograms. This patient went on to complete the 16-week extension period for the study and was titrated to a dose of 320 micrograms once daily, which was found to be safe and tolerable. We did not observe any safety concerns with TPIP, and the data suggested a trend toward improvement in various cardiac measures during the study period.
We will continue to advance our Phase 2 development work in both PH-ILD and PAH. We anticipate sharing interim, blinded dose titration and safety and tolerability data from the PH-ILD study in the second half of 2023. We expect topline results from the PH-ILD study to be shared in the first half of 2024.
Early-Stage Research
Our early-stage research efforts are comprised of our preclinical programs, advanced through internal research and development and augmented through business development activities. In March 2021, we acquired a proprietary protein deimmunization platform, called Deimmunized by Design, focused on the reengineering of therapeutic proteins to evade immune recognition and reaction. In August 2021, we acquired Motus and AlgaeneX, preclinical stage companies engaged in the research, development and manufacturing of gene therapies for rare genetic disorders. In January 2023, we acquired
35
Vertuis, a privately held, preclinical stage company engaged in the research and development of gene therapies for rare genetic disorders. We believe that animal studies may demonstrate the viability of these potential medicines to address serious unmet medical needs in various therapeutic areas.
Our initial therapeutic areas of focus include musculoskeletal, CNS, ocular, and rheumatologic diseases. We remain on track to initiate our first clinical trial in gene therapy in the second half of 2023. Preclinical data in musculoskeletal and ocular indications are also expected in the first half of 2023 and clinical data from the first trial in a musculoskeletal disease are anticipated in the first half of 2024.
Corporate Development
We plan to continue to develop, acquire, in-license or co-promote other products, product candidates and technologies, including those that address serious and rare diseases that currently have significant unmet needs. We are focused broadly on serious and rare disease therapeutics and prioritizing those areas that best align with our core competencies.
KEY COMPONENTS OF OUR RESULTS OF OPERATIONS
Product Revenues, Net
Product revenues, net, consist of net sales of ARIKAYCE. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors. In December 2020, we began commercial sales of ARIKAYCE in Europe. In July 2021, we began recognizing product revenue from commercial sales of ARIKAYCE in Japan. We recognize revenue for product received by our customers net of allowances for customer credits, including prompt pay discounts, service fees, estimated rebates, including government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US, and chargebacks.
Cost of Product Revenues (Excluding Amortization of Intangible Assets)
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. We began capitalizing inventory upon FDA approval of ARIKAYCE. All costs related to inventory for ARIKAYCE prior to FDA approval were expensed as incurred and therefore not included in cost of product revenues.
Research and Development (R&D) Expenses
R&D expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs and program management. R&D expenses also includes other internal operating expenses, the cost of manufacturing product candidates, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. Our R&D expenses related to manufacturing our product candidates and medical devices for clinical study are primarily related to activities at CMOs that manufacture brensocatib, TPIP and early-stage research activities. Our R&D expenses related to clinical trials are primarily related to activities at contract research organizations (CROs) that conduct and manage clinical trials on our behalf. These contracts with CROs set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts with CROs primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Deposits for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed.
Selling, General and Administrative (SG&A) Expenses
SG&A expenses consist of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, commercial and pre-commercial, corporate development, field sales, information technology and human resource functions. SG&A expenses also include professional fees for legal services, consulting services, including commercial activities, insurance, board of director fees, tax and accounting services and certain milestones related to ARIKAYCE.
Amortization of Intangible Assets
Upon commercialization of ARIKAYCE, our intangible assets began to be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based on estimates and assumptions we believe are reasonable based on available facts and circumstances. Unanticipated events or circumstances may occur that require us to review the assets for impairment.
36
Change in Fair Value of Deferred and Contingent Consideration Liabilities
In connection with our Business Acquisition, we recorded deferred and contingent consideration liabilities related to potential future milestone payments. Adjustments to the fair value are due to changes in: the probability of achieving milestones; our stock price; or certain other estimated assumptions. The change in fair value of deferred and contingent consideration liabilities is calculated quarterly with gains and losses recorded in the consolidated statements of comprehensive loss.
Investment Income and Interest Expense
Investment income consists of interest and dividend income earned on our cash and cash equivalents and marketable securities. Interest expense consists primarily of contractual interest costs, Royalty Financing Agreement non-cash interest expense and the amortization of debt issuance costs related to our debt. Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Our balance sheet reflects debt, net of the debt discount, debt issuance costs paid to the lender, and other third-party costs. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Change in Fair Value of Interest Rate Swap
We record derivative and hedge transactions in accordance with GAAP. In the fourth quarter of 2022, we entered into an interest rate swap contract (the Swap Contract) with a notional value of $350 million to economically hedge our variable rate-based term debt for three years, effectively changing the variable rate under the term debt to a fixed interest rate. Our interest rate swap has not been designated as a hedging instrument for accounting purposes. Consequently, all changes in the fair value of the Swap Contract are reported as a component of net loss in the consolidated statements of comprehensive loss.
RESULTS OF OPERATIONS
Comparison of the Three Months Ended March 31, 2023 and 2022
Overview - Operating Results
Our operating results for the three months ended March 31, 2023, included the following:
•Product revenues, net, increased $12.1 million, or 22.8%, as compared to the same period in the prior year as a result of the growth in ARIKAYCE sales;
•Cost of product revenues (excluding amortization of intangible assets) increased $1.6 million as compared to the same period in the prior year as a result of the increase in sales volumes of ARIKAYCE;
•R&D expenses increased $43.5 million as compared to the same period in the prior year primarily resulting from increases in clinical development and research for our ongoing clinical trials;
•SG&A expenses increased $23.2 million as compared to the same period in the prior year resulting primarily from increases in professional fees and other external expenses;
•Amortization of intangible assets of $1.3 million was consistent with the same period in the prior year;
•Change in fair value of deferred and contingent consideration liabilities decreased $2.1 million, primarily as a result of the change in our share price; and
•Interest expense increased $16.7 million as compared to the same period in the prior year due to entering into the Term Loan and Royalty Financing Agreement in the fourth quarter of 2022.
Product Revenues, Net
Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes revenue by geography for the three months ended March 31, 2023 and 2022 (in thousands):
Three Months Ended March 31,Increase (decrease)
20232022$%
US$49,067 $40,782 $8,285 20.3%
Japan13,156 10,676 2,480 23.2%
Europe and rest of world2,991 1,649 1,342 81.4%
  Total product revenues, net$65,214 $53,107 $12,107 22.8%
Product revenues, net, for the three months ended March 31, 2023 increased to $65.2 million as compared to $53.1 million in the same period in 2022, an increase of 22.8% as a result of growth in ARIKAYCE sales in the US, Japan and Europe and the rest of the world.
37
Cost of Product Revenues (excluding amortization of intangible assets)
Cost of product revenues (excluding amortization of intangible assets) for the three months ended March 31, 2023 and 2022 were comprised of the following (in thousands):
Three Months Ended March 31,Increase (decrease)
20232022$%
Cost of product revenues (excluding amortization of intangible assets)$13,830 $12,191 $1,639 13.4 %
Cost of product revenues, as % of revenues21.2 %23.0 %
Cost of product revenues (excluding amortization of intangible assets) increased by $1.6 million, or 13.4%, to $13.8 million for the three months ended March 31, 2023 as compared to $12.2 million in the same period in 2022. The increase in cost of product revenues (excluding amortization of intangibles) in the three months ended March 31, 2023 was primarily attributable to the increase in product revenues discussed above.
R&D Expenses
R&D expenses for the three months ended March 31, 2023 and 2022 were comprised of the following (in thousands):
 Three Months Ended March 31,Increase (decrease)
 20232022$%
External Expenses    
Clinical development and research$43,138 $33,101 $10,037 30.3 %
Vertuis non-cash asset acquisition10,250 — 10,250 NA
Manufacturing13,612 10,373 3,239 31.2 %
Regulatory, quality assurance, and medical affairs10,330 4,996 5,334 106.8 %
Subtotal—external expenses$77,330 $48,470 $28,860 59.5 %
Internal Expenses    
Compensation and benefit related expenses$33,236 $24,495 $8,741 35.7 %
Stock-based compensation7,899 5,615 2,284 40.7 %
Other internal operating expenses9,400 5,776 3,624 62.7 %
Subtotal—internal expenses$50,535 $35,886 $14,649 40.8 %
   Total R&D expenses$127,865 $84,356 $43,509 51.6 %
R&D expenses increased to $127.9 million during the three months ended March 31, 2023 from $84.4 million in the same period in 2022. The $43.5 million increase was primarily due to the $10.3 million non-cash cost of the Vertuis acquisition, a $10.0 million increase in clinical development and research expenses to support the ongoing Phase 3 ASPEN trial of brensocatib and the ARIKAYCE MAC lung disease clinical trial program and an $11.0 million increase in compensation and benefit related expenses and stock-based compensation costs due to an increase in headcount.
External R&D expenses by product for the three months ended March 31, 2023 and 2022 were comprised of the following (in thousands):
Three Months Ended March 31,Increase (decrease)
20232022$%
ARIKAYCE external R&D expenses$18,249 $16,678 $1,571 9.4 %
Brensocatib external R&D expenses26,535 21,726 4,809 22.1 %
Vertuis non-cash asset acquisition10,250 — 10,250 NA
Other external R&D expenses22,296 10,066 12,230 121.5 %
   Total external R&D expenses$77,330 $48,470 $28,860 59.5 %
We expect R&D expenses to continue to increase in 2023 relative to 2022 primarily due to our clinical trial activities and related spend, including our Phase 3 ASPEN trial of brensocatib, our confirmatory clinical trial of ARIKAYCE in a treatment setting for patients with MAC lung disease, our TPIP clinical trials and our research efforts in early stage research.
38
SG&A Expenses
SG&A expenses for the three months ended March 31, 2023 and 2022 were comprised of the following (in thousands):
 
 Three Months Ended March 31,Increase (decrease)
20232022$%
Compensation and benefit related expenses$28,395 $22,953 $5,442 23.7 %
Stock-based compensation8,545 7,206 1,339 18.6 %
Professional fees and other external expenses29,966 19,741 10,225 51.8 %
Facility related and other internal expenses13,008 6,848 6,160 90.0 %
Total SG&A expenses$79,914 $56,748 $23,166 40.8 %
SG&A expenses increased to $79.9 million during the three months ended March 31, 2023 from $56.7 million in the same period in 2022. The $23.2 million increase resulted primarily from a $10.2 million increase in professional fees and other external expenses driven by commercial readiness activities for brensocatib. The increase was also due to a $6.8 million increase in compensation and benefit related expenses and stock-based compensation costs due to an increase in headcount. We expect SG&A expenses to continue to increase in 2023 relative to 2022 due, in part, to commercial readiness activities for brensocatib.
Amortization of Intangible Assets
Amortization of intangible assets for both the three months ended March 31, 2023 and 2022 was $1.3 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&D and amortization of the milestones paid to PARI for the FDA and EC approvals of ARIKAYCE.
Change in Fair Value of Deferred and Contingent Consideration Liabilities
The change in fair value of deferred and contingent consideration for the three months ended March 31, 2023 was $(9.5) million as a result of our Business Acquisition in the third quarter of 2021. Adjustments to the fair value are due to changes in factors such as the probability of achieving milestones, our stock price, or certain other estimated assumptions.
Interest Expense
Interest expense increased to $20.0 million for the three months ended March 31, 2023 as compared to $3.3 million in the same period in 2022 due to entering into the Term Loan and Royalty Financing Agreement in the fourth quarter of 2022. See Note 10 - Debt and Note 11 - Royalty Financing Agreement for further details.
Change in Fair Value of Interest Rate Swap
The change in fair value of interest rate swap for the three months ended March 31, 2023 was $1.5 million. Adjustments to the fair value are due to changes in interest rates as of March 31, 2023 relative to the fair value of interest rate swap as of December 31, 2022.
LIQUIDITY AND CAPITAL RESOURCES
 Overview
     There is considerable time and cost associated with developing potential pharmaceutical products to the point of regulatory approval and commercialization. We commenced commercial shipments of ARIKAYCE in October 2018. We expect to continue to incur consolidated operating losses, including losses at our US and certain international entities, as we plan to fund R&D for ARIKAYCE, brensocatib, TPIP and our other pipeline programs, continue commercialization and regulatory activities for ARIKAYCE, fund pre-commercialization activities for brensocatib, and engage in other general and administrative activities.
In October 2022, we entered into the $350 million Term Loan with Pharmakon that matures on October 19, 2027. The Term Loan bears interest at a rate based upon the SOFR, subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at our election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at our option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8 million.
39
In October 2022, we entered into the Royalty Financing Agreement with OrbiMed, whereby OrbiMed paid us $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments equal to or greater than $150 million on or prior to March 31, 2028, the royalty rate for ARIKAYCE will be increased for all subsequent fiscal quarters to a rate which, if applied retroactively, would have resulted in aggregate Revenue Interest Payments to OrbiMed for all fiscal quarters ended on or prior to March 31, 2028 equal to $150 million. In addition, we must make a one-time payment to OrbiMed in an amount that, when added to the aggregate amount of Revenue Interest Payments received by OrbiMed as of March 31, 2028, would equal $150 million. The total Revenue Interest Payments payable by us to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders fees and deal expenses of $3.8 million, were $146.2 million.
In October 2022, we also completed an underwritten offering of 13,750,000 shares of our common stock at a public offering price of $20.00 per share. Our net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.
We may need to raise additional capital to fund our operations, the continued commercialization of ARIKAYCE, launch readiness activities for the potential launch of brensocatib for the treatment of patients with bronchiectasis, if approved, clinical trials for brensocatib, TPIP, and our future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address serious or rare diseases. While we believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be the ASPEN trial, expenses related to our commercialization efforts and our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and to a lesser extent, expenses related to the clinical development of TPIP and our early-research programs.
Cash Flows
As of March 31, 2023, we had cash and cash equivalents of $968.9 million, as compared with $1,074.0 million as of December 31, 2022. In addition, as of March 31, 2023, we had marketable securities of $29.8 million as compared with $74.2 million as of December 31, 2022. The $105.1 million decrease in cash and cash equivalents was primarily due to the purchase of marketable securities and cash used in operating activities. Our working capital was $941.1 million as of March 31, 2023, as compared with $1,083.1 million as of December 31, 2022.
Net cash used in operating activities was $146.3 million and $105.2 million for the three months ended March 31, 2023 and 2022, respectively. The net cash used in operating activities during the three months ended March 31, 2023 and 2022 was primarily for the commercial, clinical and manufacturing activities related to ARIKAYCE, as well as other SG&A expenses and clinical trial expenses related to brensocatib and TPIP. The increase in cash used in operating activities for the three months ended March 31, 2023 compared to the corresponding period in 2022 was primarily due to the increase in net loss, excluding the adjustments to reconcile net loss to net cash used in operating activities.
Net cash provided by (used in) investing activities was $41.6 million and $(101.4) million for the three months ended March 31, 2023 and 2022, respectively. The decrease in 2023 is due to purchases of marketable securities in three months ended March 31, 2022 and the maturity of marketable securities in the three months ended March 31, 2023.
Net cash (used in) provided by financing activities was $(0.4) million and $6.5 million for the three months ended March 31, 2023 and 2022, respectively. The decrease in 2023 is due to decrease in net cash proceeds from the exercise of stock options in the three months ended March 31, 2023.
Contractual Obligations
There were no material changes outside of the ordinary course of business in our contractual obligations during the three months ended March 31, 2023 from those disclosed in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2022.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.
CRITICAL ACCOUNTING ESTIMATES
40
There have been no material changes to our critical accounting policies and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022. For the required interim disclosure updates related to our accounting policies and estimates, see Note 2 — Summary of Significant Accounting Policies in this Quarterly Report on Form 10-Q.
ITEM 3.                                                QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As of March 31, 2023, our cash and cash equivalents were in cash accounts and money market funds. Our investments in money market funds are not insured by the federal government. As of March 31, 2023, our marketable securities were invested in US treasury notes with an original maturity of greater than 90 days.
As of March 31, 2023, we had $800.0 million of convertible notes outstanding. Our 2025 Convertible Notes and our 2028 Convertible Notes bear interest at a coupon rate of 1.75% and 0.75%, respectively. In addition, as of March 31, 2023, we had a $350 million Term Loan and a $150.0 million Royalty Financing Agreement outstanding. The Term Loan accrues interest quarterly at the SOFR subject to a floor of 2.5%, plus a margin of 7.75% per annum. We entered into the Swap Contract as a hedge to the Term Loan variable interest rate. The Royalty Financing Agreement pays interest at 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% thereafter as well as 0.75% of brensocatib global net sales, if approved. If a 10% change in interest rates had occurred on March 31, 2023, it would not have had a material effect on the fair value of our debt as of that date, nor would it have a material effect on our future earnings or cash flows.
The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds, and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations and during the three months ended March 31, 2023 and 2022, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.
ITEM 4.                                                CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.                                                LEGAL PROCEEDINGS
From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.
ITEM 1A.                                       RISK FACTORS
Our business is subject to substantial risks and uncertainties. You should carefully consider the risk factors set forth below as well as the other information contained in this Quarterly Report on Form 10-Q and in our other public filings in evaluating our business, including our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 23, 2023. Any of the risks and uncertainties described below and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Form 10-Q (please read the Cautionary Note Regarding Forward-Looking Statements in this Form 10-Q).
ITEM 2.     UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
41
On January 6, 2023, the Company acquired Vertuis, a privately held, preclinical stage company. In connection with the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to the Vertuis equityholders. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 having an aggregate value of $1 million, based on the share price on June 28, 2024. The shares of the Company’s common stock issuable to the Vertuis equityholders are being issued pursuant to Section 4(a)(2) of the Securities Act of 1933. The Company did not and will not receive any proceeds from the issuance of common stock to the Vertuis equity holders.
ITEM 5.    OTHER INFORMATION
None.
    
ITEM 6.    EXHIBITS
Exhibit Index
Articles of Incorporation of Insmed Incorporated, as amended through June 14, 2012 (incorporated by reference from Exhibit 3.1 to Insmed Incorporated’s Annual Report on Form 10-K filed on March 18, 2013).
Amended and Restated Bylaws of Insmed Incorporated (incorporated by reference from Exhibit 3.1 to Insmed Incorporated’s Current Report on Form 8-K filed on March 30, 2020).
Form of Insmed Incorporated Non-Qualified Stock Option Inducement Award Agreement.
Form of Insmed Incorporated Non-Qualified Stock Option Inducement Award Agreement for non-U.S. employees.
Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101The following materials from Insmed Incorporated’s quarterly report on Form 10-Q for the quarter ended March 31, 2023 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022, (ii) Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023 and 2022, (iii) Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022, (v) Notes to the Unaudited Consolidated Financial Statements, and (vi) Cover Page.
104The cover page from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in iXBRL and contained in Exhibit 101.
* Management contract or compensatory plan or arrangement.

42
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
  INSMED INCORPORATED
 
 
Date: May 4, 2023By/s/ Sara Bonstein
  Sara Bonstein
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

43
 EX-10.1 2 insm-20230331ex101.htm EX-10.1 Document

INSMED INCORPORATED
NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT
No. of shares subject to Option: /$AwardsGranted$/

THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a subsidiary of the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (the “Inducement Award Rule”). If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of Participant’s offer letter or employment agreement with the Company or the applicable subsidiary thereof, dated as of /$HireDate$/ (the “Employment Agreement”), the Employment Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is consistent with the Inducement Award Rule and applicable law.

1.Grant of Option. The Company, on /$GrantDate$/ (the “Date of Grant”), granted to Participant, subject to the terms and conditions herein set forth, the right and option to purchase from the Company all or any part of an aggregate of /$AwardsGranted$/ shares of common stock of the Company, par value US $0.01 per share (the “Common Stock”) at the option price of /$GrantPrice$/ per share, being not less than the closing price of a share of the Company’s Common Stock on the NASDAQ on the Date of Grant (the “Option”). The Option is intended to be a nonqualified stock option and not an “incentive stock option” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). The Option is exercisable as hereinafter provided.
2.Terms and Conditions. The Option is subject to the following terms and conditions:
a.Expiration Date. The Option shall expire ten years from the Date of Grant (the “Expiration Date”).
b.Exercise of Option. Except as provided in paragraphs 3, 4 and 5, the Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to the Option on the first annual anniversary of the Date of Grant (the “First Anniversary Date”) and with respect to twelve and a half percent (12.5%) of the shares of Common Stock subject to the Option on the six-month anniversary of the First Anniversary Date and each six-month anniversary date thereafter through the fourth annual anniversary of the Date of Grant, subject to Participant’s continued employment through each applicable date. If the foregoing schedule would produce fractional shares, the number of shares for which the Option becomes exercisable shall be rounded down to the nearest whole share. Once the Option has become exercisable in accordance with this subparagraph 2(b) it shall continue to be exercisable until the termination of Participant’s rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a). A partial exercise of the Option shall not affect Participant’s right to exercise the Option with respect to the remaining shares, subject to the conditions of this Agreement.
c.Method of Exercising Option and Payment for Shares. The Option shall be exercised by written notice in the form of Attachment A — “Notice of Option Exercise” or such other form as may be approved by the Company, delivered to the attention of the Company’s Chief Financial Officer at the Company’s principal place of business. The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery. Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Compensation Committee of the Company’s Board of


Directors (the “Compensation Committee” and the “Board”), or such other method as determined by the Compensation Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which the Option is being exercised.
d.Agreement with Terms. Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant’s acknowledgement of, and agreement with, all of the provisions of this Agreement, and the Company shall administer this Agreement accordingly.
e.Shareholder Rights. Participant shall not have any rights as a shareholder with respect to shares subject to the Option until Participant exercises such Option and becomes the holder of record of such shares.
f.Forfeiture. In the event of Participant’s termination of employment, any vested portion of the Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5, as applicable, shall be forfeited upon the expiration of such period. Any portion of the Option that is unvested as of the date of Participant’s termination of employment shall be forfeited on such date.
3.Exercise in the Event of Death. In the event Participant dies before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) on the date of Participant’s death. In that event, the Option may be exercised, to the extent exercisable under subparagraph 2(b), by Participant’s estate or by the other person or persons to whom Participant’s rights under the Option shall pass by will or the laws of descent and distribution. Participant’s estate or such persons may exercise the Option within one year after Participant’s death or during the remainder of the period preceding the Expiration Date, whichever is shorter.
4.Exercise in the Event of Permanent and Total Disability. In the event Participant becomes permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (“Permanently and Totally Disabled”) before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) on the date Participant ceases to be employed by the Company or, as determined by the Compensation Committee from time to time, any entity in which the Company has a substantial direct or indirect equity interest (an “Affiliate”), as a result of Participant’s becoming Permanently and Totally Disabled. In that event, Participant may exercise the Option, to the extent exercisable under subparagraph 2(b), within one year after the date Participant ceases to be employed by the Company and its Affiliates as a result of Participant’s becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter.
5.Exercise After Termination of Employment. Except as provided in paragraphs 3 and 4 hereof, if Participant ceases to be employed by the Company and its Affiliates prior to the Expiration Date, the Option shall be exercisable for all or part of the number of shares that Participant was entitled to purchase under subparagraph 2(b) and, if applicable, any additional number of shares specified under the Employment Agreement on the date of Participant’s termination of employment. In that event, Participant may exercise the Option, to the extent exercisable under subparagraph 2(b) and/or under the Employment Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three months (or such other period of time provided under the Employment Agreement, if
2

any) after the date Participant ceases to be employed by the Company and its Affiliates, whichever is shorter.
6.Notice. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to Participant, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.
7.Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.
8.No Right to Continued Employment. Nothing in this Agreement shall interfere with or limit in any way the right of the Company, its subsidiaries and/or its Affiliates to terminate Participant’s employment at any time or for any reason in accordance with the Company’s Bylaws, governing law and the Employment Agreement, nor shall any terms of this Agreement confer upon Participant any right to continue Participant’s employment for any specified period of time. Neither this Agreement nor any benefits arising under this Agreement shall constitute an employment contract with the Company or any of its subsidiaries or Affiliates.
9.Change in Capital Structure. The terms of the Option (including the number or kind of shares subject hereto and the option price) shall be equitably adjusted as the Compensation Committee determines is equitably required to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Common Stock outstanding. No fractional shares of Common Stock shall be issued pursuant to such an adjustment.
10.Change in Control. The Compensation Committee shall have the discretion to determine the treatment of the Option upon the occurrence of a Change in Control (as defined below). Unless otherwise expressly provided in the Employment Agreement or under the terms of a transaction constituting a Change in Control, the following shall occur upon a Participant’s involuntary termination of employment within twenty-four (24) months following a Change in Control, provided that such termination does not result from the Participant’s termination for disability, cause or gross misconduct: the Option shall immediately become exercisable and shall remain exercisable for three (3) years following such termination (or until the Expiration Date, if earlier). For purposes of this paragraph 10, the following definitions apply, subject to applicable laws to the extent mandatory:
a. “Change in Control” means the occurrence of any one of the following:
i.any Person becomes the beneficial owner (as such term is defined in Rule 13d-3 under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of at least 50% of either (A) the value of the then outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors
3

(the “Outstanding Company Voting Securities”) (the foregoing beneficial ownership hereinafter being referred to as a “Controlling Interest”); provided, however, that for purposes of this definition, the following acquisitions shall not constitute or result in a Change in Control: (v) any acquisition directly from the Company; (w) any acquisition by the Company; (x) any acquisition by any person that as of the Date of Grant has beneficial ownership of a Controlling Interest; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate; or (z) any acquisition by any corporation pursuant to a transaction which complies with subparagraphs 10(b)(iii)(A), (B) and (C) below; or
ii.during any period of two consecutive years (not including any period prior to the Date of Grant) individuals who constitute the Board on the Date of Grant (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
iii.consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any of its subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its subsidiaries (each a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the Persons who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related
4

trust) of the Company or such Acquiring Corporation) beneficially owns, directly or indirectly, more than 50% of the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the board of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or
iv.the complete liquidation or dissolution of the Company.
Notwithstanding the foregoing, to the extent required to avoid the imposition of additional taxes and/or penalties pursuant to Section 409A of the Code, no event or transaction will constitute a Change in Control hereunder unless it also constitutes a “change in control event” under Section 409A of the Code.
b. “Person” has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.
11.Tax Withholding. To the extent required by applicable federal, state, local or foreign law, the Company may and/or Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to the Option, or the issuance or sale of any shares of Common Stock. The Company shall not be required to recognize any Participant rights under the Option, to issue shares of Common Stock or to recognize the disposition of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Company, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of Participant in accordance with applicable law, the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under the Option or any other award held by Participant or by Participant tendering to the Company cash or, if allowed by the Company, shares of Common Stock. Nothing in this Agreement shall be interpreted or construed to transfer any liability for any tax (including, without limitation, a tax or penalty due as a result of a failure to comply with Section 409A of the Code) due by Participant to the Company, any subsidiary thereof or any Affiliate, or to any other individual or entity, and the Company shall have no liability to Participant, or any other party, with respect thereto. Participant acknowledges that the Company and its subsidiaries and Affiliates: (a) make no representations or undertakings regarding the tax treatment in connection with any aspect of the Option and (b) do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate Participant’s tax liabilities.
12.Administration. Any question concerning the interpretation of this Agreement or the Option, any adjustments required to be made to the Option hereunder, and any controversy that may arise with respect to the Option will be determined by the Compensation Committee in its sole and absolute discretion. All decisions by the Compensation Committee shall be final and binding on Participant and Participant’s beneficiaries, heirs and assigns.
5

13.Compliance with Laws and Regulations. Participant hereby acknowledges, represents and warrants to the Company that, unless a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the shares of Common Stock to be received upon the exercise of the Option is effective and current at the time of exercise of the Option, (i) the shares of Common Stock to be issued upon the exercise of the Option will be unregistered and acquired by Participant for Participant’s own account, for investment only and not with a view to the resale or distribution thereof and (ii) the shares of Common Stock to be issued upon the exercise of the Option may not be sold or transferred unless a registration statement under the Securities Act with respect to the resale of such shares is effective and current or such registration is determined by the Company to be unnecessary. Nothing herein shall be construed as requiring the Company to register the shares subject to the Option for sale or resale under the Securities Act. Notwithstanding anything herein to the contrary, if at any time the Company shall determine, in its sole discretion, that the listing or qualification of the shares of Common Stock subject to the Option on any securities exchange or under any applicable law, or the consent or approval of any governmental agency or regulatory body, is necessary or desirable as a condition to, or in connection with, the issuance of shares of Common Stock hereunder, the Option may not be exercised in whole or in part unless such listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company.
14.Governing Law. This Agreement shall be governed by the laws of the Commonwealth of Virginia, without regard to any rule or principle of conflicts of laws that otherwise would result in the application of the substantive laws of another jurisdiction. Any reference in this Agreement to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.
15.Section 409A. It is intended that the provisions of this Agreement comply with Section 409A of the Code (“Section 409A”), and all provisions of the Option shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.
16.Nontransferability.  This Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by Participant except by will or by the laws of descent and distribution.  During Participant’s lifetime, this Option may be exercised only by Participant.
17.Acknowledgement. Participant acknowledges and agrees that Participant has no right to receive any equity compensation following the Date of Grant other than as set forth in this Agreement or otherwise approved by the Board or Compensation Committee on or before the Date of Grant, and that the Option is granted in full satisfaction of Participant’s right, if any, to an equity award under any offer letter, transition letter, or similar letter, agreement, or communication from the Company or any Affiliate.
18.Binding Effect. Subject to the limitations stated above, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.
IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed Participant’s signature hereto.




6







INSMED INCORPORATED


By: /s/ Sara Bonstein
Chief Financial Officer



PARTICIPANT

/s/ /$ParticipantName$/

7


Attachment A
Chief Financial Officer
Insmed Incorporated
700 US Highway 202/206
Bridgewater, NJ 08807
Notice Of Option Exercise
This letter is notice of my decision to exercise the Option that was granted to me on ______________. Terms used but not defined in this notice have the meanings given to them in the Nonqualified Stock Option Inducement Award Agreement between the Company and myself on _______________. The exercise will be effective on _____________. I am exercising the Option for ______________ shares of Common Stock. I have chosen the following form of payment to cover the aggregate Option price for the number of shares for which I am exercising the Option (check one):
[ ]    1.     Cash
    [ ]    2.    Certified or bank check payable to Insmed Incorporated    
    [ ]    3.    Other (please describe):
        ______________________________________________________


Sincerely,


                                                                                   
Name:
Address:


Accepted by:
Date:

Note: The date of exercise cannot be earlier than the date of delivery of this notice or the postmark, if the notice is mailed.
8
 EX-10.2 3 insm-20230321ex102.htm EX-10.2 Document

INSMED INCORPORATED
NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT
No. of shares subject to Option: /$AwardsGranted$/

THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a subsidiary of the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (the “Inducement Award Rule”). If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of Participant’s offer letter or employment agreement with the Company or the applicable subsidiary thereof, dated as of /$HireDate$/ (the “Employment Agreement”), the Employment Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is consistent with the Inducement Award Rule and applicable law.

1.Grant of Option. The Company, on /$GrantDate$/ (the “Date of Grant”), granted to Participant, subject to the terms and conditions herein set forth, the right and option to purchase from the Company all or any part of an aggregate of /$AwardsGranted$/ shares of common stock of the Company, par value US $0.01 per share (the “Common Stock”) at the option price of /$GrantPrice$/ per share, being not less than the closing price of a share of the Company’s Common Stock on the NASDAQ on the Date of Grant (the “Option”). The Option is intended to be a nonqualified stock option and not an “incentive stock option” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). The Option is exercisable as hereinafter provided.
2.Terms and Conditions. The Option is subject to the following terms and conditions:
a.Expiration Date. The Option shall expire ten years from the Date of Grant (the “Expiration Date”).
b.Exercise of Option. Except as provided in paragraphs 3, 4 and 5, the Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to the Option on the first annual anniversary of the Date of Grant (the “First Anniversary Date”) and with respect to twelve and a half percent (12.5%) of the shares of Common Stock subject to the Option on the six-month anniversary of the First Anniversary Date and each six-month anniversary date thereafter through the fourth annual anniversary of the Date of Grant, subject to Participant’s continued employment through each applicable date. If the foregoing schedule would produce fractional shares, the number of shares for which the Option becomes exercisable shall be rounded down to the nearest whole share. Once the Option has become exercisable in accordance with this subparagraph 2(b) it shall continue to be exercisable until the termination of Participant’s rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a). A partial exercise of the Option shall not affect Participant’s right to exercise the Option with respect to the remaining shares, subject to the conditions of this Agreement.
c.Method of Exercising Option and Payment for Shares. The Option shall be exercised by written notice in the form of Attachment A — “Notice of Option Exercise” or such other form as may be approved by the Company, delivered to the attention of the Company’s Chief Financial Officer at the Company’s principal place of business. The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery. Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Compensation Committee of the Company’s Board of


Directors (the “Compensation Committee” and the “Board”), or such other method as determined by the Compensation Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which the Option is being exercised.
d.Agreement with Terms. Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant’s acknowledgement of, and agreement with, all of the provisions of this Agreement, and the Company shall administer this Agreement accordingly.
e.Shareholder Rights. Participant shall not have any rights as a shareholder with respect to shares subject to the Option until Participant exercises such Option and becomes the holder of record of such shares.
f.Forfeiture. In the event of Participant’s termination of employment, any vested portion of the Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5, as applicable, shall be forfeited upon the expiration of such period. Any portion of the Option that is unvested as of the date of Participant’s termination of employment shall be forfeited on such date.
3.Exercise in the Event of Death. In the event Participant dies before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) on the date of Participant’s death. In that event, the Option may be exercised, to the extent exercisable under subparagraph 2(b), by Participant’s estate or by the other person or persons to whom Participant’s rights under the Option shall pass by will or the laws of descent and distribution. Participant’s estate or such persons may exercise the Option within one year after Participant’s death or during the remainder of the period preceding the Expiration Date, whichever is shorter.
4.Exercise in the Event of Permanent and Total Disability. In the event Participant becomes permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (“Permanently and Totally Disabled”) before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) on the date Participant ceases to be employed by the Company or, as determined by the Compensation Committee from time to time, any entity in which the Company has a substantial direct or indirect equity interest (an “Affiliate”), as a result of Participant’s becoming Permanently and Totally Disabled. In that event, Participant may exercise the Option, to the extent exercisable under subparagraph 2(b), within one year after the date Participant ceases to be employed by the Company and its Affiliates as a result of Participant’s becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter.
5.Exercise After Termination of Employment. Except as provided in paragraphs 3 and 4 hereof, if Participant ceases to be employed by the Company and its Affiliates prior to the Expiration Date, the Option shall be exercisable for all or part of the number of shares that Participant was entitled to purchase under subparagraph 2(b) and, if applicable, any additional number of shares specified under the Employment Agreement on the date of Participant’s termination of employment. In that event, Participant may exercise the Option, to the extent exercisable under subparagraph 2(b) and/or under the Employment Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three months (or such other period of time provided under the Employment Agreement, if
2

any) after the date Participant ceases to be employed by the Company and its Affiliates, whichever is shorter.
6.Notice. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to Participant, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.
7.Fractional Shares. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.
8.No Right to Continued Employment. Nothing in this Agreement shall interfere with or limit in any way the right of the Company, its subsidiaries and/or its Affiliates to terminate Participant’s employment at any time or for any reason in accordance with the Company’s Bylaws, governing law and the Employment Agreement, nor shall any terms of this Agreement confer upon Participant any right to continue Participant’s employment for any specified period of time. Neither this Agreement nor any benefits arising under this Agreement shall constitute an employment contract with the Company or any of its subsidiaries or Affiliates.
9.Change in Capital Structure. The terms of the Option (including the number or kind of shares subject hereto and the option price) shall be equitably adjusted as the Compensation Committee determines is equitably required to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Common Stock outstanding. No fractional shares of Common Stock shall be issued pursuant to such an adjustment.
10.Change in Control. The Compensation Committee shall have the discretion to determine the treatment of the Option upon the occurrence of a Change in Control (as defined below). Unless otherwise expressly provided in the Employment Agreement or under the terms of a transaction constituting a Change in Control, the following shall occur upon a Participant’s involuntary termination of employment within twenty-four (24) months following a Change in Control, provided that such termination does not result from the Participant’s termination for disability, cause or gross misconduct: the Option shall immediately become exercisable and shall remain exercisable for three (3) years following such termination (or until the Expiration Date, if earlier). For purposes of this paragraph 10, the following definitions apply, subject to applicable laws to the extent mandatory:
a. “Change in Control” means the occurrence of any one of the following:
i.any Person becomes the beneficial owner (as such term is defined in Rule 13d-3 under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of at least 50% of either (A) the value of the then outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors
3

(the “Outstanding Company Voting Securities”) (the foregoing beneficial ownership hereinafter being referred to as a “Controlling Interest”); provided, however, that for purposes of this definition, the following acquisitions shall not constitute or result in a Change in Control: (v) any acquisition directly from the Company; (w) any acquisition by the Company; (x) any acquisition by any person that as of the Date of Grant has beneficial ownership of a Controlling Interest; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate; or (z) any acquisition by any corporation pursuant to a transaction which complies with subparagraphs 10(b)(iii)(A), (B) and (C) below; or
ii.during any period of two consecutive years (not including any period prior to the Date of Grant) individuals who constitute the Board on the Date of Grant (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
iii.consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any of its subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its subsidiaries (each a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the Persons who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related
4

trust) of the Company or such Acquiring Corporation) beneficially owns, directly or indirectly, more than 50% of the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the board of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or
iv.the complete liquidation or dissolution of the Company.
Notwithstanding the foregoing, to the extent required to avoid the imposition of additional taxes and/or penalties pursuant to Section 409A of the Code, no event or transaction will constitute a Change in Control hereunder unless it also constitutes a “change in control event” under Section 409A of the Code.
b. “Person” has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.
11.Tax Withholding. To the extent required by applicable federal, state, local or foreign law, the Company may and/or Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to the Option, or the issuance or sale of any shares of Common Stock. The Company shall not be required to recognize any Participant rights under the Option, to issue shares of Common Stock or to recognize the disposition of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Company, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of Participant in accordance with applicable law, the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under the Option or any other award held by Participant or by Participant tendering to the Company cash or, if allowed by the Company, shares of Common Stock. Nothing in this Agreement shall be interpreted or construed to transfer any liability for any tax (including, without limitation, a tax or penalty due as a result of a failure to comply with Section 409A of the Code) due by Participant to the Company, any subsidiary thereof or any Affiliate, or to any other individual or entity, and the Company shall have no liability to Participant, or any other party, with respect thereto. Participant acknowledges that the Company and its subsidiaries and Affiliates: (a) make no representations or undertakings regarding the tax treatment in connection with any aspect of the Option and (b) do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate Participant’s tax liabilities.
12.Administration. Any question concerning the interpretation of this Agreement or the Option, any adjustments required to be made to the Option hereunder, and any controversy that may arise with respect to the Option will be determined by the Compensation Committee in its sole and absolute discretion. All decisions by the Compensation Committee shall be final and binding on Participant and Participant’s beneficiaries, heirs and assigns.
5

13.Compliance with Laws and Regulations. Participant hereby acknowledges, represents and warrants to the Company that, unless a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the shares of Common Stock to be received upon the exercise of the Option is effective and current at the time of exercise of the Option, (i) the shares of Common Stock to be issued upon the exercise of the Option will be unregistered and acquired by Participant for Participant’s own account, for investment only and not with a view to the resale or distribution thereof and (ii) the shares of Common Stock to be issued upon the exercise of the Option may not be sold or transferred unless a registration statement under the Securities Act with respect to the resale of such shares is effective and current or such registration is determined by the Company to be unnecessary. Nothing herein shall be construed as requiring the Company to register the shares subject to the Option for sale or resale under the Securities Act. Notwithstanding anything herein to the contrary, if at any time the Company shall determine, in its sole discretion, that the listing or qualification of the shares of Common Stock subject to the Option on any securities exchange or under any applicable law, or the consent or approval of any governmental agency or regulatory body, is necessary or desirable as a condition to, or in connection with, the issuance of shares of Common Stock hereunder, the Option may not be exercised in whole or in part unless such listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company.
14.Governing Law. This Agreement shall be governed by the laws of the Commonwealth of Virginia, without regard to any rule or principle of conflicts of laws that otherwise would result in the application of the substantive laws of another jurisdiction. Any reference in this Agreement to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.
15.Section 409A. It is intended that the provisions of this Agreement comply with Section 409A of the Code (“Section 409A”), and all provisions of the Option shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.
16.Nontransferability.  This Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by Participant except by will or by the laws of descent and distribution.  During Participant’s lifetime, this Option may be exercised only by Participant.
17.Acknowledgement. Participant acknowledges and agrees that Participant has no right to receive any equity compensation following the Date of Grant other than as set forth in this Agreement or otherwise approved by the Board or Compensation Committee on or before the Date of Grant, and that the Option is granted in full satisfaction of Participant’s right, if any, to an equity award under any offer letter, transition letter, or similar letter, agreement or communication from the Company or any Affiliate.
18.Binding Effect. Subject to the limitations stated above, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.
19.Non-U.S. Participant. Notwithstanding the provisions in this Agreement, if Participant resides and/or works outside the United States, the Option shall be subject to the special terms and conditions set forth in Attachment B. Moreover, if Participant relocates to one of the jurisdictions included in Attachment B, the special terms and conditions for such jurisdiction will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.
6

IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed Participant’s signature hereto.




INSMED INCORPORATED


By: /s/ Sara Bonstein
Chief Financial Officer



PARTICIPANT

/s/ /$ParticipantName$/

7


Attachment A
Chief Financial Officer
Insmed Incorporated
700 US Highway 202/206
Bridgewater, NJ 08807
Notice Of Option Exercise
This letter is notice of my decision to exercise the Option that was granted to me on ______________. Terms used but not defined in this notice have the meanings given to them in the Nonqualified Stock Option Inducement Award Agreement between the Company and myself on _______________. The exercise will be effective on _____________. I am exercising the Option for ______________ shares of Common Stock. I have chosen the following form of payment to cover the aggregate Option price for the number of shares for which I am exercising the Option (check one):
[ ]    1.     Cash
    [ ]    2.    Certified or bank check payable to Insmed Incorporated    
    [ ]    3.    Other (please describe):
        ______________________________________________________


Sincerely,


                                                                                   
Name:
Address:


Accepted by:
Date:

Note: The date of exercise cannot be earlier than the date of delivery of this notice or the postmark, if the notice is mailed.

8

Attachment B
SPECIAL TERMS AND CONDITIONS FOR NON-U.S. PARTICIPANTS
This Attachment B includes special terms and conditions that supplement the terms and conditions in the Agreement for any Participant who resides and/or works outside of the United States. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Agreement (of which this Attachment B is a part). The information is general in nature and may not apply to Participant’s particular situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant should seek appropriate professional advice as to how the relevant laws in Participant’s country apply to Participant’s specific situation.
ALL COUNTRIES OUTSIDE THE UNITED STATES
1.Tax Withholding. As a condition to the exercise of the Option, Participant agrees to make adequate provision for all income tax, social insurance, social contribution, payroll tax, fringe benefits tax, payment on account, or other tax-related items related to the Option and legally applicable to Participant (“Tax-Related Items”). Participant acknowledges that, regardless of any action taken by the Company or, if different, any Affiliate of the Company to whom Participant is rendering services (the “Service Recipient”), the ultimate liability for all Tax-Related Items is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company or the Service Recipient. Participant further acknowledges that the Company and/or the Service Recipient (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting, or exercise of the Option; the subsequent sale of shares acquired pursuant to such exercise; and the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if Participant is subject to Tax-Related Items in more than one jurisdiction, Participant acknowledges that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction. Prior to the relevant taxable or tax withholding event, as applicable, Participant agrees to make adequate arrangements satisfactory to the Company and/or the Service Recipient to satisfy all Tax-Related Items. In this regard, Participant authorizes the Company and/or the Service Recipient, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by (to the maximum extent permitted by applicable law): (i) requiring a cash payment paid by Participant; (ii) withholding from Participant’s wages or other cash compensation paid to Participant by the Company and/or any Affiliate of the Company; (iii) withholding from proceeds of the sale of shares acquired at exercise of the Option either through a broker-assisted cashless exercise (provided that a public market for the Common Stock exists) or other voluntary sale, mandatory sale, or other cashless exercise method arranged by the Company (in each case on Participant’s behalf pursuant to this authorization and without further consent); and/or (iv) withholding from the shares to be issued upon exercise. Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case Participant will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent. If the obligation for Tax-Related Items is satisfied by withholding shares, for tax purposes, Participant is deemed to have been issued the full number of shares subject to the exercised Option, notwithstanding that a number of the shares are held back solely for the purpose of paying the Tax-Related Items. Finally, Participant agrees to pay to the Company and/or the Service Recipient any amount of Tax-Related Items that the Company
9

and/or the Service Recipient may be required to withhold or account for as a result of the Option that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the shares or the proceeds of the sale of shares if Participant fails to comply with Participant’s obligations in connection with the Tax-Related Items.
2.Not a Public Offering. The grant of the Option is not intended to be a public offering of securities in Participant’s country of employment (or country of residence, if different). The Company has not submitted any registration statement, prospectus, or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Option is not subject to the supervision of the local securities authorities.
3.No Advice Regarding Option. Investment in shares of the Company’s Common Stock involves a degree of risk. Before deciding to acquire shares by exercising the Option, Participant should carefully consider all risk factors relevant to the acquisition of shares of the Company’s Common Stock and carefully review all of the materials related to the Option. The Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendations regarding Participant’s participation in the Agreement, or Participant’s acquisition or sale of the shares underlying the Option. Participant is hereby advised to consult with Participant’s own personal tax, legal, and financial advisors regarding Participant’s participation in the Agreement before taking any action related to the Option.
4.Language. If Participant has received this Agreement, or any other document related to this Option, translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
5.Termination of Service. For purposes of the Option, Participant’s service will be considered terminated as of the earlier of (i) the date Participant receives notice of termination from the Company or Service Recipient or (ii) the date Participant is no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is engaged or the terms of the Employment Agreement) and, unless otherwise expressly provided in the Agreement or determined by the Company, Participant’s right to vest in the Option under the Agreement, if any, will terminate as of such date and will not be extended by any notice period (e.g., Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws or other laws in the jurisdiction where Participant is engaged). The Company shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of the Option (including whether Participant may still be considered to be providing services while on an approved leave of absence). Notwithstanding the foregoing, if applicable local law explicitly requires continued vesting during a statutory notice period, Participant’s right to vest in the Option under the Agreement, if any, will terminate effective as of the last day of Participant’s minimum statutory notice period.
6.Imposition of Additional Requirements; Repatriation; Compliance with Law. The grant of the Option and the issuance and delivery of shares under the Option are subject to all applicable laws, rules, and regulations and to such approvals by any governmental agencies or securities exchange as may be required. Notwithstanding any provision of the Agreement, the Company has no liability to deliver any shares under the Option or make any payment unless such delivery or payment would comply with all laws and the applicable requirements of any governmental agency, securities exchange, or similar entity, and unless and until Participant has taken all actions required by the Company in connection with the Option. The Company reserves the right to impose other requirements on the Option and on the shares acquired upon the exercise of the Option to the extent the Company determines it is
10

necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Participant agrees to repatriate all payments attributable to the shares and/or cash acquired under the Option in accordance with applicable foreign exchange rules and regulations in Participant’s country of employment (and country of residence, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Company and any of its affiliates, as may be required to allow the Company and any of its Affiliates to comply with local laws, rules, and/or regulations in Participant’s country of employment (and country of residence, if different). Finally, Participant agrees to take any and all actions as may be required to comply with Participant’s personal obligations under local laws, rules, and/or regulations in Participant’s country of employment (and country of residence, if different). Neither the Company nor any of its Affiliates shall be liable for any costs, fines, or penalties resulting from Participant’s failure to comply with such personal obligations.
7.Foreign Asset and Account Reporting. Participant’s country of employment (and country of residence, if different) may have certain exchange control and/or foreign asset/account reporting requirements which may affect Participant’s ability to acquire or hold shares under the Option or cash received in connection with the Option (including from any dividends received or sale proceeds resulting from the sale of shares) in a brokerage or bank account outside of Participant’s country. Participant may be required to report such accounts, assets, or transactions to the tax or other authorities in Participant’s country. Participant acknowledges that it is Participant’s responsibility to comply with any applicable regulations, and that Participant should speak to Participant’s personal advisor on this matter.
8.Acknowledgements. In accepting the Option, Participant acknowledges and agrees that:
a.the grant of the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of stock options, or benefits in lieu of stock options, even if stock options or other awards have been granted in the past;
b.all decisions with respect to future awards, if any, will be at the sole discretion of the Company;
c.Participant’s participation in the Agreement is voluntary;
d.the Option and Participant’s participation in the Agreement shall not create a right to employment or service or be interpreted as forming an employment contract with the Company or any of its Affiliates and shall not interfere with the ability of the Company or any of its Affiliates to terminate Participant’s employment relationship (as otherwise may be permitted under local law);
e.the Option and any shares acquired under the Option and the income and value of the same are not part of normal or expected compensation or remuneration for any purpose;
f.the future value of the shares underlying the Option is unknown, indeterminable, and cannot be predicted with certainty;
g.if the shares underlying the Option do not increase in value, the Option will have no value;
11

h.if Participant exercises the Option and acquires the underlying shares, the value of such shares may increase or decrease in value, even below the exercise price;
i.no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from termination of Participant’s employment (for any reason whatsoever and whether or not in breach of applicable laws or later found invalid) and, in consideration of the Option, Participant agrees not to institute any claim against the Company or any of its Affiliates;
j.the Option and the benefits evidenced by the Agreement do not create any entitlement not otherwise specifically provided for in the Agreement or provided by the Company in its discretion, to have the Option or any such benefits transferred to, or assumed by, another company, nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Common Stock; and
k.neither the Company nor any of its Affiliates shall be liable for any foreign exchange rate fluctuation between Participant’s local currency and the U.S. dollar that may affect the value of the Option or any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of any shares acquired upon exercise of the Option. To the extent the Company determines that a currency exchange or conversion is necessary in connection with the exercise of the Option or any other matter, such exchange shall be calculated and determined by the Company in its sole discretion, and the Company’s determination shall be final and binding.
ALL COUNTRIES IN THE EUROPEAN UNION
Participant understands and acknowledges that the Company shall collect, use, and transfer Participant’s personal information for the purpose of implementing the Agreement and administering Participant’s participation in the Option in accordance with the Insmed EU Employee Personal Data Processing Notice, a copy of which has been appended to the Agreement, if applicable to Participant.

12

AUSTRALIA
1.Securities Law Information. The offer of the Option is intended to comply with the provisions of the Corporations Act 2001, Australian Securities and Investments Commission (“ASIC”) Regulatory Guide 49 and/or ASIC Class Order CO 14/1000. If Participant acquires shares under the Option and offers such shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. Participant should obtain legal advice on disclosure obligations prior to making any such offer.
2.Breach of Law. Notwithstanding anything to the contrary in the Agreement, Participant will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Agreement if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.
3.Tax Information. The Option is an award to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in such Act).
BELGIUM
1.Tax Information. The Participant agrees and acknowledges that the Company will only accept a countersigned Agreement after the 60th day following the Participant’s receipt of the Agreement. By formally accepting in writing the Agreement through signature and by returning it to the Company within 60 days from receipt of the Agreement, the Participant would normally become subject to income tax on a lump-sum benefit in kind on the 60th day following receipt of the Agreement (being the “grant date” for Belgian tax purposes). In that case, no taxation should be triggered upon vesting or exercise. However, if written acceptance and return of the Agreement would take place after the 60th day following receipt of the Agreement, as required by the Company, taxation will normally be delayed to the date of exercise of this Option. In that case, grant or vesting should not trigger taxation.

CANADA
1.Data Privacy. Participant hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Agreement and the Option. Participant further authorizes the Company and any of its Affiliates and the Compensation Committee to disclose and discuss the Agreement and the Option with their advisors. Participant further authorizes the Company and any of its Affiliates to record such information and to keep such information in Participant’s employee file.
2.English Language Consent - Quebec. The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given, or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.
Les parties reconnaissent avoir expressement souhaité que la convention (le « Agreement »), ainsi que tous les documents, avis et procédures judiciaries, éxecutés, donnés ou intentés en vertu de, ou lié, directement ou indirectement à la présente convention, soient rédigés en langue anglaise.
FRANCE
13

1.Non-Qualification of Award. The Option is not intended to be tax qualified under French tax laws including, without limitation, under Articles L. 225-197-1 to L. 225-197-6 of the French Commercial Code.
2.Language Consent. In accepting the grant of the Option and this Agreement which provides for the terms and conditions of the Option, the Participant confirms that he or she has read and understood the documents relating to the Option (this Agreement), which were provided in the English language. The Participant accepts the terms of these documents accordingly.
Consentement Relatif à la Langue Utilisée. En acceptant cette attribution gratuite d’actions et ce contrat qui contient les termes et conditions de cette attribution gratuite d’actions, l’employé confirme ainsi avoir lu et compris les documents relatifs à cette attribution (le Contrat d’Attribution) qui lui ont été communiqués en langue anglaise. L’employé en accepte les termes en connaissance de cause.
GERMANY
No specific provisions.
IRELAND
No specific provisions.
ITALY
No specific provisions.
JAPAN
No specific provisions.
NETHERLANDS
image_0a.jpg
1.Waiver of Termination Rights. Participant hereby waives any and all rights to compensation or damages as a result of Participant’s termination of employment with the Company and its Affiliates for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Option, or (ii) Participant’s ceasing to have rights under the Option as a result of such termination.
PORTUGAL
No specific provisions.
SWITZERLAND
14

1.Securities Law Information. Neither this Agreement nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than the Participant, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (“FINMA”).
UNITED KINGDOM
1.Data Privacy. Participant understands and acknowledges that the Company shall collect, use, and transfer Participant’s personal information for the purpose of implementing the Agreement and administering Participant’s participation in the Option in accordance with the Insmed UK Employee Personal Data Processing Notice, a copy of which has been appended to the Agreement, if applicable to Participant.
2.National Insurance Contributions. The Company may require, as a condition of the exercise of the Option, that Participant shall, to the extent applicable:
a.agree to reimburse the Company in whole or in part for any employer’s secondary national insurance contributions arising on the exercise of the Option; or
b.enter into an election with the Company to assume in whole or part the liability for any secondary Class 1 national insurance contributions, payable on the exercise of the Option, including an election under paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992; or
c.agree to pay the employer’s national insurance contributions, social security contributions, and other levies and taxes arising on the exercise of the Option to the extent permitted by law, in any other jurisdiction.
3.Section 431 Election. Participant agrees that, if requested to do so by the Company, Participant shall immediately upon the exercise of the Option enter into an irrevocable joint election with the Company pursuant to section 431 of the U.K. Income Tax (Earnings and Pensions) Act 2003 (“ITEPA”) in a form specified by the Company that, for the relevant tax purposes, the market value of the share acquired is to be calculated as if the share were not restricted securities (as defined in section 423 of ITEPA) and sections 425 to 430 of ITEPA shall not apply to such shares.
4.Outstanding Amounts. If Participant fails to make payment to the Company in accordance with the “Tax Withholding” paragraph under the “All Countries Outside the United States” section of this Attachment B immediately upon request, Participant shall be liable to make good any amount outstanding on demand.


15

PERSONAL DATA PROCESSING- EMPLOYEE NOTICE (IRELAND ONLY)
As your employer, Insmed Ireland Ltd, with registered office in Dublin (the “Company”) collects, uses and discloses personal information relating to you. The Company is committed to ensure that your personal information will be handled in accordance with all applicable data protection laws.

The information that the Company holds on you, collected in both paper and electronic format, is limited to what is necessary in the context of your employment.

Such information includes:
•personal details (name, contact details, date and place of birth, nationality, gender, marital status, family members, bank account information, social security number);
•employment information (also embedded in the employment contract: employment date, job description, function/title, reporting);
•compensation (salary, bonus, equity, benefits, holidays);
•recruitment process (application documents, CV, compensation history, employment agreement);
•business expense reports;
•performance appraisals/ratings;
•holidays and sickness leave, and any other personal data strictly required by applicable laws and regulations.

The Company collects and holds personal information relating to you for the purposes of:
•the justification, implementation and termination of the employment agreement, both during and after your employment with the Company, including salary and benefits administration;
•compliance with laws and regulations, including labour, social security and health laws; and;
•the Company’s legitimate interests, including employee management and administration generally (both during and after your employment), evaluating performances, administrating and monitoring compliance with internal policies, conducting disciplinary investigations and proceedings, and maintaining and monitoring usage of internal networks and IT systems.

You should be aware that in certain instances the Company may need to transfer or disclose your personal information to third parties, including third party service providers. Common examples of third party service providers are payroll processors, IT companies, and companies that provide technical or administrative support. Other third parties may include other Insmed entities, regulatory authorities (including tax authorities) and government agencies, banks and insurance companies, and, potentially, third parties with whom the Company may merge or which may be acquired by the Company. These third parties and Insmed entities may be located in countries, such as the United States (for instance Insmed Incorporated), whose data protection laws may not be equivalent to those applicable in your own country. The Company, however, put in place contractual guarantees to ensure an appropriate level of protection. For more information and a copy, please contact: privacy@insmed.com.



Subject to limitation in the law, you have certain rights in respect of your personal information, such as a right of access, correction, restriction, opposition and deletion. Your personal information will be retained as long as required, in compliance with company policy and retention obligations imposed by law.

Should you have any questions or concerns in connection with the Company’s handling of your personal information, your first point of contact is: Mariela Pochon, Director Human resources EMEA or Hortense de Lummen, Legal Counsel EMEA.

16

Legal is your first point of contact regarding data privacy topics.

Also, at Insmed, an external Data Protection Officer (DPO) is appointed. This means that if our first point of contact (as indicated above) is not suitable in your case, you can directly contact our DPO:

Dr. Oliver Meyer-van Raay
Tel.: +49 721 / 17029034
E-Mail: om@v-formation.gmbh

DPO’s address details are:
V-Formation GmbH
Stephanienstrasse 18
76133 Karlsruhe, Germany

Requests concerning the handling of your employee data will be treated by DPO on a confidential basis if so requested.

If you still have concerns, you have a right to lodge a complaint with the Supervisory Authority for data protection in your country.

17





PERSONAL DATA PROCESSING- EMPLOYEE NOTICE (UNITED KINGDOM ONLY)
As your employer, Insmed Ltd, with registered office in London (the “Company”) collects, uses and discloses personal information relating to you. The Company is committed to ensure that your personal information will be handled in accordance with all applicable data protection laws.

The information that the Company holds on you, collected in both paper and electronic format, is limited to what is necessary in the context of your employment.

Such information includes:
•personal details (name, contact details, date and place of birth, nationality, gender, marital status, family members, bank account information, social security number);
•employment information (also embedded in the employment contract: employment date, job description, function/title, reporting);
•compensation (salary, bonus, equity, benefits, holidays);
•recruitment process (application documents, CV, compensation history, employment agreement);
•business expense reports;
•performance appraisals/ratings;
•holidays and sickness leave, and any other personal data strictly required by applicable laws and regulations.

The Company collects and holds personal information relating to you for the purposes of:
•the justification, implementation and termination of the employment agreement, both during and after your employment with the Company, including salary and benefits administration;
•compliance with laws and regulations, including labour, social security and health laws; and;
•the Company’s legitimate interests, including employee management and administration generally (both during and after your employment), evaluating performances, administrating and monitoring compliance with internal policies, conducting disciplinary investigations and proceedings, and maintaining and monitoring usage of internal networks and IT systems.

You should be aware that in certain instances the Company may need to transfer or disclose your personal information to third parties, including third party service providers. Common examples of third party service providers are payroll processors, IT companies, and companies that provide technical or administrative support. Other third parties may include other Insmed entities, regulatory authorities (including tax authorities) and government agencies, banks and insurance companies, and, potentially, third parties with whom the Company may merge or which may be acquired by the Company. These third parties and Insmed entities may be located in countries, such as the United States (for instance Insmed Incorporated), whose data protection laws may not be equivalent to those applicable in your own country. The Company, however, put in place contractual guarantees to ensure an appropriate level of protection. For more information and a copy, please contact: privacy@insmed.com.


18

Subject to limitation in the law, you have certain rights in respect of your personal information, such as a right of access, correction, restriction, opposition and deletion. Your personal information will be retained as long as required, in compliance with company policy and retention obligations imposed by law. Should you have any questions or concerns in connection with the Company’s handling of your personal information, please consult with Johannes Diependaal, Senior Director EU Operations or Christel Rössig, Senior Director Corporate Counsel & Compliance EU. If you still have concerns, you have a right to lodge a complaint with the Supervisory Authority for data protection in your country.







19
 EX-31.1 4 insm-20230331ex311.htm EX-31.1 Document

EXHIBIT 31.1
 
Section 302 Certification
 
I, William H. Lewis, Chief Executive Officer of Insmed Incorporated, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 4, 2023

 
 
/s/ William H. Lewis
William H. Lewis
Chair and Chief Executive Officer
(Principal Executive Officer)
 



 EX-31.2 5 insm-20230331ex312.htm EX-31.2 Document

EXHIBIT 31.2
 
Section 302 Certification
 
I, Sara Bonstein, Chief Financial Officer of Insmed Incorporated, certify that:

(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 4, 2023
 
/s/ Sara Bonstein
Sara Bonstein
Chief Financial Officer
(Principal Financial and Accounting Officer)
 


 EX-32.1 6 insm-20230331ex321.htm EX-32.1 Document

EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003
 
In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the "Company") for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, William H. Lewis, Chief Executive Officer of the Company, certify, pursuant to 18 USC. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2003, that:
 
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ William H. Lewis
William H. Lewis
Chairman and Chief Executive Officer
(Principal Executive Officer)

May 4, 2023
 
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


 EX-32.2 7 insm-20230331ex322.htm EX-32.2 Document

EXHIBIT 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003
 
In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the "Company") for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Sara Bonstein, Chief Financial Officer of the Company, certify, pursuant to 18 USC. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2003, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Sara Bonstein
Sara Bonstein
Chief Financial Officer
(Principal Financial and Accounting Officer)

May 4, 2023
 
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
 


 EX-101.SCH 8 insm-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Intangibles, Net and Goodwill link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fixed Assets, Net link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Royalty Financing Agreement link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Intangibles, Net and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Fixed Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Royalty Financing Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - The Company and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Product Revenues, Net - Product Revenues By Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Inventory - Schedule of Inventory, Current (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Intangibles, Net and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Fixed Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Leases - Lease, costs (Details) (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Debt - Components of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Debt - Future Principal Repayments of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Debt - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Royalty Financing Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Acquisitions - Summary of Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 insm-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 insm-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 insm-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Non-cash operating lease expense Noncash Operating Lease Expense Noncash Operating Lease Expense Business Acquisition [Axis] Business Acquisition [Axis] Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Term Loan Long-Term Debt, Gross Customer A Customer A [Member] Customer A [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Finance lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Debt Instrument Conversion Term [Axis] Debt Instrument Conversion Term [Axis] Debt Instrument Conversion Term [Axis] Europe and rest of world Europe And The Rest Of The World [Member] Europe And The Rest Of The World Property, Plant and Equipment [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Unrealized gain (loss) on marketable securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent 2025 Long-Term Debt, Maturity, Year Two Royalty Financing Agreement Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block] Acquisitions Business Combinations Policy [Policy Text Block] Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] Fixed assets, gross Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Revenue from Contract with Customer, Product and Service [Extensible List] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Additional paid-in capital Additional Paid in Capital Debt Instrument Conversion Term [Domain] Debt Instrument Conversion Term [Domain] [Domain] for Debt Instrument Conversion Term [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table] Schedule of Earnings Per Share, Basic and Diluted [Table] Schedule of Earnings Per Share, Basic and Diluted [Table] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Interest rate Debt Instrument, Basis Spread on Variable Rate Range [Domain] Statistical Measurement [Domain] Depreciation Depreciation Issuance of common stock for vesting of RSUs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Proceeds from issuance of 0.75% convertible senior notes due 2028 Debt Instrument, Interest Rate, Stated Percentage Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-Based Payment Arrangement [Abstract] Probabilities of success Measurement Input, Probability Of Success [Member] Measurement Input, Probability Of Success Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Issuance of common stock for business acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Amended and Restated Plan Amended and Restated Plan [Member] Amended and Restated Plan Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Measurement Input Type [Domain] Measurement Input Type [Domain] Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Leases Lessee, Finance Leases [Text Block] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Face value of outstanding convertible notes Secured Debt Schedule of Future Principal Repayments of Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Secured Debt Secured Debt [Member] Discount rate Measurement Input, Discount Rate [Member] Deferred and contingent consideration from Business Acquisition Business Combination, Deferred Payments, Current Business Combination, Deferred Payments, Current Leases Lessee, Operating Leases [Text Block] Royalty financing agreement Royalty financing agreement - beginning balance Royalty financing agreement - ending balance Accrued Royalties Finance lease amortization expense Finance Lease, Right-of-Use Asset, Amortization Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Term Loan Term Loan [Member] Term Loan Change in Fair Value Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Weighted average common shares used in calculation of basic net loss per share: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Share price used to calculate issuable shares (in dollars per share) Business Acquisition, Share Price Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Unrecognized compensation expense related to unvested RSU awards Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Inducement stock options granted to new employees (in shares) Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross Gross number of inducement share options (or share units) granted during the period. Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Consecutive trading day period Business Acquisition, Consecutive Trading Day Period Business Acquisition, Consecutive Trading Day Period Level 1 Fair Value, Inputs, Level 1 [Member] Dilutive securities, convertible debt (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share Schedule of Weighted Average Number of Shares [Table Text Block] Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Royalty financing non-cash interest expense Other Noncash Expense Operating lease liabilities Operating Lease, Liability, Current Lease, Cost [Abstract] Lease, Cost [Abstract] Acquired IPR&D In Process Research and Development [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Receivables [Abstract] Liability Class [Axis] Liability Class [Axis] Debt, long-term Debt, long-term Long-Term Debt, Excluding Current Maturities Royalty Financing Agreement [Roll Forward] Royalty Financing Agreement [Roll Forward] Royalty Financing Agreement Total liabilities Liabilities Royalty maximum Debt Instrument, Royalty Payable, Maximum Debt Instrument, Royalty Payable, Maximum Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Fixed Assets Property, Plant and Equipment [Table Text Block] Current available-for-sale securities Debt Securities, Available-for-Sale, Current Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Estimated Useful Life (years) Property, Plant and Equipment, Useful Life Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accrued France ATU reimbursement payable Contract with Customer, Refund Liability, Current Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Conversion Term (iv) Debt Instrument, Conversion Term Four [Member] Debt Instrument, Conversion Term Four [Member] Segments [Axis] Segments [Axis] Debt Debt Disclosure [Text Block] Entity Shell Company Entity Shell Company Deferred tax benefit Deferred Income Tax Expense (Benefit) Concentration Risk [Table] Concentration Risk [Table] 2018 ESPP Employee Stock Purchase Plan 2018 [Member] Employee Stock Purchase Plan 2018 [Member] Shares issued in acquisition (in shares) Shares of Insmed common stock issuable on July 1, 2024 (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Stock options and RSUs Stock Options And Restricted Stock Units [Member] Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received. 2026 Long-Term Debt, Maturity, Year Three Finite-lived Intangible Assets [Roll Forward] Finite-Lived Intangible Assets [Roll Forward] Milestone Event 2 Milestone Event 2 [Member] Milestone Event 2 Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date First anniversary of closing date Share-Based Payment Arrangement, Tranche One [Member] Business Combination, Deferred Consideration Liability, Measurement Input Business Combination, Deferred Consideration Liability, Measurement Input Business Combination, Deferred Consideration Liability, Measurement Input Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Total assets Assets Debt Disclosure [Abstract] Net loss per share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Third anniversary of closing date Share-Based Payment Arrangement, Tranche Three [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] PSUs Performance options Performance Shares [Member] Additions Finite-Lived Intangible Assets Acquired Accrued Liabilities, Current Accrued Liabilities, Current [Member] Accrued Liabilities, Current Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Convertible debt contractual interest expense Interest Expense, Debt Accrued compensation and employee related costs Employee-related Liabilities, Current Variable lease, cost Variable Lease, Cost Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Segments [Domain] Segments [Domain] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Amortization of debt issuance costs Amortization of Debt Issuance Costs and Discounts Customer [Axis] Customer [Axis] Proceeds from loans Proceeds from Loans Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Finance lease liabilities, long-term Finance Lease, Liability, Noncurrent Collateral for interest rate swap Derivative Liability, Collateral, Fair Value Derivative Liability, Collateral, Fair Value Lease cost, future right-of-use asset Lessee, Operating Lease, Lease Not Yet Commenced, Amount Lessee, Operating Lease, Lease Not Yet Commenced, Amount Equity Award [Domain] Award Type [Domain] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Remaining discount amortization period (in years) Convertible Debt Instrument, Discount Amortization Period, Remaining Convertible Debt Instrument, Discount Amortization Period, Remaining Manufacturing equipment Manufacturing Equipment [Member] Manufacturing Equipment Schedule of Earnings Per Share, Basic and Diluted [Line Items] Schedule of Earnings Per Share, Basic and Diluted [Line Items] [Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table] Rollforward of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Cash paid in acquisition Payments to Acquire Businesses, Gross 0.75% convertible senior notes due 2028 Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member] Zero Point Seven Five Percent Convertible Senior Note Due 2028 Entity Registrant Name Entity Registrant Name Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Operating expenses: Operating Expenses [Abstract] Issuance of common stock for vesting of RSUs Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Minimum Minimum [Member] Initial conversion rate Debt Instrument, Convertible, Conversion Ratio Customer C Customer C [Member] Customer C [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Change in fair value of interest rate swap Change in fair value of interest rate swap Unrealized Gain (Loss) on Derivatives Unamortized debt issuance costs Debt issuance costs, unamortized Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Accrued technical operation expenses Accrued Technical Operation Expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses. Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Trading Symbol Trading Symbol Entity File Number Entity File Number Convertible debt securities Convertible Debt Securities [Member] Intangibles, Net and Goodwill Intangible Assets Disclosure [Text Block] Closing share price (in dollars per share) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share Amortization of intangible assets, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accrued interest payable Interest Payable, Current Research and development Research and Development Expense Lab equipment Equipment [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Derivatives Derivatives, Policy [Policy Text Block] RS and RSUs Unvested restricted stock and RSUs Restricted Stock Units (RSUs) [Member] Number of publicly disclosed priority review voucher sales Number of Publicly Disclosed Priority Review Voucher Sales Number of Publicly Disclosed Priority Review Voucher Sales Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Shares issued upon milestone achievements (in shares) Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Acquisitions Business Combination Disclosure [Text Block] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Concentration risk, percentage Concentration Risk, Percentage Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Lenders fees and deal expenses Debt Instrument, Fee Amount Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves AlgaeneX AlgaeneX, Inc. [Member] AlgaeneX, Inc. Credit Facility [Domain] Credit Facility [Domain] Amortization of intangible assets Amortization Amortization of Intangible Assets Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basic net loss per share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Basic Proceeds from royalty financing Proceeds From Royalty Financing Proceeds From Royalty Financing Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total shareholders’ (deficit) equity Balance Balance Stockholders' Equity Attributable to Parent Finance right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Vesting [Domain] Vesting [Domain] Equity Interest Issued or Issuable, Type [Domain] Equity Interest Issued or Issuable, Type [Domain] Royalty revenue payments Payments for Royalties Entity Interactive Data Current Entity Interactive Data Current Shares sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Customer B Customer B [Member] Customer B [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Amortization of intangible assets, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accumulated Deficit Retained Earnings [Member] Unrecognized compensation expense related to unvested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Common stock authorized, aggregate gross sales proceeds (up to) Common Stock Authorized, Aggregate Gross Sales Proceeds Common Stock Authorized, Aggregate Gross Sales Proceeds Common Stock Common Stock [Member] Summary of Allocation of Employee Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Royalty Agreements Royalty Agreements [Member] Exercise of stock options and ESPP shares Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Summary of Supplemental Noncash Disclosures included in Consolidated Financial Statements Lease, Cost [Table Text Block] Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Contingent consideration Consideration, beginning balance Consideration, ending balance Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Issuance of common stock for asset acquisition Stock Issued During Period, Value, Acquisitions Potential payout percentage Potential Payout Percentage Potential Payout Percentage Document Quarterly Report Document Quarterly Report Proceeds from royalty financing agreement, net Proceeds From Royalty Financing Agreement, Net Proceeds From Royalty Financing Agreement, Net Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent 2019 Incentive Plan, Second Amendment 2019 Incentive Plan, Second Amendment [Member] 2019 Incentive Plan, Second Amendment Summary of Observable Inputs in Valuation of Deferred Consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Payments Payment for Contingent Consideration Liability, Financing Activities Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Option to purchase additional debt Debt Instrument, Option To Purchase Additional Debt Debt Instrument, Option To Purchase Additional Debt Leasehold improvements Leasehold Improvements [Member] Product Revenues By Geographic Location Revenue from External Customers by Geographic Areas [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Net proceeds Proceeds from Convertible Debt Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchase of marketable securities Payments to Acquire Marketable Securities Convertible senior notes Convertible Debt, Fair Value Disclosures Equity Components [Axis] Equity Components [Axis] Recurring basis Fair Value, Recurring [Member] Brensocatib Global Net Sales Brensocatib Global Net Sales [Member] Brensocatib Global Net Sales Conversion Term (iii) Debt Instrument, Conversion Term Three [Member] Debt Instrument, Conversion Term Three [Member] Document Fiscal Year Focus Document Fiscal Year Focus Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Payments of finance lease principal Finance Lease, Principal Payments Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Accounts payable and accrued liabilities Accounts Payable and Other Accrued Liabilities, Current Triggering Event [Axis] Triggering Event [Axis] Triggering Event Variable Rate [Domain] Variable Rate [Domain] Intangibles, gross Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Motus and AlgaeneX Motus Biosciences, Inc. And AlgaeneX, Inc. [Member] Motus Biosciences, Inc. And AlgaeneX, Inc. Vertuis acquisition Noncash Acquisition Related Expense Noncash Acquisition Related Expense Change in fair value of deferred and contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Accrued royalty and milestones payable Accrued Royalties, Current Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Rent expense charged to operations Operating Lease, Expense Document Transition Report Document Transition Report Local Phone Number Local Phone Number Operating loss Operating Income (Loss) Inventory Increase (Decrease) in Inventories Recently Adopted Accounting Pronouncements and New Accounting Pronouncements (Not Yet Adopted) New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, outstanding shares (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Unrealized loss Debt Securities, Available-for-Sale, Unrealized Loss Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Additional Paid-in Capital Additional Paid-in Capital [Member] Triggering Event [Domain] Triggering Event [Domain] Triggering Event [Domain] PARI milestones Licensing Agreements [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cost of product revenues (excluding amortization of intangible assets) Cost of Goods and Services Sold Weighted average diluted common shares outstanding (in shares) Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Indefinite-lived intangible assets, Finite-lived Intangible Assets, Impairment Assessment, and Goodwill Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Marketable securities Marketable Securities Common stock, $0.01 par value; 500,000,000 authorized shares, 136,429,216 and 135,653,731 issued and outstanding shares at March 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Carrying Value Reported Value Measurement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Carrying Value and Fair Value of Assets and Liabilities Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Convertible Debt Convertible Debt [Member] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Remaining shares sold offering price Sale Of Stock, Remaining Authorized Amount Sale Of Stock, Remaining Authorized Amount Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Share Price Measurement Input, Share Price [Member] Current liabilities: Liabilities, Current [Abstract] Proceeds from exercise of stock options and ESPP Proceeds from Stock Options Exercised Net loss Net Income (Loss) Available to Common Stockholders, Basic Common stock, issued shares (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Public Stock Offering Public Stock Offering [Member] Public Stock Offering Finance lease interest expense Finance Lease, Interest Expense Income Statement Location [Domain] Income Statement Location [Domain] Swap interest income Interest Expense, Other Finance lease liabilities Finance Lease, Liability, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Intangible assets estimated useful life Finite-Lived Intangible Asset, Useful Life Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Original Term Loan balance Face amount Debt Instrument, Face Amount Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Year Ending December 31: Long-Term Debt, Fiscal Year Maturity [Abstract] Potential award payout Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Additions Liabilities, Fair Value Adjustment Japan JAPAN Debt Instrument, Percent Of Interest Payable Debt Instrument, Percent Of Interest Payable Debt Instrument, Percent Of Interest Payable Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Summary of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Liabilities Liabilities [Abstract] Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Fixed assets, net Fixed assets, net Property, Plant and Equipment, Net Office equipment Office Equipment [Member] Common stock options Share-Based Payment Arrangement, Option [Member] Other assets Increase (Decrease) in Other Noncurrent Assets Total Long-Term Debt Other expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Offering price per share (in dollars per share) Sale of Stock, Price Per Share Common stock, authorized shares (in shares) Common Stock, Shares Authorized Contingent consideration Non-current contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Milestone Event 1 Milestone Event 1 [Member] Milestone Event 1 Inventory and Cost of Product Revenues (excluding amortization of intangible assets) Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block] Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) Cash paid for income taxes Income Taxes Paid, Net Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Balance (in shares) Balance (in shares) Shares, Outstanding Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Number of reporting units Number of Reporting Units Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Intangibles, net Intangibles, net Finite-Lived Intangible Assets, Net ATM Program At The Market Agreement [Member] At The Market Agreement Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Schedule of Carrying Value of Term Loan Balance Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Fixed Assets, Net Property, Plant and Equipment Disclosure [Text Block] Paid-in-kind interest capitalized Paid-in-Kind Interest Accrued professional fees Accrued Professional Fees Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Remaining lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security The Company and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Repurchased amount Debt Instrument, Repurchase Amount Total operating expenses Costs and Expenses Payables and Accruals [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Royalty revenue payable Royalty Revenue Payable Royalty Revenue Payable Class of Stock [Line Items] Class of Stock [Line Items] Exercise of stock options and ESPP shares (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Payment of debt issuance costs Payments of Debt Issuance Costs Amortization of intangible assets, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Foreign currency translation loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Development and regulatory milestones Development And Regulatory Milestones [Member] Development And Regulatory Milestones Motus Motus Biosciences, Inc. [Member] Motus Biosciences, Inc. Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Aggregate net proceeds from stock offering Sale of Stock, Consideration Received on Transaction Inventory Inventory, Net Inventory, Net Accounts payable and other accrued operating expenses Accounts Payable, Current Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Threshold percent of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Milestone Event 3 Milestone Event 3 [Member] Milestone Event 3 2027 Long-Term Debt, Maturity, Year Four Sales Revenue, Product Line Revenue, Product and Service Benchmark [Member] Acquired ARIKAYCE R&D Acquired Research And Development [Member] Acquired Research And Development Convertible notes Convertible debt securities Convertible Notes Payable [Member] Entity Filer Category Entity Filer Category Weighted average basic common shares outstanding (in shares) Weighted average common shares used in calculation of basic net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic US UNITED STATES Residual equity component of debt Debt Instrument, Convertible, Carrying Amount of Equity Component Paid-in-kind interest capitalized Accumulated Capitalized Interest Costs Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Interest rate swap Interest Rate Derivative Liabilities, at Fair Value Vertuis Bio, Inc. Vertuis Bio, Inc. [Member] Vertuis Bio, Inc. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Components of Debt Balance Carrying Value of Royalty Financing Agreement Schedule of Debt [Table Text Block] Selling, general and administrative General and Administrative Expense [Member] Product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Share price used to calculate issuable shares (in dollars per share) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Common stock shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Percentage of outstanding shares Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Other assets Other Assets Work-in-process Inventory, Work in Process, Net of Reserves Product Revenues, Net Revenue from Contract with Customer [Text Block] Interest payments Debt Instrument, Periodic Payment, Interest Total liabilities and shareholders’ equity Liabilities and Equity Royalty revenue payable Increase (Decrease) in Royalties Payable Debt term (in months) Debt Instrument, Term Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Amortization of debt issuance costs Amortization of issuance costs Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Dilutive securities, share-based payment (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Accrued clinical trial expenses Accrued Clinical Trial Expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses. Level 2 Fair Value, Inputs, Level 2 [Member] Debt Debt, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Unrecognized tax benefits, interest and penalties accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Deferred consideration Business Combination, Deferred Liability Business Combination, Deferred Liability Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Computer hardware and software Computer Hardware And Software [Member] Computer Hardware And Software Marketable securities Marketable Securities, Current Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Vesting [Axis] Vesting [Axis] Diluted net loss per share (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Second anniversary of closing date Share-Based Payment Arrangement, Tranche Two [Member] Payments of stock issuance costs Payments of Stock Issuance Costs Stock compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current 2019 Incentive Plan 2019 Incentive Plan, Third Amendment [Member] 2019 Incentive Plan, Third Amendment Customer Concentration Risk Customer Concentration Risk [Member] Total debt interest expense Interest Expense, Excluding Finance Lease Interest Expense Interest Expense, Excluding Finance Lease Interest Expense Royalty percentage Debt Instrument, Royalty, Stated Percentage Debt Instrument, Royalty, Stated Percentage Cumulative impact of ASU adoption 2020-06 Cumulative Effect, Period of Adoption, Adjustment [Member] Entity Address, Address Line One Entity Address, Address Line One Over-Allotment Option Over-Allotment Option [Member] Conversion Term (ii) Debt Instrument, Conversion Term Two [Member] Debt Instrument, Conversion Term Two [Member] Fair Value Disclosures [Abstract] Interest expense Total interest expense Non-cash interest expense Interest Expense Credit Facility [Axis] Credit Facility [Axis] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] 1.75% convertible senior notes due 2025 One Point Seven Five Percent Convertible Senior Note Due 2025 [Member] One Point Seven Five Percent Convertible Senior Note Due 2025 [Member] Inventory Inventory Disclosure [Text Block] Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Equity [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Shares of common stock, maximum authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Term Loan issuance costs, unamortized Unamortized Debt Issuance Expense Conversion Term (i) Debt Instrument, Conversion Term One [Member] Debt Instrument, Conversion Term One [Member] ARIKAYCE Global Net Sales ARIKAYCE Global Net Sales [Member] ARIKAYCE Global Net Sales Threshold trading days following fundamental change Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change Deferred tax liabilities Deferred Tax Liabilities, Gross Revenue from Contract with Customer [Abstract] Amortization of intangible assets, 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Percent of sales Percent Of Sales Percent Of Sales Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Values Weighted average probability of success Business Combination, Contingent Consideration, Liability, Measurement Input Equity Interest Type [Axis] Equity Interest Type [Axis] 2028 and thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Investment income Investment Income, Nonoperating Entity Central Index Key Entity Central Index Key Variable Rate Component Two Variable Rate Component Two [Member] Variable Rate Component Two Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Aggregate value Business Combination, Consideration Transferred Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other accrued liabilities Other Accrued Liabilities, Current Measurement Input Type [Axis] Measurement Input Type [Axis] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Selling, general and administrative General and Administrative Expense Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] 2024 Long-Term Debt, Maturity, Year One Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Other long-term liabilities Other Liabilities, Noncurrent Other liabilities Increase (Decrease) in Other Operating Liabilities Purchase of fixed assets Payments to Acquire Property, Plant, and Equipment Priority review voucher milestone Priority Review Voucher Milestone [Member] Priority Review Voucher Milestone Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Accrued sales allowances and related costs Accrued Sales Allowances and Related Costs Accrued Sales Allowances and Related Costs Amortization of intangible assets, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Customer [Domain] Customer [Domain] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Product [Member] EX-101.PRE 12 insm-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 image_0a.jpg begin 644 image_0a.jpg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

"CS1N \BCE2P-%^XP#&6CB L3#%T)]G(@Y@3!2?BV+B.4P<$EF M>.[DMP1?],@!#%"L$0Y@3+""SQW < !C.<*;', 4D*.)2YNX_H&.-,Y=[XZ M@ '88H\

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

0QPN*J='E3,WS.E/;((#F \U,0RC,6HD@,8]ZB8 MWVXJ*%3%JL4-ZX<#&(EI31S Z(YB9-S\NIE2W#A" $-.YSP 17_+P[G$0RVO MT27"(,MT<"O)=+V/!URZ0> ;^RQ"%;1DZK MZ@6PN\4AIS2W0+DNYUABI49PJ%4+ B<\[PZP*7CS,EZ^Y+!EBD,8-QB&)8;$ M82;./WS\."5UB"1ALS"6XB4%+R[%(>&=E'PP<$A+A_SX^7-*\B7)F<7B/9H; M$B"R26>EY:08X'&*"\X 2RN#DR:IHQ8+\-J(T9$AD8^/#QPY0X F_C9"],:\)8()OE,B[%9?*,G#)&FA\+X]N M YS=,K2XX(B3L$F]>LE$#QS>G,)RL\RZ#XEKH"S@N_#7FS><5@/L$"RS^.*..>0OOYRS20. M238JGL>!P08G#TDH_RFPBC,FQ M[O+9PI$@\+&W[]XR??GZ94J<+[?QJ"E%XAR12:I"C M$>L;AG<,0WZ)T.%1B?_N]9VCCL-[@%\6G!0_8@!#JL\1+M7G#LAIQ;$TP 5< M_Q/*8E#SA<.DO85C$C;U6.;4\!OFV+Q[]WY*LL9R ,7P0P3W-9P4E^.][0X)8/#F5U05%CR0248F))8\'PW! Y30=$I=!60>TA\QR\!Y&C@VALR(TE8-S M]^4G*S'_5Y:[PP#_4UJ+^X_!,^WG\7_+=HW+X\J\J[!.< !C1_2W//S:X1&* M%S077+\=P(BP96394B^ W2T.N9+R,T..X-57I0,8TUAR .-OXJ1XZ@ &*$QK MX@#&A#@)FY0#& UPQGUU (,=%Z$I5#!^IU+"Q]XY@)$3QEGS]1^7?0( QI18WPL',( XY$K*SPPY M@E=?E0Y@3&/) 8R_B9/BJ0,8H#"MB0,8$^(D;%(.8#3 &??5 0QV7(2F4,'X MG4H)'WOG $9.&&?-UW]<]AW R,8/<0 C(SB/EU)L0 .( !',#XE^$WS+%Q &-'(A&5F%CR># ,!U1.TPL',$Z$ Q@]PS/M9P

D!NU(@#&%-B?2\

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htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2023
May 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 000-30739  
Entity Registrant Name INSMED INC  
Entity Incorporation, State or Country Code VA  
Entity Tax Identification Number 54-1972729  
Entity Address, Address Line One 700 US Highway 202/206  
Entity Address, City or Town Bridgewater  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08807  
City Area Code 908  
Local Phone Number 977-9900  
Title of 12(b) Security Common stock, par value $0.01 per share  
Trading Symbol INSM  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   136,432,799
Entity Central Index Key 0001104506  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 968,907 $ 1,074,036
Marketable securities 29,774 74,244
Accounts receivable 30,523 29,713
Inventory 71,317 69,922
Prepaid expenses and other current assets 28,542 25,468
Total current assets 1,129,063 1,273,383
Fixed assets, net 59,556 56,491
Finance lease right-of-use assets 23,019 23,697
Operating lease right-of-use assets 21,154 21,894
Intangibles, net 67,493 68,756
Goodwill 136,110 136,110
Other assets 81,322 76,104
Total assets 1,517,717 1,656,435
Current liabilities:    
Accounts payable and accrued liabilities 179,005 182,117
Finance lease liabilities 2,158 1,217
Operating lease liabilities 6,821 6,909
Total current liabilities 187,984 190,243
Debt, long-term 1,132,188 1,125,250
Royalty financing agreement 150,173 148,015
Contingent consideration 38,600 51,100
Finance lease liabilities, long-term 29,015 29,636
Operating lease liabilities, long-term 14,534 14,853
Other long-term liabilities 9,876 9,387
Total liabilities 1,562,370 1,568,484
Shareholders’ equity:    
Common stock, $0.01 par value; 500,000,000 authorized shares, 136,429,216 and 135,653,731 issued and outstanding shares at March 31, 2023 and December 31, 2022, respectively 1,364 1,357
Additional paid-in capital 2,809,242 2,782,416
Accumulated deficit (2,856,342) (2,696,578)
Accumulated other comprehensive income 1,083 756
Total shareholders’ (deficit) equity (44,653) 87,951
Total liabilities and shareholders’ equity $ 1,517,717 $ 1,656,435
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 500,000,000 500,000,000
Common stock, issued shares (in shares) 136,429,216 135,653,731
Common stock, outstanding shares (in shares) 136,429,216 135,653,731
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Product revenues, net $ 65,214 $ 53,107
Revenue from Contract with Customer, Product and Service [Extensible List] Product [Member] Product [Member]
Operating expenses:    
Cost of product revenues (excluding amortization of intangible assets) $ 13,830 $ 12,191
Cost, Product and Service [Extensible List] Product [Member] Product [Member]
Research and development $ 127,865 $ 84,356
Selling, general and administrative 79,914 56,748
Amortization of intangible assets 1,263 1,263
Change in fair value of deferred and contingent consideration liabilities (9,500) (11,618)
Total operating expenses 213,372 142,940
Operating loss (148,158) (89,833)
Investment income 10,524 137
Interest expense (20,003) (3,291)
Change in fair value of interest rate swap (1,533) 0
Other expense, net (111) (1,249)
Loss before income taxes (159,281) (94,236)
Provision for income taxes 483 385
Net loss $ (159,764) $ (94,621)
Basic net loss per share (in dollars per share) $ (1.17) $ (0.80)
Diluted net loss per share (in dollars per share) $ (1.17) $ (0.80)
Weighted average basic common shares outstanding (in shares) 136,355 118,929
Weighted average diluted common shares outstanding (in shares) 136,355 118,929
Net loss $ (159,764) $ (94,621)
Other comprehensive income (loss):    
Foreign currency translation loss (171) (494)
Unrealized gain (loss) on marketable securities 498 (704)
Total comprehensive loss $ (159,437) $ (95,819)
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Shareholders' Equity (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative impact of ASU adoption 2020-06
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative impact of ASU adoption 2020-06
Accumulated Deficit
Accumulated Deficit
Cumulative impact of ASU adoption 2020-06
Accumulated Other Comprehensive Income (Loss)
Balance (in shares) at Dec. 31, 2021     118,738          
Balance at Dec. 31, 2021 $ 410,468 $ (214,410) $ 1,187 $ 2,673,556 $ (264,609) $ (2,265,243) $ 50,199 $ 968
Comprehensive loss:                
Net loss (94,621)         (94,621)    
Other comprehensive loss (1,198)             (1,198)
Exercise of stock options and ESPP shares (in shares)     450          
Exercise of stock options and ESPP shares 6,816   $ 4 6,812        
Issuance of common stock for vesting of RSUs (in shares)     158          
Issuance of common stock for vesting of RSUs 2   $ 2          
Stock compensation expense 12,823     12,823        
Balance (in shares) at Mar. 31, 2022     119,346          
Balance at Mar. 31, 2022 119,880   $ 1,193 2,428,582   (2,309,665)   (230)
Balance (in shares) at Dec. 31, 2022     135,654          
Balance at Dec. 31, 2022 87,951   $ 1,357 2,782,416   (2,696,578)   756
Comprehensive loss:                
Net loss (159,764)         (159,764)    
Other comprehensive loss 327             327
Exercise of stock options and ESPP shares (in shares)     82          
Exercise of stock options and ESPP shares 1,139   $ 1 1,138        
Issuance of common stock for vesting of RSUs (in shares)     193          
Issuance of common stock for vesting of RSUs 1   $ 1          
Issuance of common stock for business acquisition (in shares)     500          
Issuance of common stock for asset acquisition 9,250   $ 5 9,245        
Stock compensation expense 16,443     16,443        
Balance (in shares) at Mar. 31, 2023     136,429          
Balance at Mar. 31, 2023 $ (44,653)   $ 1,364 $ 2,809,242   $ (2,856,342)   $ 1,083
Comprehensive loss:                
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06              
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Net loss $ (159,764) $ (94,621)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,248 1,286
Amortization of intangible assets 1,263 1,263
Stock-based compensation expense 16,443 12,823
Amortization of debt issuance costs 1,724 822
Paid-in-kind interest capitalized 5,456 0
Royalty financing non-cash interest expense 2,615 0
Finance lease amortization expense 678 729
Non-cash operating lease expense 2,491 2,369
Change in fair value of deferred and contingent consideration liabilities (9,500) (11,618)
Change in fair value of interest rate swap 1,533 0
Vertuis acquisition 10,250 0
Changes in operating assets and liabilities:    
Accounts receivable (860) (1,798)
Inventory (1,187) 2,240
Prepaid expenses and other current assets (3,199) (2,752)
Other assets (5,231) (6,289)
Accounts payable and accrued liabilities (8,841) 13,363
Other liabilities (1,422) (22,978)
Net cash used in operating activities (146,303) (105,161)
Investing activities    
Purchase of fixed assets (3,398) (1,701)
Purchase of marketable securities 0 (99,706)
Maturities of marketable securities 45,000 0
Net cash provided by (used in) investing activities 41,602 (101,407)
Financing activities    
Proceeds from exercise of stock options and ESPP 1,139 6,818
Payments of finance lease principal (320) (359)
Payment of debt issuance costs (1,218) 0
Net cash (used in) provided by financing activities (399) 6,459
Effect of exchange rates on cash and cash equivalents (29) (969)
Net decrease in cash and cash equivalents (105,129) (201,078)
Cash and cash equivalents at beginning of period 1,074,036 716,782
Cash and cash equivalents at end of period 968,907 515,704
Supplemental disclosures of cash flow information:    
Cash paid for interest 11,589 2,375
Cash paid for income taxes $ 1,004 $ 635
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.1
The Company and Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company and Basis of Presentation
1. The Company and Basis of Presentation
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE® (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib, treprostinil palmitil inhalation powder (TPIP) and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company is also advancing its early-stage research programs encompassing a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, and protein manufacturing.
The Company was incorporated in the Commonwealth of Virginia on November 29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan.
The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
     The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.
     The Company had $968.9 million in cash and cash equivalents and $29.8 million of marketable securities as of March 31, 2023 and reported a net loss of $159.8 million for the three months ended March 31, 2023. The Company has funded its operations through public offerings of equity securities, debt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.
The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company’s commercial, regulatory and development activities. Any future financing will also be contingent upon market conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2022:
Use of Estimates - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.
Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.
The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.
March 31,
20232022
Customer A36%36%
Customer B36%32%
Customer C17%17%
The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.
Inventory and Cost of Product Revenues (excluding amortization of intangible assets) - Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. See Note 5 - Inventory for further details. Inventory used for clinical development purposes is expensed to R&D expense when consumed.
Acquisitions - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create
outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with Accounting Standards Codification (ASC) 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. See Note 16 - Acquisitions for further information.
Indefinite-lived intangible assets - Indefinite-lived intangible assets consist of IPR&D. IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1. See Note 6 - Intangibles, Net and Goodwill for further details.
Finite-lived Intangible Assets - Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See Note 6 - Intangibles, Net and Goodwill for further details.
Impairment Assessment - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.
Goodwill - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2023. See Note 6 - Intangibles, Net and Goodwill for further details.
Leases - A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.
Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See Note 9 - Leases for further details.
Foreign Currency - The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' (deficit) equity, as a component of accumulated other comprehensive income.
The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.
Debt Issuance Costs - Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Synthetic Royalty Financing Agreement - In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty & Credit Opportunities IV, LP (OrbiMed). The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See Note - 11 Royalty Financing Agreement for further details.
Derivatives - In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.
Net Loss Per Share - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.
The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2023 and 2022:
 
 Three Months Ended March 31,
 20232022
 
Numerator:  
Net loss$(159,764)$(94,621)
Denominator:  
Weighted average common shares used in calculation of basic net loss per share:136,355 118,929 
Effect of dilutive securities:  
Common stock options— — 
RS and RSUs— — 
PSUs— — 
Convertible debt securities— — 
Weighted average common shares outstanding used in calculation of diluted net loss per share136,355 118,929 
Net loss per share:  
Basic and diluted$(1.17)$(0.80)
The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2023 and 2022, respectively, as their effect would have been anti-dilutive (in thousands):
 
March 31,
 20232022
Common stock options19,156 15,282 
Unvested restricted stock and RSUs2,058 1,163 
PSUs671 679 
Convertible debt securities23,438 23,438 
Recently Adopted Accounting Pronouncements - In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt — Accounting for Convertible Instruments, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 is effective for fiscal years beginning
after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by approximately $221.9 million, increasing issuance costs classified to debt by $6.1 million, decreasing the deferred tax liability by $1.4 million, and increasing retained earnings by $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements
3. Fair Value Measurements
The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:
•Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
•Level 2 — Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
•Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
March 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$968.9 $968.9 $— $— 
Marketable securities$29.8 $29.8 $— $— 
Collateral for interest rate swap$5.0 $5.0 $— $— 
Liabilities
Interest rate swap$3.1 $— $3.1 $— 
Deferred consideration$6.2 $— $6.2 $— 
Contingent consideration$49.8 $— $— $49.8 
December 31, 2022
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$1,074.0 $1,074.0 $— $— 
Marketable securities$74.2 $74.2 $— $— 
Collateral for interest rate swap$5.0 $5.0 $— $— 
Liabilities
Interest rate swap$1.5 $— $1.5 $— 
Deferred consideration$7.4 $— $7.4 $— 
Contingent consideration$58.1 $— $— $58.1 
The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of March 31, 2023 and December 31, 2022. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March 31, 2023.
As of March 31, 2023, the Company held $29.8 million of current available-for-sale securities, net of an unrealized loss of $0.2 million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.
The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the three months ended March 31, 2023.
Deferred Consideration
The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022, the Company fulfilled the payment due on the first anniversary of the closing date by issuing 171,427 shares of the Company's common stock, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation.
The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within 12 months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2023, the fair value of deferred consideration included in accounts payable and accrued liabilities was $3.1 million. Deferred consideration expected to be settled in more than 12 months is classified as a non-current liability within other long-term liabilities. As of March 31, 2023, the fair value of deferred consideration included in other long-term liabilities was $3.1 million.
The following observable input was used in the valuation of the deferred consideration as of March 31, 2023:
Fair Value as of March 31, 2023 (in millions)
Observable InputInput Value
Deferred consideration
$6.2
Insmed share price as of March 31, 2023
$17.05
Contingent Consideration
The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 16). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At March 31, 2023, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.
If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash.
The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of March 31, 2023, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.
The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within 12 months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2023, the fair value of contingent consideration included in accounts payable and accrued liabilities was $11.2 million. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of March 31, 2023, the fair value of non-current contingent consideration was $38.6 million.
Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability in the consolidated balance sheet. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.
The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2023:

Fair Value as of March 31, 2023 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$41.2Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$6.2Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
12.3%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2023 and 2022 (in thousands):
Deferred Consideration (Level 2 Liabilities)Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2021$14,931 $75,668 
Additions— — 
Change in Fair Value(2,070)(9,548)
Payments— — 
Balance as of March 31, 2022$12,861 $66,120 
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value(1,200)(8,300)
Payments— — 
Balance as of March 31, 2023$6,200 $49,800 
Convertible Notes
The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility, and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.
The estimated fair value of the liability component of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2023 was $446.5 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.
The estimated fair value of the liability component of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2023 was $202.3 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. See Note 10 - Debt for further details on the Company's convertible notes.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Product Revenues, Net
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Product Revenues, Net
4. Product Revenues, Net
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.
Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.
The following table presents a summary of the Company's product revenues, net, by geographic location for the three months ended March 31, 2023 and 2022 (in thousands):
Three Months Ended March 31,
20232022
US$49,067 $40,782 
Japan13,156 10,676 
Europe and rest of world2,991 1,649 
  Total product revenues, net$65,214 $53,107 
Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.
Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.
Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.
Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.
If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.
The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventory
5. Inventory
As of March 31, 2023 and December 31, 2022, the Company's inventory balance consists of the following (in thousands):
March 31, 2023December 31, 2022
Raw materials$24,553 $27,245 
Work-in-process20,166 22,460 
Finished goods26,598 20,217 
$71,317 $69,922 
The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles, Net and Goodwill
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net and Goodwill
6. Intangibles, Net and Goodwill
 Intangibles, Net
Finite-lived Intangible Assets
As of March 31, 2023, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D and the milestones paid to PARI for the license to use Lamira for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestones intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.
Indefinite-lived Intangible Assets
As of March 31, 2023, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition (Note 16). Indefinite-lived intangible assets are not amortized.
A rollforward of the Company's intangible assets for the three months ended March 31, 2023 and March 31, 2022 is as follows (in thousands):
Intangible AssetDecember 31, 2022AdditionsAmortization
March 31, 2023
Acquired ARIKAYCE R&D$37,588 $— $(1,212)$36,376 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (51)1,517 
$68,756 $— $(1,263)$67,493 
Intangible AssetDecember 31, 2021AdditionsAmortization
March 31, 2022
Acquired ARIKAYCE R&D$42,439 $— $(1,212)$41,227 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,770 — (51)1,719 
$73,809 $— $(1,263)$72,546 
Goodwill
The Company's goodwill balance of $136.1 million as of March 31, 2023 and December 31, 2022, resulted from the August 2021 Business Acquisition. See Note 16 - Acquisitions for further details.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed Assets, Net
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Fixed Assets, Net
7. Fixed Assets, Net
Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):
Estimated
Useful Life (years)		As of
Asset DescriptionMarch 31, 2023December 31, 2022
Lab equipment7$18,982 $16,403 
Furniture and fixtures76,428 6,428 
Computer hardware and software
3-5
5,695 5,227 
Office equipment789 89 
Manufacturing equipment71,336 1,203 
Leasehold improvements
2-10
37,042 37,057 
Construction in progress—30,662 29,529 
100,234 95,936 
Less: accumulated depreciation(40,678)(39,445)
$59,556 $56,491 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Accounts Payable and Accrued Liabilities
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities
8. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
As of
March 31, 2023December 31, 2022
Accounts payable and other accrued operating expenses$56,670 $50,461 
Accrued clinical trial expenses26,607 36,456 
Accrued professional fees18,242 14,403 
Accrued technical operation expenses6,734 3,345 
Accrued compensation and employee related costs18,867 32,040 
Accrued royalty and milestones payable6,165 4,710 
Accrued interest payable2,270 6,340 
Royalty revenue payable2,608 2,149 
Accrued sales allowances and related costs11,762 6,974 
Accrued France ATU reimbursement payable12,945 12,943 
Deferred and contingent consideration from Business Acquisition14,300 10,700 
Other accrued liabilities1,835 1,596 
$179,005 $182,117 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Leases
9. Leases
The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease
and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.
The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.
The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $0.1 million and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20232022
Finance right-of-use assets obtained in exchange for lease obligations$— $9,287 
Operating right-of-use assets obtained in exchange for lease obligations$1,751 $341 
In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $42.5 million and $40.7 million incurred by the Company under these additional agreements have been classified within other assets in the Company's consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.
Leases
9. Leases
The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease
and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.
The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.
The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $0.1 million and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20232022
Finance right-of-use assets obtained in exchange for lease obligations$— $9,287 
Operating right-of-use assets obtained in exchange for lease obligations$1,751 $341 
In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $42.5 million and $40.7 million incurred by the Company under these additional agreements have been classified within other assets in the Company's consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Debt
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Debt
10. Debt
Debt, long-term consists of the following commitments as of March 31, 2023 and December 31, 2022 (in thousands):
As of
March 31, 2023December 31, 2022
Convertible notes$786,443 $785,621 
Term Loan345,745 339,629 
Debt, long-term$1,132,188 $1,125,250 
Convertible Notes
In May 2021, the Company completed an underwritten public offering of the 2028 Convertible Notes, in which the Company sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7 million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased.
In January 2018, the Company completed an underwritten public offering of the 2025 Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased.
A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.
On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.
Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a) the second business day immediately preceding the related redemption date or (b) if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes.
Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources that utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity’s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9 million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6 million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4 million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December 31, 2021, prior to the adoption of ASU 2020-06. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 1.79 years and 5.17 years, respectively.
The $563.3 million carrying value of the 2028 Convertible Notes as of March 31, 2023 excludes $11.7 million of unamortized debt issuance costs. The $223.2 million carrying value of the 2025 Convertible Notes as of March 31, 2023 excludes $1.8 million of unamortized debt issuance costs. The following table presents the carrying value of the Company's debt balance (in thousands):
 
As of
March 31, 2023December 31, 2022
Face value of outstanding convertible notes$800,000 $800,000 
Debt issuance costs, unamortized(13,557)(14,379)
Debt, long-term$786,443 $785,621 
Secured Senior Term Loan
In October 2022, the Company entered into a $350 million senior secured term loan agreement with Pharmakon Advisors LP, manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. During the three months ended March 31, 2023, paid-in-kind interest capitalized was $5.5 million. Net proceeds from the Term Loan, after deducting the lenders fees and deal expenses of $15.2 million, were $334.8 million.
The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2023 (in thousands):
As of
March 31, 2023December 31, 2022
Original Term Loan balance$350,000 $350,000 
Paid-in-kind interest capitalized9,621 4,165 
Term Loan issuance costs, unamortized(13,876)(14,536)
Term Loan$345,745 $339,629 
As of March 31, 2023, future principal repayments of debt for each of the years through maturity were as follows (in thousands):
 
Year Ending December 31: 
2023$— 
2024— 
2025225,000 
2026179,811 
2027179,810 
2028 and thereafter575,000 
 $1,159,621 
Interest Expense
Interest expense related to debt and finance leases for the three months ended March 31, 2023 and 2022 is as follows (in thousands):
Three Months Ended March 31,
20232022
Convertible debt contractual interest expense$2,063 $2,063 
Term Loan contractual interest expense10,911 — 
Royalty Financing Agreement non-cash interest expense4,764 — 
Amortization of debt issuance costs1,724 822 
Swap interest income(73)— 
   Total debt interest expense19,389 2,885 
Finance lease interest expense614 406 
   Total interest expense$20,003 $3,291 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Financing Agreement
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Royalty Financing Agreement
11. Royalty Financing Agreement
In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by us to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders fees and deal expenses of $3.8 million were, $146.2 million.
The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective
interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be 12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. 
The following table presents a rollforward of the carrying value of the Company’s Royalty Financing Agreement balance for the three months ended March 31, 2023 (in thousands):

 Royalty financing agreement - beginning balance $148,015 
      Royalty revenue payments 2,017 
      Royalty revenue payable (2,608)
      Amortization of issuance costs134 
      Non-cash interest expense 2,615 
 Liability related to the sale of future royalties - ending balance $150,173 
Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss. Royalty revenue payable is recorded within accounts payable and accrued liabilities on the consolidated balance sheet.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Shareholders' Equity
12. Shareholders' Equity
Common Stock — As of March 31, 2023, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 136,429,216 shares of common stock issued and outstanding. In addition, as of March 31, 2023, the Company had reserved 19,155,595 shares of common stock for issuance upon the exercise of outstanding stock options, 2,057,694 shares of common stock for issuance upon the vesting of RSUs and 671,112 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430 shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved 9,406,112 shares of the Company’s common stock, subject to certain closing-related reductions. The shares of the Company’s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first anniversary of the closing date of the acquisition, and will also be issued upon the second and third anniversaries of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company’s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.
Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (Note 16) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition.
In connection with the Company’s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved 550,000 shares of the Company’s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. An additional $1 million of shares of common stock will be issued to Vertuis’ former stockholders on July 1, 2024, based on the share price on June 28, 2024. See Note 16 - Acquisitions for further details.
In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.
In the second quarter of 2021, the Company completed an underwritten public offering of 11,500,000 shares of the Company's common stock, including 1,500,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, at a public offering price of $25.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $17.5 million, were $270.1 million.
In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as SVB Securities LLC) (SVB Securities), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an “at the market” equity offering program (the ATM program), under which SVB Securities acts as sales agent. During the third quarter of 2022, the Company issued and sold an aggregate of 1,289,995 shares of common stock through the ATM program at a weighted-average public offering price of $26.68 per share and received net
proceeds of $33.4 million. As of March 31, 2023, an aggregate of $215.6 million of shares of common stock remain available to be issued and sold under the ATM program.
Preferred Stock — As of March 31, 2023, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
13. Stock-Based Compensation
The Company's current equity compensation plan, the Insmed Incorporated 2019 Incentive Plan (as amended, the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders in May 2019. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. On May 16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the Company's 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. On May 12, 2021, at the Company's 2021 Annual Meeting of Shareholders, the Company's shareholders approved the second amendment to the 2019 Incentive Plan providing for the issuance of an additional 2,750,000 shares under the plan. On May 11, 2022, at the Company's 2022 Annual Meeting of Shareholders, the Company's shareholders approved the third amendment to the 2019 Incentive Plan, providing for the issuance of an additional 3,000,000 shares under the plan. The Company has submitted a proposal to its shareholders to approve an Amended and Restated 2019 Incentive Plan at the 2023 Annual Meeting of Shareholders (the Amended and Restated Plan). The Amended and Restated Plan, if approved, will provide for the issuance of an additional 10,500,000 shares under the plan. As of March 31, 2023, 245,789 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the three months ended March 31, 2023, the Company granted inducement stock options covering 484,390 shares of the Company's common stock to new employees.
On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i) 1,000,000 shares of common stock, plus (ii) commencing on January 1, 2019 and ending on December 31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C) an amount determined by the administrator.
Stock Options — As of March 31, 2023, there was $116.5 million of unrecognized compensation expense related to unvested stock options.
As of March 31, 2023, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria.
Restricted Stock Units — As of March 31, 2023, there was $35.3 million of unrecognized compensation expense related to unvested RSU awards.
Performance Stock Units — As of March 31, 2023, there were 268,442 PSUs outstanding with an unrecognized compensation expense of $10.5 million of unrecognized compensation expense related to unvested PSU awards, which assumes a payout of 100% of the target.
The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2023 and 2022, respectively (in millions): 
 Three Months Ended March 31,
 20232022
Research and development$7.9 $5.6 
Selling, general and administrative8.5 7.2 
Total$16.4 $12.8 
There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three months ended March 31, 2023 or March 31, 2022, as the performance conditions associated with the PSU awards were not probable as of either date.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
14. Income Taxes
The Company recorded a provision for income taxes of $0.5 million and $0.4 million for the three months ended March 31, 2023 and 2022, respectively. The provisions recorded for the three months ended March 31, 2023 and 2022 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.
The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company’s federal tax returns for the years ended 2019 and later, generally open for certain states for the years 2018 and later, and generally open for international jurisdictions for the years 2017 and later. The Company has incurred net operating losses since inception, except for the year ended December 31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of March 31, 2023 and December 31, 2022, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US. However, given the Company’s valuation allowance position, these reserves do not have an impact on the balance sheet as of March 31, 2023 and December 31, 2022 or the consolidated statements of comprehensive loss for the three months ended March 31, 2023 and 2022. The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
15. Commitments and Contingencies
Rent expense charged to operations was $2.2 million and $2.0 million for the three months ended March 31, 2023 and 2022, respectively.
Legal Proceedings
From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions
16. Acquisitions
Asset Acquisition
In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to Vertuis’ former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 with an aggregate value of $1.0 million, based on the share price on June 28, 2024, and pay to the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions.
The shares of the Company’s common stock issuable to the Vertuis equityholders are being issued pursuant to Section 4(a)(2) of the Securities Act of 1933.
The following table summarizes the purchase price (in millions).
Shares of Insmed common stock issued on closing$9.25 
Shares of Insmed common stock issuable on July 1, 20241.00 
  Total purchase price$10.25 
The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.
Business Combination
On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company’s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company’s common stock, following certain closing-related reductions, to Motus’s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35 million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022, the Company fulfilled the payment due on the first anniversary of the closing date by issuing 171,427 shares of the Company's common stock, after certain reductions.
At the closing of the Company’s acquisition of AlgaeneX, the Company paid $1.5 million in cash to AlgaeneX’s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company’s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX’s manufacturing technology, in each case, subject to certain reductions.
The shares of the Company’s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.
The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.
Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5 million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.
The fair value of IPR&D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&D assets will be determined based on the
anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates Use of Estimates - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.
Concentration of Credit Risk
Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.
The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.
March 31,
20232022
Customer A36%36%
Customer B36%32%
Customer C17%17%
The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.
Inventory and Cost of Product Revenues (excluding amortization of intangible assets)
Inventory and Cost of Product Revenues (excluding amortization of intangible assets) - Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.
Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. See Note 5 - Inventory for further details. Inventory used for clinical development purposes is expensed to R&D expense when consumed.
Acquisitions Acquisitions - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create
outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with Accounting Standards Codification (ASC) 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.
The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.
If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.
Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. See Note 16 - Acquisitions for further information.
Indefinite-lived intangible assets, Finite-lived Intangible Assets, Impairment Assessment, and Goodwill
Indefinite-lived intangible assets - Indefinite-lived intangible assets consist of IPR&D. IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1. See Note 6 - Intangibles, Net and Goodwill for further details.
Finite-lived Intangible Assets - Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See Note 6 - Intangibles, Net and Goodwill for further details.
Impairment Assessment - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.
Goodwill - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2023. See Note 6 - Intangibles, Net and Goodwill for further details.
Leases
Leases - A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.
Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See Note 9 - Leases for further details.
Foreign Currency
Foreign Currency - The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' (deficit) equity, as a component of accumulated other comprehensive income.
The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.
Debt
Debt Issuance Costs - Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.
Synthetic Royalty Financing Agreement - In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty & Credit Opportunities IV, LP (OrbiMed). The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See Note - 11 Royalty Financing Agreement for further details.
Derivatives Derivatives - In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.
Net Loss Per Share Net Loss Per Share - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.
Recently Adopted Accounting Pronouncements and New Accounting Pronouncements (Not Yet Adopted) Recently Adopted Accounting Pronouncements - In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt — Accounting for Convertible Instruments, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by approximately $221.9 million, increasing issuance costs classified to debt by $6.1 million, decreasing the deferred tax liability by $1.4 million, and increasing retained earnings by $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.
Revenue Recognition
In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.
Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.
March 31,
20232022
Customer A36%36%
Customer B36%32%
Customer C17%17%
Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share
The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2023 and 2022:
 
 Three Months Ended March 31,
 20232022
 
Numerator:  
Net loss$(159,764)$(94,621)
Denominator:  
Weighted average common shares used in calculation of basic net loss per share:136,355 118,929 
Effect of dilutive securities:  
Common stock options— — 
RS and RSUs— — 
PSUs— — 
Convertible debt securities— — 
Weighted average common shares outstanding used in calculation of diluted net loss per share136,355 118,929 
Net loss per share:  
Basic and diluted$(1.17)$(0.80)
Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding
The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2023 and 2022, respectively, as their effect would have been anti-dilutive (in thousands):
 
March 31,
 20232022
Common stock options19,156 15,282 
Unvested restricted stock and RSUs2,058 1,163 
PSUs671 679 
Convertible debt securities23,438 23,438 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Carrying Value and Fair Value of Assets and Liabilities
The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):
March 31, 2023
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$968.9 $968.9 $— $— 
Marketable securities$29.8 $29.8 $— $— 
Collateral for interest rate swap$5.0 $5.0 $— $— 
Liabilities
Interest rate swap$3.1 $— $3.1 $— 
Deferred consideration$6.2 $— $6.2 $— 
Contingent consideration$49.8 $— $— $49.8 
December 31, 2022
Fair Value
Carrying ValueLevel 1Level 2Level 3
Assets
Cash and cash equivalents$1,074.0 $1,074.0 $— $— 
Marketable securities$74.2 $74.2 $— $— 
Collateral for interest rate swap$5.0 $5.0 $— $— 
Liabilities
Interest rate swap$1.5 $— $1.5 $— 
Deferred consideration$7.4 $— $7.4 $— 
Contingent consideration$58.1 $— $— $58.1 
Summary of Observable Inputs in Valuation of Deferred Consideration The following observable input was used in the valuation of the deferred consideration as of March 31, 2023:
Fair Value as of March 31, 2023 (in millions)
Observable InputInput Value
Deferred consideration
$6.2
Insmed share price as of March 31, 2023
$17.05
The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2023:

Fair Value as of March 31, 2023 (in millions)
Valuation TechniqueUnobservable InputsValues
Development and regulatory milestones$41.2Probability-adjustedProbabilities of success
14% - 97%
Priority review voucher milestone$6.2Probability-adjusted discounted cash flowProbability of success
16.4%
Discount rate
12.3%
The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2023 and 2022 (in thousands):
Deferred Consideration (Level 2 Liabilities)Contingent Consideration
 (Level 3 Liabilities)
Balance as of December 31, 2021$14,931 $75,668 
Additions— — 
Change in Fair Value(2,070)(9,548)
Payments— — 
Balance as of March 31, 2022$12,861 $66,120 
Balance as of December 31, 2022$7,400 $58,100 
Additions— — 
Change in Fair Value(1,200)(8,300)
Payments— — 
Balance as of March 31, 2023$6,200 $49,800 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Product Revenues, Net (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Product Revenues By Geographic Location The following table presents a summary of the Company's product revenues, net, by geographic location for the three months ended March 31, 2023 and 2022 (in thousands):
Three Months Ended March 31,
20232022
US$49,067 $40,782 
Japan13,156 10,676 
Europe and rest of world2,991 1,649 
  Total product revenues, net$65,214 $53,107 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory (Tables)
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
As of March 31, 2023 and December 31, 2022, the Company's inventory balance consists of the following (in thousands):
March 31, 2023December 31, 2022
Raw materials$24,553 $27,245 
Work-in-process20,166 22,460 
Finished goods26,598 20,217 
$71,317 $69,922 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles, Net and Goodwill (Tables)
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Rollforward of Intangible Assets
A rollforward of the Company's intangible assets for the three months ended March 31, 2023 and March 31, 2022 is as follows (in thousands):
Intangible AssetDecember 31, 2022AdditionsAmortization
March 31, 2023
Acquired ARIKAYCE R&D$37,588 $— $(1,212)$36,376 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (51)1,517 
$68,756 $— $(1,263)$67,493 
Intangible AssetDecember 31, 2021AdditionsAmortization
March 31, 2022
Acquired ARIKAYCE R&D$42,439 $— $(1,212)$41,227 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,770 — (51)1,719 
$73,809 $— $(1,263)$72,546 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed Assets, Net (Tables)
 3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Fixed Assets
Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):
Estimated
Useful Life (years)		As of
Asset DescriptionMarch 31, 2023December 31, 2022
Lab equipment7$18,982 $16,403 
Furniture and fixtures76,428 6,428 
Computer hardware and software
3-5
5,695 5,227 
Office equipment789 89 
Manufacturing equipment71,336 1,203 
Leasehold improvements
2-10
37,042 37,057 
Construction in progress—30,662 29,529 
100,234 95,936 
Less: accumulated depreciation(40,678)(39,445)
$59,556 $56,491 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities (Tables)
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
As of
March 31, 2023December 31, 2022
Accounts payable and other accrued operating expenses$56,670 $50,461 
Accrued clinical trial expenses26,607 36,456 
Accrued professional fees18,242 14,403 
Accrued technical operation expenses6,734 3,345 
Accrued compensation and employee related costs18,867 32,040 
Accrued royalty and milestones payable6,165 4,710 
Accrued interest payable2,270 6,340 
Royalty revenue payable2,608 2,149 
Accrued sales allowances and related costs11,762 6,974 
Accrued France ATU reimbursement payable12,945 12,943 
Deferred and contingent consideration from Business Acquisition14,300 10,700 
Other accrued liabilities1,835 1,596 
$179,005 $182,117 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Summary of Supplemental Noncash Disclosures included in Consolidated Financial Statements
The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):
Three Months Ended March 31,
20232022
Finance right-of-use assets obtained in exchange for lease obligations$— $9,287 
Operating right-of-use assets obtained in exchange for lease obligations$1,751 $341 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Debt (Tables)
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Debt, long-term consists of the following commitments as of March 31, 2023 and December 31, 2022 (in thousands):
As of
March 31, 2023December 31, 2022
Convertible notes$786,443 $785,621 
Term Loan345,745 339,629 
Debt, long-term$1,132,188 $1,125,250 
Components of Debt Balance The following table presents the carrying value of the Company's debt balance (in thousands): 
As of
March 31, 2023December 31, 2022
Face value of outstanding convertible notes$800,000 $800,000 
Debt issuance costs, unamortized(13,557)(14,379)
Debt, long-term$786,443 $785,621 
The following table presents a rollforward of the carrying value of the Company’s Royalty Financing Agreement balance for the three months ended March 31, 2023 (in thousands):

 Royalty financing agreement - beginning balance $148,015 
      Royalty revenue payments 2,017 
      Royalty revenue payable (2,608)
      Amortization of issuance costs134 
      Non-cash interest expense 2,615 
 Liability related to the sale of future royalties - ending balance $150,173 
Schedule of Carrying Value of Term Loan Balance The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2023 (in thousands):
As of
March 31, 2023December 31, 2022
Original Term Loan balance$350,000 $350,000 
Paid-in-kind interest capitalized9,621 4,165 
Term Loan issuance costs, unamortized(13,876)(14,536)
Term Loan$345,745 $339,629 
Schedule of Future Principal Repayments of Debt
As of March 31, 2023, future principal repayments of debt for each of the years through maturity were as follows (in thousands):
 
Year Ending December 31: 
2023$— 
2024— 
2025225,000 
2026179,811 
2027179,810 
2028 and thereafter575,000 
 $1,159,621 
Summary of Interest Expense
Interest expense related to debt and finance leases for the three months ended March 31, 2023 and 2022 is as follows (in thousands):
Three Months Ended March 31,
20232022
Convertible debt contractual interest expense$2,063 $2,063 
Term Loan contractual interest expense10,911 — 
Royalty Financing Agreement non-cash interest expense4,764 — 
Amortization of debt issuance costs1,724 822 
Swap interest income(73)— 
   Total debt interest expense19,389 2,885 
Finance lease interest expense614 406 
   Total interest expense$20,003 $3,291 
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Financing Agreement (Tables)
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Carrying Value of Royalty Financing Agreement The following table presents the carrying value of the Company's debt balance (in thousands): 
As of
March 31, 2023December 31, 2022
Face value of outstanding convertible notes$800,000 $800,000 
Debt issuance costs, unamortized(13,557)(14,379)
Debt, long-term$786,443 $785,621 
The following table presents a rollforward of the carrying value of the Company’s Royalty Financing Agreement balance for the three months ended March 31, 2023 (in thousands):

 Royalty financing agreement - beginning balance $148,015 
      Royalty revenue payments 2,017 
      Royalty revenue payable (2,608)
      Amortization of issuance costs134 
      Non-cash interest expense 2,615 
 Liability related to the sale of future royalties - ending balance $150,173 
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Allocation of Employee Stock-Based Compensation The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2023 and 2022, respectively (in millions): 
 Three Months Ended March 31,
 20232022
Research and development$7.9 $5.6 
Selling, general and administrative8.5 7.2 
Total$16.4 $12.8 
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions (Tables)
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Business Acquisitions, by Acquisition
The following table summarizes the purchase price (in millions).
Shares of Insmed common stock issued on closing$9.25 
Shares of Insmed common stock issuable on July 1, 20241.00 
  Total purchase price$10.25 
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.23.1
The Company and Basis of Presentation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Cash and cash equivalents $ 968,907   $ 1,074,036
Marketable securities 29,800    
Net loss $ (159,764) $ (94,621)  
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Narrative (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
reportingUnit
Dec. 31, 2021
Dec. 31, 2022
USD ($)
Jan. 01, 2022
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Number of reporting units | reportingUnit 1      
Debt, long-term $ 1,132,188   $ 1,125,250  
Accumulated deficit (2,856,342)   (2,696,578)  
Additional paid-in capital $ 2,809,242   $ 2,782,416  
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06 Accounting Standards Update 2020-06    
Accounting Standards Update 2020-06        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Accumulated deficit       $ 50,200
Cumulative impact of ASU adoption 2020-06 | Accounting Standards Update 2020-06        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]        
Debt, long-term       221,900
Unamortized debt issuance costs       6,100
Deferred tax liabilities       1,400
Additional paid-in capital       $ 264,600
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Concentration Risk (Details) - Sales Revenue, Product Line - Customer Concentration Risk
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Customer A    
Concentration Risk [Line Items]    
Concentration risk, percentage 36.00% 36.00%
Customer B    
Concentration Risk [Line Items]    
Concentration risk, percentage 36.00% 32.00%
Customer C    
Concentration Risk [Line Items]    
Concentration risk, percentage 17.00% 17.00%
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net loss $ (159,764) $ (94,621)
Denominator:    
Weighted average common shares used in calculation of basic net loss per share (in shares) 136,355 118,929
Weighted average common shares used in calculation of basic net loss per share:    
Dilutive securities, convertible debt (in shares) 0 0
Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares) 136,355 118,929
Net loss per share:    
Basic (in dollars per share) $ (1.17) $ (0.80)
Diluted (in dollars per share) $ (1.17) $ (0.80)
Common stock options    
Weighted average common shares used in calculation of basic net loss per share:    
Dilutive securities, share-based payment (in shares) 0 0
RS and RSUs    
Weighted average common shares used in calculation of basic net loss per share:    
Dilutive securities, share-based payment (in shares) 0 0
PSUs    
Weighted average common shares used in calculation of basic net loss per share:    
Dilutive securities, share-based payment (in shares) 0 0
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Common stock options    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 19,156 15,282
Unvested restricted stock and RSUs    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 2,058 1,163
PSUs    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 671 679
Convertible debt securities    
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding    
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares) 23,438 23,438
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Assets        
Marketable securities $ 29,800      
Liabilities        
Deferred consideration 6,200      
Level 2        
Liabilities        
Contingent consideration 6,200 $ 7,400 $ 12,861 $ 14,931
Level 3        
Liabilities        
Contingent consideration 49,800 58,100 $ 66,120 $ 75,668
Carrying Value | Recurring basis        
Assets        
Cash and cash equivalents 968,900 1,074,000    
Marketable securities 29,800 74,200    
Collateral for interest rate swap 5,000 5,000    
Liabilities        
Interest rate swap 3,100 1,500    
Deferred consideration 6,200 7,400    
Contingent consideration 49,800 58,100    
Estimate of Fair Value Measurement | Recurring basis | Level 1        
Assets        
Cash and cash equivalents 968,900 1,074,000    
Marketable securities 29,800 74,200    
Collateral for interest rate swap 5,000 5,000    
Liabilities        
Interest rate swap 0 0    
Deferred consideration 0 0    
Contingent consideration 0 0    
Estimate of Fair Value Measurement | Recurring basis | Level 2        
Assets        
Cash and cash equivalents 0 0    
Marketable securities 0 0    
Collateral for interest rate swap 0 0    
Liabilities        
Interest rate swap 3,100 1,500    
Deferred consideration 6,200 7,400    
Contingent consideration 0 0    
Estimate of Fair Value Measurement | Recurring basis | Level 3        
Assets        
Cash and cash equivalents 0 0    
Marketable securities 0 0    
Collateral for interest rate swap 0 0    
Liabilities        
Interest rate swap 0 0    
Deferred consideration 0 0    
Contingent consideration $ 49,800 $ 58,100    
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details)
$ in Millions
Mar. 31, 2023
USD ($)
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Deferred consideration | $ $ 6.2
Level 2 | Share Price  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Business Combination, Deferred Consideration Liability, Measurement Input | $ / shares 17.05
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 49,800 $ 58,100 $ 66,120 $ 75,668
Probabilities of success        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.42      
Development and regulatory milestones        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 41,200      
Priority review voucher milestone        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration $ 6,200      
Priority review voucher milestone | Probabilities of success | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.164      
Priority review voucher milestone | Discount rate | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.123      
Minimum | Development and regulatory milestones | Probabilities of success | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.14      
Maximum | Development and regulatory milestones | Probabilities of success | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Values 0.97      
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Aug. 04, 2021
USD ($)
shares
Aug. 31, 2021
shares
Mar. 31, 2023
USD ($)
numberOfSales
Sep. 30, 2022
shares
Sep. 30, 2021
shares
Dec. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
May 31, 2021
USD ($)
Jan. 31, 2018
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Current available-for-sale securities     $ 29,800              
Unrealized loss     200              
Deferred consideration     6,200              
Non-current contingent consideration     $ 38,600     $ 51,100        
Convertible notes                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Convertible senior notes                   $ 309,100
0.75% convertible senior notes due 2028 | Convertible notes                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Proceeds from issuance of 0.75% convertible senior notes due 2028     0.75%              
Convertible senior notes                 $ 371,600  
1.75% convertible senior notes due 2025 | Convertible notes                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Proceeds from issuance of 0.75% convertible senior notes due 2028     1.75%              
Convertible senior notes                 $ 203,400  
Probabilities of success                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Weighted average probability of success     0.42              
Development and regulatory milestones                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Contingent consideration     $ 41,200              
Level 3                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Contingent consideration     $ 49,800     58,100 $ 66,120 $ 75,668    
Level 3 | Minimum | Development and regulatory milestones | Probabilities of success                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Weighted average probability of success     0.14              
Level 2                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Contingent consideration     $ 6,200     7,400 $ 12,861 $ 14,931    
Recurring basis | Level 3 | Estimate of Fair Value Measurement                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Deferred consideration     0     0        
Contingent consideration     49,800     58,100        
Recurring basis | Level 2 | Estimate of Fair Value Measurement                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Deferred consideration     6,200     7,400        
Contingent consideration     0     $ 0        
Recurring basis | Level 2 | 0.75% convertible senior notes due 2028 | Estimate of Fair Value Measurement                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Convertible senior notes     446,500              
Recurring basis | Level 2 | 1.75% convertible senior notes due 2025 | Estimate of Fair Value Measurement                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Convertible senior notes     202,300              
Other Noncurrent Liabilities                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Deferred consideration     3,100              
Accrued Liabilities, Current                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Deferred consideration     $ 3,100              
AlgaeneX                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Shares issued upon milestone achievements (in shares) | shares   368,867                
Motus                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Shares issued in acquisition (in shares) | shares 2,889,367     171,427 2,889,367          
Shares issued upon milestone achievements (in shares) | shares 5,348,572                  
Potential payout percentage     50.00%              
Percent of sales     50.00%              
Number of publicly disclosed priority review voucher sales | numberOfSales     3              
Contingent consideration $ 35,000                  
Motus | Second anniversary of closing date                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Shares issued in acquisition (in shares) | shares   184,433                
Motus | First anniversary of closing date                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Shares issued in acquisition (in shares) | shares   184,433                
Motus | Third anniversary of closing date                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Shares issued in acquisition (in shares) | shares   184,433                
Motus | Level 3                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Contingent consideration     $ 11,200              
Motus | Other Noncurrent Liabilities | Level 3                    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                    
Non-current contingent consideration     $ 38,600              
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Level 2    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Consideration, beginning balance $ 7,400 $ 14,931
Additions 0 0
Change in Fair Value (1,200) (2,070)
Payments 0 0
Consideration, ending balance 6,200 12,861
Level 3    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Consideration, beginning balance 58,100 75,668
Additions 0 0
Change in Fair Value (8,300) (9,548)
Payments 0 0
Consideration, ending balance $ 49,800 $ 66,120
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Product Revenues, Net - Product Revenues By Geographic Location (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 65,214 $ 53,107
US    
Disaggregation of Revenue [Line Items]    
Product revenues, net 49,067 40,782
Japan    
Disaggregation of Revenue [Line Items]    
Product revenues, net 13,156 10,676
Europe and rest of world    
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 2,991 $ 1,649
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory - Schedule of Inventory, Current (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 24,553 $ 27,245
Work-in-process 20,166 22,460
Finished goods 26,598 20,217
Inventory, Net $ 71,317 $ 69,922
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Intangibles, Net and Goodwill (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]        
Intangible assets estimated useful life 12 years      
Amortization of intangible assets, 2022 $ 5,100      
Amortization of intangible assets, 2023 5,100      
Amortization of intangible assets, 2024 5,100      
Amortization of intangible assets, 2025 5,100      
Amortization of intangible assets, 2026 5,100      
Goodwill 136,110   $ 136,110  
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     68,756 $ 73,809
Additions 0 $ 0    
Amortization (1,263) (1,263)    
Intangibles, net 67,493 72,546 68,756  
Acquired ARIKAYCE R&D        
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     37,588 42,439
Additions 0 0    
Amortization (1,212) (1,212)    
Intangibles, net 36,376 41,227    
Acquired IPR&D        
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     29,600 29,600
Additions 0 0    
Amortization 0 0    
Intangibles, net 29,600 29,600    
PARI milestones        
Finite-lived Intangible Assets [Roll Forward]        
Intangibles, gross     $ 1,568 $ 1,770
Additions 0 0    
Amortization (51) (51)    
Intangibles, net $ 1,517 $ 1,719    
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Fixed Assets, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 100,234 $ 95,936
Less: accumulated depreciation (40,678) (39,445)
Fixed assets, net $ 59,556 56,491
Lab equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 18,982 16,403
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 6,428 6,428
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 5,695 5,227
Computer hardware and software | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 3 years  
Computer hardware and software | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 5 years  
Office equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 89 89
Manufacturing equipment    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 7 years  
Fixed assets, gross $ 1,336 1,203
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 37,042 37,057
Leasehold improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 2 years  
Leasehold improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life (years) 10 years  
Construction in progress    
Property, Plant and Equipment [Line Items]    
Fixed assets, gross $ 30,662 $ 29,529
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accounts payable and other accrued operating expenses $ 56,670 $ 50,461
Accrued clinical trial expenses 26,607 36,456
Accrued professional fees 18,242 14,403
Accrued technical operation expenses 6,734 3,345
Accrued compensation and employee related costs 18,867 32,040
Accrued royalty and milestones payable 6,165 4,710
Accrued interest payable 2,270 6,340
Royalty revenue payable 2,608 2,149
Accrued sales allowances and related costs 11,762 6,974
Accrued France ATU reimbursement payable 12,945 12,943
Deferred and contingent consideration from Business Acquisition 14,300 10,700
Other accrued liabilities 1,835 1,596
Total accounts payable and accrued liabilities $ 179,005 $ 182,117
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Lessee, Lease, Description [Line Items]      
Variable lease, cost $ 0.1 $ 0.1  
Lease cost, future right-of-use asset $ 42.5   $ 40.7
Minimum      
Lessee, Lease, Description [Line Items]      
Remaining lease term 1 year    
Maximum      
Lessee, Lease, Description [Line Items]      
Remaining lease term 10 years 10 months    
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Lease, costs (Details) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Lease, Cost [Abstract]    
Finance right-of-use assets obtained in exchange for lease obligations $ 0 $ 9,287
Operating right-of-use assets obtained in exchange for lease obligations $ 1,751 $ 341
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Schedule of Long-Term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Debt, long-term $ 1,132,188 $ 1,125,250
Convertible notes    
Debt Instrument [Line Items]    
Term Loan 786,443 785,621
Debt, long-term 786,443 785,621
Term Loan    
Debt Instrument [Line Items]    
Term Loan $ 345,745 $ 339,629
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Narrative (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Oct. 31, 2022
USD ($)
May 31, 2021
USD ($)
day
$ / shares
Jan. 31, 2018
USD ($)
day
$ / shares
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]            
Paid-in-kind interest capitalized       $ 5,456 $ 0  
0.75% convertible senior notes due 2028            
Debt Instrument [Line Items]            
Initial conversion rate   0.0307692 30.7692      
0.75% convertible senior notes due 2028 | Level 2 | Carrying Value | Recurring basis            
Debt Instrument [Line Items]            
Convertible senior notes       563,300    
1.75% convertible senior notes due 2025            
Debt Instrument [Line Items]            
Initial conversion rate   0.0255384 25.5384      
1.75% convertible senior notes due 2025 | Level 2 | Carrying Value | Recurring basis            
Debt Instrument [Line Items]            
Convertible senior notes       223,200    
Term Loan | Secured Debt            
Debt Instrument [Line Items]            
Original Term Loan balance $ 350,000     350,000   $ 350,000
Debt issuance costs, unamortized $ 15,200          
Debt Instrument, Percent Of Interest Payable 50.00%          
Debt term (in months) 24 months          
Proceeds from loans $ 334,800          
Term Loan | Secured Debt | Secured Overnight Financing Rate (SOFR)            
Debt Instrument [Line Items]            
Interest rate 2.50%          
Term Loan | Secured Debt | Secured Overnight Financing Rate (SOFR) | Variable Rate Component Two            
Debt Instrument [Line Items]            
Interest rate 7.75%          
Convertible notes            
Debt Instrument [Line Items]            
Convertible senior notes     $ 309,100      
Residual equity component of debt     $ 140,900      
Effective interest rate   7.10% 7.60%      
Convertible notes | 0.75% convertible senior notes due 2028            
Debt Instrument [Line Items]            
Original Term Loan balance   $ 575,000        
Option to purchase additional debt   75,000        
Debt issuance costs, unamortized   15,700   $ 11,700    
Net proceeds   $ 559,300        
Initial conversion price (in dollars per share) | $ / shares   $ 32.50        
Convertible senior notes   $ 371,600        
Remaining discount amortization period (in years)       5 years 2 months 1 day    
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (i)            
Debt Instrument [Line Items]            
Threshold trading days | day   5        
Threshold consecutive trading days | day   5        
Threshold percent of stock price trigger   98.00%        
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (ii)            
Debt Instrument [Line Items]            
Threshold trading days | day   45        
Threshold consecutive trading days | day   10        
Threshold percent of stock price trigger   10.00%        
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (iii)            
Debt Instrument [Line Items]            
Threshold trading days following fundamental change | day   30        
Convertible notes | 0.75% convertible senior notes due 2028 | Conversion Term (iv)            
Debt Instrument [Line Items]            
Threshold trading days | day   20        
Threshold consecutive trading days | day   30        
Threshold percent of stock price trigger   130.00%        
Convertible notes | 1.75% convertible senior notes due 2025            
Debt Instrument [Line Items]            
Original Term Loan balance     $ 450,000      
Option to purchase additional debt     50,000      
Debt issuance costs, unamortized     14,200 $ 1,800    
Net proceeds     $ 435,800      
Repurchased amount   $ 225,000        
Loss on extinguishment of debt   17,700        
Initial conversion price (in dollars per share) | $ / shares     $ 39.16      
Convertible senior notes   $ 203,400        
Remaining discount amortization period (in years)       1 year 9 months 14 days    
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (i)            
Debt Instrument [Line Items]            
Threshold trading days | day     5      
Threshold consecutive trading days | day     5      
Threshold percent of stock price trigger     98.00%      
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (ii)            
Debt Instrument [Line Items]            
Threshold trading days | day     45      
Threshold consecutive trading days | day     10      
Threshold percent of stock price trigger     10.00%      
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (iii)            
Debt Instrument [Line Items]            
Threshold trading days following fundamental change | day     30      
Convertible notes | 1.75% convertible senior notes due 2025 | Conversion Term (iv)            
Debt Instrument [Line Items]            
Threshold trading days | day     20      
Threshold consecutive trading days | day     30      
Threshold percent of stock price trigger     130.00%      
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Components of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Debt, long-term $ 1,132,188 $ 1,125,250
Convertible notes    
Debt Instrument [Line Items]    
Face value of outstanding convertible notes 800,000 800,000
Debt issuance costs, unamortized 13,557 14,379
Debt, long-term $ 786,443 $ 785,621
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Schedule of Carrying Value of Term Loan Balance (Details) - Term Loan - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Oct. 31, 2022
Debt Instrument [Line Items]      
Term Loan $ 345,745 $ 339,629  
Secured Debt      
Debt Instrument [Line Items]      
Original Term Loan balance 350,000 350,000 $ 350,000
Paid-in-kind interest capitalized 9,621 4,165  
Term Loan issuance costs, unamortized (13,876) (14,536)  
Term Loan $ 345,745 $ 339,629  
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Future Principal Repayments of Debt (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Year Ending December 31:  
2023 $ 0
2024 0
2025 225,000
2026 179,811
2027 179,810
2028 and thereafter 575,000
Total $ 1,159,621
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Debt - Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Debt Instrument [Line Items]    
Amortization of debt issuance costs $ 1,724 $ 822
Swap interest income (73) 0
Total debt interest expense 19,389 2,885
Finance lease interest expense 614 406
Total interest expense 20,003 3,291
Convertible Debt    
Debt Instrument [Line Items]    
Convertible debt contractual interest expense 2,063 2,063
Term Loan    
Debt Instrument [Line Items]    
Convertible debt contractual interest expense 10,911 0
Royalty Agreements    
Debt Instrument [Line Items]    
Convertible debt contractual interest expense $ 4,764 $ 0
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Financing Agreement - Additional Information (Details) - Royalty Agreements - USD ($)
$ in Millions
 1 Months Ended
Oct. 31, 2022
Sep. 01, 2025
Debt Instrument [Line Items]    
Royalty maximum 1.8  
Maximum    
Debt Instrument [Line Items]    
Royalty maximum 1.9  
ARIKAYCE Global Net Sales    
Debt Instrument [Line Items]    
Royalty percentage 450.00%  
ARIKAYCE Global Net Sales | Subsequent Event    
Debt Instrument [Line Items]    
Royalty percentage   4.00%
Brensocatib Global Net Sales | Subsequent Event    
Debt Instrument [Line Items]    
Royalty percentage   75.00%
Secured Debt    
Debt Instrument [Line Items]    
Proceeds from royalty financing $ 150.0  
Interest payments 150.0  
Face amount 150.0  
Lenders fees and deal expenses $ 3.8  
Effective interest rate 12.40%  
Proceeds from royalty financing agreement, net $ 146.2  
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Royalty Financing Agreement [Roll Forward]    
Royalty financing agreement - beginning balance $ 148,015  
Amortization of issuance costs 1,724 $ 822
Non-cash interest expense 20,003 $ 3,291
Royalty financing agreement - ending balance 150,173  
Secured Debt | Royalty Agreements    
Royalty Financing Agreement [Roll Forward]    
Royalty financing agreement - beginning balance 148,015  
Royalty revenue payments 2,017  
Royalty revenue payable (2,608)  
Amortization of issuance costs 134  
Non-cash interest expense 2,615  
Royalty financing agreement - ending balance $ 150,173  
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended
Aug. 04, 2021
Jan. 31, 2023
Oct. 31, 2022
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Mar. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]                  
Common stock, authorized shares (in shares)               500,000,000 500,000,000
Common stock, par value (in dollars per share)               $ 0.01 $ 0.01
Common stock, issued shares (in shares)               136,429,216 135,653,731
Common stock, outstanding shares (in shares)               136,429,216 135,653,731
Offering price per share (in dollars per share)     $ 20.00     $ 25.00      
Payments of stock issuance costs     $ 16.2     $ 17.5      
Preferred stock, authorized (in shares)               200,000,000  
Preferred stock, par value (in dollars per share)               $ 0.01  
Preferred stock, shares issued (in shares)               0  
Preferred stock, shares outstanding (in shares)               0  
Motus                  
Class of Stock [Line Items]                  
Common stock shares reserved for issuance (in shares)               9,406,112  
Shares issued in acquisition (in shares) 2,889,367     171,427 2,889,367        
Contingent consideration $ 35.0                
Shares sold in offering (in shares)       1,289,995          
Vertuis Bio, Inc.                  
Class of Stock [Line Items]                  
Common stock shares reserved for issuance (in shares)   550,000              
Shares issued in acquisition (in shares)   500,000              
Issuance of common stock for business acquisition (in shares)   500,000              
Contingent consideration               $ 1.0  
Public Stock Offering                  
Class of Stock [Line Items]                  
Shares sold in offering (in shares)     13,750,000     11,500,000      
Aggregate net proceeds from stock offering     $ 258.8     $ 270.1      
Over-Allotment Option                  
Class of Stock [Line Items]                  
Shares sold in offering (in shares)           1,500,000      
ATM Program                  
Class of Stock [Line Items]                  
Offering price per share (in dollars per share)               $ 26.68  
Aggregate net proceeds from stock offering       $ 33.4          
Common stock authorized, aggregate gross sales proceeds (up to)             $ 250.0    
Remaining shares sold offering price               $ 215.6  
Convertible debt securities                  
Class of Stock [Line Items]                  
Common stock shares reserved for issuance (in shares)               23,438,430  
PSUs                  
Class of Stock [Line Items]                  
Common stock shares reserved for issuance (in shares)               671,112  
Common stock options                  
Class of Stock [Line Items]                  
Common stock shares reserved for issuance (in shares)               19,155,595  
Unvested restricted stock and RSUs                  
Class of Stock [Line Items]                  
Common stock shares reserved for issuance (in shares)               2,057,694  
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Narrative (Details) - USD ($)
 3 Months Ended
May 11, 2022
May 12, 2021
May 12, 2020
May 15, 2018
Mar. 31, 2023
Mar. 31, 2022
May 16, 2019
Stock-Based Compensation              
Inducement stock options granted to new employees (in shares)         484,390    
Common stock options              
Stock-Based Compensation              
Unrecognized compensation expense related to unvested stock options         $ 116,500,000    
Options outstanding (in shares)         114,780    
Unvested restricted stock and RSUs              
Stock-Based Compensation              
Unrecognized compensation expense related to unvested RSU awards         $ 35,300,000    
Performance options              
Stock-Based Compensation              
Options outstanding (in shares)         268,442    
Unrecognized compensation expense         $ 10,500,000    
Potential award payout         100.00%    
Allocated share-based compensation expense         $ 0 $ 0  
2019 Incentive Plan              
Stock-Based Compensation              
Shares of common stock, maximum authorized for issuance (in shares)             3,500,000
Number of additional shares authorized (in shares) 3,000,000   4,500,000        
Shares available for grant (in shares)         245,789    
2019 Incentive Plan, Second Amendment              
Stock-Based Compensation              
Number of additional shares authorized (in shares)   2,750,000          
2018 ESPP              
Stock-Based Compensation              
Shares of common stock, maximum authorized for issuance (in shares)       1,000,000      
Number of additional shares authorized (in shares)       1,200,000      
Percentage of outstanding shares       2.00%      
Amended and Restated Plan              
Stock-Based Compensation              
Number of additional shares authorized (in shares) 10,500,000            
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) - Stock options and RSUs - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock-Based Compensation    
Allocated share-based compensation expense $ 16.4 $ 12.8
Research and development    
Stock-Based Compensation    
Allocated share-based compensation expense 7.9 5.6
Selling, general and administrative    
Stock-Based Compensation    
Allocated share-based compensation expense $ 8.5 $ 7.2
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Provision for income taxes $ 483,000 $ 385,000
Deferred tax benefit 0  
Unrecognized tax benefits, interest and penalties accrued $ 0  
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Rent expense charged to operations $ 2.2 $ 2.0
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Narrative (Details)
 1 Months Ended 3 Months Ended
Aug. 04, 2021
USD ($)
shares
May 24, 2021
days
Jan. 31, 2023
USD ($)
$ / shares
shares
Aug. 31, 2021
USD ($)
$ / shares
shares
Sep. 30, 2022
shares
Sep. 30, 2021
shares
Mar. 31, 2023
USD ($)
Business Acquisition [Line Items]              
Consecutive trading day period | days   45          
Motus and AlgaeneX              
Business Acquisition [Line Items]              
Aggregate value       $ 165,500,000      
Motus              
Business Acquisition [Line Items]              
Shares issued in acquisition (in shares) | shares 2,889,367       171,427 2,889,367  
Contingent consideration $ 35,000,000            
Shares issued upon milestone achievements (in shares) | shares 5,348,572            
Share price used to calculate issuable shares (in dollars per share) | $ / shares       $ 27.11      
Motus | First anniversary of closing date              
Business Acquisition [Line Items]              
Shares issued in acquisition (in shares) | shares       184,433      
Motus | Second anniversary of closing date              
Business Acquisition [Line Items]              
Shares issued in acquisition (in shares) | shares       184,433      
Motus | Third anniversary of closing date              
Business Acquisition [Line Items]              
Shares issued in acquisition (in shares) | shares       184,433      
AlgaeneX              
Business Acquisition [Line Items]              
Shares issued upon milestone achievements (in shares) | shares       368,867      
Cash paid in acquisition       $ 1,500,000      
Share price used to calculate issuable shares (in dollars per share) | $ / shares       $ 27.11      
Vertuis Bio, Inc.              
Business Acquisition [Line Items]              
Shares issued in acquisition (in shares) | shares     500,000        
Closing share price (in dollars per share) | $ / shares     $ 18.50        
Contingent consideration             $ 1,000,000
Aggregate value     $ 10,250,000        
Vertuis Bio, Inc. | Milestone Event 1              
Business Acquisition [Line Items]              
Contingent consideration     1,000,000        
Vertuis Bio, Inc. | Milestone Event 2              
Business Acquisition [Line Items]              
Contingent consideration     23,000,000        
Vertuis Bio, Inc. | Milestone Event 3              
Business Acquisition [Line Items]              
Contingent consideration     $ 63,800,000        
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Summary of Consideration Transferred (Details) - Vertuis Bio, Inc.
 1 Months Ended
Jan. 31, 2023
USD ($)
shares
Business Acquisition [Line Items]  
Shares of Insmed common stock issuable on July 1, 2024 (in shares) | shares 500,000
Aggregate value | $ $ 10,250,000
Common Stock  
Business Acquisition [Line Items]  
Share price used to calculate issuable shares (in dollars per share) | $ $ 9,250,000
Shares of Insmed common stock issuable on July 1, 2024 (in shares) | shares 1,000,000.00
XML 81 insm-20230331_htm.xml IDEA: XBRL DOCUMENT 0001104506 2023-01-01 2023-03-31 0001104506 2023-05-01 0001104506 2023-03-31 0001104506 2022-12-31 0001104506 2022-01-01 2022-03-31 0001104506 us-gaap:CommonStockMember 2021-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001104506 us-gaap:RetainedEarningsMember 2021-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001104506 2021-12-31 0001104506 2021-01-01 2021-12-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001104506 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001104506 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001104506 us-gaap:CommonStockMember 2022-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001104506 us-gaap:RetainedEarningsMember 2022-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001104506 2022-03-31 0001104506 us-gaap:CommonStockMember 2022-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001104506 us-gaap:RetainedEarningsMember 2022-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001104506 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001104506 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001104506 us-gaap:CommonStockMember 2023-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001104506 us-gaap:RetainedEarningsMember 2023-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001104506 insm:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001104506 insm:CustomerAMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001104506 insm:CustomerBMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001104506 insm:CustomerBMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001104506 insm:CustomerCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001104506 insm:CustomerCMember us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001104506 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001104506 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001104506 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001104506 us-gaap:PerformanceSharesMember 2022-01-01 2022-03-31 0001104506 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0001104506 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-03-31 0001104506 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0001104506 us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0001104506 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001104506 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001104506 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001104506 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-08-01 2021-08-31 0001104506 insm:MotusBiosciencesIncMember 2022-07-01 2022-09-30 0001104506 insm:AccruedLiabilitiesCurrentMember 2023-03-31 0001104506 us-gaap:OtherNoncurrentLiabilitiesMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel2Member us-gaap:MeasurementInputSharePriceMember 2023-03-31 0001104506 insm:MotusBiosciencesIncMember 2021-08-04 2021-08-04 0001104506 insm:AlgaeneXIncMember 2021-08-01 2021-08-31 0001104506 insm:MeasurementInputProbabilityOfSuccessMember 2023-03-31 0001104506 insm:MotusBiosciencesIncMember 2023-03-31 0001104506 insm:MotusBiosciencesIncMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001104506 us-gaap:OtherNoncurrentLiabilitiesMember insm:MotusBiosciencesIncMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001104506 insm:DevelopmentAndRegulatoryMilestonesMember 2023-03-31 0001104506 srt:MinimumMember us-gaap:FairValueInputsLevel3Member insm:DevelopmentAndRegulatoryMilestonesMember insm:MeasurementInputProbabilityOfSuccessMember 2023-03-31 0001104506 srt:MaximumMember us-gaap:FairValueInputsLevel3Member insm:DevelopmentAndRegulatoryMilestonesMember insm:MeasurementInputProbabilityOfSuccessMember 2023-03-31 0001104506 insm:PriorityReviewVoucherMilestoneMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member insm:PriorityReviewVoucherMilestoneMember insm:MeasurementInputProbabilityOfSuccessMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member insm:PriorityReviewVoucherMilestoneMember us-gaap:MeasurementInputDiscountRateMember 2023-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001104506 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001104506 us-gaap:FairValueInputsLevel2Member 2022-01-01 2022-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001104506 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001104506 us-gaap:FairValueInputsLevel2Member 2023-01-01 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-03-31 0001104506 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001104506 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2023-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2023-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 country:US 2023-01-01 2023-03-31 0001104506 country:US 2022-01-01 2022-03-31 0001104506 country:JP 2023-01-01 2023-03-31 0001104506 country:JP 2022-01-01 2022-03-31 0001104506 insm:EuropeAndTheRestOfTheWorldMember 2023-01-01 2023-03-31 0001104506 insm:EuropeAndTheRestOfTheWorldMember 2022-01-01 2022-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2022-12-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2023-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2023-03-31 0001104506 us-gaap:LicensingAgreementsMember 2022-12-31 0001104506 us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0001104506 us-gaap:LicensingAgreementsMember 2023-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2021-12-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2022-01-01 2022-03-31 0001104506 insm:AcquiredResearchAndDevelopmentMember 2022-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-03-31 0001104506 us-gaap:InProcessResearchAndDevelopmentMember 2022-03-31 0001104506 us-gaap:LicensingAgreementsMember 2021-12-31 0001104506 us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0001104506 us-gaap:LicensingAgreementsMember 2022-03-31 0001104506 us-gaap:EquipmentMember 2023-01-01 2023-03-31 0001104506 us-gaap:EquipmentMember 2023-03-31 0001104506 us-gaap:EquipmentMember 2022-12-31 0001104506 us-gaap:FurnitureAndFixturesMember 2023-01-01 2023-03-31 0001104506 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001104506 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001104506 srt:MinimumMember insm:ComputerHardwareAndSoftwareMember 2023-01-01 2023-03-31 0001104506 srt:MaximumMember insm:ComputerHardwareAndSoftwareMember 2023-01-01 2023-03-31 0001104506 insm:ComputerHardwareAndSoftwareMember 2023-03-31 0001104506 insm:ComputerHardwareAndSoftwareMember 2022-12-31 0001104506 us-gaap:OfficeEquipmentMember 2023-01-01 2023-03-31 0001104506 us-gaap:OfficeEquipmentMember 2023-03-31 0001104506 us-gaap:OfficeEquipmentMember 2022-12-31 0001104506 insm:ManufacturingEquipmentMember 2023-01-01 2023-03-31 0001104506 insm:ManufacturingEquipmentMember 2023-03-31 0001104506 insm:ManufacturingEquipmentMember 2022-12-31 0001104506 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-03-31 0001104506 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-03-31 0001104506 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001104506 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001104506 us-gaap:ConstructionInProgressMember 2023-03-31 0001104506 us-gaap:ConstructionInProgressMember 2022-12-31 0001104506 srt:MinimumMember 2023-01-01 2023-03-31 0001104506 srt:MaximumMember 2023-01-01 2023-03-31 0001104506 2022-01-01 2022-12-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2023-03-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001104506 insm:TermLoanMember 2023-03-31 0001104506 insm:TermLoanMember 2022-12-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2018-01-01 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member 2018-01-01 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermOneMember 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermOneMember 2021-05-01 2021-05-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermTwoMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermTwoMember 2018-01-01 2018-01-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermThreeMember 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermThreeMember 2021-05-01 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermFourMember 2018-01-01 2018-01-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember insm:DebtInstrumentConversionTermFourMember 2021-05-01 2021-05-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2018-01-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2021-05-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-03-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember insm:SecuredOvernightFinancingRateSOFRMember 2022-10-01 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember insm:SecuredOvernightFinancingRateSOFRMember insm:VariableRateComponentTwoMember 2022-10-01 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2022-10-01 2022-10-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2023-03-31 0001104506 us-gaap:SecuredDebtMember insm:TermLoanMember 2022-12-31 0001104506 us-gaap:ConvertibleDebtMember 2023-01-01 2023-03-31 0001104506 us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001104506 insm:TermLoanMember 2023-01-01 2023-03-31 0001104506 insm:TermLoanMember 2022-01-01 2022-03-31 0001104506 us-gaap:RoyaltyAgreementsMember 2023-01-01 2023-03-31 0001104506 us-gaap:RoyaltyAgreementsMember 2022-01-01 2022-03-31 0001104506 insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member 2021-05-01 2021-05-31 0001104506 insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member 2021-05-01 2021-05-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2022-10-01 2022-10-31 0001104506 us-gaap:RoyaltyAgreementsMember insm:ARIKAYCEGlobalNetSalesMember us-gaap:SubsequentEventMember 2025-09-01 0001104506 us-gaap:RoyaltyAgreementsMember insm:ARIKAYCEGlobalNetSalesMember 2022-10-31 0001104506 us-gaap:RoyaltyAgreementsMember insm:BrensocatibGlobalNetSalesMember us-gaap:SubsequentEventMember 2025-09-01 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2022-10-31 0001104506 us-gaap:RoyaltyAgreementsMember 2022-10-31 0001104506 srt:MaximumMember us-gaap:RoyaltyAgreementsMember 2022-10-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2022-12-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2023-01-01 2023-03-31 0001104506 us-gaap:SecuredDebtMember us-gaap:RoyaltyAgreementsMember 2023-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2023-03-31 0001104506 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001104506 us-gaap:PerformanceSharesMember 2023-03-31 0001104506 us-gaap:ConvertibleNotesPayableMember 2023-03-31 0001104506 insm:MotusBiosciencesIncMember 2021-07-01 2021-09-30 0001104506 insm:VertuisBioIncMember 2023-01-31 0001104506 insm:VertuisBioIncMember 2023-01-01 2023-01-31 0001104506 insm:VertuisBioIncMember 2023-03-31 0001104506 insm:PublicStockOfferingMember 2022-10-01 2022-10-31 0001104506 2022-10-31 0001104506 2022-10-01 2022-10-31 0001104506 insm:PublicStockOfferingMember 2021-04-01 2021-06-30 0001104506 us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001104506 2021-06-30 0001104506 2021-04-01 2021-06-30 0001104506 insm:AtTheMarketAgreementMember 2021-01-01 2021-03-31 0001104506 insm:AtTheMarketAgreementMember 2023-03-31 0001104506 insm:AtTheMarketAgreementMember 2022-07-01 2022-09-30 0001104506 insm:A2019IncentivePlanThirdAmendmentMember 2019-05-16 0001104506 insm:A2019IncentivePlanThirdAmendmentMember 2020-05-12 2020-05-12 0001104506 insm:A2019IncentivePlanSecondAmendmentMember 2021-05-12 2021-05-12 0001104506 insm:A2019IncentivePlanThirdAmendmentMember 2022-05-11 2022-05-11 0001104506 insm:AmendedAndRestatedPlanMember 2022-05-11 2022-05-11 0001104506 insm:A2019IncentivePlanThirdAmendmentMember 2023-03-31 0001104506 insm:EmployeeStockPurchasePlan2018Member 2018-05-15 0001104506 insm:EmployeeStockPurchasePlan2018Member 2018-05-15 2018-05-15 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember 2023-01-01 2023-03-31 0001104506 insm:StockOptionsAndRestrictedStockUnitsMember 2022-01-01 2022-03-31 0001104506 insm:VertuisBioIncMember insm:MilestoneEvent1Member 2023-01-31 0001104506 insm:VertuisBioIncMember insm:MilestoneEvent2Member 2023-01-31 0001104506 insm:VertuisBioIncMember insm:MilestoneEvent3Member 2023-01-31 0001104506 insm:VertuisBioIncMember us-gaap:CommonStockMember 2023-01-01 2023-01-31 0001104506 insm:MotusBiosciencesIncMember 2021-08-04 0001104506 insm:AlgaeneXIncMember 2021-08-31 0001104506 insm:MotusBiosciencesIncMember 2021-08-31 0001104506 2021-05-24 2021-05-24 0001104506 insm:MotusBiosciencesIncAndAlgaeneXIncMember 2021-08-01 2021-08-31 shares iso4217:USD iso4217:USD shares pure insm:reportingUnit insm:numberOfSales insm:day insm:days 0001104506 false --12-31 2023 Q1 http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member 25.5384 0.0255384 30.7692 0.0307692 10-Q true 2023-03-31 false 000-30739 INSMED INC VA 54-1972729 700 US Highway 202/206 Bridgewater NJ 08807 908 977-9900 Common stock, par value $0.01 per share INSM NASDAQ Yes Yes Large Accelerated Filer false false false 136432799 968907000 1074036000 29774000 74244000 30523000 29713000 71317000 69922000 28542000 25468000 1129063000 1273383000 59556000 56491000 23019000 23697000 21154000 21894000 67493000 68756000 136110000 136110000 81322000 76104000 1517717000 1656435000 179005000 182117000 2158000 1217000 6821000 6909000 187984000 190243000 1132188000 1125250000 150173000 148015000 38600000 51100000 29015000 29636000 14534000 14853000 9876000 9387000 1562370000 1568484000 0.01 0.01 500000000 500000000 136429216 136429216 135653731 135653731 1364000 1357000 2809242000 2782416000 -2856342000 -2696578000 1083000 756000 -44653000 87951000 1517717000 1656435000 65214000 53107000 13830000 12191000 127865000 84356000 79914000 56748000 1263000 1263000 -9500000 -11618000 213372000 142940000 -148158000 -89833000 10524000 137000 20003000 3291000 -1533000 0 -111000 -1249000 -159281000 -94236000 483000 385000 -159764000 -94621000 -1.17 -1.17 -0.80 -0.80 136355000 136355000 118929000 118929000 -159764000 -94621000 -171000 -494000 498000 -704000 -159437000 -95819000 118738000 1187000 2673556000 -2265243000 968000 410468000 -264609000 50199000 -214410000 -94621000 -94621000 -1198000 -1198000 450000 4000 6812000 6816000 158000 2000 2000 12823000 12823000 119346000 1193000 2428582000 -2309665000 -230000 119880000 135654000 1357000 2782416000 -2696578000 756000 87951000 -159764000 -159764000 327000 327000 82000 1000 1138000 1139000 193000 1000 1000 500000 5000 9245000 9250000 16443000 16443000 136429000 1364000 2809242000 -2856342000 1083000 -44653000 -159764000 -94621000 1248000 1286000 1263000 1263000 16443000 12823000 1724000 822000 5456000 0 2615000 0 678000 729000 2491000 2369000 -9500000 -11618000 -1533000 0 10250000 0 860000 1798000 1187000 -2240000 3199000 2752000 5231000 6289000 -8841000 13363000 -1422000 -22978000 -146303000 -105161000 3398000 1701000 0 99706000 45000000 0 41602000 -101407000 1139000 6818000 320000 359000 1218000 0 -399000 6459000 -29000 -969000 -105129000 -201078000 1074036000 716782000 968907000 515704000 11589000 2375000 1004000 635000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. The Company and Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib, treprostinil palmitil inhalation powder (TPIP) and early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis, CF and other neutrophil-mediated diseases</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including chronic rhinosinusitis without nasal polyps (CRSsNP).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company is also advancing its early-stage research programs encompassing a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, and protein manufacturing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November 29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450623000009/insm-20221231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 20</a>22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     The Company had $968.9 million in cash and cash equivalents and $29.8 million of marketable securities as of March 31, 2023 and reported a net loss of $159.8 million for the three months ended March 31, 2023. The Company has funded its operations through public offerings of equity securities, debt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company’s commercial, regulatory and development activities. Any future financing will also be contingent upon market conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.</span></div> 968900000 29800000 -159800000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000110450623000009/insm-20221231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5 - Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with Accounting Standards Codification (ASC) 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2023. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' (deficit) equity, as a component of accumulated other comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Synthetic Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty &amp; Credit Opportunities IV, LP (OrbiMed). The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note - 11 Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2023 and 2022: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.777%"><tr><td style="width:1.0%"/><td style="width:59.238%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2023 and 2022, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:66.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2020, the Financial Accounting Standards Board issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMwNTEzMWZjYzllNDRkMzA4MWU0ZjZiZWEwMWY0YWUwL3NlYzozMDUxMzFmY2M5ZTQ0ZDMwODFlNGY2YmVhMDFmNGFlMF8zNC9mcmFnOjAyMWFiMDllNzVmODQ5ODFhZDFmNjdiZDUwOWJlNGU3L3RleHRyZWdpb246MDIxYWIwOWU3NWY4NDk4MWFkMWY2N2JkNTA5YmU0ZTdfMzM1NDQ_8cbaef6a-2c2f-4321-9d61-a0c7c579a956">ASU 2020-06</span>, Debt — Accounting for Convertible Instruments, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 is effective for fiscal years beginning </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $221.9 million, increasing issuance costs classified to debt by $6.1 million, decreasing the deferred tax liability by $1.4 million, and increasing retained earnings by $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</span></div> The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the three months ended March 31, 2023.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.36 0.36 0.36 0.32 0.17 0.17 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestone payments. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5 - Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create </span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with Accounting Standards Codification (ASC) 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of March 31, 2023, the Company continues to operate as one reporting unit. The Company will perform its next annual impairment testing for goodwill as of October 1, 2023. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> 1 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' (deficit) equity, as a component of accumulated other comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Synthetic Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty &amp; Credit Opportunities IV, LP (OrbiMed). The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note - 11 Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three months ended March 31, 2023 and 2022: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.777%"><tr><td style="width:1.0%"/><td style="width:59.238%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,929 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.80)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -159764000 -94621000 136355000 118929000 0 0 0 0 0 0 0 0 136355000 118929000 -1.17 -1.17 -0.80 -0.80 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of March 31, 2023 and 2022, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:66.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 19156000 15282000 2058000 1163000 671000 679000 23438000 23438000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In August 2020, the Financial Accounting Standards Board issued <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMwNTEzMWZjYzllNDRkMzA4MWU0ZjZiZWEwMWY0YWUwL3NlYzozMDUxMzFmY2M5ZTQ0ZDMwODFlNGY2YmVhMDFmNGFlMF8zNC9mcmFnOjAyMWFiMDllNzVmODQ5ODFhZDFmNjdiZDUwOWJlNGU3L3RleHRyZWdpb246MDIxYWIwOWU3NWY4NDk4MWFkMWY2N2JkNTA5YmU0ZTdfMzM1NDQ_8cbaef6a-2c2f-4321-9d61-a0c7c579a956">ASU 2020-06</span>, Debt — Accounting for Convertible Instruments, to reduce the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 is effective for fiscal years beginning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company transitioned using the modified retrospective method. The impact of adopting ASU 2020-06 on January 1, 2022 resulted in an opening balance sheet adjustment increasing debt by approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $221.9 million, increasing issuance costs classified to debt by $6.1 million, decreasing the deferred tax liability by $1.4 million, and increasing retained earnings by $50.2 million, with an offsetting reduction to additional paid-in-capital of $264.6 million, net of tax.</span> 221900000 6100000 -1400000 50200000 264600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of March 31, 2023 and December 31, 2022. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the three months ended March 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company held $29.8 million of current available-for-sale securities, net of an unrealized loss of $0.2 million recorded in accumulated other comprehensive income. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the three months ended March 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisitions of Motus Biosciences, Inc. (Motus) and AlgaeneX, Inc. (AlgaeneX) (the Business Acquisition) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022, the Company fulfilled the payment due on the first anniversary of the closing date by issuing 171,427 shares of the Company's common stock, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within 12 months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2023, the fair value of deferred consideration included in accounts payable and accrued liabilities was $3.1 million. Deferred consideration expected to be settled in more than 12 months is classified as a non-current liability within other long-term liabilities. As of March 31, 2023, the fair value of deferred consideration included in other long-term liabilities was $3.1 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of March 31, 2023:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:21.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.2</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.05</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the Business Acquisition in August 2021 (Note 16). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At March 31, 2023, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of March 31, 2023, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within 12 months or less is classified as a current liability within accounts payable and accrued liabilities. As of March 31, 2023, the fair value of contingent consideration included in accounts payable and accrued liabilities was $11.2 million. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of March 31, 2023, the fair value of non-current contingent consideration was $38.6 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities expected to be settled in more than twelve months are classified as a non-current liability in the consolidated balance sheet. A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2023:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:25.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$41.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 97%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.2</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"/><td style="width:38.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Consideration (Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/> (Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility, and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2023 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$446.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of March 31, 2023 was $202.3 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the 2025 Convertible Notes. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 - Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details on the Company's convertible notes.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 968900000 968900000 0 0 29800000 29800000 0 0 5000000.0 5000000.0 0 0 3100000 0 3100000 0 6200000 0 6200000 0 49800000 0 0 49800000 1074000000 1074000000 0 0 74200000 74200000 0 0 5000000.0 5000000.0 0 0 1500000 0 1500000 0 7400000 0 7400000 0 58100000 0 0 58100000 29800000 200000 184433 184433 184433 171427 3100000 3100000 The following observable input was used in the valuation of the deferred consideration as of March 31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:21.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.2</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of March 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.05</span></div></td></tr></table><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of March 31, 2023:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:25.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2023 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$41.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 97%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.2</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"/><td style="width:38.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Consideration (Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/> (Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,070)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6200000 17.05 5348572 368867 0.42 0.50 0.50 3 11200000 38600000 41200000 0.14 0.97 6200000 0.164 0.123 14931000 75668000 0 0 2070000 9548000 0 0 12861000 66120000 7400000 58100000 0 0 1200000 8300000 0 0 6200000 49800000 0.0075 446500000 0.0175 202300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the Company's product revenues, net, by geographic location for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div>The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div> The following table presents a summary of the Company's product revenues, net, by geographic location for the three months ended March 31, 2023 and 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 49067000 40782000 13156000 10676000 2991000 1649000 65214000 53107000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.261%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,922 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, the Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.261%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,922 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 24553000 27245000 20166000 22460000 26598000 20217000 71317000 69922000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. Intangibles, Net and Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangibles, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D and the milestones paid to PARI for the license to use Lamira for the delivery of ARIKAYCE to patients as a result of the FDA and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;D and PARI milestones intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company's indefinite-lived intangible assets consisted of acquired IPR&amp;D from the Business Acquisition (Note 16). Indefinite-lived intangible assets are not amortized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the three months ended March 31, 2023 and March 31, 2022 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,756 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,493 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,809 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's goodwill balance of $136.1 million as of March 31, 2023 and December 31, 2022, resulted from the August 2021 Business Acquisition. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions </span>for further details. P12Y 5100000 5100000 5100000 5100000 5100000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the three months ended March 31, 2023 and March 31, 2022 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,756 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,493 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,809 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 37588000 0 1212000 36376000 29600000 0 0 29600000 1568000 0 51000 1517000 68756000 0 1263000 67493000 42439000 0 1212000 41227000 29600000 0 0 29600000 1770000 0 51000 1719000 73809000 0 1263000 72546000 136100000 136100000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. Fixed Assets, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:33.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.401%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,982 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,234 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,936 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,556 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:33.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.401%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,982 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,234 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,936 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,556 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P7Y 18982000 16403000 P7Y 6428000 6428000 P3Y P5Y 5695000 5227000 P7Y 89000 89000 P7Y 1336000 1203000 P2Y P10Y 37042000 37057000 30662000 29529000 100234000 95936000 40678000 39445000 59556000 56491000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. Accounts Payable and Accrued Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:57.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration from Business Acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,005 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,117 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:57.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration from Business Acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,005 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,117 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 56670000 50461000 26607000 36456000 18242000 14403000 6734000 3345000 18867000 32040000 6165000 4710000 2270000 6340000 2608000 2149000 11762000 6974000 12945000 12943000 14300000 10700000 1835000 1596000 179005000 182117000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $0.1 million and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"/><td style="width:53.860%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $42.5 million and $40.7 million incurred by the Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>other assets in the Company's consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $0.1 million and $0.1 million for the three months ended March 31, 2023 and 2022, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"/><td style="width:53.860%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $42.5 million and $40.7 million incurred by the Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>other assets in the Company's consolidated balance sheet as of March 31, 2023 and December 31, 2022, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability. P1Y P10Y10M 100000 100000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.684%"><tr><td style="width:1.0%"/><td style="width:53.860%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,287 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 9287000 1751000 341000 42500000 40700000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, long-term consists of the following commitments as of March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.228%"><tr><td style="width:1.0%"/><td style="width:37.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,188 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,250 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company completed an underwritten public offering of the 2028 Convertible Notes, in which the Company sold $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7 million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of the 2025 Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their 2025 Convertible Notes at any time. The initial conversion rate for the 2025 Convertible Notes is 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2025 Convertible Notes prior to October 15, 2024 or their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the applicable indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the applicable series of convertible notes, as determined following a request by a holder of such convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the applicable series of convertible notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March 31, 2018 or June 30, 2021 for the 2025 Convertible Notes and the 2028 Convertible Notes, respectively (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its convertible notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a) the second business day immediately preceding the related redemption date or (b) if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. To date, there have not been any holder-initiated redemption requests of either series of convertible notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources that utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity’s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9 million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6 million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4 million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December 31, 2021, prior to the adoption of ASU 2020-06. The 2025 Convertible Notes and 2028 Convertible Notes have remaining terms of approximately 1.79 years and 5.17 years, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $563.3 million carrying value of the 2028 Convertible Notes as of March 31, 2023 excludes $11.7 million of unamortized debt issuance costs. The $223.2 million carrying value of the 2025 Convertible Notes as of March 31, 2023 excludes $1.8 million of unamortized debt issuance costs. The following table presents the carrying value of the Company's debt balance (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:58.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, unamortized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secured Senior Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company entered into a $350 million senior secured term loan agreement with Pharmakon Advisors LP, manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. During the three months ended March 31, 2023, paid-in-kind interest capitalized was $5.5 million. Net proceeds from the Term Loan, after deducting the lenders fees and deal expenses of $15.2 million, were $334.8 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"/><td style="width:45.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.276%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.277%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,621 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,745 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,629 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"/><td style="width:64.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three months ended March 31, 2023 and 2022 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"/><td style="width:57.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.306%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.675%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, long-term consists of the following commitments as of March 31, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.228%"><tr><td style="width:1.0%"/><td style="width:37.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,188 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,250 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 786443000 785621000 345745000 339629000 1132188000 1125250000 575000000 75000000 15700000 559300000 450000000 50000000 14200000 435800000 225000000 -17700000 25.5384 39.16 30.7692 32.50 5 5 5 5 0.98 0.98 45 45 10 10 0.10 0.10 30 30 20 20 30 30 1.30 1.30 309100000 0.076 140900000 371600000 0.071 203400000 P1Y9M14D P5Y2M1D 563300000 11700000 223200000 1800000 The following table presents the carrying value of the Company's debt balance (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:58.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, unamortized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,443 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a rollforward of the carrying value of the Company’s Royalty Financing Agreement balance for the three months ended March 31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"/><td style="width:72.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Royalty financing agreement - beginning balance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Royalty revenue payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Royalty revenue payable </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Non-cash interest expense </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Liability related to the sale of future royalties - ending balance </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,173 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 800000000 800000000 13557000 14379000 786443000 785621000 350000000 0.025 0.0775 0.50 P24M 5500000 15200000 334800000 The following table presents the carrying value of the Company’s Term Loan balance as of March 31, 2023 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"/><td style="width:45.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.276%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.277%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,621 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,165 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,745 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,629 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 350000000 350000000 9621000 4165000 13876000 14536000 345745000 339629000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"/><td style="width:64.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 225000000 179811000 179810000 575000000 1159621000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three months ended March 31, 2023 and 2022 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"/><td style="width:57.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.306%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.675%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2063000 2063000 10911000 0 4764000 0 1724000 822000 73000 0 19389000 2885000 614000 406000 20003000 3291000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150 million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150 million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150 million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150 million. The total Revenue Interest Payments payable by us to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders fees and deal expenses of $3.8 million were, $146.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be 12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a rollforward of the carrying value of the Company’s Royalty Financing Agreement balance for the three months ended March 31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.456%"><tr><td style="width:1.0%"/><td style="width:72.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Royalty financing agreement - beginning balance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Royalty revenue payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Royalty revenue payable </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">      Non-cash interest expense </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Liability related to the sale of future royalties - ending balance </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,173 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss. Royalty revenue payable is recorded within accounts payable and accrued liabilities on the consolidated balance sheet.</span></div> 150000000 0.04 4.5 0.75 150000000 150000000 150000000 1.8 1.9 3800000 146200000 0.124 148015000 2017000 -2608000 134000 2615000 150173000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. Shareholders' Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — As of March 31, 2023, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 136,429,216 shares of common stock issued and outstanding. In addition, as of March 31, 2023, the Company had reserved 19,155,595 shares of common stock for issuance upon the exercise of outstanding stock options, 2,057,694 shares of common stock for issuance upon the vesting of RSUs and 671,112 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ved 9,406,112 s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hares of the Company’s common stock, subject to certain closing-related reductions. The shares of the Company’s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first anniversary of the closing date of the acquisition, and will also be issued upon the second and third anniversaries of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company’s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the 9,406,112 shares reserved, subject to certain closing-related reductions, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (Note 16) i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the third quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2021, after certain closing-related deductions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company’s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">550,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of the Company’s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. An additional $1 million of shares of common stock will be issued to Vertuis’ former stockholders on July 1, 2024, based on the share price on June 28, 2024. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2 million, were $258.8 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the second quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of 2021, the Company completed an underwritten public offering of 11,500,000 shares of the Company's common stock, including 1,500,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t a public offering price of $25.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expenses of $17.5 million, were $270.1 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as SVB Securities LLC) (SVB Securities), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0 million, from time to time, through an “at the market” equity offering program (the ATM program), under which SVB Securities acts as sales agent. During the third quarter of 2022, the Company issued and sold an aggregate of 1,289,995</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock through the ATM program at a weighted-average public offering price of $26.68 per share and received net </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds of $33.4 million. As of March 31, 2023, an aggregate of $215.6 million of shares of common stock remain available to be issued and sold under the ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — As of March 31, 2023, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.</span></div> 500000000 0.01 136429216 136429216 19155595 2057694 671112 23438430 9406112 9406112 2889367 171427 550000 500000 1000000 13750000 20.00 16200000 258800000 11500000 1500000 25.00 17500000 270100000 250000000 1289995 26.68 33400000 215600000 200000000 0.01 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. Stock-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's current equity compensation plan, the Insmed Incorporated 2019 Incentive Plan (as amended, the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders in May 2019. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. On May 16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the Company's 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. On May 12, 2021, at the Company's 2021 Annual Meeting of Shareholders, the Company's shareholders approved the second amendment to the 2019 Incentive Plan providing for the issuance of an additional 2,750,000 shares under the plan. On May 11, 2022, at the Company's 2022 Annual Meeting of Shareholders, the Company's shareholders approved the third amendment to the 2019 Incentive Plan, providing for the issuance of an additional 3,000,000 shares under the plan. The Company has submitted a proposal to its shareholders to approve an Amended and Restated 2019 Incentive Plan at the 2023 Annual Meeting of Shareholders (the Amended and Restated Plan). The Amended and Restated Plan, if approved, will provide for the issuance of an additional 10,500,000 shares under the plan. As of March 31, 2023, 245,789 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the three months ended March 31, 2023, the Company granted inducement stock options covering 484,390 shares of the Company's common stock to new employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i) 1,000,000 shares of common stock, plus (ii) commencing on January 1, 2019 and ending on December 31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C) an amount determined by the administrator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — As of March 31, 2023, there was $116.5 million of unrecognized compensation expense related to unvested stock options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March 31, 2023, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— As of March 31, 2023, there was $35.3 million of unrecognized compensation expense related to unvested RSU awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> — </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there were 268,442 PSUs outstanding with an unrecognized compensation expense of $10.5 million of unrecognized compensation expense related to unvested PSU awards, which assumes a payout of 100% of the target.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2023 and 2022, respectively (in millions): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.058%"><tr><td style="width:1.0%"/><td style="width:47.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.068%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the three months ended March 31, 2023 or March 31, 2022, as the performance conditions associated with the PSU awards were not probable as of either date.</span></div> 3500000 4500000 2750000 3000000 10500000 245789 484390 1000000 1200000 0.02 116500000 114780 35300000 268442 10500000 1 The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three months ended March 31, 2023 and 2022, respectively (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.058%"><tr><td style="width:1.0%"/><td style="width:47.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.068%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7900000 5600000 8500000 7200000 16400000 12800000 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14. Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a provision for income taxes of $0.5 million and $0.4 million for the three months ended March 31, 2023 and 2022, respectively. The provisions recorded for the three months ended March 31, 2023 and 2022 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company’s federal tax returns for the years ended 2019 and later, generally open for certain states for the years 2018 and later, and generally open for international jurisdictions for the years 2017 and later. The Company has incurred net operating losses since inception, except for the year ended December 31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of March 31, 2023 and December 31, 2022, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US. However, given the Company’s valuation allowance position, these reserves do not have an impact on the balance sheet as of March 31, 2023 and December 31, 2022 or the consolidated statements of comprehensive loss for the three months ended March 31, 2023 and 2022. The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.</span></div> 500000 400000 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15. Commitments and Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense charged to operations was $2.2 million and $2.0 million for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</span></div> 2200000 2000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16. Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company’s common stock to Vertuis’ former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to issue to Vertuis equityholders shares of the Company’s common stock on July 1, 2024 with an aggregate value of $1.0 million, based on the share price on June 28, 2024, and pay to the Vertuis equityholders up to an aggregate of $23.0 million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8 million in cash upon the achievement of certain net sales-based milestone events, in each case, subject to certain reductions.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company’s common stock issuable to the Vertuis equityholders are being issued pursuant to Section 4(a)(2) of the Securities Act of 1933.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"/><td style="width:72.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issuable on July 1, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combination</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company’s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company’s common stock, following certain closing-related reductions, to Motus’s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company’s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone events, and to pay to the Motus equityholders an aggregate of $35 million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022, the Company fulfilled the payment due on the first anniversary of the closing date by issuing 171,427 shares of the Company's common stock, after certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Company’s acquisition of AlgaeneX, the Company paid $1.5 million in cash to AlgaeneX’s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company’s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX’s manufacturing technology, in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company’s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5 million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;D assets will be determined based on the </span></div>anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes. 500000 18.50 1000000 23000000 63800000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"/><td style="width:72.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issuable on July 1, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9250000 1000000.00 10250000 2889367 184433 184433 184433 5348572 35000000 171427 1500000 368867 27.11 27.11 45 165500000 EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

F,VF\&@4=>>Q)1P@D?0"0D;=PAR M"/@RR,CV(ILQ)6((HIPT&6["Z.<2,2X"824J^;Y\PFF\:5<[5/!(7RW:&B$@ M'#"&V%H&_'!UJOMJT_/5.M7)S.:UPQX.?$Z%!;(\=_HM<1#Y7(,]B1GJ-D&J MH;=U-UVTQMEH^W92EQVGQ,LU[TLW)B5<=27 VT5.1\I-\Z2Q0-$WCQ/^3$:8 M:<^9&B%:;U@:<"2DJ3FJ2JNAG<:VL.6^@)5#[6IETKRER.@B?LQQ&6'AC8L! MP^.\(V_77M,RE3JE M4'!]P9MB^A+3/X'IUVQ8SKJEO1T9[U+1Q=E=N98 4I,3##,ADRO)9+(\.)AQ M[)HD4GFV495@Y9MJDLQ-79IO!0$?D)A]C$[;^HGMQ_#T5R[AES<(Z!E>*0>B M=$"1A<+DV$M9B"?; JF>9DP1;&&8Q:#('4]\"#T\);VLWY(ADAB!I[F[(;,T M.(H9%VNX79+-*2UB])SU,RH%P-P8%Y=N)'XA/AU&B&/#65L90$*F)F/N%D3D M L);1!%/(KO4;=DSF1$$IO>CL,Z>*5-,::FDNV[EHN8Z![J(.F*1MT!9;T&O M00**-)9ZN)9'. Z'2J: 5;U+\MMLW3TL\0W)26W+V[(2-R5!V,B"FPU1B)7&RYOA4,.4NQEA-0VD/PFL%/B)%MYNLBW/RMT\AFP M%*5=X(@'"5*X1]>($(4+1%^:!+#$+%!9 ^645WR'XD;?C2'2PF0PT6WL?(HI M9DO,!I*%-E2T5(MV73=T7DO%,L5#3'S6IHU5CGD]A6R3Z[@YIPHQY><7PXT>3"(-M8-9$02HK"EE_P(S<(H/92:I9SG5O*#44 M/?\6]685SD>BQ[7+K!AP&F4VU;+/03ENK;DWG%2BV&SA$&0*(B,_7*9Z7[TJ MOYJI5AK3KK2:EM500MQ:EBZSK&7MG;VMUL-]MJE+=H:K^,UJ&)?E\W/^: M;+>>4U5#?HX1B >QZM M%W,DTQMA@6@],&*Y9*WY\#BG.D@: 0>U*+WP9D0[3YW2"*=!,*4QJY0KMAXLW0V[0W>X M!F@/& Q]6[W'Q:Y &T(3O&N5V 9FZ;*'#$M,W !50X';@]W.47>V4]C(%V2T M 8>Q3.5A;Y??G>TR+-_Q67_!UK%%[S+\@K,[1E)MW#@-,HQD1O0?NK>((Q@2JX&ZT/1 W?1E&;%L@9+_O8 M@9%-@SG8A6X6B5@:17UQ-:?^8=.][@[=.]J.0_I.Y*S=ZVL#D8P*A!^O5)@7 M:<8*OTTT)U #K> /$6*>A8Q6@7)-^^52;O+3S7+$0K.UH12CX]R(ATT7X\[0 MQ7-79)#CA(LC]"4(2@3$ZIC# ?.SC<#S,"]'<]&W\05E M#USNK3*OJT'N!;?84H%R@;.>4*\0$'U$#Z7V[:6:8[,V-KNSAK'9 MKA^G:>>.D^O4,:D-:55VBF3E[YU39\ -\&O+<\D#*R<4M2=[$"G9MG8HR? ? M:A-3M.D5U-KKAD.Y[N00=(8<0(H^>X[K .QP%*I@1GI/&2NCJOWX:D9P-ZRV MJP1WC8( H F-=4"2N.R1J@8+RI4%-RCI&T;!DI3UZZG*TEAS^E0M4;V4BUY) M'L-KW$1V26&71'*.DU!NJG+=$DL *?&%F&84 7EEN?&>T3*J"6+/9;>R61ZV M*O%']XB]P42PKDI]Q=% FXU6V,X&+*[PE+HG!7\J[$>#]$O8@;808OM2 0MGH;G"!NLI/ZGN7M\D+ M%50FNPAV)0F (G)J*HO,NI9P?ON,BKI0#OSV#&RFO,MN+^P'0D@R=(7?7B!E MN%+%C5_#<[=;; 4\=#/ M3M>RHX)[?$CUI^1W"?HN!?WD#<:F7T"D/>QC(*0A$FEYMH+;=* !A"R82:L& M(T@*.4HCDY17QH"YM7^\/4L4?Y7&K,Z1RI3W ;-B4L*9X'[> M/4(ZGQ,WY40?S'RG ";HI!:XIJ$4J T9_+'#S>V\%[OKX;WH#/?Z>'%Y/GAW M,GBPV4!KTZOAHBBR>:>N@>E8/KCZ*B]"U:JGF;@@7&X^&_%L4Q[E0.*P64#? M#4"?V]W>WNEY@QPK%+"PS7.6 )EY@1O$^#D!=6FQ/1(&%R>'!B4>$8]0=\&B MQU]S3"O?-?C1>8@D[.D5PJ&"%,37 *>6/\HB4O(J5X5(?QMTEQ?/==/4YP8'VT$#H@G2^!YNTN#:0/6]L=ZME==_ M-E1%9E,!XT*2YG0 MEDJJDX-Y=? '[!#A5T6Y=P \:M%"^/C*)6="R S]2 0 M% LA>4IOV&PJOC:H-J5*3M>+(O64$ZJ>"E(YU85_$6?A[1[U=Y>R.&_C,)MN M]AQ#K%(Z"OKS8%0%\:DA,6NN&/%*=2*B7=*T4_X)&$(PRMAG#R,W6(BN<^CA M'N.UP>K#SDR=$O&%5$?0A6O!XV?RNLB'6!- %/MB;[!U:.C]A!,K<#)8&9*F M#-$"A+_S\N5S)GRF9$2AJ2!,EKOK$8'"G9MKZ05X<_SNUY./[]?P7.VLFQ;= M?WZP9D>K(7)TLQ>%I&(<8;H[,(G@HL+ M7,Q]F1UJ"C!>'&W*8<&V$?6J<[!X/C+(H28NY+"7H@VZ'"">KF+_K_9][@E"Z%^ MIX3#24UFQ#-*\QIBW"283+1U,AM(&J>#$CSHM_@:HZ#D-\*MR;2IX+"@&[P% M]3GP E+9ZSQ4>/$R$FK?&-4*WM KIB7ZG=TL1*Y0B\(#5FL8;9I &U]Z9'3DK5^W$)1QE38^C&;3)WQ=G5Z#C(T]2$>ZV#@?"2#41RR8M/=:4(Z4#ND$B'O7+3 M74[=Z!FX9UO?U'UNJ7K6)=L +],.U M&=?&]6, GSFFW'$20\1 R'JRSO/ M=UYS/S2[W?P1_G[Q'+N]8MI<0/=G<9YZB,/C[+^ZPNI60KL?\:O\'/WN?^0^ M<"^5!$@;_,-G/GA\6, VFJI>^L1@%XK";TVJO]I'&W](X=%Q,Q/"_.)SM35B^;"P=O-[N,@ MVE>Y2-6.4NBV^9.WTI86OL4TO2G]).#-M@EV/0#5,R%:5*Q1C+WK>[N[!UL[ M+Y]O[>!+G,_/C#DC;T + YTAH-X]MID5)GDCRKU!T+I_S!8,+% MP]7EA6R9#*C]8C!V%-AWK(I^S )84E91OWL)>.L,FC7-[RVV[KB@QX6S'0Z# MSK B1)!*D9+A0&9Y %_ZXDXQ"&0:KY;4B PD3,#0\]0> %TX0*6:KRJ.HJ_O M\(:>%\H7[+\1BTS.JQ8#BRVX,.9)4+&UY(B.4T,E]1&@2713\F2\QA[QW3?.P00Y=6B_.BD?[E((?N&(J7U.; MZM?C\_>#TW^M9=KX:6Q+GYP4P+7#TZ/';5CQ-EP.WCV>A15OPO\. M/@S6LX[E 6W"Z?'E;\?GR),NOG;XP6SBJ3#[VY, :[G_O:WZ?\PG3[PT&=6^ M*CGR=K;WYI]?EU^"Z3CH/L5B5WD/O9)_%K?5_K/]^>1V]CO'AZT8>;0A3'VM*-SL8K)3'F^Z#) PT6"-="&*U"!'G!@!FJ09=3V MLAQ?;44BP-AU&H\5UEC#0S <+,,UP^'4?OE$$7'38#",4\K<]0,866[BL658 M#7E8&9NA7I70LWT%&T&,8=1B\"U9)T?SLXO/_XZ>/_GUS^/Y9ACS$C*T+V'V-&/ZY<[FK=7]$II.1"CJJ0 FZG^@:/+@@C MA-7A] N4+,#!""\X=SRO5%ACXB1[!^B42O6??>.#OK@.0$:^U0C-$U)Y 3SY MK6W3?F'Z1IK*0/CI8F!* WLL$0V@9SX,X378Y"!E3Q5W-W"1/WWG,G6E@I"J M<$ HPSBR_\"^23*5] BE$K_,MLVN.,J-3(8AV!IP^,9 (F-J%4,+]HI6EX2U M,L=9I44G6%Z$1%\%FK)RA[&_:%Q![V '%XX6P=04F9MMD:1I>K#H%5$L=ZWM MXKY7R2?8C@L9#]X[,/<6"WYR^MXN^%H*IH^G)Y?'1][?3TY_/3I;QSJ.!\85 MNYE$^PB$@4 8'__>*2",AW(VUR86?JJXM0320YX0B5 82.(^*_8F7#HGD&UN M*E#IL5UKHVI&MV@&3NIY#3UWX#3W*@T_"S*E[B^U/J)*.4]Z#V3!/ M4ET%J;J>QEPO#?\F=&_COY'$]L3RPA2S6WTL58\,;0>6MD)=5B+6L+ MRXAV\+8'2P\=:TM"JB.E?5-+@K *CV:H G\G%,02?1!QD"_.-FDVI%)0!J.' M[-Q((3UL74J":RF)N'JW.V1VQ\&(@+[5?.KMO<'[+D93[6/U_XYA0!>QV#YD M/2[*')A4@#<&"E+JL7K*SU071?9G MB,:A%"VIS_J6S*HBTHJ6%V!XANJ:8#X+B_\/&$.*B/AW=06OE2ZV-C@2%\(V M]O=VO&/A(2O5O[B=_[/^][V)>;!PK*G#G(_=!1^28 MWS3(+WO6/]+-C.N3R^,/@U42BT7OHE:A:.Z:0$<==)3)QQC"MM#4K:[G)-49 M.ZSJO4 *Y-8@E21O%_(T]=PN$YQRBB7E!E$'KDD+5RUV"_+UF.!1$;W$$,ON M'KZ35G:3 8RT)/[M[Q[@6_?WMNT5#KH1&A*DGCAH8@^7O>ZO"WL]RS,+;S5@ M?.$.<-<*6!WVTTX%LPU+,!<&N;]B#S6Y=(1!(3?[';[#UL(P5X-C4:BA1938 MH.^%6)N ;7'Q.)Q),U_BDE& A^4B8VQ[?I(Y( ;;89!E:C2E@;ZI,W<1$4V" MH,"A-A.>8'IY 0!-C87-GB'0G89E]]O/TAW2N)NA(1Z!6)L[!49G\X/K\X.QV\\XX&EP/OP_G9 MX?'%Q\?L/[\[^=7SLG9Y=GAP>>QN2O^J=G;[[U^8=N=8=9U&C 9@% M9NPO.Q*ES=CO']Q%&'V3X0U2;Q'GB;7(>L:_?8('$T3WN\SOF1:G$_*E:P+] M1 1-8*='&".DFA7+%!WX#-)KQ/>?DO,_M1 1B!?1XNEWPZ@PNK([,T@I<9ZM M,VS8&!%^)[DJ:2J-CS2AQBF\/F1UI2H)J)%+X7'WT9<_3^),F#86N]V2@1[T M7]9/U0%A=MT*7^>.#[L'6B$^@[O@KFDMUH.",T5Q _O0,_O.BPUC:$ M%_:\H8H^$0_+RU!#=5=9E.,M-S1K?:2#KZ4#)X_6/88;*DRQK?!0^T[=9D/# M8 Z>.3\@O?2\/^(AD% Z2@)QF8_S:,3QE?WGKRD1MH<057&"(O-QE[_S+I?R MKC=2%8)L@L,81WA&,-R9EIU)]"B!Y:>C M,^<<##A\K-#1;CD0.H?_[)4SZ,$$ \;,;F@(^KOLW4%U(4!%4ZGR>J 86DJ")2$+['$'OO,.&/G ;O)@](F. M0:C5E>3).8#Y5L]$RY3]\>&BA#U;[?7)\+<&)__VOO3M_AYNFGR;Q?-7VWUW M:VD._%5I8[?[:VY$N8X&X[>@5633]C;>BFJ>(L)MW) 7]7B,OO88X7JSFUJ$ M?:_(#76P/\N%;Q4]7!6YE^2M\/.$\U)\08:N^!MJD5,WFX450T8!-RDH92A7 M3D1Y)(KOJZIC5R#CX&MBB>Z>A6H(.URWG^G\:Q7*(VRGUAL:=#]NX+$U8G9=?E(T%?340#71^SR)'1W MTY:*7$<%T"OK!S,%#X3_&MZO/"H6> 'PMN02(TM$T0K #*JYR#L 5]J"8H_76]\Y,[5PQ M*5H@\4R+7BL!)RKJIM4ZXJ.%7E(F=S>S MT)UA#PXBYOP%R UZE='2B;V>QK/:)L]TPCV*N:)#*NML=DTY<8@XVA)7(R,OD%TK-8I?4$ V]C+ #/-$$3PHML$W*?4.20_IK"6DRU MTGP,)@",SB9/$*I[858$$5-P?&U&MBB%Y]#C)1TYYCF=%W9V&R=G#A0SR14B M]6D&:Y?XG8JX]&^>8 X$9G'J$.FX&&K?\]XBA$""993JHWK MG=7NI9AI!\_V1CO?7IXM"5[/N9[KKS\]VW\=T$;U@2#O7^8^^:4S;/]>XW%K M:9=>%&U]G.Y^$DN@_&2T/ G1PL@G0;; ?VFJ-;8ATR;I4S 7Q7=2P_<1"@;4 M3Y*$SV#/9@(RTL;<).5(M_10\TG]UXV!^ 2C8A'G'(8Q*B]%&YT>\[VRWC0R MZ:FH-BU,9Q\!5G>[=X+A%Z0TLH8WC1!5@D4P^WG$#VP M)2O8ZM^40!%P/\4EU/1]^5ES^3(-9QPD*:@IE.,,0S1!V."N*8O?9/7+?I_[ M7(OWV 8@5-Z'>#3%_3@BR'[8[]]R,%OP%,-BH?)Z_/YX\)U'V+PV<;**=?%^ M \V40@R@?[[+9S-LCO&.>FA@(F<*2@>NR$K$\6V=05_+JGZ\/,QG7<_#[([ MX+,02%I@"S<%"TTQXH:8$Z32@G8R#T;I#RYQ!V&*;9LSL<)Z5-CX61PP!B# M6%]GE$B9>!M''\XVJ>_LG!8;C *PJN#S3,-0Q/B":=6D.&J-KO7$/050*1BHJ.OZ89^$E,*"[1"T>Z&8>)7WO+"3,P/=ZH9.M M*UBO;Z]^W)[;W_=YG.\]5X%(<\H MGI$U?;5E%=#^9#:<_MB4B^=7='88#?4:,PF**KD)J:&CD_KGUEMK2/XZ&_ZV M;N._R/1\BJ['")VE*6BA.R_6;0[/G^WL[7E_5TF8)OD4Q,BO&B,ABQ_ZM)US MK59JS.E \(AJUK(-3Y'B9)PA&6B=4FP.YY;;-5.O I\=T]Y0I0'59J9Q43K\ M8U&/2[Q/=: /2YV)\N]NF,I=*C0ZI%6?^R: MJL?]7Y_RJ<>]>JR4ZE:E5'=$ZF/1TF/1TF/1TH]0M 1_QN-O+UJZ7K1$7.Y+ M./!C-+XW$X33"K(?3.__K3 M[OZSUVD:3.K+M/>R#N#@LB/?ZX$K'B>6N84';?OS77!^^^Z#^K MV.8O;YE;>)>.XX]2O"S%7[9+\:?8%Q?^-\UFX2__'U!+ P04 " #1.Z16 M#Q!GG\(E @!)0!4 $0 &ENS[GM,[PF7G/+B[?0.;H>EC"1N$V?#%D2,4:*!+DAE^_5U9DC!@L,$62"74 ML3>65%E5F?FL,7.ME7_\W[-VJ_8E%+V\V_ES";]$2[7_^^:/_R_+_O-VZWUM MI>L&[=#IU]X5P?2#KYWF_=<].2_R@\-^ MC2!";UPL7B.C+36<9)%&DC'-66:YUO GO-3,DP \9QAB:648R MY:7,7"2.412(9^Z%?TT1QQ1'YW1@S%.D<&!1V& 0CLP$E%Y[V(?1P0@[O==Y MK\L(EG\N'?;[)Z]?O3H]/7UY9HO6RVYQ\(H@1%^-6BR-;D@7?7[9_FI;\6IX M<=PT/^O?_MR\T\H[(4WEJWYA.KW8+=JF#U,-3R$H0R3#Y/)]O?S:0T[I^'7X MU7_J[[?=86B;+._T^J;CPO@N>/[Q=\:4+EO3NVSNPXT1]8)[>=#]\@HNI#Z1 MJZ//OS=9U_MQ6\^QUOK568+@RCQE\,)KC<<=^-Y489XAE5%\^9Q.KWWM(>F' MX%^Z;CL-@B)ZI>W97:/ ],I++\?]S81>&TVZ.FXZZ&4'QIQ<-HZF9\NFHPO7 MYM-U!YU^<7[[Y(\N7KNA5_2_?3+\^+71ZY;I'/RY%#K9SO82T'HP_LT?[= W MM71;%OX9Y%_^7'K7[?2!@[/F^0F Y8;?_ESJA[/^JQ*;5V_^Z[_^ZX]^WF^% M-VD>L_$,_O%J^.,?KX:/MEU__N8/GW^I]?KGK?#GDL][)RUS_KK3[03H0'[V M.C4,Q?!C[GWHE!_A>@/$2)&[X?O/^ELA_KF48^J8T3P*'C#CU&BJ-%8$.4Z( MPMY^7BF[@A'.OJ+:,>WTZI"_7NU _\[?P7 *T]KH^'#VO^%\J99[>+2GG\[M M2O?+>[+U98_6!_YH]UG?WT-[NSNE[VFCM770OZBL[9_6+M?8>J?/]YD>TOU(_W5Q9:S76 M]\A>^]-A?66MW5A?:]77%'I/]L_W=IW8;VYZ^]^L6OK^5V?4?4+SZ>PO..Z^T-LM_^>-I8_T@:[0WH MSP;;(SML;W?K$/K%ZD=N=,\G>!?O[#>[%XV5M]#WC^=[1_OM_95EZ".\^6CY M;._H\&B_>7BXO[YVN-\\.&]@=?&^N=JO;Z.S]\TT+D<^8Z^U=,)F3*8_W-+, M!N9&!I9$FF/QG& M8]OQ*\AK\$MO ?&/(";?0,P)ULB,+X_J[X &^&_3Z77CCAZ+K!ZZ_W/';H?B2N[!Z!M9E M+[>M\#[O]:=+"&>;V[KMVFN=S:.MO [@;*[4 3@ J G J#[NXW#QOK^8:-Y M<+:_\I'721V]IP!P^ZRU>;1_U" ;?'/]X]EF\VU[[V@+P&L<[@%9[.W"^X_V MX?-'#D"?C>^!=PWVR8YHM.MT[^B8[:^L\OKZ?E[VAZPEL@#B@>]M^+S2.H:^ MQOHY.AT1 ZXWZ[1Q\)E2IQ6R)'.!@\;VQH U!B99#&"96:X44\#LW_,Y_C7" MI1[:-A0/(1DO _/!&ZXQ90$#I7*"#1",D]A0;$J2(6.2(0N2F0V2X4 IRI.0 M4=#\&8O(9D8QFRFN>1#8$X;D@F06)'.%9!2W02FI,P L9HPZE%DC0R9#E(2K MX#1^-"FS4$R5)!EC,5@A2F1@BX)BDLYEE@J?&>.LU#BR8,4,2YFT +89WW5[ M_?5NUV\6"\KX.A -*$1Y;6%F=8S2PHX]$HPVOE W4A$PX#96#P>*T$ MPQ4$"<..1U0N3"XHX_E11D!@FNI ,Z:4R$R!E3I0:6%DC+PF#) YWU+&Z?UE67:()\.-U=6Z5ZSSF[2QN;NUM'>[M]Y MO0WT=G2,&HGN5@XN&D?+<*^C,"Y6;_K#^L7A-1L4WG\!?4;[_SE$KOVI8W;U M8//H^**Q\O?A9O/O=H/4%$Z_6+8UP__2R%P59KEG$J5,9 'F4F4I!%-FJAG."._,AKOA/KM+V/Q%0D M4R7H[Z+Q;DQ_R^?UW3603_".BT_M3: 'N.=P/[4]\OG^RL[IYN[?\(P="K34 M"G]MG>_O^A-+F*BO;)SM[6[ ]1W:V-UCC95CZ-_:,?2+-,C?QXWF,M]K0W^; M/M8OZAAH[3.(%!.B,!EQ)/F]!&?:"YP9Y*3C4L/D_\B)^170UY*GFG<[M4$G M'T+>&:3F2]?)P#+,B!',,2V8%]&D>!@NL/%41AE+HQ:K$1FD#XD,?'!YV[1Z M?RZQFS2Q$FQ_H]/K%^6*/7C,7T+13Y0P_)B"?[92L 4\)2WFPYUHNO2!&Y>Z MZSC==[$/^@=X^J(.NJM^M /OJ9_7R7YKCVR@_?8.V0>=="F?VA_I7GOC#.@" M]%?]?',%9 [(L$83WK<.] %R /IWU@ 9=5,^[:]XD&NKT+]CMG>QP1KKC$O.55L3"-CHG@@D1C&L#.7&>..T1@M9,A-D\JTL<=P*:RW8)Q@4%+/<9&"6ADP'CB-8 MR-)1MO2&HI=2:/*KLD1X%RD!CTQ29DQ04G"$0/489:13"UDR$T2R^:TL074]5J\(,12AXT+OEA##%/WX MNE<&H@+9U,IHR-=]\(3_7.KE[9-6B@8M?SLL2JJZ&DWX\JSGX1&OKC]C^/ZO M+QWUH=<=%.6W,@SU]8A4AP3R,R;R^$&A#!D"WFS>_&?]T_>DG943$^%NO;XI^"G$JPS0RZ!S"X_N^7KOLIK_2E)9Q.]>O MC+^/7_+JVD3=.F_>6,V8ML$8S%C4QG',%%68"*Z\-9\WRND"%I^!Z1J&%_=' M,\"O3-;XROUF($F]C H+XX?,;XV_IZ><>N,.C#J M$%AA#"PPIFS03/$8";8(42;I>$9G@P"OS^A5FOK)&1V4_'Q]RD8A]*]WME<> M/)O8@&\F9;1<4V8=\#(3RDO#G-!4&%K.)BE77&9J-LDXLNY79_-#*+83(5X. MS^=?H%M7FY;>I.EWBY^<^&_N3S^NA$ZWG7=N>^Q]V>/:(UY=[_V/4[N+\_)Q.2YB0%K#IQAG&44?$X1!$8Z?MM/J4LHS&1N)V'X:>[EG]9Y B^;OMDVX'OO:6SW(0 MU>-F\'N[V]GN=]WQ>&WEUE==^T*@(3<8$IY<&"1))Q0VT$7P=Y M!1ZY04'2N8%I*_1-W@E^U12=O'/0JP@^3AMA2'2,8\6"XI99% U#." D@U%S M@\^R#K)IS<#/["!.?RJNF3/X_N;,C7G[%7.&>:2M%S!U@AG"K*"1:>[ MS)$8F^>N,W_8BU[1?_UN*$5 :*S&&%Q_F)2Q&9=]]R2][7T1X->/PVF M(H*'>$]!<7OG%&,2''+J7 S"&L.CT^P)!<]LZ?(%W?Q [,B(1+0JK:&"I4ZT M +450C3(BV YGUVZ>>; 28F="MY1IC2CP1N%=;",!>X"D5Y/8=E@MCC_)X": M_J(&Y21$02RW#C.@4X6="YYIPHU'A$YC,6@>;?_I QTP!^].,X:L9E+#?S3( M2!72Q!*LY?P!_:C+6-,'U(&QKB((90]V>U#&6H\D%M)29$S$9!#*VD>,'VJM6;R*UMPUZ 10B+J$%$B4(8M M,HI83YE)QJP5HT6R>8!F&FO-DX,I&&\#M8(+#QZ&C58"0RFIK161D:#G!J8G M76N>'#Y>@0^!HY>.*P;6)@@\HJ(ARB@6M0AS@\^TUYHG!YG5X"!PK)%%GA$I MM:&(I74@(V6R(Y\.LFG- %A<4@I'*0T(?&!K$)!Q9(HK114+X>E")N9&+4]J M>4(%'(()(G!N&65(P61#W(.TCX@PQ+XGFSDJ* M/(E$!F;G!Z8G5LL36];7#,=H?$AA=HXIPXEG5#,F+ >#:G[PF;Y:GA1DT7+) M9'":I8I%7&@NO?$&1<-%\(I,(3ZW\KPU_>AA[6C:&/%"8C"("0;+V&'D+ F> M.17X_*$Z_879J0"MG-$2 M+@6ARDPZJ=R(ZVOF#'P)3GT@2C%#@ TUDH@:CJ/F1OJY@68:'N#D8 I:262= ME!(+YIDQ(C#MM'7:I<#&&7 )*V1QO.MV7$CU)9. V\I[ MQV_/WX:..VR;XO@Z?-NF%7JCLI2C\D/O@=U^-3SO.QU)):AN*,E1^-B>45"I)8<,;L<,9T(KB8H,Q%[XB/:?'<&!^Y4I*QB'"L MU#K?@I;O3\MOYT3*7P\[%29JRX-U*%DL7@FLE5/$,LU,E'@AEQ>T7!6YS(GR M1BADRJP&$A422@6@9^2H,6PAE^>3EM_-HURV++!H&0W"!Z8Q-12#+\DP#XPR M:]E"+B]H>8;E\J4G6823;I$JAJ9?OJV:D\9^V60'FCS8L0Q4>^%1("#P&8K. M&FRI ?,<21\UU142^LNGIO#?4N1J^Z35/0^AW +8+'/6YE'B8>%51(RJ9'Q2 MG([UL1QI8U.X<.!5RHN9&2"G8X9Q#?ZPIH+'R'P(H,J\1MR YE)(6UQ]CMP* MO7Z1NW[P)91);O6VMG?FD2NYQYA8L*DM6".11"VC0#3Z5(B08E8E_W"FP)P* M9WJ86!"HTAGAF&!*DU2K0P>9 JDIIM7GS ^A*(]/!]NMK"@WEQ%I2D1G+!4, M,<.$4-8(L'D02%UCJ'952CB<$1BGPXV:.J>XH92DJ%ZG" 4 &76<\D!QI2Q7 M>(+/6X-496$[N$&1]_/06SUSK8$/?GA67?MDT"^=JW[[ Z9M M/DV%NXD#31LP)<98YBS7(1!*D1**,,69KQ)WSR=93,>J=BA5:@&3.@86>01Y MH4-,IV #A5"4GP3EG]YLDLZ\N5K ML[F4&,Q8JBQCQ&'& U/!$*%M0%2(5"EB(3%F@SBF$PXG73H ,$1M=3K UA*A M) 7'1&">SOL:5:/ CW^\RD_3Q&4)R-Y:MVB$TZ\''7XHNAWXZ,HP]F_CUN]S M'.(=6/^P=Y4L!&:!IF/WMES>3%)],:@,RO#Z,1T@/6BO#/('3<^770 M+AM?:=K;2G*_ " G%<%R>Y?>FEY^4P&9HCB'%V^5L17!+[<325W>OI+W7*N; M[J](8@VU2GM*A5>4IS,=#;764^,"XBH&KBI%39EHVJ0]FJOG[=!&F[&RUNJ2]>(!0YZ3C$J$?.,&(4D%T#=$T6=#UG=*V\M#%@)9%'S!!JR_.:O?%@Q"@?GHF\I@NZGC.ZMIYHC"W0 M< K&=EHKQ(63*,71&!SU[%?EJC(IS895.[F"82X$;I$E.L4NA^# R:5<2J85 M.+Z^8M2TL&HK+B4G1]<:2VD)2<>:,F8D,H)8*XPWD41K+7H>=+VP:N>-KB5" MS#+BE-$6M#\U2FN$A(Z>12&=?!YTO;!JYXVNA0O"6.^,1I%Q%[20T2'GI H! MQJTW%)N[@UCCPO3@8XV3[N3 M(J&W@U[>";W>LOMGD/?RK[LT9;);O=L?]-[FW9[+@<9#;Z/C'GE/$&=(W?M, M2V@ZD3W!B 7&,2*)F69"(WNJ"H,CXE1)!&U$NI MTOEHUIH@J"**6TUYL/-/4LXC' M1:GD.*Q%4S2K-#5K>)(,R?M'HNB,H@G@:< R]\$+Q[UF$7%# ]78(R$T(\SI MV5]U?FM:PS##$/KON\[S>=M'7IK^@1\'[IUB&* 2Q# &6 MR$ON421@)<5(:85L[>_CN=PZ,*$3_C.G]BVB6%L4E24C:H;H]WXS; P!N" M4IA4P7:=ONB<%#(W"B%W8R]5)KN]?-6P"9!;:C)^WKW+5V'#E31:6*8%P&XM M5U19P4TJO (4,/NPS]26PAS1X'4+2QC0NQ%S+U,P-5'2(QL14(W6@?(X^V3R MB([3@E1GB52-!!O1&.>DDXPSI9$)3%%) C;>J0J0ZA4R&1/A^;N6Z5TMV+B2 M:*%[DIZ\W/%;X2 EWW2+\WH.6J#?[53&V^?&1Y06T"7%+%BGO7#!,Q:P9UZC M"IPR\B1P_; W*0=KRW0.PM>4K'K>R=N#]EQ*K^=CF"M+/6&68\@_M'>ZJ^AA2<6%ZLD MBYZ'Z(,A+&G.8*S5G/HH;>"C+,:Y1^M'LF9FT K,BZB]Q(XQ(J5R6$;'$0[" M!,*K5*1H1IEL^K6&*#/$4V6Y< K0YHHXB:*,X))K(T*5#HF84=:!UN/J MR G6NW,T56]4CEG%5 "IJ2CQG! "<"%7@BQA<"^CX" M&C,KL?;1@B6&K$UA<23ET#M!8L5"2!<">@X$]"-P^JPP6Z3"Z"JQ I!#'[3Y026J_'KH'A3DYS)T9,5D975*0 M"5I[QZUF3C(E*,2;D;XL-N%)\_CTCIW MPD9E@C7>LJ\D_?#>_ 3_$8'#/.#Y" L]WJAWP.'QQQUBYO!R&72;A$\H!N2DPA8 M7\F@JLJ&=4HB5XX :(X%%Y7G04N!!)..B;)""Z,Q";@*05L/ 6Y\ MTT;G0]%-.5+5%K*"@QF+J1($7'X/EJOPJ7HM52!7N:U4Q$@E4)R^H%6@3)'W M5+#@F:+4L*@YUI2ZB)2Q=,X$[2SPZP3WOS##47 IB X,!_!6L-)!:RQYI-+0 M.16V[W.7GM,Y6#XHPG 7H2("EAB!G/34"6]9I$AI,%]E#%98!S]4*NQR9I&; MOE!-62 8"X4Y)RR5, R(6$F=#TI*Z:H0E3>SZ#Y.82%)L&/!AI("MH(+P MR)#(P=68,P$["V[&Y(2LB 9SC0/X&(()RZT"_T+)2()VV#(QKT)V-I8%IB)H M,5>1>*88!W,U556G)LJHB>1*2#,JC+E >C:%+0\D@D)DR.' A(M:(,VIIE$P MSZ@5GG\;XG]Y<1X7YS@E@E.)!#:"&1*4 M! _26>-59$A3,_N+<[."Y>,D:""*(@>?$-/ E!/:,\1BJI5%4%#C&BVS;+S, M(#R3V\$ -SZ"=:D\59X93E6@W()#+Q5&%H4J;1$_"*>U00&J;U"D2+FU_"Q] MFLNM"[!.,!*$,$1 XVEA$5BAX/L9L%$ YPH$WLP@K(\C*(-C3!(AI+(L@%,N MC6/I-%BD#!:*SYF@?'*D)B]$/QERG\J2EAV^[&?OKXJREU/WU\124ELH;_!-'.,T=80,A0X;"-7 3, MO+5SYX1,@WH>ZPR#Z5,/]D9%;IE$D3 *>D%8@1RW)'JKC*W 47U/032SHM/! M$U7.$.>4)BR%7F+K $!,$ XJL'G1Z5-%:W)ZG>,0-+<&P!+,!J1-#(13:3WQ MTIJYT^N7A]_%F+LPUXM$DC+L; !O%XQL3H3%T<"T*T&0I]JX.1&;3X;HHTC+ MP*54@GENX&\ZYLI+1*.T2&-KP7.=$VDY#9 F)R0I41S\' LPF*324L06\!1C MA#E$695"7N^OV^JF,XC&@9.:=P[F6U &Z91 7(H8&+7: !N2(*-@.N*H*E"" M:?90?21A&:630J245Z8XU0@+F6+I!#4S MD@:O%$>:(\HCGC>!>;E-'$PO''9;?J-]4G2_W&NC^(<]>5Y+18PHJ8P!Y:K2 MR=O41&)D!-(Q5GE-YD[7/CGIS.\Z$:TTB!U! _:&2.]$(HA:Z-$1I!@KS"IPOOR#H'K7+0L)_"("($]14P=)Z796JC MM2 +X8\@S",%."%P1Y5%R#(D544!FU][D)H4FJ!-P!P<469L1%$'(QU8')[& MF\4(GT(L/G3>'A3C?4TR_4K\E([!&@OJ71B&B#-@)A)B61.M4 M0%-*P3CGI K^YYT%OINA:+_OFDY%N*0LC!^),0*!>TFUD48;YQVQGG 9*["K M-ETD)N@],FYP=.!$8LRD!=7BHR8Q>">I%R./!"->0206!Q#=2"5$?$)'C&FM M:-IQ%2Q54-3*!>83%PN*P6X;>D9 ,T.[;4$\526>:Y9N23[WLW1O4-JO;#8P M*734!B&O0&-'2XR203*%:0@QEB$R.)F\U2.PQ>$[5X035LF/FE!B.J-.:"&= M9\R!C\2" V,\1LJ1Y+(\FR"13"F<%K135=JY*IN&U',OV723T'YEN8DHR;FF MG*C E"0FA6DB!WI0>A!7M,*6TX*^'LEP4M0Q+ZU/,1=4<"65"(DABNER6CV[@OOWF@'_3TIO+)39C-'\H),/"=Z;\TOZ;0]/VAPB Q?&]XY_ M'W]/-]^U;F4(R$@1!&$X8BV%QIHKECS&:'@%S*\J,<]B"6T63$%B*0*?0ZA M+".(:<9< '>56 3*Q%;!YY@4T3=/NPNB?Q9$+[AD.J* .3$,F50%+SKB.7:* M.6'(,S*3GH+H%V;2#+@&C 1EK:%4(LVP5I9BHI!3Q&MOQ+-R#9J'15@X!\^" MZ@G5RE.!HXF1&8JL"TP3Z[ ARA/VG&SZIZ'ZA8$S"P:."Y@&;9VE5C +TCX& MB6PT-D3EA6//2-BO=0?%0M8_!UG/@K"&,&RYXX? _QATQAKIG).N? MA.@7HGX61'V@PCA#%19 ]9(;ZWDJ=Z)0)"12268_!FI&H'R4<"-E)(\LR%AF MRV)D'-:$*6]XRFN1%8B?G3ET)AAP00-*I0FCYMXPK9T!AUB8:#P-T0A4I4K2 M"]-DEE/9P!01Q"+G&:),6Z-]))ZD&LE:4:RJD'NX, 2BH\I&SY0A MRD5#)-%21VV4+,BFZNM*9^G ?.8UFK0C_#$+'G=_1DRM->UO!#8I4!.IQN_36]/(;A]Z\ M,T5Q#B_>"B?=HA_\Z[53?=7TE/X-1MBS":1P1'HF MA-?:@B#W448A$7BC"X9;,-R3,]QL!#\^"K\ADHXNHS%*Q)F(S")%A0#K2EBG M"![72$&SRV_OBN!S( N7MZ!;UTEH.Q%O\ G81R>2ITI%11/*W&%4*!($LE(Q M\*JM$HYB8K&BE(PV,!/PXW(0,TP!GTR1)P-T"XR\*X",P-\$%NWD!X?]M;QC M.BX)%&BWO;FV-2F2F'\*O%&% VCPWE4XT(36Y2*+5+)4JAO^2F8U880)^!"U M%E(LR/6'[R_?(DR!GW^6:?RIY%-N? MVF #HB ;'&6!$P,0*Z$LXMH9ABI00/Q9 3^Y,C1(DH@YE@YD/U.&:<85MI[4$$EUZ>Q5!(AZW *0_+!:!2$-IY3IT+DP57HG/G907(Z M1\D'2G7DD7+IF914"\R1QUXK8>RXS$]U>?(IK:BI<&*4'AL.ZI(9QD@T%CN- M;?#*:*V#%A7GQ*>U@J? ?X1*'9#DW#G!0)!:PZVR&CL>K>.X2H=R?D^2;G7/ M30M,I8,B/%;=]>GS8BKP#!R--72/>7PM()L<9HB;!DU$B%8X@J$G#AO98QSGX0Q8(N'B7&0J> >!0I M8H%%K+0R6% "NKC-@NCP.:4Q+6,X.24Y.5"6=J1V5 MP9+()))61XR#9D[@8(/VLR^JGI>Q]2ARR5OL$+;"$(68"&"%"^^-0MH:G\X. MGGTBF$=4#.: 1E36,\&")#I2&Y7Q41C+OF['/A-4?OC2ISR]ZU'P)E3[LEA2 M62#/4+ BO8P*60;^C2<5.+SH.8OB"6W%*Z^]E58);BW#,AHOF"02N8"C,QA5 M:-OA>5'#]':YM%%JI;57B#OI4 6"]Y9/3>&_]>E6VR>M[GD(V_VN.]X\28?:5@02K;!E M!M2XMX)AG(ZR#1$,."$X0=B[RD*R%8!WUO;.Q6!A3 =C+68 M@;IEE&'K 14;)'@^W"%J*@O+AU#$;M$V'1>V#TWQPW6760&$$4V4D"82#*"$ M8#W&8 0K$40ZN+L"@,Q(FOSC).*Z$ 5%WAF.F;9"\R DBRDVQH%/.CYV3H[W M8C5%LPK3>.URV?TSR'MY4B57EB_KW?Z@]S;O]EP>@(5Z&QWW^-NM\O[;K3JC M: +6HM784^R-DBHM_'D=L(E"FZ",=X2R$;?-<&&C[\/X"5@-?@8@'P7 ZSPV MH7)&X.L%(; )TBC&E+5.26PM#4Q38\4W,6<+<";NBTVJ,"K7UB(2& Z$61)L M1(P ?R&A0)>%,/NZ;(:X:U*'@S,.HBT%_6F5@JQ1CN4:[A5[EL*G$?6(*TQ :G13)&)-4X M'0"(G:!<2BKETZV03VO-F$G+G=$N%;\#FSFM$U.O%9=*NN BGP)-5X)R!)&@ M7J-A9; 912":8Z2>JV"UUC&,K%DVMF;%[%JSLR<+0-VR^]NS8C+V+&(**9#D M !YFP1J%6'128N)!XGM.YP/1<9-4%6"YU>KVTZ,?:S5L^J :0Z0$MQHWO!XWF;8$O^1@%_N-P]#W13' MH7^Y7?'XPN"^/A6>V/Z6 -Q4BH:(W#"32C$C%X,1TAN"%*6S[U/-!I*/XER% M"/PEJ"#*:F:5M!%[)*F/(+VUIW:48B7'*58SO#PX&RC=S+2Z[PHAF=@*(?:6 M*8*#-]0P1[4A!/@N""DD(S26^\E8(X[%K"+YH64Z#=.^6E5I.?5YHY,2;%*J M#31H'N:%7X9[_6.S&]8I60:+";";E"8RQP5STC!IA!92:AJ-03'") [9#0$V M)!M_6(!T7VY#)4SD/MQVH^FOK,<[+-+1 F#6$A:,,B(FPT_B=(I8Q&2T>T PW\R2/'](<43@U1$<$HY\@Q'PZ+PABEC4FH2=]H$/]:)'(]T(GRH M-*1/RJ2DA.F^*O%JTU\IC<6"TM($,&XH$SYHD+J">!2\Q&#OB(HCFJ +?KGC M4V0'3)%/C>811\Z0M<1Q2K4&SQKU.57)-'P2 MP&AO';,>,R&8]\J*$*.G)(6S*>3#Z-0[ "9;(/00&7@3HQ^C)FB%FC--@\F@, MYH^RD7*GYDV"/6L*FXH,$RQ$4(O.I[.,TB&)'D?FB$%&8NU5E0KOSB:JTRG] MR;R.D3AJ44K>Q,E30HX0IJT"N&V%Y,9LHCH57M4(4Z&0T8%0)J('PQ9^"6![ M1*.))[,;,#^LU5KD!P=E]%=9$^5JPD/> @B[G5!>P),2\S,40#RA\'Q+F75: MXF Y8RYE57(+'HTEF'"/V RG3#R( B9VV-S\44 4"/L@M;?@/=YXI*T8/F8TNPFH:C[A[ZKGS 37N5GK\$B MZPX*&-[PZV$PONR\S[^\^0/^C)(<$ ?[,CH0B8QYBA0.+ H;#,*1F8 ^)XR_ MWM/KG[< S7;>R0Y#.E+T-<4O^4G_]]/<]P]?8X3^_Z6RY9L_>B>F\^8/6[R" M^X>?AX_YYF$GQGOP)[)6B/W76,'#QK\4Y1O*G]*X,M/*#SJO4W1**(:_Y)U$ M+:^I..DO#5\Y?JKKMKK%ZW^A\K_?(\Q,%DT[;YV__I\F$$ROU@BGM:UNVW3^ MYT7/='I9#^8R#AOV\HOP.KVU_'8Z'"B#Q[2 JL8#QR2-M79]<%>&]4V/H8/] M9!:/&]AN 8ADT-&6.>F%U^,/O_N\=](RYR!.R_>5-_W>-L4!S+KM]OO=]NLT MY64E$&=:HY>4[QM>_HK&2S1$I _(]_WXS:/++\M+K_K^VVM:O=3H[LOH);Z\ M]JI\=C%N,":+$A"X#T:5)NC/);IT8^"CH>"3?JW7;>6^-@9K=+W?/7E-OKDX MHHW7J(;+5WSMPZMRHNZ)Q$1)!;,;M")OI96=QD9S=:6VW5QNKFX_B&ZFT=OM MU7<[6QO-C=7MVG)CI;;ZGW=_+3?65VOO-NOUC>WMC [C6$7=,[!%KI M=SLO:BLOW[VL$<29OK/;(Q9+="=N$SE3 F)M5 M)>R2Q[XT*B5"/YW;E>Z7]V3KRQZM#_S1ZI?]=7VT>50_;317+^J[^T=[%ZU6 M8V7KN'ZQS.J[.VC_:#_?WUT]K>_NH;W=G=/WM-':N^A>U%=VSNH7:^T]4N?[ MS8]H?Z5^NKFRUFJL[Y&]]J?#^LI:N[&^UJJOJ;/W9/]\;]>)_:-57%]OM/?; M:WE]9?D,WM.N7QSS1M/G>T<;N '_WVQ^/*T?U;_X]4_,__5W:Y^TOMBCDW:] MN7.Z1_;;>[L;I_65503ON=AL'N,&^3NO'^T0^#]OK"R?U[$ZKS-P?QG M4F3(6)DQQ$QFP6O+L/+<>NG>_+ ;RG- MJ+;9"?^^9S]_OZ:/Z24GC%1MEM3Q_<>R"T]*3^O=-0IR+S7[!)3_<0!F6"A: MYUOAI%OTEVIE!;0^O."L_SKF9\%G_6+P_)CC^/RSE9%JY%TF3- 9XX9F"@69 MH4"=B9(SPOG2F__^EY9,_'Z3/\9D=T^"62YRT[HOL=Q.\D-A^>W?!_;DGFR( M[]6GCSO+6\W5K?=[M:W5#YM;S=J'G:WMG>5&L];M#EVJZ^SNX9>L#>\\3+=EX$YGY\$46>@\-_8_^OC9FY2^ MZ5SF*(N@&AW+-*4F0Y1SRBF)2JBE-_44N#@D6(I?U-+$_ZRFG!D:W=RJALZ\ MO?=/82T6T+]R>>5NI1E-J_<,M>;%9R\$3"ICF1 >^(9AEYD0:28(5@CSE,PW MUIILH35O[5-S:[FQO9%TXT)M7E>;_4O.&^O-6'3;=V$XJ;_];M7F*^TWY[VT M.EQ;RUNA!OR5UHP?43:NELO Z67#=ST[T7= /W,?7:2>9"D?,F,QN$PKSK*H MB4:*A6#3W@$@GU$DJ;Y+^%5EA>;1J6DK')2AU)U^2CE[=A1UC#X+Y!!67&54 M&0?*E)C,*D2S %-K/!),6+/T9J.Q75]=J6TTWMTDJB?!I^TP/.P:>"0_=>/N"G)RE#8Q;]K5N MSGGWY.E5)WH2J98R2@IP&\H\DC*QY%UWT.D7Y^^Z_KI##D-PK\MZ B=%]TMZ M3D4]\;76-]J-797*?QVN-?>/]YK'I-Z;)4;V]!V/8.]UL_MVJMS?0_OH.WFLZ^&TMWV]O'6XV]\[J M*^ZTL:9.WS>7^_5M=/:^F<;ER&<>G :];#,/CDG&J%*9,1PE->U2YALMPRH^ MY4D.Y.9.M3SB@>^0][7=N04G_(@3FN9L8Q3V,,RJJK#I^-0DOG&=Q(-@$6DD M,V&$SIAG-+,8Q4PQCFE44G"AE]Z +8JU))+<;7M659A_8U24)/Q;*5]KX#UV MP7TL:D>#(N_YW)4>)%@9^5597#8K#DPGORB___L9%RFZ;/C/ M>^@ 7HCJ'XGJBYO6R'NZU0I_;9WO[_H32YC8;&Z<[J^O'=>/WK;K)/7C(X)W MG];7]VAC90/OKV]0F(OSO8M&;"Q_#LHC[10#0>]$QB1XA,99 7^X#-Y'JKU< M>@,44MO9KOT%Y'%JSM.VQ"N28@VO"_T7-T+4YD?,W4O*75_H78B*R8N*=_!Q MLVAV3Q=NRP\%!?J1H-A?WSMO-#/ M/N5ULE4*"AJ$DMAEBA":,>)T9ABSF988"XF)5(8OO7E;Y/X@G(*15'PC'1Y_ MN7A$)J61MEE\ "<7#+*%#SQCQ+2Y_%EX8HBC*"/<@0?MK,FTX"Z3WFEP,13W M2BV]2=+I[U#TPOGWE[;G2-',EKS]T 5.:>WG)\.EI 67_)!+;KC1C$L920R9 MIS@D.E>9E9YD(40PK@2S8&HMO4%*(?E,1WQN8_]8[>MYLP=X3-/J*D2L;@4S;WYV#X&N] MY"_56J;7KQ5E*.)](9O6@+?!;BCR?@Z/'.[PAP*&<3(H>H.TU=_OUJ!%6F/& MY#?[[V1TI+"O9==__2NT^+31 8J^Q/JGH@.H>*GHST4 ?.^Q!+V45$_\L52_ MQ/1!V9(_2(TRWV\FA5YX\J#;<0A2%.@_-).;.;]5AG9$HP[K#G@V=X] M;.9G,3.%*?5.[[QM808F,BNC'.H)S-AM"[O3G:_&*$2J)*1P-M0%M6ZG=GJ8 MPR]?Y>I#7-+O92?__ARH\!%M[)'2.\?$EE*@DC;V<&5F<_ZBQL@KO:>6;ZW6Z?W3,]^%=>Q>KI'&T=V-EILOW5UJM^F[C$.QSVCCZB.K- M9;:YN\'V+GQ[L]EJ[^^N'=6;>Z31@C[>C.&1J4"#\N N2*UW".;M3X3X+/CC\?AC MI "V2_F_8(Y[,,?J=>; ,,L"1P\L(6U*XXZ9X1%G E%D O4T1C8,$WYZRI^< M)GYF7#'6&JLC#3^,@;^Y-9;T?^5WQ9Z.<6ZL]W,ON9&!9)Q(F3%'9*:]4IDT MPDG+D%#<)H.KY\T_M?56UX(3OAU:X*+6AN>8_G@7X)YKP--RR#^?27*6O=XFK*VLC)O[(T,";YY/@G2S>EK-7\(-5?+9N>%,&% MTF? I%8F+/=JO\%#@3EJO0'8P+W#;DH/&">)]0]-_^903LWU_J;.#F\>C>;? M+\H5F-_(E2%;X#-H9(\2!U+V-"W-:%1+I/GHY MD^%FX+M!44 GAKFI2:_V37_0JZ1X^*4E]]//SCB!M+$9881D# N3&49H1AFQ M1&J@JK2=MQ=Z-]GXIW) ?Y3 ?%^6/'N4W-/[OGTX]$9WJE-PF1Y\KXRX:LC. M)#] =+3S?A\D3JE$BFXG63*M\UH J^:\5I84-J[<6%TQ?3-,WKPA5;\^X^JR MZ=:@%8:0,<23S-P*!X/6,%QW.VO6?DL7Y>\U0LG+48O^85XF4IVD1*K'%J_# M7E\*S-#[]U.)PRN3FN9T)!V?G3@\8)\UU0PKS#(K)8A##=:.Y9("=W@>/77< M(;\0APMQ^"3B$&2/J;6@XZ%FG -Q6*1SFV0H_"6 M8FSU@"1IPRRU@Z)[VC\<7WX)=F$S!OQAME5PWGEXO< MV*KGQLY&4/D,K(5\K2Y1O ,>.^@6Y[.X)W'VU0 M^'S<6%_EQ=O6_O-M79]=P/ZO8S -O@F7_9FK'#CHH[W5SY"7S?.X-T7C97641I' MX^@8^KQ\WB PA[MULG>Q'QL?/U,6L;6(9\RF#!6#8F:$=)FS@A"+3;2!+KUY M?[MW"Z=[1S6E_98(V+_5:C6:?[S?U8OUC]S+1A MR'F2$2=BQKAGF:4Z9I)P&FE P2'QP_J!]U<"^Q2%+.^ M(QR_LUSVHI;?OLJ7Q]OV.\I=#K #.]URDV+0&RZU 1C#>M>WU//L%N6[6N?I MY:6 MCS>A?S/7MY^O+9TM5GL?8[6W=QA:K4O%]!O01[GF.JSJ=X\5S?&6T5[H316@ MQS=.TT3=IM+*=2[;[;8L6*_=ONV>55*Q_=*V_MEGAK1,I\=F'@64,8=#9D"= M9%%0*Y22W(0?FXC/=S?I[#Z298HY0LOE_DO=C#S045G]%TD<%*%VFA8)OYTW M:]PQJ*I!QV>CCL;RO]^?K-MAG*:Y5NXV@TI+9PZ64J$,.@8O\YJD\,9JQK0- MQF#&HC:.8Z; .B*"*V_'1V)S! +"!Y>#P]K[B!8*V ;P//0L].CM1//V-.G:6<9DH&E4JDA,P2D9(_ MG21&4<.Q7GJ#J7C!*'DA]675O#'";VJ]J8J3$NNQIBR^3?)T5\+A:]VO-#&E MK<%JG,SW[>%[=T8K7PU8OH>=?R]/Y?H!DR?=H7G\N@@IF.=+^.;(R:^#*'N/ MOMYB+/1TT/_VEA^=4OG0PS+ETOB>P^*K^W, W%0$*3F#)37&IK&E_6X9Z#^]GU/6+@\;F]XVMOL=[<\YV)TP%1MM;$" M,UY?WGKWU_73>!YV4ND3%Q"Y8A/.4#?O(NJ5U?],*:1$OU2<_HS:P/BEH'+B MP1]2OR3J?MKH(8_E+Z6Z7_S+K8O:XI<7M>^DK!@?A[) R@\[!_;HJ KO:S#A M0Y%:09_,S/2E=E@DJ_U?]S@Z&BV]^0!2:Y69XJ:QZ^#'D+OF6ZU=/D2/UJED)EH,?:Y8)\6^F,I&ZLE1Q7U>&51ZE6>@0U6NGNXTKW MOG3W*SV":E-/[;=!QPQ\#L+IWV4NRTIP(546O+8>4^DADB]O:"GQ[ 3_J&8?K5_TL6:0IB M*<)AZ/123OO[;J]W34^,RV3TX7VANKH!YJ#"MC?T?I3D/PS*J_1(*NY%Z&I[ M$;K27H2NO!>A*^U%).('SV%H(E0=AT=U%BXW=!;^PA- R>;87WB"C.6%)?XD ME$K(=RWQ,C#TL-N"!_?^I[;ZSR#OG]]MBU?7"$S3,!_F;!I)M830BSNNF8@U+,7]9=6+XLEE9(5?FB-OR?!W.KV!JELEK'=P?@8S]I6WCM>2-NY M( !V5QV!A;2=8>#D2-K>%6NYP&PF,0,CME\ +J6D_5!T7?!)N"Y$Z5R@^R-1 M6J%%CD5QK!DICG6].M;U\EB;S;]6MVJ_6A7KITK(+&I-S1#Y/5XV!UH4FYJ1 MOCP0M/?AP+2&%D9Y-/7"Q)@38!?NVLSTY2'(C3MX1D &1=[/ MPW!-;*<7TL61X;J0N'-" @N).S-]>0!RF(PD[EUY< O09A.TS?),P8W.\"@K M>-1"CLX'L.PNVV@[+LEK^\XJ')R>6^_=!#>=#JSTVF% M7J\LU3 ZM;?634[(:=X+M7QT]GGO10U@"$7H.'ASWH'F>:^V!D[*UZ,44WY8 M2@P@Z/>-3J\=/+@Q .A)PC3X\@K^??B8,I?LED8O:J;V*4_'YN6F-OX9Z.%% MN<*4NCAZP>C(\!?CIUY[[\U?3\/-7P:]\0_IN:,?NX/B6B?OZ"/\?# \^?TT M[Q_6P,9(\_8U*ZXWL+WK=9,$6K]POB03I?G+6O.6B3>M7K<$S^2=WHV' %"% MKYV8HE_V9]6XPZ\M4@/3*>&^/*W>G)P$Z'SGX"Z8\R&QG!3=$Y!SY^D9:1*Z MIYU0O+R#J.]W%.SX9-1'.0OV%N$[U=,PR20.I$U'\,W$B;37#[L4\+ K1ZR+ MZSIRJJ=[?GM@8>WRK,+K 5DW:?6>B-"EGYB>*4W&<&-[- _O-AO;F^\W5M(I MOE?F9+L)/]17&\WMGYX2\9TIF37ZJ.*1QM\Y+VN&^GZ[&/RMU#+= 3S#@Y41 MSEPXZ2=]5?MB6H-A8DLO572MP?#,OZMV+J]0+Q$2$S] %].7^B?/Y?W^-4[) MXW3V?H]]DEK.0WI_FJ-CU3WBC9?>+"=3[0&%,.9__,^4$,H29[7QD>[/F"+& M9ZJ-YX+\#'4\M.+29/7?O<9Y[QHX(QV7S"5X&6H7# MXG]RM/=AC#F=L0?S1"S_FT6>N'W,[P9% <*I9DK>>/U3Y/+C,5:25+]Z;1,X-*'\,\@_V):J1;=30)ZR,A1;;K&X_V&_G]^ M:8C3HNC[C>V/_.QUI]M9*XPK:T<-.GE_*VT%#GI^:;Q55?Z0.T$8,HPQKBQ3 M-FBF>(P$6X0HD]1\WDC>%*(4+]5\<'G;M'I_+F7 #!W3#NF)V8$Q)Z\3)2UW M?/IG]2L9+???F:(XAVG[E%:DEFK#V#QX[UG_=6?0SGRWW+M,CP7V@ND+):.5 MBZ.>?CJW*]TO[\G6ESU:'_BCU2_[Z_IH\ZA^VFBN7M1W]X_V+EJMQLK6-7+==>ZVS>;1,]HX:K7ISF6SN;E!X MSU'C*+7=@/?7<8-\RN'?BT;S4^L]W3K<:Y^U-MM_'S96WA[6CP[@?>YL_^@C M;1RMY?LK!^>;ZQNH3G;P'O1]]NUEFC_7=L;*.S]\W5?GT;8?B--@X^ZR ,==YG MTCB1,:E]9A!WF;"&.8]"U((LO=%"O=!(_O'J.HGQ66C9-RGKZ.NU?,\/^'WOOVM16DFV+_A4%Y\2]W1&:[GS,?+EV$$$9 MJ@[[-N"RJ:YC?W'DT\@&B2T)V_C7W\PEP%@"%Y@E6(CL:F,,TM):F3E&CCES M/LX,V,I(K3'28$$S*2M%0)_ 2"< )2/@I"80-.->6.>85&OKS/25PKO2T0\H M85F2Z:86_9/'<5L:H^+X?G \KRQ4\#0Z'H'$& ")0#"!"K LVF31H*-^;3W+ M"H9=PO&3\3-M>)\?8SKIC:./67IG@/R4J+BI+?>HR:@M47$^Z*\NQGPW3BL; MMA%(.4#$.3CD'S!!NN?0A:KNVSDE?E#B%SA@Y;1^B/7D@ MMZ4J*I#O"T"X!^K\GP#/B >D66,X:CG8Y$UR6GI#;>E( MUA=X9ZJJ#HKNXKDMC5'Q?+]X7@BLX(((H3GP3-" G@9PD+*/7:&D,,>-9 M]//T=@C/;?HIJ.FR]M@?3>UA&S+C; 1NG*ZS>IS5VNE(9:=EL%.^I\),C>(H M8['[] M,.Y;.TRIN%\:[D^_QSUEF*?&&(BI1*0C$=G,T#+3 $U4\6Q[>%]PSQ3O<_UH MEOWUU,[?*JMN+:@IYM)(:T*IH*.TCF')*E+QGA :+2K"U=6'Z M0G0IA+XZ;SHJB"J2[PW)<_K(YBE3D5(PA!- RQ@X7[PXE)' LSZ2SF0DRSX: MVB$DKWSI@-\&PZ8,W&&TD]AK1@1&"4[R/^[NNEEM4FI+7IQ-P;_+#+PJM[*7 M_IS$QG:KG-0>)^TLJ NO%;-):6!$"$!N,RV\KZ* MO2RV[;34"&]77CP)FZ7$Q"967ELM+?RP(#.F40"$82)DQ@$5;*4$_ Q<, H"!BF.-# M;5Z[C)D\>07*VG0)RBOOO]@>3NWP_< =QCND\REG5?W?ULLSHM M;@[#WT>C\'EP>%@]$\M6$NBH:*BP70ILY^2!,PB;%?>X]#D>]7@B/LZO?B675?YICV^\0LR@6H:+94&1+ 6T&H#QBE1 MLE=\YJ)H8PFUU+3/.Y727UT+'54)%;C+ NY\9"7%F!QF>1 E9J&0'%C)L]+G M.B;FDS*1KZVKK!/(JM8#?0P)L5<+AK][VFL3?)Y"CX<;/OS*4&^[Z;Z5==MC MW?<+\FWT]0U5=WKUYV*T1TO#M-Y;0G MQ&GMIC)73FN5T^9/I**(1J$%QDN,B\XBTB0;(25)0Q1$:T,+I\F2IL/%H^"T MU4]@[J[_[.H&OO\>6#Z MO<%P7%I5/"^=,#HI?7ZN6E:/K6'G [0X7=W!7/G3[//6P(??4/=S_8%7HQ5T M;9[]0,VSNU\S]:)OR[$];9K"EC\^B>$R?.[B+%LUH^:J1UP9TZ7MWC0O M9^OJHF3D;&E=DD.U4%/;1LZ'Q9(BT1MM,090/BA $44I*4* HC+)I6AX4Z!- MF3XA=S9QNG?05=EJ1=FJ[08\E:T>A*WF7#(,%=5,)J">"D#F)5@4')C7EL;D MHY4VLY5F?=JI%AFKYG9Y=#>\.KT,OJ]0\P,A7B,]EUF9YISY3ROOM\[[BXE> MW LJ#!J(1):@;>)*-)8!ZCC+:I4A0[>VGEE?=*G(>0W9[JBHJT"^-R#/AW%' M5,$Y"CK%")F521%P31/V%+G@7 C9U 5N+4:@0T'6AXO+6:%4<)=X"I :9J2OW !AE,'//!@"$O1>KJV+ON:W;D<9_><8!7* MRZU,4Z&\5"C/20PE@]6">*#$<\ \CV!HMAI$-)9;00W.H&Q(EZI8/FF'RV,( M6/>+D0-W\;@\X78N;>FEZGQ?)K$NQGA';KW':$$1F[)&R:@B61EKRKTEPS].4WE"0;FF 4;HP=41()ED8-T M.E. D,%+S- WI,_PSI6V[@OZJR^YNAL+?363;$8W[?<.1\/W,(WCH^IR6KJ$ MRD.]GT>Z#/SN:.@KE[;,I5\76V**@$1HK0J-"D!C(N29-'E\99[-)+F@V+3$ MY*Q/]9W/LZJ[J;LP;DT.51@O'\;S=0:(]"ER X(D"AB=!T-9 ,.-Z4&NBLC7HU.[>'TM)>:8]YRFF7?CV,LC7R,C9 M''RSSS:&H3+3,IAIZY+ V/[2U&:7QOID)201BI_&*]#Y?V ]DV@I)A9"9B9! M^E2U9:P]4E?,:D.ZQ1CH"NG[A?3I]Y#VVA-!4(%7C@,Z3L!2CB"I4-:DTN>I M5#]$W2>TK43T#@7.=%=JO,BOR#=:#H8R]":#T)S[CH;5=;%LG?'KR23?QF3R M8G3DLLXK'_MM,EYFD9="HB*0YQXB14-+^58YG<$52J11@\AS!TB] D=2 ,(( M!DD5CRPU8);\SMVAJO^CE82A&LCQ\+E#E9Z604\["UHC.!9=M!Q<"A30N@"& M)0:1.^ZB(YJE$AJ+?<&[5'2^>CPZJC4JG.\7SG-J X-1UCL/B98><9YRT"9_ MQP3E@EGAC'8-G+7H4E_9E?=JS'I-7>+H^:I):0VEM9J3U6 MNJ*P&H^><)9 4L,!94E&T)^/UX@DE1D#&E%G%<)*!^V8(#BK,N*94!%G>-=]O'L6_[W@??7S M>!^;G^;UM3V,[M1LY<;+Z+$U%7F -BPK.Y;W>N0:!I_.+WSV?B@O?GYAZ0R& M(5O6S\$T$_4P$>I'1Z/RJ2/_L=_[WS_:W%_&<8/<5C;Y[=W?YG?YV:V\+G?R MTH[WQJ^G=AK#?^SA2?SVT6<;/*D;_ TV^/?3G1??;?"?PN__P?!__OOP+3O\ MY#X'^^(LC)%IL$K@5 2U<%F@0#$2,8Q6B>#_K%"O&81_9QE6!?18UQ$-AJ- MI06[S!0!2"D#8[-1*;U5@B=%C0YKZ^096:REN?"#WK$=]SZ5V?VE=^VR:WHF M3NYAQ37+:[)Q,CT8C3,'AYL9*W49WOLR_+KS^9TVC$45.7 K3;9U) >75P $ MS9,DS"V=3"=3.RS*MB[+CBY+NIMU6PB2H+<0HU" MR"0X(P685"J3".I2L+?ENN6MJNW)Y*3R7*<7E T.4S 1&),!T%$"UDN2[0)) MA&(NZ50Z;7'91V;ZC"[&'ES!<\-P2V);WG9;EV"GER#;>?^.N2@9I9G)$LE+ M,/-/IC.I 9FS/A""FF!W]%O=*1_'JDH1=;8 LF(S3I90;0V3>;5V]&'X]< M''_W*]:?_3._]SCF3_@4#T\O7)QA\*D&7B\O\. 2K!N74CV-;!7*\Z&-PLAL MEY,\H(7AT3&P/-M6PDDC1+)6$EU.([FL61,K#-ZVH@@J>)<*WKE0@I!\D"%$ M*+ZT$ISR8 MVL.:*K'T&I@78_\R#_WV\,5LX"L?M<=''Q?$A"'64J<0!(D,D.LL['GDH#R5 M@4?+F%*E1ZPFIL^0=2C(NN9*=%105!S?!X[G=$6DQH2\1H$20P!]T&"<%^"" MCXY'HJ*C!<=*LSY>X7=E5G-I\1V'+CH=YW":7IF-S-AN5H=IBJ-W-Q0X>(01%O,VF#B,< M,+$(CB4.0AOA@J7:!&R4AI!]?H72^&?U6JP"KG]>951<=P/7\RF:C >O/0QX,X MG P^Q5YO,,P_B-6[<0\=/LXGHDDF?W%Y&K:;2?CW:#+9C=.]M&^_5,YJC[,6 M:VV3;.Q(03T$XK.UQ'1I]D$5Y"E-3"EK!??%"TMT;?6QPMANL=7'[;!=X7L[ M^,Y+#BZLE)Q"#-8"TAC!Z!#!L^A$T(XFE>&KQ JZ.;JK-&:E("97)#'^X\S; M\<^S=,:EU(AXI&GC#^H2:0Y]SR9KJYF:*CO:XZW%XMHR:A.#L1"]],54XF#R MY@,D.D-#="Z%S%N()8CJ[G929[K WT?)B$<*_P<0*Q7T2P;]G%@1BE*C;00F M8NGK4VKKRXQ\@@91!F%=2:C2JF_$8M1DRY4C[JEXQ*V$U",K<-5$H%ZEL*# ;WN<\CTD8G;C#.*LJ<(<*.5<-XX-2W?]^D*%9&?I?0I&PC6&HF\$R M-X/%DN>,2+3%\<2YRY9KGBXP3/.\+3#! M'6J]14$J*JKVA;-0W;0-(#.ZTJ MCU8>[92,KCQZKSPZ+ZI]=)S1=JJ-T9,?O!\/S.Y,9-&<_*739J(Q.?C>&A+:M@OGP=A>G!.'I?>>#: MY-M;K,OW<#*]_BWW.+(_'$<^E^UVZ6NYVX9F.!&4T^2]B8B!$TTC)NFB)32A MC>0=-6OG;SH8?RO2]3Z"&T?[$6S*#_C<'GZVIY.U?WV_!/-JFQOW^2&;# M_]JX^J9?7$;2ZPO\]$:I]]U95:\<4_7^<3*T)V&07_O/SC_9/P;#WO1@=)*O M$2;]7OSB8R;8XSB>V>B]_,CV=D_14.PW/F@X/3_-H3V>Q.?GW_QR7J%R,&SN MJ7G3+]^S<$' O!^C?-[LUV?@T.P9"EGP<>9..?O@,^@\:Z SMS_-?J?H,Z3J MVE^39_3:W_WHLI0]H^;G+OOCWTDMEW&SC%S_Z\N7_1N7U2V/V>ZG?./"DK]) M*4QSDVN L*#D&7P\P?S&NR]/O<:O!KL;/XZV-O7O?U?C]Y\>'7P=G_WX U[ M>_3FK_SY'][F[_\0;S:6V/G][:"Y'_;;AU+(Y,U? M^=]'^?O-PX_Y7M/.*?EZ-)HZ!CR( EM@A%QV'%%$X M)[3&4L2DCGA[(R[R0.O (G!3VO>4;N)6HP,MC(B2!H9$U1%O<\2U<%%K98!J MG@"Y)^"LBJ!B4DSHZ VM:[S5$;>.DJ"U!*-M9A7E/3@N UCKG3*TE!*4:^LO MQZ-PXJ>]E6.4P?DO_^]%?/Q&CN*('&2MZ(,$]6B.2%)&BX-9P;:AF MQ O&- WNW69SL$L)A9N=\+Z:+;'?QJ.C%_F#RBW\-9@>O#B9Y/&(XZTO_O"D MC./&9!+S_\.CR39X) 1!YPC"$&Z^M2]%G M],X%F[J7;5!Y:T5Y*ZB((08K#.48:=8;@E&;6ZSEM\ M7DK2H(U""7ER(R#S K2* :1$BLZB3*7KE>!]2CK8?/,V7I&?#UE^[-=8>?_) MWG$=FFD]\C9/#] RZY&/V,JG;557P$_NF+N#1><+.DTI MTZ ,27G'I X6Y4TD&'4$>\U1$/@O'B[K)!"D"+"G1T'DBTCHJ$4BM2 M1[S-$0\ETY;["-+3/.+4JFS-$@=YX2/U(I'(4QWQ-D<\$E?R!CF@]BZ/N'9E MQ"F@HHDKGSPUL83X3*8EGN=XSM'8^T<\-YQZ]FB4=YVOMC'M\FL'PZD=OA^4 M>!>;+:KIY)^W\4BN>%&CAW3AE5M-W1]I'NYJX[EUUU;% M\[W@>=Z#99!0KV-)O0W%\ZZR3-&6964NE K<$,I+UQ+6IZ:MU-L.9==VU^9\ M%2>Q">TKN;0A"Y7#T7$)2*Y5R.[QD' V!9F.-K]-P-;,1U9)J3526CP.=$)I MRKD':40$C"Z!$X9!-)0$*KQPE!524GTMVTI M-H+#AJ/!<#"9CIM4P.K5N#?-\?ML$C(];7PW!96A6F:HO1<+JH.J**R.'%S> M7 ")L&"%E:#1L\@82G1J;5V9OKE[$%)U;707U*V+C@KJ^P/U@NPP2005RL&7 M-H""$+!!.0A*Y!'VA#@NU]:%["M_1M+P^/&WYVS5$?'O8F.RW.QE[8O M9F*CF8A*3ZW1T^L%S9%G31HKLQDT<[HZ"29HFC4'<<029*1>%!HHFRPZ9#0J39Q*DS[-< A52X-V#],K[.5X<9 C$ MK#-ZR0[&O4^ECW,1'B&F.!['T/@]"BCST\3AM*FL- A-9&S&[J7JID_,&W*K MQE5W5R;7E&'_]622[VPR>3$Z6IVAB/RT0WQ7MF<[X]S&QX M,ISNI6O>.H=0^M!H J B)FP#"90R%-@/$J52B=QROM<+7;IO5-AW6Z7(&\%^ZL/ M_Z4$SU;X+PW^GFNKXGG9>)YW0['( ME),.2),RSY.%S,@$, L[*8)%QN3:NC9]S>_2A+16]*D5?99"6]O#3W$R+0[N MWJ"AC"X\V)15 M&'*A#6=HJ"^IZ:0OV H6D:R07IIW[<>0KJB]'6KGM!:C3$:O*2@A26E3)\ 8 MA^") F(U]S0YIG7W>+&B& M*"**E")$&0.@X1:L%0RBEX%+QQ37H;25Z1-R%TNOQB1U&,%+T L5PU?HB@.1/ O5 I:!5YXFOKO,^NJ%_SF".&.EW__;I@Z\&YKLCB M.?8FG^WQ$_-,=.. Z,_A..;!^!K#[W8P+/[DO>%F?J!/35IJ=2ZW2%C^DN38 M/LU_W@6N0C9Z'##&139XFIKQ.D&TBM(@C8^V'!;U15=\R]5!T74'Q:WPG 9? MLM3]&L>C"N7;0OGT>RA+*RVAW(!1T0,*@V 0!4BF4#/G=4172J;KC/=?'H__ MXKQQ<[[9^&,2N*]7KKS#96]Z$,?GWI;O&Y]5@^T>(V?*-%QV[\X&7.7+ M6_#E^\4$L++Q"49 .52 &!)D:M3 )7-&Y9U.8I$^M".66G6U=-#5\I/(K19- MB["><\$884W0DH-T0698"P\NZ0A,9H-&^&28I4W&.YIN /OI)&T56Z#G8E[] M\2P4I#>U7Y:4M/5($S>Z(3V^Q?:==_<;#$_R2)X%_XV&DU^;:9R];K],XM:7 MZ=CFR1@,[?AT>QJ/)ID R^V.1TU-QW,_=&6_]MCOXX*H$=P'F7/1I,"FDF"FD M-4WZ"#>)AXTQ.J/\,_OXUSB,:3"MS'T;YOZP6!C H,N3HS2H*&G6@I& 99I M-H(#<\I%:\G:>M:('3H,J,=[73_>JVAM":WS:5XVRRPK*'#M$%"Q"-II!&:- M$S3/3!(9K5QWJ<5,U\143=-_G#)L-TZO3-"_,W5W+A;M?]_I$;N]*W7#=9G7 M4LU,7L:6M5AIP+(0G. 49$Q-Q(D$&Z4'YQ1JD10:96?.1B47D]P><_A8):95 M):;E>4 K,2V/F.:TM$ OC%(ORQ2WJ[?9M;O:EAT/\[A-SC]W<[;H+K8P4K>P&VQAB_4C5 JH ME->0!.6 B1(PP1O0)G'%9)1EAG[H"'SHE= 045T'=UP'+GCFE"9 D[6 2@=P M42$01R)#*@F))4KU&5TL2= -95,MKKI%W8B8[FAY56):,C'-VU@>DZ=> DJ9 M )%JL'EG B.88[-HZ>:87RT]W8XNJQOV[!>/>CHZ/,FXW9/IF=](Y.II-I?DU^H@NTY(>MT0^S M05IVN-+YI&W,YFSWY,C%\5XZVTV:G66R]VV*JJ>WO;W'+Y99I,JEY$G>;%26 M(C3PO M) ]1:8P*1A'O1U16SL%3.A&E=+\M;+YS83"H!00CC2QMV!P:Y R9] M$-0AE[RT..:RS\5BI$V'0F]JH%S[6T7KL7)UJWA(Z,\G,G#EO; (6BH.&$4$ M&PD#Q7BPS'@5BB>MFRNF;A7WOUX$S0+"H07"I,KKA9ALUA*?]XO@$ G-XB"5 M^@"Z;]AB*G&'MHIJWJZB>5OC-*MS?F7B-#<^V<&AS0#;'[UH'!ZOIR/_\6!T MF"$XJ7M=RWO=8MIX4)8I*S@P)1@@BP$T=QZ"Y]D\XA*5#S62LU+70S];!R,Y M*W7=,W7-YTTI+X)@",0$"BA\IJ[$#)"\NC43(AC".QGKN>KU S- CL?Q( XG M@T\7]7[^4>3C/Y]?FUU]MV&X3\*ZT4A<;?0]5&[_(QVQ-@MDJ2[CYK?1./]S MV/,GXW$<^M/>=)RO=MB41ZD-;!^T#.>+RV0VV_S/9NO%V63ME[F:W>?&,.Q_ MF[F-\.%DUK IZX:]M&^_O!R-FU],I^.!.YG.Q,-+FR]3TZAO)0>^7E'TP#HE MA$=0FAM 2A"<1)KE /.&8%*6JFS)J(YH@7J,\WAD?R6"3A/!O/N>1"I]*OYZ M)@&M4F"((\"](^BE)HZ[M74T'7%GM&04=%_D?&L/T'MO!\,SBZ"707UDQQ]C M X+>)&8--)@.?K(.T^.M7_R0=9BNX[<+#T<:C2>9DUY?3$YEM.4QVO:"M/&* M*VT2!1$C 0PETUXS!E;((/.TDRQY"J/INYX]UJKE5=]4_#\\_N<4#?&>N4@2 M)!,C(&$$'$T]<68LL/3C(W><#3-GS<=%A.G!N7_VTAO/ M1I=\>XMU^09/IM>_Y1Z'_8>#C'.)PY>^EKMM=AQ.!.4T>6\B8N!$TXA)NF@) M36@C>3M;^]?WZS$MQ;MSGA^SZ MN5N8P?L?577EJ&[OOM[9VNQM[[[8>_5R[]7&_M;FM:NN*_?\XC*H7E] J3=* MO2;IZ"R0\?_M;?W/R6!ZVOO'R=">A$%^]3\[_VS_& Q[TX/12;Y&F%Q_NS]% MEF?G5.=,T&SP^;D.[?$D/C__YI?SW60P;.ZN>=,OWW]>6?OSGJSR>;-??X/% M,S*#QMG&>?;)9[]^UOQJ3JW,?L?Y,TJO_S5Y1J_]W8\NJYX1K7[JJC_^G>#M MWZM\9O#GKGK_]VJ>"<4>R;W2?%DC'LO-LF=MHT$(A[%MIC=_1_0W";,U2WCW/#,O3'&;O3XY.#AMY MV0SN9DP#/YC6P6UW<)NQ;4[P9TOXLM^Q^2AO#2+&I ,!9 K0^@-$" M03E!@S%*&N]FQ6\4OW.\Z2-K)K]I=L#,X5Y9 MKD66^SK'88,HDXZ2P =N8PT16*8K!S7"8ZC0@@>J7)( MD5#!UM997RK>%T)6GJL\MX(\=YMH4.8C:AVLX42AL-PEJSP)&DVT)"I^/=%= M$P1:&6^IC,?G&(\K:Q*5$931!!")!4,\ Z9L8M$Y2CDOC,>DZ#/DK45_5K+K M%N:?+-G=@NN\L=*RY%%0C5$+AXXD6ZH;$Z*BU7<1=97%;L-B8H[%B!2"\,1 MYO$O_;446(T!*$N66R6XMV9MWI,<4QDTS13'@3'2)*HC?)Q;1TIZ>/CH;E[ MJNYY\:$7H?+W#= 7L]"3IKCGT7&>E!(S_MV=Y"M[&'R!@T$(R=O_>T#\T7^&]B]SLO?AX]?=S?\^V-O_[Z-=MD-WON8Q^K"# M;W_?9CM__?%Y[_7MYJ\?_N_7/_,]>EIR\G:^?J0[G]\I::DS!D%P MJ0&-#F 3%X N%;Z4PC.UMK[Q^L^>#:/CAG!9*3!!Y 7 ODO!>.!*IIV_1JU3 M8S$0XX)4UDNT#)WD"8WP-D5%J?V!N[AZ41Z"?>@E]OF<[0],4H:4;&8,7PII M<@\VSR"H+*P$YBF-7J^M,XE]2>Z205N+37576+,0N$83O->(2FC'O4]1.FM% M\@:KL.X&=/D<=$/00IAH@"!FZ#IKP%CK(5*G/$\ID3\TBG5EQ7 MKK&:-'(K+: 2D2W<&F=^KK/&3:N+ MUVO4:W3U&O=<0/M!<7]='\;.29]ZC2H%OY>"2E&O8_ @]741(<8A8], M!=-25[8J!]N2@[NO%^Q+8@RJ2!"D(A&0"P&6>0DN<1T<88*+T$++M6I:5C[I M2I?'RB%XU7M M'']:?3X&4Z)>8[G7J$W*\B85DV1..$\Q1:]I?NZ A@D;".-+:.)1-K$;->FH M^UQ+^]RED,[S(]7 2/0T[VN^-/#(DPHNY%W/$<6$%*A\(DVZX14M?&IWPI4 M_OUW[ZG OW_@+PAH43=@M"O.=K>Q>YL<8A5G]E^;KKW820Z&ZS'-- M9]7*3[?AI].%:B])<::D9J"=,MG^CAX<+>V3O654T"2(RO2$8O%H=W6B19X8 MEA>ER7T!^3_V\"16'+>!XX5Z)DYQ'00'Q5(V,"(O[4^L!,T8&I?R#(?4%/^O M*%Y5%'LT0B=%?> )H[8N6YB*2N4XL3;1="\HKJ9$:Q"?+^?!DN3(48/A)1R+ M\;Q5"^QVBO04/2@R.!N8Y)"I\ M,4PTN*@%!**Y1$>8U#CCO3N7,+J_8\+NM3JKKVSWE4\A"KFP9%,X>93**7%I M33%SIV4^['V*DVGIXI9_]^KUGS_G2GN\1P-==J6]RC,S'OAI#,W+-C[;<6@. M"GX;C5,<3$^:&ZS;UHVWK;W7WQQKY<1OY_T[KR0+*AB(,A7'&@]@)+50JAWX,C^X$=:Q75[:/ZZW>H_OR.8S)8TGS[7WZ@>H7+L$!35O^ ?.%3$AY:7E V"0 M#HRB&GB(UIJRD18)U26R?0JQ$\V";V*"S]U?O?BE?!]K3EKUV3[04=5&^' R MF3;]J_='W_H[EM:.V\.SIHZ-[>OF?;>OXO^<#":#:7P=QY\&/LY(_E7TH_?# MYBH-WU\A4V5Y-L_>42>"(:2$]C!1?(H>+,E?O&6! M&^,Y$:Z#/+E:)R%_VT%RQX[]P7G[2%;;1_[LF4A>WY(J(EGR":U'*ZVQWE&" M2HFH9J6C;F+'U_:12V6I[PI&;;Q3(EB-0H)6' &M\^",0(B:2\5M5G32EOZ1 MIL^Q]AQJ$_"=-%NM3)KDL/ M?ILL_VB#B]Q)(8-$XI)36=UI99R3"5DTUS-=K7?\,&<1<[K.1\UDZ8]"F3: M1$LHA0K!E\+5";G0KM0[[G-B^E**VD*RLMW39;N@>0PT!>6%1B9LMF693I9I MJS$9&5MANTIHMR*TO3E_G+$V89 :%,I2@,00,%G5@2J]VX.,(0B:"8W?I7A[ MI;)*91VDLELPF3,I>D$-<20@4\I83K TP;&J1/6R:J%V@=VV%\]$!=6:F2C M6A$ G>&0YY(#LUPKC-QP'F;'#5K?N8C)/7>2/+^1\T4M&A9[@%"-2P_,\R.% MT8D[C M/_- !)?4NZUVNR%T^L9")S>CCD8OC5J(FNA088980%V&$5DIZSGDD MR*.S))MA";70FFN,9T;7#5KSU;B(Y2F5/Z<+A2!-HL(F X)3!9@-9L@ZQ0") M>3)%\)3P$N3*15^*.]=IZEX"V9U1>W_\=3/0WMJJZH+A=$<^6K2;6B.C:CCY"45TA*PG"$@40X<#1:,$-[&H/)O50E?X$)5+JI<]"BX2$<:HXTR M"N%08+0:G0W>V*1L$(I6+NH&%\U'&2B6IRM8!29J JB2 ZU9 N:$#JG,I6V. MW)1F?;Q[D:?*1Y6/?O[1;G,\YKS0+&M^(I!@4,P([Q0G@26F(KH?$%(-!G@8 M9II322@2Y5)KD-YGE<2U 6,R1[F4=!9.Q%+'"C-)(_M"=:2 ?R6E)T=*M^ D M9I"F9$.TB.A16\$"D@9ERRF-6/$R@ (^%@F)6@ MLJ46."+'J-?6E:@*J)+-XR ;:G56/%G0"\/1>:8I2AV412\-EY97BZP;3+1P MJJZLIXYF*K+9C 8TQ(.-5$'T7'HK923$K:UKU3=BL2UGK;^SS*"6%PO=.)_7 MPCOU&D_R&D^I%^]NG-;>NX_Q&BL9LG ;-UB6?PI5] 931"&D$2K88$FR0L:@ M65/&AI^7L>&U4?O#2\+W"ZXPAXE%YC1PJ3R@#)B-4R6!ZY0M4QVI9"7.4IB^ MDHOA"X_9$=:Y:SQY0J',45JR+Q^%WFRZ2C=U7K]9FX,&&]7]@M]K"/"R];"M?6.;MS#-T/]I&'KEK[U$'=@ABMH'Y(4"\( MTT"\\8PG(,3(C.H@09K82AJT&Y]26._6#2=)N;M9D; M'9=AG_3L,/2V7K]\V9LES-3LH>NSA[2W1E'!%(DJTY6Q#(6EBA 9BQC1MZ:K M'W::J\W>[TY1'S864K@MWO"<<_;'M<87P[&,_[U"D57#L)J51QQT0#V"BR#9&0QRAHZ1RXMMZE M (N*XI;+CCBC=9YFKG1 EJ03UE(ME=1KG;@_A\;HL4SF9R3N " M*D 5$"QFQ"N%,?.U\3+IIDPP7^5&L/4:E?:6ZC.IM/? RF;>AR)M*#M:!*M* MM0,9-)@8(Y"2#)4<,S*:&>^9#O'>WWA1PF!R?&A/R\W&'U-#?>7C?.53"" N M--D4WAFE>=,R(?8^Q

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
/4$=I_;6+E:7[#S2;0:@T9E]9>N?DBM]6R&W\(S:C:?P42.5K5<(%]K M/R)]6)CMS/?Z"^CF^\]%>T^A-KG9JOK3A@#XNM0[&V6^@294\A='/EN3#$6O M"]BX$DSG438)DGL.:M/T./!J01PW&SU^0U7#GDOZU6E8%JWV$OI9$GTN_(4_-^KKP.)54 MK59G1]:HNZU>\ MKLOF5HJJ/DF=\G_K>[X0'D4DX0A&DBD6D8A &A $ Q&EH2Y7+KB5A^:%\LR- M:3;!%=5.<,5N%6*NZU187ZJX&CTSWIIP3$;FMAU-0*-*:ETDS*K(Z@>\Z^KIJ]M"QT%PQWW<3"?:RO M=3[)1IIGU8<]YGLX5M9=RF/M,2HE3#U,H++U!(EBP0)N5R%MB!1S8V/MGY2S M;)EM(@7UO=8FQK#5"'SUY/"MC?G1MQWKE6ACXG19A)HFU!\_BA7XT,4: MUF\-K2YM,\B&UQEC#]W8]QP[=:;/C]4TQ:8'(.F\XK2-#"]4=GH 3*=K3P]I M;&#.#'U7N:F.''H)HXF?P$1BIC;*Q(-8NQCZ,HQ\&HH8":N-\E[K3,^&DP'B/SCCD4]KD@CJGL*JO#7MO3YFL M]4V*VFF^>M(K]?M\D_C_FBD;OMGJT(B)"(6Z?%Q,(?*8@#14D]H+6*0S!">) M+Q8K[=ML-HO-N[::XAL!QONNM:U21PUVV1.*30T+LA':;MI;C(,9)XR#[LB$ MH8&M_3 ZL0%] C]_:U#^TTZID.OS,%M3BCUBCOC&HN-)R<@>D.=,-:"%8316 M1T?HO.BJM[=-W-E"4NF%$8F@3W$"$4H(3 7U(8X\AI!(4627P_-('W.S/0YK M).1%#FNJRG(E@*A6PU*5'\/7C(=LT/?HP&F_5Y_H0T9HMLQ63UTQOCB)1$P3INR4(( (!P1B7_HP% F- M8LD3&EH=X?1W-S8!1B(;D' MXS1*(8IU]"/Q$LA"$47$1S'A1CZ=5KW.;>K7WE2Z=._[F\__@]P__*\WMA?I M)E";7I<[!G#T2W'0"@PZB9N[K:W,(SC^6*'D[#+;I,^)KZPM8#B\F+9Y^=+K MY^M\E?&#[)--]A/!ZZRX]?UH?;GZ278I0V]$65_1U#0R(@F:L<3$6E5%]6M>'.CM=VKSUW]=AQ/0*=AF\5ZJZ-^Z5C>UEI3 M2[/(\5=@>W$]]=A.>*,]U;!><-GM$GWGM^!.A'NAZW&7P)Z^-W?:R[!%Y+-@ M(GO4#=G&XAYY4>Z4796/=H[FDC'>IAT-O2H^/R3[GOTPOB(5T_;XY@E MJ:K&\8-'C-.002S#!"+FQ1 GL81^*+W$D\*/2#(H0N)8;W,S/382@EK$0=X@ M_?":$8 ST,8^9+'#:WB@1!\.KD,ECO;U,L$2?6J?#)?H?6G@.6N1W^H"3=K' M=Z? NB0BE9[T(/+\%"(J=!P$\B%/L?!(@D,JK#*T'N]F;B2AI;L"2R4K5-W= M6QZU'D>2132,O#""C)-((1D32"B5,(YC)A'&'HT\&T<=!TA.X)0S!I*&)]<7 MXS,VLVI0ZI)Q#4C;?*OMS0GXC:R;_G#&W?_T@!0& MK=?'N\[IX_JV%'6TQ>=BN7Q7E-I=IZN.?1+FJ&MM@P+";:VKJUKPY5 M=654[;0\K25UJ-*!^73DD0$VD[:^WN?5JEPW\[PF@!ORI,_&?B,_LOOU_2*D M+)4!83#R)(((408I#D/HH13'B4ABX@ECD\F@P[E:3/>->!9+N0FZ!E:18\Q& MGN1U//M6W"O0X==*? 5^&P5("Y/(,: 36427 VMG'UF@U&L>F;0SG75DH=6> M<63SWD 'B:')<#]DN7B_$O?5 OF1,IU( !F*8XA($BB3*F20$1ZE82AI0'TK MIXB+19H;F7_1V>GA85YS2R^&RX?*S(Z;=@!&7AEV*R*=S"E/VYSRSRLGU3&T MOVNU0*V72P<%9R"[)+U,L=?AO?:$;Z*M= 3U,.>)ID'B^T85N;R]SH\Y=^:QND*D^H(APJ&5I64OPMSH82.JZ^#_OF$PLZ+& M!7=D9CF3#& +^U:+45S(AH,X;GZ /@'FD"? "##? $F+0VM"-'FH].[HR8/ MTJ?UJEJ17%^/+T)"=/I-#X94\1QB#,'4EP2&7AH+Z?M1:I:XR*R[N1%;6^B@ M2_.H9;[JDH3MB&V??-,0_7Z.EA/ MPNBM"SUC?Q.D6C?I+ZO-+_]/)DH=;_34%6 -4\,( >Q0B7:0\19C"%*>! M#$DJ8F3DGC&H][D1SS:!-MA(6@?4?;S^Z\"2K7:C869=C8;QR$1T&;S#_6YM M8'+MAVO4]\OXY=K 9=SHZ[=P+1WV0^=9[6JQ,IR0V@ MM1E%N05P9%[JA+T"M;@U)6T$'C4MK3E,KDI7G^]PVG+6Q@ 7VX];=L=?=Z7:V*>U'> M%,N,/6W7?Q&P$!-E:@4A1HKF_ BFH8[T21$BC",BD17-V74_-Y9KI0>Z/L%M MGMD[-EBB;T9IXV$Z,J-U<+:9$QK1P78[7U5K05?B(AQCW$&91I*B!CR()6^@-1#*<%Q M["7"*C[\=%=S(ZR-I*!J#H*; W20U=(.KV?5 [;ICM$%A*/O%#OT]H_1&T%= M[@O/@>%L/WBRHXGW@><4/MS_G7W#_FKN3>M8K(L<+%(O2+@7I9!+X4.$B818 MX C&U&G'VW:9LO>IIB[)UT==$,\\NT/;S.7YL-Q6#L?921\E;7 M8,IS'$>\A!,9GO$=>'<8^K[4.>B.B=^Z?L^J/ M5R)G=_>D_*.]D:5!*A.4*NJ1$88H2'V82L$AYK$R"&+.4H_94,^Y#N?&.WOR M BTPV$@\\$K\+.9FY.,2R9&9YS(0K4G'%!E'C'.VNTGIQE3YYUQC_-Y@HCDX M[OBL2"SG!W4M$.<(19)#B7@($?4]F-) 0$9P+'D:!,)'EI1CV/7:L5*? M2KPKB1H<D(Z>K5Z 1?-3B M(_9XN6,JTXZGYBQ+0(ZPEVT+ [T+LSQ;B0_9H_:/7JD/*E/SKW$U^8W\9U'6 MR?H^JN^N7+#6GZP M5:!UUM$!Y4J'-@^EUF*HUZ'E*)GQW(C8CTQV[F&W]T85$]2)('_.'@V/JVR [N>OD> ;^U3Z>?:1YU!JJ<^7 M=QF,Z>#T+BZP?:D,+\,POB3-RSFT+#*]G&SJI9*]G-.M)]_+V5<'IGSI II? MK:LL%U7U1=S6ONMU9#PC/F.^\&#DAVKG37P$J8]B2#S",<8)$MC*C;RWM[DQ M=2?;H'SQ_;B:F9?.T!J9F$V!LD^+8@* JXPGO7U-F\S$1.V#/"5&+PTC"/M#9RL3KT0N9*9+:'N1Y\4$,H\%.EV0A&F(.$P"F7(L<.J99= P M[&]^:W;KI[HB/P!M9+1=P_L!-EW+G<$V^IK>(M:("I2LH!46_-R*>_KD:L#B M;@2,LT6^O[>)%WLCU0\7?;/7'#D"->5.=64H$<<1C#GA$.F4/"GQ,(PP(\)/ MA% V_T7N/[,L7GO$7V50[=D3H)I1Q^50C=WA*I M9YX><*/S]OYA63P)44<3W*A/Y(Y40OL=!IZ/VQ/Q*/%\DH0QE"0-U?X_"B A M(H"18B:<8!JRT"CTT;3#N=&"E@R\_7)S8W'98(*KP>V-8[3&WCBTTC910J"3 MM_8[!C6* ZYM3)"TN+-QC.A$%S8.D+6[K+& J?>FQJ2=Z:YI++3:NZ.Q>6^8 M'=8=YUZS?ZRSJ@ZHUE[?JZ?WN:(X4:W:(*]/I?Z_9OV/:]WM)[D7".AI"[F'* MN)?"./&XOHP+U! F*?012[@7TCC@TNS\[>4&<9ISNW88"ZFOLN_52+(FU6,= MX5N/;IW!2/WF_UTOGX!_I9@R0"\^P&;;@.D';63CH%,([&AT!1J=0*=4&U&L MJ!-T:EV!1C$]SHUJ[K89;D%VM"UQ)-2DVQBW0#[?]CAN?< VJ5[X/SWHGJOK MG']6?9896[51V-_R;%6UIJB?^E0$PH."Q %4BZY:@6F*(= MW:EY:]/M4:TUW-NIVK\]L+[N3E7U;3%[-8^:TDC5)WE3JJ\P>R#+]_G?!2F_ MJH$0B]@/$1&>#X5'U?Y4)C'$NN)G&DB"PUC]);:ZGAPFQMQ62_5AQI:%>H?! M;[;U&!_4D==.K0"L_9BU"CK,I5;BZ0IH:4$MKL.ZP!?!Y:J$\# AIJTV?!%0 M!X6)+VO->1C@YVWM\@5-2,1)+*"(: R1CGVA-(U@&K,P1DD2>"QR%/WW^;!D M^EQHK8T^6QZ//@._:]%!*[N[0+_=<3#C._?HCLQO_6%]IL"Z#.4[@M/X$7R[ MGL?>'G!:\5NV5'9?D8NWCXH)@^YD@F#J^SR$.$F%SJ^00H)) M! ,J:,(01GYB5/+D=!=S(Z"-D*"6$@06>^3C&!H<-ER,S,CD<0#*D!.$X^A8 MG!9W6C[ MX84R50,I!91(1ZA$O@X@56 6S'>ID;NVV%;+Y-R\BUHT": M&4P7PS/VV>DS9!PZ1QA!X"I6[6@?T\:H]:EY$)O6^_#PK+0W]2GGVYR_(2NQ M8"B.N?!#R##E:JXC"2G&#(9(,)E&:1@G@7UZVKT^YG?5O4G5VL@)E*! 2VJ? MLG8?S/[Y[@2@D>>Z-3*#\MD>U?ZBQ+;[+4Z>X?:H0L=2W1Y_<.#BK>\Y7I%* MX)!/XJC,$U9 ME/A6"90L^I[;0O\N*RM]&X+I4\MZ*)BE&*SM0PH]A0=B#YLJNL.AY6FO#'I(#&V1 $P-. M6#J/%-4)S?*ZCRY.Y_7N9>DF"]U.O0CS20?4HH! EH([!W&N6MU8%E1 MQHIUOE(FZQ==[UVMQ]6W!VV\JL'RO+BU-Q,K&'HM3*ZC?J=6Z+WU9HL)$:-&)K#W9E,EAZBYAA;V;K.T=TY$7* ,P1C'LK ME%R5"#7J<]K"H#8P')0#M7IY("O5UZX+Z@4126,$ Y\RB%@H(/&%@)Y4OTZ\ M((D\13O%BBP-::=NUHI7-HV/-Q6^ZCX &5 ?O87)D"&LE1^; OHUMI_<>PJZ MFKU-H]-.SSU%#N;?_E]=Y)2[IE7M7#TH(UKW\HR^K(.$:)V,HZ5#>P["*-G0 M-IV\8#*TYXKVYT([>'K8U_J6E+E:;ZH;4=8'29OO-9+,XVF"8*1L4(A\22#V MB ^YQVB0!I[@B95#WZF.YF:*?A0KH!"N=*1!$Z;P9[N5XR2B9@S@ J>1.: 3 M45] -0&*H]# .20<$<');B:E@G/*/B>#L\\/HX,FY=(FY>H'/4CZ-%GG]A7$ M#V0:>I!0R74D0P*)EP;0"R03+/%\$7LVC-#3U]Q(H&(R:-548X.&(+?IZFI0P#%1^SADFKXQUS5V'(FR.O(A,/;7W%!+% M$ G*(46$0DJ0[[$@##QL=!$TJ/>Y4EG;E1]8YP+YQR /J4!\E I2\T@$1 FJJ??*F@%91R+^)VR>(<0#B- M2_R.H%VB(3>8FBU0#G :>7'9!:A-E>?>J#\#@Z-5X50ODS+Z&56?L_&YQR]) M0+ \%CQ<9TY1*+KQ0I!XV=F$_T]GL MZ*41%^S(>P5:B2W[?;@]F0) 3GP+/P]'8(XD1^W(,^0#O7 M;$-0>AVOS[4QG5NUH39[3M.F[PRSY3Z*U6M2W=V4Q6.F-NBOGKY5FLD5K2NC M4>W,KYG:B->]+@+$L!]%"4Q\3;745_L\'E.8A,*+J!<+*6(;!T7SKJV(=P(G M1NV1PI3HX.=U52=O_Q-X:+4 ] G(3@- -BK868 6HV)F!XZ#]7)^'V=HRM$?,D7UHT?&D5J(](,]MQ0$M7!KG<5,L,Z;/#^U< MODXW,*/IL1-5T$DYBM?7>3"7TUR^;;>GG8X M74B/AH&(*(PEE1 % 8AGVT]@+I56BH2-]S&VG\[K('T6YJL\"N/9W M[C)DKXG"K*O;(!H%;%V_#A$V(XD+<1N9'3;5+%KQKD!O+?$!#EXGM7?FV'78 MP\0.72=5/'3D.OWH0#?P-K'Y9[$DJV/F_P)%!'NI4+-?1 (B(4-( T4+(DU$ M&N& Q9$5#YSM<6ZLT&T_V8Z[25WG89,4OFQ444]4MN%&Y_$W8PFGJ([,&9VL ML,-MG(V]-32N_,K/]C>M@[FI^@>>YL8O#J.>OY(RTP5L/@A2B==JZBPPHCB6 M:0*U;0&1ST*81@F',DX2C' <^V:)0D[V,#=JZ00$2RWA54T@=OQQ"*(97UP$ MSIQ^\)(+D0U%5C?N-WJ>L MU5;ETT.;;J%Z)611BDUQ;^VOHZQKU8?:F9=/[U?BOOJHE-0V=[%4/=UVYLZ" M<2YC'W&K(6DE :VUTK1P=E['2^@R) M7!EG<$VW0;,8LM&W4_4(_:SU_!/0LQML505;7;L1;9^OU;T"^^IM*@VZ#K<9 M=1"T> MF'*8AH$'*4LQ3HE(_(19Q1:=[&IN1F3M, MH]U@-C+%[@KY/[NBK->K59G1]:HV.U<%N"'-3?T(Y]SG07(5"'2ZHVFC?LXJ M?!#B<_Z-@<[9I7@@&6^/SZYS_DG7+VS\B+KS%N%YRLCT=0Y>'>WLI3[$$4X@ MISA)0DF)I%8>A09]SHU16I&[D^ZFJFE1EWIDK0_+D-0Z)NB;$8UC3$=FG [. M5MP:S5K@UN%PA#,O"X!<^2T;]#BM#[,Y! ?^S!:O#C1DQ*UVG'I3W),L7R0Q MQVF<$NAS0B!BB,(T(*GZ3QPE(<,IQ4;>A4=;GQNYM,)5X/=&/LMXO7WD#.V2 MH7B,;8H80V%O91Q3V95AL=?VM+;$,;4.S(>C#]E-U*I<+5ZO[]=+HB/$WDHI M6%L?X).\YDT03OL-!KX4<9C&T$-1 %$D"232QS 4*:(2I31$B]R;E-Z M*S5HQ+[J2E04$G2B6\YWBP'H)X%Q8!V9&1PA:DP;]B#U<8EJ;8='U+^V'&+1 MT23$8J]XQS8#WASH9G9?E*OLGVTHZ\:-31_9Z[K7.C.<]@JJ%M3W>,HDAKZ7 MI!")-(0I23SHDQBC.,(TP49$9-OQW.AH5VX]7VI7'EWWO8X/''!);SP"9N;( M&+B.S$?/(:VS0;[O(*TEK[5ZOB7LWU.@^&#'B(A<>A'T52$9/:Y!"$&$3<"X0,!26IT=GL\>;G M1C^=<%;I2$X@=]ZTN0R/TQSR#QU#]Q'))(S5_)D97_S4$/M2BVA[I/D<0],#S N0&?VX4#[V@##B8/*&XLV/(Y^U/?.AX0KW#(\93 M#PZ;S/4)I;YS;8XG=YSUNO0I 59; %] GB*U.9 T@)A$*4S3*/%P[-%86J4; M.]?AW*9Z<^"^%7C7Z=1NSI^%VHP"7 (X,B/T83="HA539!Q1QMGN)F404^6? M$XKQ>X.3L>BM7NTLN*F;M.UN060:2NPE4/B^OC4-$20BH##UHBC!022]Q.H* MXTQ_"1#D22:F,B,&1(8$'\."#&0G+D;EF*_ NSVQEO@)::E"+[1Y1BUPM[I&=*&6+ M$X3M4KC88=6;R<6PJ>D2NMCIMI?7Q?+5 ?3]0525$*US<'[;K!#Z/Q^+U=_% MZG5QKSXX)OCUO3Y:7O@,!R)""'HRQ1#A0&IG%PDCF81I&+ 8(6%,XW9]SXW. M:TGK"ZDK(-.OMU2, R_WB7!LLGIEH9ANNXM M$0.;<%HQ9EN=HWKUM'VFK=Y15W=H2CRH7J]S?J,^MX_J VP]@#Q)(I(PG04V M8!!1I'[R@@2&4H;(0[['$Z,U94PAY[;X=)$/6N"AOIACC*79P<9+C]#(RU9& U(\%C/W43RE.N1]&BUSM8'Q[ */; MO%3&T#@BQ//]3<1.SD;]--O<^K55EO=SJ_MEWWM\97][/0 M9*>D6$@I@I!0!%-&?(A\0B$F.($^13*@<8A)8N3\-F,'YQ53C,#*Y[28F;%QO-XI<;7QNP9Z3;J/, M%=BH,]6H6)QS3#4Z$YUZC#I*=B<@+I#M/0^YJ(/I3D=FM^\/]-ON_EW*.O)1"3RU;$#$E$+:T%UO;@:+#"NT!IY =D':B/GD%(4O8A9D+\KY"8B]Q,(.N)K M$S!Z^;BW@>GXUD2//3XU>F$ 7WYA=X*OEZ(XK/U(JHP1'>NR7-=I+7-1)RQ: M1&D:)-+G,,"18M%4Q_$FS*\+_4B,$JSD-&91^_[GQJV=!GKOW.F@[96FP-X5 MJ/5H@[YJ3<#O6A=0*V-#* .&RH"8QQV D>EZSMA;4/RX8S 1\>\B6WM=#1B< MKSJOE(,3_ M1[5U!!C0[W;HR7.>]U>:"9@;>=K8=UK&6V4I\.%;!KOXZOHH? MJU=*WS\641(3$L4)#$@B(<*$PC1D#/JIQ&&(2>2;U9J[0(:YK46?B^523;WZ M4DS-NH.2C9;7E@,&Q?!6^6E>*;O65P%_*HJH6R,-A@IB 8P/V_/]7E,5- MD>6K+^)1Y.\4D2GKCJG>=@YMOX@\*\J/Q4J\60N%,6X/KE(I/2^A&'J84HA" MP6"*B#*__"A&- WCB$;&F_\+!)D;%WF_)-%_UW6P-C<;52TXR)7D%>!K ;3P M%EO.2T;)8-\_$?8C4YG6 M1J@%H/H!4!K29@]Z*IT46[U KPIAV-(<>ZEPR+ MQ9' 1,,ST=G 9&<9$MWN:K;/7T M6=QF.M]UOM+^> L<)2R.@P0F4E=$CGP=5AU**%$D:"B04(N7R=ITJH.YK3F- MC& K)-!2FG'921#[EPX7T(R\)%BB8LPAYU0_8KY6@OUR6SS^JEYM+%?UP]9@ M/=G@)&1P3IUNDI]];G"A\VWYC.M'DBWKK7.A@RB*?#>Q?7O2N"FQ@##R4X)\ M&'"UUT4B1I#X(8?4]VE PI"I:6ZSZQTLR=SHX*-:R4O]\5J6LQ@^%&8[XTD M'IE4=.WS_9I#&T7T+KI1!>SJ9,Z.UK:GC4^ MZ7IU7+'GB]")IP8F1NS"FMMJ+MOO#X=Q*A/$(=)[:X2#&*8D0- +TE1P$J(H ML2KT=+*GN1G4VZC\KL"3I65]&E.S.>T$J9&G]Q:D3LA1IOI9*%PE.3S9S[39 M#<^I>Y#6\.P+%U22U GL!7]3^YXVOOIU,IS/0G61,67=UD_5,;+*,/XDWQ6E M%)G.TU(M)$XD]22&DN,4(A8S2 B-8!BD/B,D1BRU*K9PJ4!S(YE-<8!" M9L M(RLM?.U"]Z@4TE-+_>WSEV^V[CN7#IT924TY("-S62TD:'0!C3*;R*-:'QV MU&G4[/:;O!!70!\0:'>@K5Z.*V$Z0-AEO MW:_O-T%-. @%CF"0R "B).&0)IQ"&1'$&48$H=2X:,1NRW-CRE8XBSH1>SCU ML]E%VH],2ZU<#C-(G]3VDLH0>^U-5Q3BF!I[]2"./C#,&MH/9=RYX6Q^K+(B M_ZROTOV%'Y#4ET*JN1BKG5."(IBB2-:;IL1GL8>QU2V%<<]SF[7O\VR5D67K M&J/EK+.PVIDRYKB;V2RCH#DR"QQ$2N^(W?VCAK>6W)WU88V5(S/#O-])[0EK M.)X;#O8-#,GPT=:_>=TN?C*D,2*I!UD2"8AB%L/4B]6F3%\/)(QXH>>9)^W8 M;WQNC+,IIO3:)I7#,\#Z>>12&$:FBBT"0SSEW<_A<.*9H2=):MEO\A>U]?3(\J9H//8MST5-FIK1=-R( MVP8,-0*#3N)1SDMM(')V+F#0Y<1[?W,0#O?W%N\.OT M\MI>ZQ^'MY]C'$(V,JT,Q&K !7\O$A=<\A]O=^*+_E[E#B_[^Q\?MC3N> W= MD/)367-/>T3&?19^S,^QW MKD>NP ,IP:,6M\ZHQW6MAK+22?9 I84WS*YG,P1FQHEC8,?>*NQX+EX!);!V M$&I$;JX\MAD;W!DG%A YLDU,>IS4-+& X+EE8O/J,#YZGS\JPZW(Q@!?,ZYQB]K(5+,1]@IH[#;R;BY/.YG=$8TY/HYXQJ##26G& M'(#G+&/QYC"2^9:7@BRS?PJNQ,81=1DJ02>U"D M3!$[X1*FBLTA)U**B%&.(SX@W;P+]*=/-O]2@V#&_@Z_Z)&I?RLI>)9_?D=> M=[1O"(PCSC_7VZ2$;ZCZ<[8W?6WHM;D492EX6QOU=5&M]%*RB%@0,"$3R(4N M<1=QI)-)1%!@7_&,1#3@AI$K9WJ:WT'7M[S-#:^FA"Y< ;+.#U"7N;.T)T_A MBV(J0D_ABT//AT@$'DPY]B&/)8I]/Q:^M/*]=(#N%$OGFT,\K\!Z"[@;<,TX MV@%D(W-SXU?0H?6Z0>MC3SW% 1X$O1@X\QB>Y& K^BB7<(- MF')(@9M 7B4 >458.#HR=:\YV-[?5MA48K#J)0=&)O(F;LO ^.0]W M/V&Y!W%DANKPVP@+-M)N0JJ1T9:[3GAV3^UC![Z9K_Y[IJEI)W1?E1?%<= MZA(U.JBC+'+U(VNJ0U[_R*H%B3R/1UA W]?Y9[R80QJ$D?IGS!A'@8BE4?VS M0;W/CORWPM?30HD/MO*#?064C:54L*R=:S:H,Y@:VV[#L+(D>UJU_>DMNL@6)[;KL,:&49N[TA6UG?#6ZNXVJ9K3T4J M8L\/($FQA"C@/J0R1# 40>H%GB\C8G5"U-O;W,A+"]LZ.?PFB):U!MV.G_KQ M->,C9ZB-S#\[@.U("GX?);V]$2B."*>_KTD)QDCMYX1B]M* S>]?29EIF_>S M6F*TKUN1JQE2K[2)LH)\'R$8^=I)-:4,IC30I:"P[[$PH"&GQIO>D]W,C3(Z M0760E0 ;4:TLFS/ &FQOG< U,E=,@)3%1M8)8A-M8$\@YVA3>1:)WLWDZ;>G MVT2>U6!O\WC^:7OG_:\EXKG]\N F%D2C/4W\K!_JBN@USJ]UN:S(G^ MJ *[;O/''Q@:,?,N6XJ/ZSHND2:"4C^,H"1"0!3R$-) ,D@QCYD?4R_F1G4H MCS4^MZG7QGIH 4$CH6TLS YPYV?@)7",/ DMD!@0Z7*H\@7A+3N-31S3&7C?OE?K^(MBZS%:9J-KXX2CUA!\F/HQ3DJB=@N 0A[&$29QXJ8^E MC!&WBUSI[6]N4W>WND7MZ5-M!+8-4>G'V>RLP2%Z(\_T7>!J)Y6MK YCMRUQ M<78[W]_;Q/?Q1JH?WL";O38T!F6_M-[V9&-[NA;R5" >41@1+X0H3A)E>:5?RD*_CU;&IKH-HB;<8QC'$?FF<.J MG;MN0:.<;5H Y"PPY7R/$T>F&$-P&)IB_NJ ,\^NTM[KXIYF>7W8HZBNRGA[ MZZPV-'G5^.V]_<=:65+OVVB JDD'>)WSVIU2I_0AU=T-R?B-*-LR?J())56D M):GO84@\/X8(I02F?N!!+Q!QBB@+/;,S@ZD$GAOMO5;CK;?B=:@O>"@S=ED8 M\&0#;W"Z.[/A')E].VW!CKIU.K.MPF!'XRO0Z PV2G?Y6O7"U^FM&M"U8;7J M=?QRI_R90.87X@+S8^R9?1H3'8C/Z1.Q.VR?<+QZC^VGD&.Z"X )4=V[2IBR MWX'.'J=+DU\WT2^[?G-_%Z1\IV;I D?8#Q*,H2!1 )'T&22,<(AEE-*(I7XB MK?91P\28FXVQ*VH;]-GM$TBMRY6N3AI;NHL,&R&S?=?XN(]L##0*P%H#\'Q? M=E6[0]>IUW>UN0):$: U<>A\FTTPB;" MO75ZMSY*.@:I\>G1A4"-?V#48--*J$S)1D:G!T0]&+@[$SK6R=3'0#V*'CGY MZ7MZV/S7^4S42W?*/'LC'L6R>-![FI9C%A$6G HU[VF8Z/(*2%\P^PD,XS2B M-(SBP,XVZNUM;FS0"5OOG/A67#LVZ ?8C!2B'2\\1\Z,"2[ 8^2YOY%LA.OI$UH[FM_/6Y]T1I]0 M[?D MJ3\KU=1;]6[DU5/7QM/K):FJ-\4]R?*%QWR2>KZ:_91&RG# ,4PQ$I!C'D@WV^Y+C$M."BW=8V;\M-C0&U\ MU.<&P/&/^O9+0=>2@I\U:G\:X0C "!=W!WX]?4U]X'=>[2,'?@8O#7 .;2)F M/LF;-574OWQJ?4\%ORFSHE3VXF?QF(GO?RW6[$Z47\A25 OJ4Q('NBXST[Q" M?0(Q)R[H8*,#?2:530+A4/K1* =UIH7\Y:#<5(6@_PV"@" M*JV)A>?>D('JYZ<*>$D[@Z,LF?HL&T_#SUGUQZNG5R)G=_>D M_*/.AN$CY$O$ +##;R M#LH\=Q9Q,W/6)8XC+P^70#@DX-((%W<1E_W=31UR::3\D9A+L_>X[.^][-!\[-'3G6'LUJ;4\BQ'$4PB!*8\5.?@(QDPAB&2:(^P$29HYT8PHY M-S)KI*J+&"A[8/V@IN-]IA:159$+0-A=)A[;G)HZZJF.=*HN#W6Z?*P-+.@9 MC.#(-'HR7J55"["$]R-BH#0I(N[_NEPY"N2NKX$E_"KQ2;ZM5IFN@UDM(B0$P52J MT4[U#05F$*2SR*IBWU[S-XP!IYC'SQT4-8_[(A]!8[FG'9X"F&+EJOC".-^ISV7L(7CX(#" MNH%A?'7$(#J6KRB.?>RGA$$N_5215:3("GO*0HD)H2'R4<*LR,JLV[DQ51UB M7F5UD1L[,Y$EF\/HZ%/JSM1 MZK32I;@3:A?V*-[GK+@7NH)N72S]*_EQHP.7B_QZM2HSNE[I7=C7XH;HR,5- M$481B2"): +#P%-&%0ZHKL-!H8Q8P!F-/2_Q[)R['$DV/S>P6C' =C73A;N4 M:N#GI2XK_6<[BG,UA&8<^ +#,C))-N.QIQ)XWXY'7>:[R4NHMH=*-;TQK)4# MN]J!50$:_48IP^D8,ZTJJ22G9,93/.=MU\XZNVF]$J7]!;H6_("BAQ!,( MAB0*(4+4AS0E,61A$#(/I6J^6)5_Z^ML;G;D_OUPJ82]TIGV6G$OO%W?!7G@ MS?I Z":_5;\"-^=1N_Q"_0@<8UVF[W;ULA?I1Y0^>XE^[)UAU%$?J[\BE>": MQ12%U7UG57E+IJ M_8)Y(2=F0CH(=1760Z>YSK;*@UG9SE:H^A:W&[:TJ MV.KLCI4G&!A'I#ZFI).N"1- _GQ)F:++H5&G=/4^5W9Q[?SP3HCK>UUJ=!'Y MC,G08[I,50!1%,602B^&B,4H$3P@#%M5Y3C1S]Q6@@\B5]A50 I-_756(S7_ M[>K4GX/6C+$= #8RV]9%-[8B7@$E)&BD=!EPV@N#LVC3X[U,'&K:J^IAG&G_ MXT.S';)2*!9Z(YK_O\_;XL-5FU3M.N=M$L"=./J%'V'!8II"BI((HC3V(!:4 M0IQBAB).::"V;5;9$(>(,3?+/ 8)9X/PT1[Q/"$0(I##$F2"I0@P;W8J!2R26=S8\#V MI%\).X#E3D-JS&5.@!J?L5J,IJ@L=!X2=]1SNJNI">:LTD=HY/P[0\GB41EL M1?FDTUE7=X+K>ES-_85.1%D^:M_Y,,4BD1CZQ"=J^^5S2!-,(4,H8E3&+(EC M.\XXV^?7K)W0+BG%&"%G MS'*^QXD)QAB"0YXQ?W5 T-[U\I:(7/R'HK,VR4I /4\B(6! @11*)0UXM$8 MQ@'B(O19E/CFX78'S<^-1#H!+<*A#B'K9XK+@1B9%#K9KK3?Q2_G,\^80&(1 MVW41-!-%9>U#Y"A\ZJ3BO8%/AV]-%[)T4N*]8*/33PWTIR@%SU;O"*L3*K9Y M4GV=)ALQ J. I1#%VC.7)@$,!!&I]"+*?+LP@B.=S(VL&AE!)^3 '+9'X30S M=BX%:60BL\;'WD>B!P!7OA''NIC6)Z)'R0-?B+YGATWWW4H]G^3S.CX+A)"' M64(A"H2OBXU12.*(0)&@U(^PY(%GM?/I[VYN%'"VJ)@=%YS!.HID$H0R@#%+ M)42,1Y"BB$,>Q+K F\^D]!>YN"4KP;]."GG:0'[0]S3(.P79C'K=?:9C6Y// MOM"#\MCNV-@,$T>\?*:S21G:3/'G7&WXUJ55T#*N=J<+/_4DBP6'01PHFL9) M"-,XY)!XA&&4J@N6J)L!41]#U*B M=F4L)CP,@B!"R,K']&@OVM>,OJBA_!F<6A\QC>L^K?:ZP M AN'2%%L(D6BJ#=*.+:+][H8Z6FBMQJLQP/6C',O!FMDYNWDJRN3UQ)>@5I& MAP6E^B!P55;J:!_3%I?J4_.@Q%3OPP-.YV_*_Y^[=UUN7,?2!5^%$3W19^\( MHP]!@B30_Z6)MC +KD6LH,I54%4U4 I:CFVJS( M :5I!JI4R:+(85H*^XWZ(4E3X]N-KHD9KJ3NM$W41EV'?>M!?"UV]4.A%ID. MMH 9/9->T>13:, <]OQ# 3?2]K\O@&[G 3:@#!X-##Y@O%,"&SL.#@RL;@B4 MBWFOG]/O>0M>0(@*!C)&$4!%1@'!2H&*8L%*"E/!G+HF#J-1KE/4] M41@ V?)@(0QTL<\7?%&[/A?S&(]8J9A[DMXV$_/8Y(N)F"=N\CJX@X*Z&HRH(K4)(T-1%7!:"PQ !7!*;Z_QDGV6R]6M.%'5L*_[O9'1K:UZ/?_U7W &J_](?A%2S?E\_6M;MFS]XICM> RN*DO.E""@%.UN M82$!,7U.6(6JG)-*KW;53*_TYBOQ?4WK]1@0OQ87<49QCB'5=JC^'$IQL-P(VSZ"-I]K:[#)/)':E^Y_[$I M#WRZ6DK +-6SB(1*+CT6,&Y.Z%D#CU(YSU_IV=9O_O!C_57]M>D.:KZRM?Z^ M2?%Y^?%/_L/DAWY:U9V[++^8A(9MZ]%9F1:8F*YT(E44H!Q5@"+,@"Q3"65) MLTRE3JWI?#69FOO;*YG4QB"P4N"YV9R?)ZO>*I,4)'N[VD.=19LUM&*+^0/U M*(7G/XQVI#3*X$3FKF^;\3 %@5LSDJ][P_%Q?S@V8]@:LVL+';!?WK6 ANJE MYZW'N'WVKH7KJ ??U0_TX]O_DHTYA>S7KYB6,E>L $R9[B.H((!260),(,UR M24H.G<*-#IX^-5[LE?/*Y&56YKD"BB )$",9H(Q7 "F]FM?S&572*1+% M5O#4)O>93B'Z4[IK%'+%)J#U>%@>L49 .?:I:S" W4]C'=$*=4!K*W;<,UM' M,(Z.<5WO]R.POHQ/H]V8[M##%&&@4E(HA *9*)&AJ!00694@)4) J!A$;ET8 M3PF9&C%MSM-J^5,NGZ4IAO'HW@?A))QV7',M2+&/;WOUVF7/5L%PY#%D?B"B M."EB5%(8,O(U 0Q>ZS;9A9S//B[7&SZA)K)1?J!K^OZY-EMP,U4H 2N( .$\ M XC@$K!,+S)RQ4O*1987I54>TR5!4YOTG:[)GK*)T3;IU;6;^Q?1'9[_(3&+ M[5MXPF5-!K98G""$1O)_>UC]_)_Z$1T7Z!]V%'#QP:/0@*UY&RJPOM[S?)$N MY%?5;A4?=E3KO(W/R_N:+ALC=;6^SD \:+"SVC[4$HZ+EK M/-TL_D.*9T-_=_7J2=;KESL],NO;I3![/$]F[._-GLY,H1)6:8I!613:Q>*Y M KA &(A289IR7-+*J9JQK>"I\=A&VYNDU;9L/VR;+;/F$YS3),RQPP M!!% 944 2XD"@A%1XJ)$B.+K*BF?$STULGK?1@$T[3IPFSO<1_&8.;970-FQ MIYO#<-BQ5AR0(_/6F4K)NSSM7O4H3=?<$8M6$?FLX#>N@GP)D,N5CR\^P8_- M3*G"M?PR_VE6EX=5)O9K4'SLNB;\3=+Z7@^>G'%(29&6'&0E5P )B@"AD@!2 MZ"5D5:*TQ$[4YJG'U'CN8LV?FT2_Q84;Q?F.D1W?C8!\9/+K+ "M"4254KPGSVL=YQ@5L&E1NNYZ? M:'_>[Y,@##&7FC%):DX/J_%Z"=: >UI7(!4J3L%!\KCA"^Z0'$4U M>#S",V-%=J':FWH8_32I5"4SC 20*D\!PF6J>8I2H/*R8*ID&:).@9BGQ4R- MEVXY?WY\7I@RAD:T/0R;-M%X_]_? MKYKU[ZOUW^3ZF^2KAZ6I%-<>8'Y]:C.O9ER5E$)> B687BF6RO2RQ1C (DLY MSUF98K>8[C&TGAHS_759;_5,^'X[U+Z?85++CK?6J^2YMSUIC$7)ZLDC!6Z< M=\..&"Y#K9V7D3O)7CJ$,2 M*@)^%)W'#9\?X3Y;)Z?%PMVZ?M>NS>/CS4;27JO]2KIC$!-\VF MIM%,852QC.DU.1$0(,01P 6DH"BP2BG1KF]1V8?!.$J?VB>GT[__ANPZI]\D M=&-#\F",2!IC1?*TJ;OUR_.3_@A9AO;YC=/P9R,Z^I'IOP>^U7VO3[DF\2WP MK?Y):T"RL2 FX"XQ/A&!'RL(*/ . 8*>0(X'$GD^M 10XT\[3V,1?)]B&^I MNJVX?HE/L*A(BA$0D#-@6H&:*K\E("*EB(I2%##MW M]:XMG&4^?[\ M^$CK%W-XOC/"_+:QNYMD_?)XWV;?6,?00V_'9I,8T+?>R.B/8T4; [;7:F*S M8=%'7"91^B=''X'@T9JA]7RC\,Y(<)^/!XTET.^C\W7]0]9&[# 1P(":_5IM1^3H0=*]9.=1C/<,=NOHEMP^U;%V0S0D] M$KS@1:77ZZQ2 ,&B,IVT-;&6,,^*'.=%P9WB'4[+F1I7;LJY[/1TC'#C")T;(PS ,H6(>SD@9-^AAV-2CJ(<+EU]1,+Y+J/[P;"H2=#Y> M&UUUVC6%VVK>686I, @S*!+F?M^=]?7>/"H\^TV-I;+[:B(C[&.WE1UN.GB.F^2BZMKJO2;D'Q: MU4K.U\]UP#AW?S1#UAAW4V#\&N1> )VL4>[W)#]Z; OTF@5ON_6RV]8B7!)> MY06@5:Y,OT@*,*PP*,J*(UV0WFK:I7>&5]YH+5XNY:(.R^A9)^K;O:_T'#T_KW*C8L5\ K"-37*MA M'\ 4<]/O A*!Z.FSM;IO;;=9^K=R^Z2_BO6A@H=UK^Y M_4GG"Z.7_IK]1=^[GM&2R@J*##"EF4BOV 2@I.*@*"!DA:!IF;JY9)$4G1R? M=;X$W>C95JI\,)I>49@KUB!;^G83&+H13U+VC=QW^!+V:XWF9DL(]\TMCR_+XU[YZ;^5(VC5:*:8>K"R]=FIQY M+=_X8W,ANP9TNX8MJ& I%1R!,L_:K$P$*-8_Y:G$6.6LP+G3QI^'#E/[0NST M3?B^PF[?!)_!4!4GF!0(())+@#*( :&" E)F),MS DE1NK>6BSPDX_6>.]#U M)F'R8;XTV4 )\VFIYC- )2JK3&$(\IQ"@'+. 2-$ )Z)5#+*\B+%KEWK1AF> M^&WM7@V.7(I11\;.4XJ,=60G:*-]LJ>^63)NZ>K5&$1H-'4%@($\%A\-1G5& MKH#HM9]QS:-\SP;Z[9FNSAW+,62(90"F;2-9IK]%!:I Q7DE2:4(%TZA%H>/ MG]J'?ZN=9_7 0^QL]^5]$8F]XK(&PV/W_)3-P7;&#QX^\J[W*<..=[1/7N4W M83](MOZ\;-9UFQBR:03S34OXJ)1L2\'?R=JTGJ8/>CXSQ1G*$=#.2@50R5/ M*DD!+5*:0D3+0CIUV722/K7IOE715*GJVB!I,G7T5=SPM^.$:*A&I@RC=[)3 M_&;77LKH?I/L -^I'XY5O% +1#INLD?E)"]87E.6WT/"AR?<\G\\SYMYESPO M"4Y1GBD 89X#Q$P[FI(5H"P++@MF&HNC4$$)^X*GQF-MMR_37G:E3-CG+FG5 M;&NV5?<2NE,_7#S"P6#8>COA(8[N!QDH^X82G=))I_4V$&%?\W%B#$YA-4)D MP8'8R<03G +#)8K@Y/T>Z?9WJ[4FP#E=W-&7U?-Z[[.O,LPQ%Q)(I$P)F)P! M?7L)!"TD+K*,0@RM\^K/BID:+VT5-5WRM*;)T^6OO@NJPY03#JO(!+.#J5/2 MQCER@/EUI^T8*#'/++5[OW$_S0OPS_ MUS.M->9,!!&L1>/SO X]0N\ (!7J\!SSQRM2^ %H_8;!%ZZ MU,??Z6M)?-(Z]9'J?9S?\F$;LOZ[7,_*K"1%E66@JB #2*H48)%R0&2&:<9R M*BH']\=2ZM2F_T;OQ QA4O>)%6JC>D(WNM\D2VG)"6[#8.,O10 WMONTP=7H MG&P25K9:[U)7V@2\&+BZ.%@1\!W+WPJ#LZ,+YHC7L$=F^[ 1'31'^P[]-=>; M/3C^N^3/M11??\IZ.7_XL=X*,'M_W[]^^K9I@D?R(LU0#G"6<^W/B0S0HM*_ M8J121*G^-ZN#0A>A4V/X7NUDJ_?>[#":)[\8W5T*P]FB;\'L$3"-O?%F!Z=/ M"T?KM]J>V2/@.Q*Q7_O:NC&Z(TZ#A&[[K/'XW-&Z SIWO=>SW]&S?KI)AKM= MBD_S/\U/FZ3E0@F)"9- PTP!RLVY,)0*P"R3,LM*H=PR"LZ+FAIS;S5MDS=5 MKZMCDZ+SP-J=C82!*S(I'R*U43-"4OAE-$(U"SHO:-Q^0!<-/FKY<_D./X[H MV@:]?ZY-P8EM]T IRKRH3 ^,C!* <*H I52!0E14II5).6(N]'!2RM28H5>O M;U[FV)KQ-(YV;' U.I&)X+;OYK8!*$9?Q4$, DW_TS)&G?F#9KZ>],,7>Q;D MVK16;%,@MZ&D)L.WDS,KD$ 5S"I0FD[3B)=Z>2K0 M*QRP_I4M-J$J7%V4-VX-*UOSCZI46=_HL:ETFZ60?%Z:TT43.*9?$+WV62W% MK5[M"K/B[?UF"A'-,() "A.M2CD&)!,I$(1AB=.B@L(J-\U%Z-2(QVB=;-5N MN[+?))WFR59UAZT/6^PMMI0B(!J9?:S ]-E0LD7584,I KHC;2A=]\JZ;25-\77XS>ULF[$Y? MH+\A]>;7=[29-^;^]I6\E_S',9EG3CM38V@]M2_)7B&?KZR1]<^V],'GY=/SVE3N2;8&F2L^2"7KNBVV MX)T!/?3,%/&[_G#%6"M.3ZDU-*DRD'"2C+$I99@;*L MI#:?G(.G3NZ38%S!9CWG=''8)MLH:^G_'L(VS,;>8,0^:O;#P9H"3]H]1%'Z MACUZTK_MJ.GP6:-0QTGU-U/[]#_Z>9-]J9Q/J_I2FOLNT,4DG[7T,6,*5TP4 M#*0H)0 AQ &N*@RX]A>APE+/9J=\L*NTF=I4[XUQ/-2\;D#L7+/18(Y,(IMR M8R;K[EQ-COWMSKW0N:TYX;RM(*@&\J*NTV54[R@(;*^]GC /O7*!_KML+Q:CVMORY7VX5BNW(P;6&T>HMYJ_6WU6*A;3)US6:B%##C M.01IE:< "4W E!0<%+3*!(89TVSLM4*/JO;42'JW:NNZA>PL3UK3DU^VQO^Z M<51$HFEE"T#2(G"3[&/0K?J20Q22/PP.20^$8Z63D5XJQZ7]9%Z5T=;VDWE+ M_#<#1AFTT+L!<95^F^V 40;B['[ .-(]SBH/*U]T3=GO5W=Z+O^@C;P5HLT; MIPMSG?X*8EY52@'.F/X*EI "5E898!271:G_2U56Y76<)4_M0]9I:QI:/?7Z M)G2K<"*TQ@Z':TY#8'%N&0O8R+1_5%VG!_E^E6QT3W;*)Q\B@NQPC!D+[)'. M,D."[G:RZ0/T!OFQ6HC/CT_UZN=!RR\,D>*F M'PCE&08HJPA@::: S(4JF:080N7<'N2TK*FQ_5;59+ZGJT=_CS/0VJT# @$6 MF<5W6.VK&2& W@*.D,T^SD@:O^''L,DGFWYB*V&PL2/9&F(:<.R-16M+U)"" *B&ZBYYA2;C=J"\'K*C+I4!'NG+ ML6LZ7TKQD=:F#T!SR_6BX'EA6HY]D&K.Y^M9FL*4$HB JK "",$6(4Y*'D& M89'34J:Y&Y5>$CDUQMS34*^\6Q5=V?$BRK8D&!*[Z%S7*9MLM$U^V4>R5SA M6K0[.L$XZZ+ D:G)%H!C!K*^TS,P8:_4QOO5\J>LUW/-8^UF"!<<,UJE0*DV M4DAD &,, 98D)5E15J*0,WT'6UD''IR7YC)!]F7&FR?F!.*I5]@QN& 5,O0 M@3! Q0X,.*C\M*=GH.TB!S1"'>@/2!KWN/ZRR4>'\1:W>*9-<[YZULO';Y++ M>7LLH>=&GZDYRUE>(IA6IOR9_B\,":"L8 !E62%A44I!K>();81-T -I=4WJ MK;*.B=1#R-I112B\(G/%%JJ=GIL^UK>+Q>J?;9WO-L*HEF*^UNO=9I>$'3#S MV@*M4 G80Z+&S<.V,/HH'=OF'L\Z^/R'%,\+^55]FB_G:_EE_E.*S\NU?ET, M8741U%VK&4412FE. <38, PN3.&M%#"2,T0EE(ABITKXUJ*G1C4;S4T.2Z<[ M:)5/=MIW01*-9X\?^T&QXZ4X4$=FJ8 HNY?%=P8L5&%\>\'CEL9W!N2H.+[[ M$ZZ*[V[N5VW-_5K^1NN_Z[6;?G);_:H+&TXA3P56)1"Y7DLACA5@&.E558%9 M2AG-55K.EO+!+._NG<.YAX5;33+23;(C%2(N(39GS7K"/6[53IJMWEYAW1?& MP7(-%@S64<.T&Q. %S7(IA(NK92%S M:C[6_@Y&(Y=SO1I9KM:N'&0#MAT#!88P,O^\WO^Y2?9R=?=4#D<_#O@$(A\; MB:-2CP,$KXG'Y=8K>ZY^U,2V?C$MY5=+PW5M1F6N,HHJ1@"AB *4(0A(F2-0 MH*R JL@+7#C%%0U*FQK5=#HF.R6=4E/M +9<6!NA4R.17=H+,WD#GJE.0RC;44AH["(SR7Z:T0["")5^'6 )G<@S M)/)MTG L0#B;1&-SKT<*S+M:+ILVKH[]9;%B=/&[7'^GBVUY:ZXD9(B4>C64 MZ7516A# &!* 5U6.4[TH4JE5M**-L*EQRYZZ2:=OFY+7:NR0?7$)XF&""0U< M9&(9PLRG^-XE\!RR50*".%*"BM<+Z):)8@G*8/+)I6>,EV]B:<+OXF:?U)_Z6957G&!%$, M$ 13@"I9 8)3"/*TI+3@B')FU?5R0,;4"'K;P[73,S&*)JVF[CUN7\,Y3,J! M0(K-P>[X>#6Y/8/ 54UN7S]S]":W9XPZU>3VW*5^&VTFHHLV/^[JU<^YD.+= MRU\;$QZQ+9&_J]6TZY63%VDN9 FRK$( 06)ZY9 4%)!(202G>>'42LM=A:E1 MPZ[Q [U<[2S4,-CMR\4%-S*EF,6>T3[9J&^2\'XQ%B3SY:_)#O:=%5%Z]?B# M&&A/ST.!47?X_ %ZO=]WQ9.N/*#\,E_*S_K'9I8614K*0H*RS,QR5%& 65:! M5)2E*"1"%7(*@S@6,34"VVJ8_&%T3%HE?0\B=T ZGCYZP1.9@AR1\3]P/#(^ M]"GC3L#;'"T>&7CV//'X2L]#Q+;@I&S+(-S5\R6?/]'%)M9JIDC*BHQ@P%-> M <1(#B@G B@DBPKADHB">T1B#@JU>K'?( )S$S:X4HGJ].];@3UM+' \6!Q$ MWO)$\6H@1SI*[ 'K>WYM54TN5B5V/TVT@234,>*@K''/#VW,/CHXM+II>HUA M9I+)E**L "4D7"^O4@$PQ0(P+BE/D6(5=/(^8BH[-3_FJLX@OG5B8[P$EA0Y MD:&-S;!Q1G5235YB!8'$4/7_-RU=+@:=Q)1Y71ZV_I*9IVG)7]<_9*W_7#_+ M?34W&<2P4B5B'(&<4I.13?67)-5>+Q6YQ+S,SJWV2:]^LJ=_Q#1O5^P"IWY;BW^3 M='!7<,ZEB#L_QR.:Y+Z>/SQ(0[ ??^I'M?'M)66"H+P"!>(4(*(H8+1(@1)I MAB"27!16%;#."9@:>^U43%H=G5(&SJ(X3$8AL(E,-G%@<8CIN!*>D>(W7L,4 M*$!CP/C!8(Q3]XT7>#&@]4&0Q=!U?C[ P)3I7^5% J4DYP[>6G'(J;&9!L-$Z-B\D>GI.,2_ 20=G[5=?!$ M)C-'9)P=H_/&!W)]3@@8U;DY;^!K]V7@2N\CAW,U)OY2KYIF5N1Z/A=%"7B> M9T<#(J=&L/L[19OE6TW M'WZ__2^O#&M+]!VW[(-A.M[FNS.<_COL5NB$WBL?%OHVN]Y60)S=O[:[VV,O MYK?5^KEY-U\U?"ZU0X.Y(!2 M3@#/9,72D@E:6<6*N@B=&B&U:K=39J.JP[Z$+= 66S@1X(O,/1UR>RK?: >( M_UMRNX=E_R>/U!Y;:!VV@2) /-+6D#W4@3:-'*$:W$BR?=9XFTN.UAUL.+G> MZT'?OVL3:/.CK3;6M"W$OLFVHOS'/Y_DLI$S(3$A*C/+5)8!1!@!M"(4,%'! M%&&"*+KQ[9 M?-F^.N]72Y/%T&5K-G/19C6LEK=UK5^#KKC)^Q_FQ\_+VT=SLOI5G;EEVT(8 MSBK"BX)B!7+$D>E/#[6[S0I N"Q$4:4RSYTB!D?2>VJTWQF0S)>),FO>G^V: M=Z5,7R%9FR[CQH7G6ZO,CSNS_$-'QGI+[/8G)CCVD3]@&XN3/9/;S/;-.!^8 MD.R;K2_;OC.=Z>9].7?KS3;@Y27Y=2EYMU 4K!9[U+[0]8W3CAV&L[5@B&(*1 MN6('7I^>]VV#GE:V.T(/1QI6H 2BCF%9HQ*(E=FO:<3N)F\?8],ALXU&-I6) M:_E#K^CG/[6KPU>/FZI=##),P5'+ ,LQ)+K,"2J=2)M:2IT8R M^]U?NR#] ]633O?D%].2S;(JG?MH6#LHX3&.[;)\??\YN5VOZSE[[EJQK%?) M':W;4.7@18>=$0KGSEC*'=O!<8/CA,OC^( 03M!FQ[O*<\@(RD&5"F;J% CM M_(@2(%KB%*N"2F95@7A0RM3XZ)N9&;+3+>$_:/V@B4G/F=53OR"]RN>Q.XD) M!MC8/DZPDP(K!*(X-*,>(%B9.>S 7'=@L%_>[;ZFR\U9Q-.J7L]*/>U%7BJ0 M8K/X8:H ."L0D*KD-"\+2NV*XPX)F=KTW]82W"F:=)JZUUH\ G1XUH>"*?*D M]T#(J]KB.0BN*K=X]-#1ZRV>,^M4P<6SU[I/\B\:\\7=C]52_O[Y$6!6A_ MPESI"0I-4\2\8L0<2:S6=.'H>.]D.$W1K:11]AJ=,W-.0>CH8/L!,YI[;;<) MXN]='YL?VK?>D_ VGO6QB6?]ZA.7^LUM_:#:^.@?9/>_GY>?ER:3=U6;1L T MA84L]02'*=7N-<\X($HH #D269KGF"+J409P4*C5VSU^&<"-AN?#$SSPM:. MZ^$:APPV>B:_;#3]U01_["D;CA>L, G$$,.R1N4**[-?LX;=3;XETO_9ESG1 MK'17KY;Z1]Y%3]RM%G/^TOWWO?QS_4X;\O=96>0+)'_W_&@N2UH2@]=7]T M67=U1_,BU MU?W .:ZL[OF<4%[772V?Z%Q\Z,-I^RW3;94I./*57M6R[L8'*]H$,]Q\G7K M@F'_IO[>9BQZ]?=KVPT/00 GT 7!:-ZAE1)O[#:Z '79GW1ZFA]E_M_2A,%( M]JO_=C3$# M#9,=@XX/?F1&W1B4]!;U&^ F<:(S*MFSRO3FUM-_OIAWR1GQ<+;^OM7M\)'@FRH+"DF*0EU+S;HHY8"JO "XH M(;"B90DS%]X=$C8U-NUT31JC[$VRVIO!33>I?]%>4_>CXX)]$'([#@T%9&1F M[#'\WF'8:7JSSX;A.,\&D4!,-BAJ5'ZR,?HUZUC=X\/[$MX595F92X8J"D!0-($ &8:(ORE@56F41,.87:6LB&!0(T_^+ZOE0U^[\_Z@ I1+ M"K!>AH *$RP(X23+*Z<$I@A*3HWB]FPT*07UQLIDJ6>EB7LR?S4_MZ5XGKMN MPYO,@X,>SXX;1U'> #O2?.MQC_MD?5KR32ZGFZYE@/$.5V9XJL7%S$0)8I1S@ M"IK.UY6$Q*E.]!DY4^/]%OC&;".K5:UG>\L*:_JG:\&F<[!:'XE>"U;\,T^# MC%9Q>[[Y2Z]EP*C7"SB$.[D\*67LH\DA4T^[D8&3;V>?9=TT;=+D9AC7 @.8)GE $DH31/L%.0%S7!)"B9):4,%@U*F1@3[&CIV MGAE&[_*"1[KB6]E_M"TUP_8F_+ZM]UT'W[V*)/=RKS-5+>[V'.= M^9/.%Z;&P*=5_9TNY ?)UM]-:]+6M6C;4?QU64NZF/^W%&V6ALI)+EC&0,%, MHHO(M#^ <\T)*E,P$SG/!7=:1+IJ,#6"V&GGD0?CCK_E$BXFJI$IQ>B:[)2] M2;;& .V+ 6/.3;*'^I>@+6V\D0NUD'*6/^XJR1>>HR60]X-\M_3[8*SV?.Z. MUE_K[VL3B=DVO+B3=7MD-RLJF@DA)2"5,@GT>04(8AA4)1848Y'ARJFWGIW8 MJ7':5NO-(?T3W=2X-6?S8K58T+I)]&*T.Z=W/*:W' O;+?[0"$?FMQVX_>F] MUEF_RDFG==\^1^O=G>J'W/-W 2K8MK^5T)%W_EV .-[\=[K;=_]?M$4$Z.*. MSL7GY7OZ-%_315_[2E4<"BXIX,BT:6>* $(J"3)%1,FPR"%T\\&&I$V-FW;* M)D9;H/FHU]=U@WT(8MN=\D# 1=_R/H=9C(IB-J $VW8>DC7R_K&%V<<;P38W M7=__?-,Y&.*B0F;?)B\)0 4J 9,,@1Q6BJ.<"XB5;P?T:6[?'#?[=MK"&R_X111Q3-1@I26*4!<5 !75 "A,E[ 3&7Z/RYNTEE)4R.]N]MO MG_?QM/.)@J 4F?BV.B8[)2-X0A>A".0%G9NF<%S1N^YN+!A]U MK+E\AW\=U4_SQE2(TY[)2GS2?VMFL"QHBFD.5)Z;6HNT!%0*O7 JI*Q2"66* MK'R'02E3HXAMG=!.TZ13-6EU=:^E>@SJ,#4$@RKV^90/2E[U5,^B<%5!U>.G MCEY1]:QAITJJGK_8-R^S67]5)E.DN5V*[[+^J=V0YOMJ(68YK5@J8 5HBCA M4&&3TU&"DNMU@_Y;EKI%2)\7-;6I;S0U:=5/]4H\\W522[U >S:YF/)/OGAN MLS/IXZI>S_^[^PCJ:^=ZS=UG*73%1)RS-<\.A)T3$0;>R'2Q0;95LTV1V2B: M&$U#YFE>0B-8EN9902/G:%XR^#A#\^(=0:MQ]/GEQ[G(12E1H?D$*)1JHBGS M%&".!2@$RA J1 %3IV6(H_RIL<^VS@/MZSR(3O&$]ZGB75[X?JJX=XZXZU I MF*5EI@*_T)YZ8M2O_MV SP-HUF&TLPWLC:?60BCE?D+X]3]92;I+K&42\C% MK8IR5OH4RI]<@L:RSLG%QUS=*NV#?*HE[PKMZ)\7LFT5NQ2W>R[BV2S)F2QI MP5%:@)(5!* *,8 +S@ IN10P+5!>5FYU^T*I9C5[1ZWD]T4VS;\G=*_EFM@S MT+N[VG4#:,>))\?G^B\;K<5S9^:IBNA88CBNE(X]N-J1^I11RLR>V]T;V$]-0C'?QJC MHK4WI(%+^=C+?Y.:/\[PG"L.Y/X@/VK]SG](\;R07]6V64;? /W>)#[LRL97 M%2,5SP20.9H6ZU?PFZ75WXS]K M\.UH+P:DD=EN&,WDCU;Q.(SFBE8@(K,6.RI_N8+QFK:<[_=>W9MZ_\T=?3&/ M->XGY_6S7N#.*9LOVK2L7NZ,%J:^/M4,Q00&"$$!] I5@0J9F#N)&)+(94_4 M0?;4]D/OC0RS/F\-2)XZ"UH/@W8V)(N=$<[K=>LAL5Z2QP Z_JJ[0_=N#]U> M\61/\\N?"I\EM2M@X5;-UI+'7AB[0G)B[>O\"#]6^XW6?Y=K(V277#ICD"%- M50(H+AE BI> I!P!BI045*)<(*LNR4-"IN9;[71,FJV2;G1T$DL[WKD6H<@$ MLP?.]\O@.)/(D/6!V.*DB%%I80W50Z3>=.8#VW;0NBX6#M=)WHX^8_N MI#>'-XG)4&FO_B!Y&\Y]\$_93?>KOO=)FBIF_?XMZK7?F#<0(WVP^L\68?6]8N>#%VS=VEV[+5? M\XG.Z_;IN\82?0H-5DSP-&< 0Y$#E!6F[0,G(">TJ@1%%:%.U?0D04-NNZC;C^7;]F?38/+%"F[YE,^=S,E[)I;OD_GN=-6ZVB_;&6F]>X2#-6$HE!*3(*4)YS@$L$ M385 56%4*&B7*V4M<6IDL5$XV=/X)MGH[)MB>1%W._H(BF9D'KD62/?$2UMP M0N5?7I0W;AJFK?E'V9C6-X;P1]ZOEC]EO3;'\]V/31L0-><2S@J2"L4U^4@, M)4 08< PY*! E5!9): F)7\'94#RU$CH\U(/ UTD?*MG\F04#5*QSWX\?'R: M0"B/[>3LJ;WYI86]U3R6TV.!510O:$CN&[I%%G ,^TDV#[@V_.=VN9ZW"2_S MGWL;WA_;Q$HI/FD3WZ\>GYZ["D9?U4=:+_7*K]G4$MS%JM \S8G,%,B*O-*K M,0H!+=L3>)QK9RN% CGEIX97<6JL>+=:ZT'6O+AXZ1)5;C;F[:&+FK MPCI2M%3HP0@>5Q5,P3>*P H-\/E8K>"2KOT(;;<.NPC7V^5^L$6_6RR^+K\9 M74V%MG>TF3>O8B55180HRQ0HXV(CYH-#O^Q- NZE]>O9I MZ/"@HST<-1;WOQJ>:LUN_^&+;[A8V+%V_9",/((C?D-V(W5S9IPVIRTBT1^0 MK85):^)(GXZ \ ?_:H30[8T^& %A/?^M""G$-WIFNPHRRZ/^R#0CA4!,%)KI M$0*(D!Q@)"H@F5*H8I@*Y;2WL(_).<.'^Y>J,!E";0^BV&SM)- M'6LP8KNS6K.;KK_[GH(WR4[WI+O$C-.K/^[?$3*J,@"RP6(LK]%EY(C+ + = MQU^&>*A'YQ[3#/&K:C_.WZ0)I3#U\;??YRX,=):30I*",, Q+$T', @HY 00 M27E1F9- 8K41:RUQ:C[Z5M%-&DJS6AC65%V'EJ?!(WA/T(?I,0J4L7@[G1..J5#8^G0("@TIB/U"PJ K5L#(1>AOW=^AA$7)=4>,6E (K2 M5.5I6A296_J/D_BI]JV/=:"_>TJ@PSC8[L?&0C?Z1NT L,E.]^2/*(=2 M?K@%3$-T$#YZDJ([,*=2&#V>XED_89=&]GGY]+QN]XO:\+A-D[4L@WF*"(!5 MH9?[,L, 5[P 4HHBI1F7*'5*L[XD<&HDUH4'#8=\^B%K1U(A\8I,2_LIB:VN M_;9PAUZ$TR1;;$+58+@D;MQZ#);&']5FL+W/MUWCZPHOMTROHBE?SRI4"L6R M'."4:.\HE0JP#"H@.2GU_^>0<2?OZ+RHJ9'(IB;;7J6H?W?MVG@65CL>"0-6 M9 8Y5>LI^6.C:-#.C9?0"-:Z\:R@D7LW7C+XN'GCQ3M\SZ977'L/C8F1;!=O M7Y_:@.R/?\J:SQLI9MJ_J$I<9H K5@&$!0144 +27- J+Z#DRBDI^:+$J?'% M1N$N>EGV:II#@_;$.EEU^G=UQK_?W;D>55\: -O3ZH"P1C^PWD>TU3;IU4VV M^H8\L[:$)MBQ]25Y(Y]<6YI_?'AM>Z,?]_PNM=/#5X_RRZII;G_2^:*-LEOM ME8WYL5KHYS4F!H_/D)*L(#@'O$Q3@'+! _FX\8WKJ#;L4]$*"-SD4&Q4SWYQ2C_:[)5/UFOMKE'>Q;8(7 MB*U 0FW3VSQ9QWJZX^SJ8_ MJ1!YBK'2]$ %(WH5)!E@)2>@K-*TXMJ%2+E5NL"PF*F11*?H9J^@5]4A3N8\ MGL.T$ ZEV'LJIP"Z?,SC].;9AQ$%06RDV"&W5\LM3.@B#H.Q0>?O'B\@Z*(% M!U% EZ_VOZAW:' M8ID2136/U>Q=US-L!<"6.$\#:\H4G3F/1Q*%?<9.T&H;DAO/V!Z.$$R)&9H+S1AX3P,"U MUR\[-B$XFWZ0LYQGB!"3$29Q"A"M4D +DNEEB$QQCC.8"R* 0<$ X@0"BHD$>8&0R!$M2[>F #9"IS95=XHFM/L4ZU7W_-'L.B7/K=9Z M1:C]BV&M\DG<[)ER%$?=:(UA"%6RM>%CGV MFM$:A!-K1_M[O=,C3*6CNWKU/>BGZR%?5[^----.R"FGW/7%QZ77$*S M%04K2 %*,PIHI@10&2JQ$!7'+)VM5VNZL&,E>]%.W+15(-YD,N'\;9FWIU[W MA+TDOVA6$LE\^:O^3V]!0K/\R7=)'9E7TJ3NYDP*4P8I R23#$B6,\$AAB4N9C]ES59C0KLO,.:N$=<^JD-- MM8MHVG%Z"(0B,_A1@[T6JU UTFR!B-(];T_,&S;+.S9VN#?>B>N]T\^>:OE# M+AOMG791$9K>OZI[^N>,BDJF!85 54JS+$$%P((3 &G%5)$KQ4KEXB@.R)J: M9WAO9"1\7V&/]-DA<.VX(1!DD>GA0,O#!-F;Q'A_*Y5HC6^2V_6ZGK/G]29A M]HZ&/:D=Q ?]FC5]1@!" M1 DD.*AXHL^!LM77.5SL/ MKRVAA $M.J,IZ M/U?B+ZN5^.=\L;A=OMXSWZNEZEA)S^F9$WJU-WJW\2FO#WT.RP9'J+CGA5J@ M+Z:;[%$_H5ZPO/ZF^CW$L[[G:OE@]@W-3L*[E]_T'*WUY-U.(40@9)7*@%0Y M!JBL]&J_S/7B/RO2DA%6<>7DG@^+FYJ#_C=)Z^1CVR@^^2!YZ]3\Z[_ ,OV/ M'+H6_!S&V8ZJPJ$7F9N,HJ#=CC:JWB2?]&M+%TF+YT;M.(5 K1 *50QT6-BX M!4&M##\J"FIWEV9'EU"DV8$#8U"C_4%?# KVVR1^MOHXY*8,X6QYN!T(O]@&W-W#N MI]P6B(0ZZ1X2->YIMX711R?>-O=IBE\DA_O=STS;OF:%?B%*:6R]Y@2,5>]N[WN]CE MFR4[9:.TO!@ )7S;BU/"WJKUQ8#A ^TOANYR8PYN8FWJE]E_WLV(X&5>9@+D M*1, ,4$ +0L.L,RJ%-,,:B?#AAUVCYP: _PG?:)+N]F_A\OP#/>S-O(L_L_; MN]O?KY^HQ[8-G 'U%W=SL?]E-PWW'C7*5#M6?3.=3OR+1VG2P["UWOW_JC;E M-_2JH74F*:$L3[,45,HDK=,B!5BD#"B::H^]D"A7]EV3[61.;=(=Q5CVBIM. MM=OZ,+WN#A4Z+0=@>/)&@C6V4_^FB#H40 V/[$C54(,@[%8DU0VKP8JIEH\: MKWRJFVT'M50=;[UBF__=Y0VA=Z\WA/I>0%^?U\V:MH=LOS^W06LIEKDJ805* MF#. 1$X 8:D I2IQB3@1,DV==_=#:CBUK\2F\]5JIZA_7XSPX^FPJ?]6HS3] MO?S>2OW#SLZ;I+,T\ 9^C$$(N6\?5+_QM^MCP'MRESZ*H.O*7W:!Y5U@RWZI MO;U.V&U?I6WK=UX@5O*4FU0^") J!:"BK$!.):N00"F13OVJ?169&N5_?WY\ MI/6+V92VKC\==F3L6'T,O".3]Q;?/H>EC[<[P/P@W*ZU)#&F)*TM0SFJ\2>E/7[#.E0?U?IZG@\U_2/&\D%]5>UKZ[N7]@C9-=]Y&J818,5.# M')N>3RD&-,LX2)D2A,H<9= I/F] UN08L%?54>4,[4*VZ?N>:0S!;>K!A MP(OMB_KCYNY.7D8DE&,X(&E<%^^RR4?.FL4MOBDTAJOJIU776ZHM;?Z^V\)] MOQ)RABE+>2HE$*85+L*E66DC"3)(N$ Y5EA:G6E:RIL:A?39(0*YS]OXD!H0Z#(_8]*2;[^JC[^R7^8#:-OFC6^ M+DUY)_.?C_]XGO^D"[E<-]_TXJ>>\[44YA_TBNCP#WM7SC J<(%R#DJ>(X!X MR;2K 2F0.2TAY4S3@M-&3@0=I\8KG8G&3Y>]D8FF<3VG5LNN0IW9B6A_D#LC MW!@HQDC;,=@;CU]LAV@[=!O[DF^M,[1LB][==*7O]G2_279F]9>8T7WUQ\,[ MWJ_T%W[Y;$Y[OC[)[@L?L$A>Q!$*Q-(Q-!R5Y2-"_/HK$5.4WU?FKE[IMW;] M4JP*%BAG#*\AH1- MC?<_S?_4\[TKC'R3+*5C>M8@KAD4'-*L "54&E?.2T#+U,#,48Q,/FU3&$N\LRI*_)) M*5/CWD[)UJ%^&@S8=P#2CANNAB:*@1+0"16YJ*%>2 \:P H*42I2IHIA8-8NY M*&EJ\[Y/C&[: ['5DT>JTWE0+1?$(:"*?79X*CYM%U2TB5*+0 T7T0FUI#PK M9]R%X25SCY9W%V_P;H%>F^Z&'V3WOY^7;5?4W[4978&OKB[1C/"*DI(K4 FA MUQ5EF0$"D0(%)@1E@A,,E5+^H]^L,MC9(\13UWCN)?2S?-6=2"P?NFC)/D1R5D*50:H7& ** M#""LIR<=A\ M[;>:;ML(],J>3VURWWNP0B74)L2PL'%W(ZP,/]J6L+O+CT/>=>V+OO^092A< ERJ' A6"DK2K$(,N;#'.4%3XXU>SZ15 M--EHFOQA='4,5,&)>0"$059\6,2A*7C'U-#Q>O]TR% MH-LHZ;:,W)VLVRVI&>(PA04FH"IE"9 H.2 8YZ!(,T05R5/M=SCE09P1-#5B M^*J4;'O2/[45'C49=TF_;?JO6"T6M&YV?W7-!#Z'MAU5A, P]GXFWWS^L>JGO^W M%#/*6%4HO?90C)OZP8("+#D%(J-2YARE1>K8=>BLK*DQQOY!QTU"MWKVQ0+\ MZP8,X6U'&(%0C,P9AR5T.T63G:9!^Y9=@B-XKD* M>6[F2]DT6@*;+UL7IHNX?)#+M>E[-!=]T.4F OMEM[LY@QQ*032[B#++ &(4 M 8:P!'F5P8(AF,O"Z23U*FVF1T(;S1.^K[KC4N:J 6(I19F2".12Z6] RC"@ M2J6@2JL2ITI*65*WKK:C#=$XK::T;F!SSL(G,&"6"]2Q!B'V*K:W(]DS9!/R MW8[#@2TWR=::F[WSL8"KW1"PAEH27Z7+N.OF$+ =+:Z#/-1S!6XR"!_[,F)] M&803K4,=T]DH9:9CM+'77WZ07.T*/5\C-NL M:NKU[#?ZY_SQ^;&/%C)4W,! M>^7L'(ACG(9YY2KK(S-&KU? &+FSU@[-=WW3WES7O^WF^?'S1IG!9\W8S,WS M%_A]RVXY?WY\7IAHL/8XZ\3\-NW*M]W9B>1,E)4$%<.E7M)5I9Z6&0&"YRB7 M>F966+HLZ1SE3VT&[ZF?K-JC6G[P_9NW%KBM$%R'Q,Z]B AT9++8Q[@[#C_I M8_QBU/^US(%_#5?JHOH8G-*]]#=_'7%M.;+..N.7_>)XW M77N/=R][OW7%KV"*RAPJ#DIE4@9ES@"A.08XU_\B,2D5=&I\XJK U'AOOX#6 M=I6^;\*-J:BU]X=KZY%9CI/E4BLB^K'76L&!OZ*@F1MZP:N<68I_H])G;N"< MKX?F^!S/@\(NS?U50 M(P8Y@4YUC:RD3HWZWH>I.F*'N.6A86@<8Q\?;B \KN=!U\E&ZZYQ5,"S1!>4 M0ITJ6LD<]WS1!8:CDT:GFSV7I&U2Q/O^Q ,K0A7,"4"9:2J%"U,$(^4 (RRI MH%7."N&2T'#P="=N&2NC(=D<./DD31V"9[DT](4D]L*OKU+Q/O1!SDF#0RW6 M#IX][E+LE%E'"ZV3%WDTL/IMOI#->K64'W_J)\%^3Y+D2E2L(( CB@$J50:8 M1!PP@02"F+,BQ];]JDZ*F)H_L%4R:;5,H$/'I-,8#L_:,,C$WN!]#64(/V#W: .GWG> V?!C4_Z.\T?*4'KWU>F@>MZI?V MM*M9?U5W]4H\\W7?9K?Y^"=?/)NN(+>/JWH]_^^^"^]G_9HL'^9Z+=91[-UJ M,>S,2*<619D926#-C)"6GQJU;,[O5@C;4 M['OTIFXZ43?)+W)C;4+WS#77SK<&]^Z4941GU%?!@N G,,"1/Q&V8[LU-+E] M-;8[6_L<^%^3/SI[K1J/C#?>#I^L"8S[2!^]&.,?Z+L9>1 &O[RQ9(_W[8Z, MWL'7/[8L[X(QJT=Y3_^4S1V="U,;L5*,,(4H(*PD )GL;UH2"'A9L3PO2X$I M=HNT/1;B,LG'"9]M]_>>M':)6M7]87BR-BH[EX)Y#:C=UL9U($7_ K9XM-HE M1KW 927/&Q^N9LMK 6.79SECX(E*+.>NO"XQ8N\U?&QF6'(LB&G9 MJC(,$(<*X#)G@)495BI-F2R]\AY."9N:RW[J4#+YPZB;M/JZIFH/X6S' :'0 MB\P&_L!Y![(/(1(X3OVDJ#<)0Q\R^ER4^> ]OFVIOC_2Q6(C888R52FR.V@3AISW/[I]&5^W_U/=%ZWAYSO7GZ3U/2Y;#L) MTV;>M!5$)"%5(6D)&"STIU^[]H )R(%B5$F2%QR53M59+LB;VM=_3\>D5=*K M/LLED.V^^P&ABWU:XHJ:\Q??$HM '_U+TD;][EN:_OK3;WN;9P!JFZ:]UV%\ MAO*4B3Q%H$AS31R("X!IQ@$I2Y*6*,LS59#U?B>]K6J_MZ.-(CLM;_UI: M1-^W+U?D77CA&,]4P!(RQ@"MR@P@21$@15&"E*LL%9(SEO,>SX]+,1J:&UG_ MG\+2CF^O0B*B(UZ/GCQO2>LZ\HYC5LQ=>Z6OM$?"G M6O[C62[YRX?5(YTO9T0//5F)A0!W1&W/ T-\GNXQ*:+]L0.+;^&:7 M(3CKGUG_+N?K9I:E-(<842"KPA2UP3D@B)6@ M*EA10"DRRJD+XYP6,S62Z;0TIZ[U1L_DV2CJQBEG,+6CD>N1BLP<.Y"V*B9_ M'03)F32&,0C$$V>$C$H-PX:^9H,+5_O6^5CQO_]8+?0=C8EV-R5$UO+#O.&+ ME:&\7_1]*I M[KCZL ;=R H601) <944AW2)[PH$[ MSCE>5'@M5YC!((M,[9VBH-7T.( Q< "0'2JA%I?#PL9=5UH9?K2DM+O+(Z?@ M=GW_0_Y&Z[_+]>U#+>5>8]0,5U1);BJC%B5 BA&@?Z\ +G+]%UI)#JV6DQ?D M3(V2;^]_,[&^#S6U+']U"<=AG@B(3F2"N%TG6LND4S/9ZNF3/S6 ED-$>AC4 M1@HJ/X->H+CPRU ,AG8/W#Y>=/9E&PX"K"TN]UQE,E<*\8'G-9'X/\2.T M;8MT6?^3:/?[:OTW MN?XF^4K3L&EO([" 4'$&M,-F*B1RO8Y-BP*P/"O* A8F_\V%_*)I.C6B_.NR MWNK65H_=*+_ID>K&F?%&V(Y?)S%NL1U'8Q1HK4KNZ$N[/K^M:WV)[+AY:U_2 M&GC3I3=KBY(7:7*;-S;=F)SFYY"EC:+#'XC4X^DYZ@<@.MRO/Q;Q!5Y;4?>@ M%%QSNQ0?F_7\T13VW8;L-%_5X4>O:6M8[JWZJ7:C$4:@2M,,H!*G@"BI0(GS ME!>DD"EW:V494KNI?4#V2\(>UDYLZV";%O%?5G29]('!OA5X0XRKY4;"6XU6 M[,_&V8%JVAH86^.274AG8RY^Y?LW?4U?JRHG5Y3W#8A^\-J_(71[H\+ 6$] M7S4XI)#KO@A:S'L#T7)=]\4WOLV;O[][,?_]B7+],N[X@6&4$XD*H*!D &48 M IQF"A288UEF:5&53CU)/728,KO?R=K80!\Z9F^+A?ZE7C7-Z[(Y)OY0*Z&O MU63"7I+U#]EN$U0,SF)'I42O,!Y367 M>3W#D\3H7'Q>_J_YTD1;2?URKFMHBI6V2B:,2PUD#CZ;_^2N]^PO6SU)H6E&R:;131!>?I-S4G]<$L]?< M.JNS6@*R0GV@(Z/R+PDNI>/Z_/ M=C<-3AE*HP A@F:6 YU4.L>!,IB+(2FHG.EQ1R0?N#C)!+UWJ7S*_-HS[([G\_+_NH[N:;Y'+^L^WN MRW-8IH5$F@13O4#D2 "B5XB@+##F:0XEPW"VE _FF//>W@VSD6WU4I/NI3[2 M(.K"IE4TJ;>:.E?6OXR[G=L5#,;1JN^W:B:_;!3^-9DODRVBWRXCZE.1WQJB M<#7Z+XLF/N[U(O)^?H%9NQ^OC9]W_4E#%,&L!(I0&:Q MAS&I "E%)2@A,A=6E?Q//7QJ/E>KE#FNAMDO[-=DHZY]0>XC](9YXUI,(O.# M*QQ.Q;C/V>U5B?OH8:.5X3YGQGX-[K/7^#D*7^L'NNS[^+Q?+9O58B[:7_2" M[*Z+>>D/WS_-EW3)YW3Q7?^E#Z!L_;L@,E2D;MD; W3*$]9_APSNS9N_PHQ*1' MM2'S7?YE,ZL$KS*>4@#3O H-[T9\@H"[3H254&J:423A@G'MB.-UP*<:&(K M)J*+UT:6F\,.VE;$Z!-1'8,/CF"THX=KP(E,"*UJW9'G)42<">"/3"^N^U5W&SVTU[+4\9OG]M )O>/;#KI[FG>? MQ#:Z6+_TN;3]QWS& M)4(R5]3$'>A%H((%(#3+@4ISTVF.%E1:=9HZ+V)J7]=>R:3NDXJ?.C4=@HQ. M(SE,0V'PB4PU&V@V^=9W@:!QB+ZZ&J*18J]"-LU7U;:GV'F[/$NEPC0##.<$H+3, WZ_3;]N\\75)LEE*9PPIAD):$ T0+"3"F!%!2 M9@5$),\$=&YQY:;#U(CCXY^RYO.F#1)JVFFQ>C)Z]EO$W^_N^@:\5_3B]1@I M.\*)C']D.NK43#K];Y)->]^+A1FITB]&\FE5*SE?/]'=EMKDITY5[A[T=\(.R*?TCA'9OV80^S?OCDR[J%[ M/\=2]VT:1T<&_VS7Z=ARO0^\V["ZOK*C_CZ:BJ_MJ?I,\9(2@060-(, <2E, M4H, 3!!>%!6%1>J3/#4@THHYQL^9VCB&VFL7YE1LWNN<<*.T:[V=\X!;1QA< MA=]H$09=3/"V&NT&M/>#H/D$&%R"(UR P5E)8P<87#+Y1(#!Q5N"]Y&]?32M MM;M WSY YV^2UO?_7,T@PU694@QXD1+MNRH*&,LP0(I73%#*E5OE'B\MIN:0 M[FMJYLU\U^V3]@4(]4N)@G5+'1@?2T\R-NJQW<.AWJHW;

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c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�.KX$^X((&T-F M(GSO\(%;%>4-:DG;:)\.Z6$KI-<4/.P8=<0!]9K'D'ZBQAV@D6V4B^T8T_SS M/Q_U[P$;L]+RVBJ_S8W"0EELP?S=HW7?K+N'HN/WG]O^L^O8"N:8F,G5.E!G M0!UY'MZ5_9'0?E:F\^HEU[?D#LL$B'P7-B(0<2I/S"^GV"\H$,L3%=)RZ*73 MLEAX"FN_0UW)%8&VSXF%\-?:[??\Q>#HX! ]?QE DWEF8NT4')!3<"_S&KX[ M'@R/7[1^O3\8MK^Z8MC#%X/C9^U??]*P[:_:P^[13O!NP'ZG8 ?^_TH )8\/ M?ZVPUYL*I/>]$TI^$,_;0VY[6+(+_TVS6?#J_P%02P,$% @ T3ND5I.Y M2JK-!P ]R, !8 !I;G-M+3(P,C,P,S,Q97@S,3$N:'1MY5IK;QLW%OV^ MOX)5L(T-Z"TYMF7'0&)[$0-IFZ9>9/?3@AIR),*DCK_X>J7R]O_OKMF8Y]I]N[?K]_>7+):H]7ZT+MLM:YN MK]B;VY_>LGZSW6&WEN=.>65RKENMZY]KK#;VOABT6M/IM#GM-8T=M6[?MVBH M?DL;XV13>%&[.*>2TOYN.2M,'+,APD7XD6_?=P_Z29"MF7*1-!IM_]9"Z(7YZG)/>:SZ!^_QF&V!O/RWC>X5J-\$$RJ MQ:[SYL1H8P?/VN'OC%H:*<^4G@V>WZI,.O:SG++W)N/Y\[I#&!I.6I5&0:?^ MD- )ZH7':53Y&.-HE=$^ZW6:G76U%R9].;WZ M._6*"FTIL\-["<(M[3=RWV\R(?Q7[FMWV:6T7J4JX?3Z^_;ENC)#GMR-K"ES MT:CT2L/?V=?2\J;./BBM%<_8FR9[*Z?*U=GE6,F47=_+I/1J(MDO*7PK+3,I MN\E=!J*XR1-C"V.)->HL">Z?,3_F_L=G1R8)70%6F//,FRFT)Y#*1SG$[(Y&,WTG,NS*FPSL!93"E#CD*)4D, ,3<(3)C.!7T2[L8L MU6;JYH"P746]H65^)JYLKLZ7MTP]M_Y#=KOGAN:O"5M$W0=Y4 M3$^^N6'%4-M21O,8G0#[5R8Q(GL0S+G98\/0OE$FUGQ1N?H0!Z&KITC$9_BHZ*R M(X\PH/$9+<05=,1HD2Y[3Y2N391B(K)S$S.0H)SP^/2V5CPI$%'N![T7Q6;I M^>T!P@_9E70H[N"P0)*?CF:=^#OAI=N_"Q'I4"(RU4R1FDUI,0 6X42YL+0A M)?,P#A452U)8)18K-0^AKKAY&:YZ13K4J$ 0T,49K438Y+ARZ)10W"HR0,4, M$J@NIY%*1ZP>5H8+*2 0 7914 C;F]"I0"6@DE)SXB^8%9189@?TB+EF-47B MVU"2("@&_1^J#3X!ER>.L>$FQO9>SUM0VY\)]D8<4#I1@H#$';;71'G< 814 M1!"ZN!7S2 -[B@^55GY&&6;7M(3[ (H0[PC9-=&5(B0PZWUE4%&B?'3P.F7$ M!,6D" J$?!4?=U<% 47H"*YQL?88FM(_//<^C,H7TI(*J_3392<; MSDNVL#!D]$'8( ,$-,'?# @"+!,]O1TQVIA4E4!HV0#$(UB%\I))DM)21%:2 MP-IXF7$>;^BX!*.X!$-4^TAVL"6< DY8XQMRE9HH:6780='F*B\7NAQ&3<;< M+;(DL4. 'VW.P2S!^HK29M@GW4E=;:^(\V/^#JP?*H]PU#'?I3XJSE4Q&7=C.Y8Q%^CHY&(5[\!$ M5:E &.%%05&/*</MW+T5=P92"+>$*^?D[^E4_J@T(_\5E4HE\/5US?I6__S%N' M+Q_HH O[BG_K=ONP=YLS"_A.6F(5S0LG!_,O9TC-A>:S@S">NKBF;X9JRY<5V MV^E)\[3]<'.[V5FTM<+8<7Q8X J>OZSU:AM&:IG"^P4B3<<=;![BJM7&X#S4 M[$VQH['@@G:]@VYQS]!ZMG()2+-MNB=ZYHM?#&XAKAW1WS\^<^%SZUIKL2;V M]^;3=\CG..$IV7DYYBJ6W0_<7?Y5#3]X%X]\4!QLV7RX;70KD-RWN-K?+V5\ M-'U]+,]^O/;<^/U(8>(/: ;Q!'DBMWY1LB2"D ;:RRY\"#8H_7:73_P(I?J, M/XD)/\ZY^#]02P,$% @ T3ND5@A3\F6T!P 2R, !8 !I;G-M+3(P M,C,P,S,Q97@S,3(N:'1MY5IK;]LX%OV^OX+C8J<)X+>=M''2 &V2P0281[>3 M17<_+6B1LHE0I(:D['I^_9Y+RH_83IMN=]IFF@^.)%Z2]W%X[B6EL^\N?[VX M^??K*S8-A6:O__GJI^L+UFAU.F\'%YW.YY6S7AJ M#RIH>;X];O?O MC2AZ?I9;$S"?0_]TF8;9&2S(=Z'%M9J8432ID;HNFS.KK1L]Z<:_4VIIY;Q0 M>C%Z>J,*Z=DOV(*;ITV/,+2\="I/@E[](:$3U(NW\Z3R,XRCE9%+$WI] M4OKJ7S]>O[J^^?Y)[[A[.NBU^W?57IGTY^DUW*M74FA'F3W>RQ!NZ;Z0^WZ3 M&>&_=E^WSRZD"RI7&:?'7[I3)-=3)7,V0_*<),IKMFO.1PK';,YNS:^ $M<0? ZP6>P_3 K&$_ M6%>P7K?UCWM\ V^;=&-/CF8 RF%+'!(4Y2"!3#@D)8@;=H8D ?.=3E4V9K^AGW7\NG:P'(0,* MY34R%R7!N0I3&.A+< W-3N.64,T*F#E#-\'&BTTW//YH#]X3;9K@3&1(PVG-5$?!6MIA(N)G00:K1>A[_VO-^:&@@3 ML?9IDD2E(8"86P0F3N>C/AGW4Y9K._=+0#@Y43Z@< J,T\.D-[1L;L35+Y79 MT?;QAW9XR&[N^.&IK\-6TS=!WM9,3[ZY9MS)& 5X58VU)&\QB="/M?)3$B>Q M LN=ECS="^4S;7V%?D0$SNH4CM+93 H\]NP WA<2X4PNOGJ73;F92/82:^Q- MI2'1&_!6[^A 'L:NO2.1[M*MHIK#)!C0^(P6X@8Z4K1(EP=/E-^9*,=$9.KM3'2F0C0FCP7&YK"WW ^0#G;X>Y/!#=BD]2CYX,K+GA\/<)&+/ M>.4?WH48=BP1LGJFQ-FVQ M6;,1-2HP!W3Q5BL1MSZ^&GLE%'>*#% IM40.-#12Y8GNXY+Q,3=$AL#>"@IA MTQ,[E2@15%9I3L0&LZ(2Z[2!'BD);>9.7(TE"8)[T/^^HN&OC;'Q-L8>O-!W MH/9PBG@PXH#2F1($).ZQZ28NY!X@I.J"T,6=6$8:V%-\K+0*"TH]^Z8EW$=0 MQ'@GR-X1W:A.(N6^JPTJ*]25'EZG5)FARA11@5BG3*1!!M2 '5ID27@F$=1@ M"5K O2K!>M\BN+)#=C7CNHJKG#PO\YSVCS/XS.^I$) 9'\!7Z79_N1!1A([@ M&I^*DK&MPOUS/X11^4I:4L65?[@>9>-E+1<7ADP^B-MF@( F^,: (, RR=.[ M$:,=2UTBQ)8M0'P$JU!>LEE6.8K(1A*X,UYA?< 3.D3!*#[#$/4&DQWL".> M$];XEERM)FI=&;=6M.LRU4J7PZ3)E/M5EB1VB/"C73N8)5I?4]H"&ZA;J>M] MUI9\\Q,<Q/G#;[0R?HDM*]4/\>P1NM&6(U,2H:I3Q*I"G4M^2YR?\G=D_5AYQ#.0 MY?;UHP!0%Y-IF[9G&7.!CEZN5O$>L-25"H01=Q04S91R//*-KXH"M? ?,II1 ML^3>+?ZWFDY0M+Y$UL@=EE@3P9"1#Q#.>)!4Q[V9:%B9F=4S25QL^*0^#W,U MA&G2!VVTZ>MT^Z]S=WV[U56R>.G<:'!;[DYD5CT-@R4LL.^YF#+/8TE%[33'/7+=PRMIQO0IMFVW9,\\_GAWDUP'SX[]?'W[@NF MU0IXN"L?OS?^9P\\)B/O>7'X5S7WX'4Z5H&E:YNI6'JY/GFI77"XZX-.Y+@O MG@C>FY7>7Z!M?9-1VO11RBB=O\[DSE<:ZU4=";V[[L+'6-I5V.WR@0\[ZM_T MF4G\X.7\OU!+ P04 " #1.Z164V>!N)(% "C& %@ &EN#,R,2YH=&WM6>MOVS80_[Z_XNIBJP-8+UN.XT<#N(Z+&$CC-%:1 M]M- 2Y1%E!(UBH[C_?4[4K+S<+)VZ]HD0X5 D'GD\7?'>S*#%T?34?#I; R) M2CF!))D!5-,9(0[SOBT!K5$J;SG M.*O5REZU;"$73G#N:%:^PX4HJ!VIJ'8XT"/XIB0Z_&7PPK+@2(3+E&8*0DF) MHA$L"Y8MX"*BQ6>PK&K62.1KR1:)@J;;;,&%D)_9)2GIBBE.#S=\!D[Y>^"8 M309S$:T/!Q&[!!:]KK%]VO8[ON?2YOZ^WZ7A0=MO'L1A)R3>O.-Z[=\]!.G@ M]')-H=:#F*1*=Q/XOKRLV2S MPTS1*V41SA99SXA4*Y=NR*'@0O9>NN;I:XH5DY3Q=>]5P%):P"E=P;E(2?:J M4> Q6 65+"XG%NQ/BI@0GOFY*B%WD ]G&=V(X#4UZ/''X\F;2?#;2V_?[;>: MMG<;]E:D[X?+OQ=7"6@'S#W:"_&XJ7PD]8W&Y\'D[60T#";34W27\]F'X6D MP?3)(_<.X(,]LTOQF>CF?6]./)^!,,1X&F-%VW];V]L?LMSG@;RYR$GQ=2++/(JF#% MYNG_J) QR2 4649#G9%@Q50"*F$%O%\2B6?.UW!.1 R3 MK$@QY4RR4$B<8/)/7244?GO9\OLCD>8D6YOO/8B%!$W*$:.(@&813GY'9)A4 M(=1KE,F)%! SCL0*"(49#9<2TR5*3+((QE=A0K(%Q:R6IJPH-&C\TS,CA ) ME13!70,IT9H!.B(,,-XH 7I],%$ BT&B42N57)S;C5'VW#%>T;D MG&2TL*97G*YA&"I-T3;<0#I!W.V#A^-Y3J(($[[%:8S.T\3S-C[+4+V9ZEFM M_?S[)\A_E8B>+O"ZM[=!_83P!NJ77KD=[6W.\=K:MHU4VZ75;?FG8J7%?M,QN M7[OD?WC(CQX,Z\UG=OHLP]":$G.D&,85P:41CL)-TR!,A_%> MRQ -X6@C18YF433,JIAE) OU.#*,3*-B(B_.6O+2B 3&<;-G<2=&VH]73'Q= M3H8?\/S4@7YN9P!%YIQNW4G(B$KM2ISD!>UM/OH1*W).UCV6&=1F43\E;A\O=1X.":]T:=1:DJO.TN_:!^V6;BX5=I0JVFQ<]9VVZ3L=%>W2 MN@=VUWV8[-K>EN88WB5_E*! ^W]=:]7N"&E(BN1 MWT.LHD&OF5^!MXFJI2KT;G?54VKFQZ=3MZP#_$Z_,.^=PFOK)U^OS>>OD&]1 MPG.2"#_N:X:;_3L\S7N%&/;G(6:@C.PD-.[Z*OD M!_I\U":5=[>_;A1:-QN%!HB=J5]J+J"^2BBND5BD1A0A8Y5+-1\2JVICT^U7 MU>=6?]CA,UF5L]KID*Z%6= ,"U9^0VZM%HX(E@1!W"J0N:8Z)9J=\D7+LRK=WE];_Z1U8;6\:.1#^?K]B2G5M(L&^\-+PUDB$$ 6I#6G8JNVGDUE[6:N[ M]M9K0KA??V/O B$DUU[5:Y/3(826G;']S..QY['[STXGP^#3Y0ABG29P^?[D MS7@(E9KK?F@,7?#X$B(N>:2T$2UQU=5* 2:YUU77>Y7#K+ MAB/5W VN7--5TTVDS)E#-:T<]\T;_&6$'O_6?U:KP:D,%RD3&D+%B&84%CD7 M<_A 6?X9:K72:RBSE>+S6$/=JS?@@U2?^34I[)KKA!VO^^F[Q?^^:P?ISR1= M'?[.0-,*HU0P[?J=!9ZS5]NOM5KW>]ND?/H)TT;UHD^M5 MPEY74BYJ,3/C=YMUYZB5Z=Z24QUW?<_[O6)=C_N1%!K'4]B^>"RZV>M,LQM= M(PF?BZX-J5(T79M#F4C5?>[93\]8:A%)>;+JO@QXRG*X8$NXDBD1+ZLY3D,M M9XI'A6/._V2(">'9O\L"\A'VDW#!UB'X=0-Z]/%\?#(.7CSW7WF]1MVI[\+> MA/3#<'7NP&K>"ZO LX?E'O)"G&VF?A%[P]%5,#X;#P?!>'*!J^5J^GYP$4 P M>?3(_3:\=Z;.T('I:&C0%XS[C997??3@!U,8G$XN@]'ID^)\A^F.]PHF9Q"< MCV ZN#H97(RFM[1W(",8B3['B MC$4H%3K8\G.@8P8OGC>:O:%,,R)6]OD0(JG F#+$*"DP0='Y+5%A7.Z@?K6H M322'B"=H+($PF+)PH;!:8L1$4!C=A#$1%"% S!1#<%L@ M!?H"1Q7&59@21>!$BEPS+JHPC#F+X(P+(D).$IA$$0^9,A&:/LHXJH#O-(_P M(5NH?$%P!K4$LQU,<3,P41SUP&X#)@9"96;XN.U;^I@$+OM&)#,B6%Z;W"1L M!8-0&XM)X"K:"8)NM1_*GWMJY>/+K0/_$&RD90I%BP3S*41*$S.?FSE6[,N" M*V842&XHF);9Z#<.R"%@[OBM WJXH6V;$9ML*+E#1=(L)B"U.88,=GHF;YXT MB_6212YP':7$4H-K5A-TI?AVAV+"S9K-%,L-FU5C)DD"V Q'Q_Q&0X;TYE7; M*MKD/79(K2BURPR]%DDQ&1(7K1TSO[,FG%]7.;YM X:?\MG=YC69)6R3.E)1 MIDS:)"3+67?]T*,\SQ*RZG)A4=M&O92H.4KEF=1:IETCDZ_-GA.2I.32TEJ8 M2P7=[#CM5L.(:(UYK.EZX%)?.U9?NYKNVSIMI^,];/8NW>.^JP#_K#K[EJR*O;Q9B-'_3Q'?SEU@ MC@R%1,9\+61$&%J=8'2:40W;PP.*X67,PQBX1J&1H#(Q.B4'(350QLRIXI\? M LS[L@_L?V;4TJV#R6R%(T5X-A"AL: '"A@SBLG:!PXSR"93=X??"LW&;:%9 M!;GG^C5Q"@?+F&$;A>*,,H2,ZHZ9?DBDRX'MD:9471O^\!C#52GC^+6UFV#F M3*!02V[%;6A)$,&"((@=P9@OD/TB^GT5]VM6W]_F^?W;Q!KBG5MFY 9%MV%WF_RE1O*\K>X+[4WM\=_ 5!+ 0(4 Q0 ( M -$[I%:N2V@4T$< )<' @ 6 " 0 !I;G-M+3(P,C,P M,S(Q97@Q,#(N:'1M4$L! A0#% @ T3ND5@\09Y_")0( 24 5 !$ M ( !!$@ &EN'-D4$L! A0#% @ T3ND5C(X)/\>'0 <18! !4 ( ! M_7\" &EN&UL4$L! A0#% @ T3ND5LA/7K3P MI0 )V(' !4 ( !#,Q,2YH M=&U02P$"% ,4 " #1.Z16"%/R9;0' !+(P %@ @ &? MS00 :6YS;2TR,#(S,#,S,65X,S$R+FAT;5!+ 0(4 Q0 ( -$[I%939X&X MD@4 *,8 6 " 8?5! !I;G-M+3(P,C,P,S,Q97@S,C$N M:'1M4$L! A0#% @ T3ND5CY_9V9A!0 %!8 !8 ( ! M3=L$ &EN#,R,BYH=&U02P4& P # B P XN $ # end

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

&[S>&?3ANR::L M?=<>+=VG&@/7;.WQ82C>VQU:ERL&S6Y.UN"I;L1$4#4ST/!T\#&SG!@$L.5& M::8-#PQ&7DD=M>NE3O[KY(B&]A1U9K7*),^O6,=8PD*$02+PT16:IM M2!-4JLIZO.RQ1@%=H<727)H-=8S)PE8F?D5Z=="S("SXC-*&GH*83)O0AZ>6 M@-'1?E:0V\0M%'W#9NI5K;OM%MWK>K\[B-=;,G**FO="TQJJX^'%>2)&ULG551;]LV M$/XK!W787@S+EI.VR&P#2=JB!5H@2+'U8=@#+9TLHA1/)2DK^??]2#F:-Z0& MN@=;XO'NN_ONR$_K0=Q7WS '>FB-]9NL":&[RG-?-MPJ/Y>.+79J<:T*6+I] M[CO'JDI!K)EWBIML^TZV>[<=BU],-KRG2/?MZURCS=L9-ADR^S)<*_W M38B&?+ONU)X_<_BCNW-8Y1-*I5NV7HLEQ_4FNUY>W5Q$_^3PI^;!G[Q39+(3 M^1H7'ZI-MH@%L>$R1 2%QX%OV9@(A#*^'3&S*64,/'U_0G^7N(/+3GF^%?-% M5Z'99*\SJKA6O0GW,KSG(Y_+B%>*\>F?AM'WLLBH['V0]AB,"EIMQZ=Z./;A M).#UX@!)V8INQ09M]VQ+S7Z=!Z2(CGEYA+L9X8H?P*WH$P :3V]MQ=6_XW.4 M-M57/-5W4YP%_*3'0 M_/U<%\8D%\\GB1?IRG>JY$V&F^+9'3C;_OIB^7+Q^QD*%Q.%BW/H/S^R\W#+ MRSF=[\H][,0/T '/5#;*[;FB( 1E<"K>+4^#\O1+,2]P1(U)MPTH,"PF _2# M0L/X.69JQU/"\9009EPVTY!3*%Z*&2Z][SA=6_,XIX^\5X;NG)3,%:KS],Y) M2P$:$:N)SUE* 3:=LH^D088ZY<)CW#\HIZ7W9-3@>QW\C$JC=#L2%L0Y,BE# M=Y(A-"H0 D%HZ?>S^E+HPV/;GTHI47SL(\U'*$@ M@1W2X7#UMF07()DSF"W$+[:>*H&_E;'791B31S HC$8XFB\>$P(9=$;,@?\# M/:#7U"C85;2QTZ"CJ@/'0KFN(ZC8TQ[]YH%I@:4K^%=4@QN&'KL@7L?9IBF@ M@,3D9.(89ZE\0S5DW<^?.];YB2JUC$,3M3?FZVT8!6JR3O)^/:K:/^[CMP$G M9*^1U'"-T,7\U65&;M3;<1&D2QJWDP#%3*\-/E'LH@/V:Y'PM(@)IH_>]CM0 M2P,$% @ T3ND5M6C-]ZI"0 7!X !D !X;"]W;W)K&ULO5EM;]LX$OXKA#?HIH#K^#5QVR1 VN[B4B"XHFGW#CC M%Z].3ERR5AOI!J90.9XLC=U(CTN[.G&%53)EHDUV,AX.3T\V4N>]RW.^]\%> MGIO29SI7'ZQPY68C[?T;E9GM16_4JVY\U*NUIQLGE^>%7*E;Y3\7'RRN3FHN MJ=ZHW&F3"ZN6%[VKT:LW4SK/!W[3:NM:OP59LC#F"UU](2FD,I5XXB#Q M[TZ]55E&C*#&'Y%GKQ9)A.W?%?=?V7;8LI!.O379OW3JUQ>]>4^D:BG+S'\T MVW^H:,^,^"4F<_Q7;,/9V;0GDM)YLXG$T&"C\_!??HU^:!',AP<(QI%@S'H' M0:SE.^GEY;DU6V'I-+C1#S:5J:&2L,I>Z=ZE\]^&IT.7S]BQ+0V8OH8]V_&Z%'J;MU&IX.V M\:[#']>Y>"_S$I7*P>@+OU;DQD+F]R@F'+0J%;\IZT'2%U(45M])K[)[L599 MVL>U2J",3F0FG$>%BR100[1G;DEF$)Z5,$N^A/=S)[E:=Z5IYTK(D@C=:F75 M"E*(9C8<]H?#H7!K"<,J+I'HV4_S\>CLM2.A&YB#2DJ^"&\JC>-S0;BF;'B\ M-EFJK.,$@3"=I_I.IR7TWZZ-@!"AS86#1N%"81:;)=:P\N[3ECEWY3W$I?KPO$?10M%/@EU_OANI.9B4K>S0: M# %B6<81)C!-*WOV3'Q?YDJ,YX%EGP-2R'O2]Z#/1%G0\_TD.1I/&J$(J4BD M6^-LE"N3M59W"FW&T^D$G-')@.N(D"GX-@D'OS*3WJ 8P$K!>H1"BR?'X^?5V)QN[0H"RARE;#%HY>3 M25!PB<(P6^+G67@8$O2?.$NDX)ZL86S,D&.8&+U*M7);6W>=NPV4>6!02+2J MGH[$R\%X]AUDK,I^@B.)A^*3\8"%/;6.Q&A(C-N%IRC[0]7M04.)GFG%U>U; M,1_.0E.Z_0P1H[,7PQ%? SR2K$R95GJ*,W 4""0SJ(,_E6.74MNFRNC.RAHT M/4F@[AJPIJ 13R21997@1BG()3 3* 762\TV,Z4P%H_!"LD-OD[#Y=)V'(R( MF22FS(DM,/4!,$G'U<%\6U[81:E4>64QY506L\OVC$AU*G+CQ5H2]H)H6?H2 MALD,M-3A<;MT]"CE0B&U;"IA=8 F+'RK]K"KXOU%?,O*X* M69!/M%Q8+:(V2NA0TH3W)M,INQ?1\DUUPT:KUC3/0L,LQ*>*5QO.=[S3.<#\ M,Q=7Y0K#H9AR3HX.-.=6BH3JA99P$L"$!=\87X;0764KJ7+U[WZ E2?U\FMN M79Q1V_?AYQV(52J?%?3'_?G\Y?]R>G9$S"MWX*7"B&C?B^LRCA6#6+V M"<)8H9K9H2'!%&Q ^U;%OQD>W ^:'D+X=N>&SF8@T]^1*Y2'[CN'@@[6#P(Q MFD_[T\GDB:,"YU<%6]HZ5)M3,#-EYZ'$+/W*8:)UP/^&<95/7"E-QYWU)]-Y M?W8VKO2(==BH^K>W>DAMS2+?XZJCR:P> OYR\X\@NY\N->QST1I+56[5'>W# M=Z;$#F_%<515??6,5*&PXLT8L.=/'"K>H9,C&A&&@$'CW>I=EMD2%D<,A;_8 MSK2L!U@.?BO4]YV!7@05^\O!(?5 E[Z(LTZJ5QH],,/0EG,6+!4G9A6*.%+$M'65ZU/*QYT>E;=X MM*8=#O;##-A@GU[B1*@=KY)U;C*SNO_Q WU3[]UXE3[FNBU&ALBE7Y^MX+:: MDB/N1L]M40_8#VJJO[P=- +S+YJH M'"I 7C6;I71\-AAA@MJN-;@2*4G;\NL\X@]XHGDG3/@-_:/XP_.22CG*#[&F MGNG:KUNJF7DZXQJ&,WB215*E 0WO2;@V,$>M-&"3^.7B!O?'<0K55R*%^BJMWI,GAD_>FT_-$]:)?;W[T0 M >?(0S]D)PJ:MU>@U*@@K\")4$2)50J%HYR/>5XR2B#A&.H0<>X:U/?143-F M[1P_0WSJ=4GH5B<@P[AO4"EM5&AWJ5IB?*^ZAA2+&(F!^#5&;M6GH8*31M8RY4H9KBN*&E*.EX\;V)SIT+6$>=0S<<)BK[T='8@/K>CSZ/W M0K7E-:K2.T:.P#*\RP\&\E 4PJH)J*,ZX,,+HLFS^]:\X;>F?FNVAN^%RMA" M5]6_-ZM@']>XK8&L="$U6AA'Z&P5=[O*F)O&99VK[)/#0XF8J.[M+GB;'=#I M;$!@$5Y@+.DF^@=C1J4KLM,J9)?J/]C5*; +2LS=E3X4ZO[$ 1/60"6."I^& ME"JLW6>CP*XW*!T3#:**RC9)-8MP+R"WR7REN=RH [3K#TMN_6S_#0C.9CBE MLY@]0+]-NT7LHL=WK>B?.@%G=Q!C8TE^@4A\U9NP6Q^-3F?-\!@XH7^566L_ M_WEW0\>E*2)7%U*<(Z4K8(PYVNY+76\DW(%7$CO-93\4Q*/+WNL/'Y_)3?'Z M7>R\A8:U^D^RUW6%M-[A=O-+TO86*T&]R'C@>AA+RK",5<]4*!B+>#9/QH4ETW/L/O-!12^C$"$53*48.JBJ Y([HF!H/R4*. S6( M@DRI'=$XJWZS%""FA1@[Z=CU!>FD]<4/2\6*OVM2K.&=\/&OOEM_.KT*7PR; MX^&[ZXVT"#F&8;4$Z7!P-NL)&[YEA@MO"OY^N##>FPW_7"N)U*8#>+XTQE<7 M)*#^H'SY/U!+ P04 " #1.Z16"<8LP:0; #06@ &0 'AL+W=OK=1"7^GN\^K2PJIS7=@? M:/&PF)ER^KRM_\M4W?7KO6_WBDK/55]WG]J[OVE9$!%8MK6C?XL[>?9HKRA[ MU[5+>1DH6)J&_Z_NA1&/>>%$7C@ANGDBHO*=ZM2;5[:]*RP^#:/A'[14>AN( M,PWNRE5GX5<#[W5OKG@WBG9>7)E%8^:F5$U7G)5EVS>=:1;%95N;TFA7[/N_ M#EX]Z6!J'.!)*=.\Y6E.MDSSM/C8-MVU*]XWE:[R]Y\ R8'N$T_WVY.= WY4 M=EH\/9X4)T,]S3PX2F-]W3+>&,+_N^SF>LLR,W_C"V8QWLV/AXJTTNW M4J5^O0?:XK2]U7MOOO[+\>G1]SNH?1:H?;9K]#>?G<8=>^\Z X*IW1A]7S9" M<5C\>JT+H'6EK"*%@9\[^*IL&P<"IJIB;1C6E477A.O@"U+-SA6GP(;00 MIEN#_';7H&R!G2MKX(U5#7,L=*.MJNLU_JY7.""\BY-\;@Q^NNJ(EOT?SLXN M#T#I?^\-, _DO0$+@9,570N?;G2A ^&JJ0KEP*JLD&H'PZFN4/,YJ#T-K99( MB8/15JU-IGQX730R+&2Y4LT:E]*T,.&4&'7.WY)% [ TSE%_^RK!8\"G+PV MH,<6-*LN]/U*6Z.;4M-C\..MLJ;MX3D@RJ8KX8D\^; ;\)L6LFJC9J8V'8KI M<&%"VC<.B*L5SD3F@5_L\B&MOM5-+S0C;8U+1X0]+;0JKPLDNJT*$N4&?U%6 M"Y/APVR]?3\FQ=VU@1'PA=[QF)-BUG?(35C'DC:^:R=,6I0;G%O(*T!FVCM< M"@P'K"QO#I'O58%[ R23O$Y@_?!9%YVZQ^?JUCG<9!P,^&WP.U6"1#G3L4NI M%7.M4\W"S%! 882ZKW!VX.7*MC A0NL;[IH%\ZMKDQ7 M?#+N9LST_/NC@1GZ$%31-&!^>]8BTNH5Z!]PBBR(ZV?_]"KNE1&,0YD.3B)> M\N@61R?VNPYM$G@]4Y/?*Y5C;M,?:'-@YW#27--7-5AS5O7A@VSSK@$ R&R' MO\,>H3&<9XLQ7<]DX6Q+M88O;V&C:$QW#2IWV&F[E&^#;?U\570 N%P/;MKI MLK>D]I-BV9,DS/NF3>-H2A[:B!0ZA*A(;]3UL,NF@T(#4$!#2U@6MA2]QYQUL .XAZ&K5E\,MJUJ@ M%!+8_QI?!Q^$ Q SHSFL0%M)@VB+_8SYB+TC"T>FDDP?69FE!J6KVKI= ML RJNNQQGL1ND6Z#6%8:B"DU2 X:G&SP;W @W&;V=+"J,(MP B=#$70%FS^V M8OH6$9MI&*(3U)T!_BY6"D0+#6CG)HEE&W5&$UBPM6*A*B.6&W<2):]MD%KZ MZ/H5^@;Z#!-J4(5NT^@*4KBPN)4B2,'S ,W!YX&;R_UK M=VVU+FIE%ZC%44B5\TOF)Y:,?35BW^(C67#S_C/27$N0Q5GQ=/3O])_ MX:NW_-5)\M5YS8_-[# MPP:^AXV9]SA< 6$IVR;O"<$S%N4U>'+M<1";,Q#D:[-BT[*;P E^ [JM*C"C MX$*ST<"?SWJ'9A*>^V+:=OC@T^"#3W=ZS8L&-;FU;%_/ 0P@QRY%7#]Y'+>O M[[VB@Y;9SOP1W&P$.H(D1^.X_SP5X//CL&#;"(&#D6!3 NH+$DXH"B;#61N- MZ@G^]0]2:899Y+_9NS.P57=A@Q"#MO;FT#2''M/AX^";Q04";ALZ>\*[:"1) M3&\Q&4!^F:DD7'R_,L*'=@:1A':EA_5@;N= )LX$L37,#FX3N%*U=PW!/8N< MJ<$W7LP+CQ0*<&YNU+=THT2Z(! Z QN9&5],@"G]R@E& 5H&-*'GO32,?" T/T4#. M'7CS[-/%W\_^Y8U:X!<8NQN*/.:6( M^9S /^0 ;9D$3_X[H%Y3)@'IJW;9S!?!9K[8::W.8K@WFB)Y_-N2'O'F0:/1 M$?8F#^4Q.@?T#B)<0 @(4"!0+25'T=*#8(A@S?08\ [5G3!#?!*C G0ULQ 9 M"Y\5[I]W2!@&S\ 3LS!:IB&+=6<8B5BTG^AW18( 5&J2SB!>:+8@KD+9DB@+ M_O&..8]I\1M&3'[%)?GR"C M9$(LM@^A".%2WD-0%$=>&#H @L>WO$[?,>3 /#UCFQPY16&@A24& T9$Z1D5 MEDE&L_!-0I4!7R'(U%92-%&NV.X0 3&+H1R9Z=+O_MG59T"UQR\.CP#COO5D MG$0BTE)R08");T("%F DD6#LMFQII &GQUVQ%8<) M*8>:T8T(/!D?.:4#!^\0B'@?7W$&G),7A+H)_0(ZH_C0>:%^;,Z780'PL9$( MDS-/8([\ B=AA21W%7O[!:;8@$F4<6+\*"Q L3?-(/K-R:GT7%NO_5OYD)J% ML2I)4ANA)2Y75E]CA?96$UE;?,^(^_UBSP,JBQI[^/SH\79_9-[91DSV (4QP6:)<+ELG1S2#P"'?GP4,"D;OYS87!D(FJ;!L MMYC S1KU?5-"R&93)IR90G/A8#D)7&EPOM3@>2@6I2B5M6N)]7JI?HTQ*EJ@ MMKVA2">=A-@B DL&A]"9T$-'"I'LO4:SCN"U)17'!P%F,V4(=Z?%#]ZO&)^[#EN[3:@] A$W4VYEY@ZG M,N))"$QSF!MC[!%LGF6CAY+/F_N 13,3U"(W\G&23JM\<7,M.#MN@RI<"0S#,)\O!4R M <>G$/UFP7":#4CJ#KM"]F]#R/[M PE&X;(^K,UM5IX5RB98(8R_7\3?S^3W M"_ JQA)./J,HF[F#XN&5:RP;\&<)HX3)@P_Y#!=P.I2/I_'/N#.DP28I4\*9#\(DE4Q=,: QT*5FC24FXZ@)#U^#'&U%G1H&] MT]_S['?&:9*W-6FIS^I(T24J?[9,3\"FG=D2>C#0C O)<[2QFZ3O3$T '5?Y ML:\[K7*ST+96] 9UUL&+,4W84#UK0 MU#(V%83*X%DZ;S)Z C(T6)F,,'#E7$^KR*N0"IC MPB[)3,JB8%Y$'_XE+"0S"G?18^+(E.RH)&?PD.Y@6%<3[JQU2';-8&EMXTNF MJ9Q/,#A@JPQKU)FWYKHOIJ-3MPC1-0 K7 =LV+ROP9'/-X=08T+%:H'$#D.7)2Z$ME R@IR'Y#*$=]XD>ANI085/X5C\ M6$);ISE1'6H>T^*#V!;\B7( B 5CS2\8)2$N3 1LRN!92IA*K#GCPBY@J=K< MZ'K-5I&S<FS'HI MQM(OV"4-\8]TUY!5!PTE/"4YE+&W@AF7) !EXYHJM&-D[8SI>(,")W[O6*F# MAI&4DAGJ'F61O<&1J/,7V,H9[-IQ A]/"1>%'KM)\;/N,BPV7ES:#?*X3VPG M938)^+B6;*B[#O=W$*)X6T,!,X&:.YWDF#91#_V3V*(H66#[(5#XD( M=DDU"WE OB49BQZM35T=4/;^EK-,-E\R&Q54;=_1E1NGZ"!" K/1"Q;M4)KL MJ)E(6C,F5)R*C>^5QOJ+"VDTKY8 H_*(G[M%LG>&3 M\?AC*G:;.:<(C2EN<+';MAUB&L(5'5'L$^1]@[V*&%-2/K01+R%I#T33&$]@ M3&L6"\U902X/8/T@47)?1MRQCXN$?L_S/H'1?HP?8\C'#/2&3S[L1< M(3DAA?X0F,9-;U2WQ":6?+H< -)^"0"AN1M]WWDA&1$OE.9!M2T #=]%^2== MX8[,U7IMA@1\CSH/Y3^11$DMR,SQVF7TNHT-SJ MM9A^[$V2F@%67MDZ\S$?0+5XI@FS21QB^D])*1$#6FV[]00[W:56!U*[$F^* M9HS]&O7YI):.,[PX)4<6P9DQ>1LPR6N!_]C.L'U\L K^7#=GZ(;^Q_^N7S089I:+.R3+]T+-(/X(26 M6 DE]A&PS#0\SYT .>PZ)V"@[K4?/.3'0X*"S@=XXJW%_< GI@50MR6W0>TW M(#2T&!0^;X?'QN1Y$=ED@P32N3MK)>=MYIS/"EFL6->0Y;$%\VD9U6%&,0(? MV3G?%E9VH61(F77T8[[*1$5 Z5SB/?MID_TE0+>.*JEKHVOV75Q#J/HR=I12 M+B@4$S).<[& BP,BL^"8JM9.B]\ 4=#W@ZT9EFK'YF#O!K">>H(Q=^,S:#*M M.+Y(/J_9F]+'\4SRD<[7>2'%CMO MF^*/OVR(092+_7K2MH](VI]*O9H4'ZRB\S$_:,RB@'>\P"(GIEXO M.N7;KGZF9!5^#8#CZLYT?_ G_O7SWSDI_Z."N7B'_?&]'-]_PV7NSU=%A=ME M10[G?4.I?6SC]>0GQ'(>734N]$*' 8)/4AA1+71TXI372CO+?5?+V?@AT\$D M,FPV'(HXJH=$!!T5.I,#J-*)\Y[39\:-C)>,D \MO_N.!IJ;QTD*8\!:&9%4 MM?IG[T_1(?5I.=1=PS?7;8U9R&^*?4QS@;H=R)B0O"/IPEX>-=+'P-&AVL=O26 4L(^F*A"!0X M%-!IF_%L2\GII6RG?>EE8[*,,YO+YJ6*VYA@N+I3HY-;!XYWJN,[/>M&M?CA MUXH+YWJ2JG/JF#DLZ%OCO^4^FAR_8-CJ>Q!]MWET79I2)+R+\A )G8^5QX 2 M9GZGQ>@0'[" M^V&"1@Y; A=Z/@=#+Z3EW,%Y#Z]XX1V&GE?K!K[N (I_DF,.DPHC[^/Z.*0]XB;_8F?D( M(_LGJ>[FSQS_0J<9,43%G;CX;5+\=%GLRRL'P\2OY\"N=:8 T!\"3+3]3KD< M70Q3.S$M'#$"'Q]!"@.(S,C0/!!=HV5 >6H5- \F32H#ISX".H M!2?O_MPHH\>.6=JI)1Y/378*Z:-L1+_R58>M=H@ '( QVV$,Q-@M06"'Q?'Q M3I'\4EQV$JWXR0/FV#= C>8]'O\V6X>=7B\W%_E!\L@\)^?*$N[)1N5[C]E% M,CEL<&(G5WKI0%JPS\=T=VHE%1GX8\*GX!LZ2&P+,*6+X1;B4?=I\6YTFD?T M,X_AJ"%\QF$"P6 M2?(!-QG][\7 _D#HMC="B6*G*L3K@XYWWO?S!K.,/^&\ER!35P@O1S7B2PFIKG^$Z3$\W,5SHJ[&J^^>(C0R^2:D+'7R;W1 M-3(01DEY'D7.FI(%!7_9_W1U,/(U0@6'/WYV\'-:7<]^O\3?O0S"6OF2 @)8 M"2%WX7 ?D'L82)5#(\'6-10W -,"/[>L,>?_:\11*[PK%] M\(HX^8@=7[P59_1\T]L6SP(CV,>QZ<#=R='AT6FAYNCDWL'TI&C'SZE@7,#"[]M=+^1<&45598T,(K8C !(_VU>GT.+XMC06>!>% M3J?N$ZR,KQU/G\77N&\SO&H1OC7D7JFCE2SK5\^/IB?Q%;Z C7H5G>[D'@H\ ME"]G2OSY$NP.@O@!KT60%B9D]U9>S<'Z#]TZ/3B;^%@DW7N13,I$W,7YFR_8R?CSRE1NTO=0E% MJC*6ND!8E@8-&IV=1^@7[PK(>N*H5BV=3(C7@=4D#T]QSO,@F'BB@<]$QDG+^!!D5#4K0'+H[P?,SI2ZTC1$2#)?K MS,G#=GKE7A;[QP>^K+CV:TVW(/+T^V+_9/!LUOZ6G,J+$)"&@C>?'@P2[&F4 M3>TZ\-"S@W" 9?R94(AY[+RHC_O/#Y)#9)G \('S+I;X\6XZ-Z\P9E:+B!'\MC4K;L<97%# >#Z5^(0"NJ3" M8+6^' 39'7(E.XT<&$:H(FOC&=D>.?VU<0PI:>0;7\=P/[8\A;TMLD6@.1_P M^;I.1)8(F.-W%"@^K"$8BB55=;K08W3JEU*CXPO,PDTEF*KYL"=(3J_@1Z3>I>0/+S2+=V*% MDDKHS*,;;RAIL0+ NE1TYRI=.!5^0)FR9M9C9PX=]@Y )B*C4 "BI?^3B:0:]$/=SA#%3S:OSAF4 M@O%2C7%C3$R+A@9[7()!COT_FWZ@Q'N)K%$%2@N#-#5K;_6HIW^27#(,"UO0 M5[GC\JNT!?6NLYO'HT?0'.WO+UR?RA:U=T M93%@2Q ?^A-OU]$6'X#?YRU$%_(!)PB76+_Y%U!+ P04 " #1.Z16=C?\ MG9\$ Q# &0 'AL+W=O29W+)[V>Y2EFS![I'!6]66F3,4=+L^[9 MW"!+@E(F>W&_/^IE3*C.]"SLS9BCUYKP3=;8;MV*= M.K_1FY[E;(T+=/?YW-"J5UM)1(;*"JW X.J\0N,;D]XB5)Z0P3CW\IFIW;I%7>?M]9_#=R)RY)9O-3R M020N/>^,.Y#@BA72W>K-[UCQ&7I[7$L;?F%3R?8[P OK=%8I$X),J/+.GJLX M_(A"7"G$ 7?I**"\8HY-SXS>@/'29,T_!*I!F\ )Y9.R<(;>"M)STT69#- K M6(BU$BO!F7)PP;DNE!-J#7,M!1=HX>".+27:P[.>(\=>O<['@Q9[@SH*@V!O\(&])KI_ M7RRM,U0U_S01+NT=-]OSG32Q.>-XWJ%6L6B>L#/]\BD:];^VH#VNT1ZW69\N MJ#.30J)/VAP-1^6H?_SJ3CLFX3>CK86YT4G!'=SB$ZH"Z1Z@*(<)+%_ I0AW MJ4&$;\RLT3JX#-6&QC;Q;4=T1\966E*'^Q Z7R=0>;/!4_X&YCH S"N I@)H M]@%>ZBQGZN5G;\1#E154OH4*S'J#7K:4R,I"0U]H0&7"T[I.CMZM_4]FI5;\<[6)40GG_W5DL=AG<=A:]1ND6O%A10L'% 5CX=PD!#ZBR6T M'5U33BU2/NE+X-( U302V&P)L(J J@EPG5&"P)8\BHH'KW@L:QY)Q4,1#[GE M$;2\]Q]+=S#D4SRIZGSW#&HL!0HT 7;:3$( @^.?X" :GG9/1L>'_OGTN#N* MHT.X0J7I-"Z%']X3;J I%' F>2'K4)5L]QE.(!J,NH/A$*)HW#V-3^%ZM:)O MF-<)<:&O&"6"%T8X.J)QN[C??S=O MVKS4BM@XX=.>X-+MN-R3_9\ T"Q@'7GW=?1!,%H2_CX:-PT1F^U5CL_;4702 MDM8_&O&+:V5T5G4G*]-! M%+>]N=??5?ZJYO[S-5A-/=N*L/F[\[:1\QT2#>4$*>40EH@*\ T=WW/\':5M ML/ZMYZ,H3%&<']8RE?-U#<[0_'$'6C MT:!LGM%)1-=I:]/$@^[Q8+R]-95C;V>,HY-H'895"V$T*2>Z>K>>AR_*,?!5 MO!RFB?M:$#6)*U+M'YW066_* ;5<.)V'H7"I'7W8PF-*,ST:+T#O5YKJI%IX M!_6_A.E_4$L#!!0 ( -$[I%90R_#:*04 #@/ 9 >&PO=V]R:W-H M965T!JWXIQ6<1 MQ)+QF A8SSO7SM7-2-,;@F\,=K(V)]J2%>??]>+.GW=L#0A"\)260''8PA+" M4 M"&,^YS$ZI4C/6YX7T3\9VM&5%)2QY^!OS53#O3#O$AS5-0_6%[WZ!W!X# MT..A-%^RRVC'2.RE4O$H9T8$$8NSD?[(_5!CF-I'&-R$ID9I>F),-=P(CL4Z*(]*X%^&?&KQB3)!OM$P!7(/5*8"T.-*DNX3784@ M+V9]A5HT;=_+)=YD$MTC$@?DGL_R=]'="5$MX!XXYX4>$^%109. MC[BV.S@A;U":/##R!J^;?,ND%W)MM22_7Z^D$GA*_FBS.1,Y;!>I,^=*)M2# M>0=30X+80F?Q_ITSMC^> #PL 0]/25\\8B;Z:0B$K\F2"K%G\28W@,8^J=F# M!-=2 L9/__C,Z(J%3#&0;2:=5-INTE, 9,U#S&0-0>DC0F3 =ZBO4AM6:HD* MJ")4 (FRP^437*\UX&T&&/,2<]M+A= 2,;]8)D0%@$1>86U&W64QYD 88CK+ MBRN"!\,+RI-1]\.!ES[#%D+BY*.;CX/"5TLJ Z/4TQ-X3AFJ,UEP1B['4^NR M-KY_-W4=]V-MABB^0^X*;4AF^!EQ+ZUI-;SDPSH24@6"ANA205B,, Z/V9K_N@4/HA6((F;N?Q,SIV=/AL9GU>SM<4,&MQK^E[@YUJC! MV%P?C=O$&C;8FNL3<1M-#PY*-3._3M2P45G#1J=K6-;T=87Z=:6KB7'\79RD M&#),:QWT# Y2E!8NZT#;:MA)I6^I8;P"PS08LJ.2I!)U(R@L0J;RE,#TAM_N M?F1#@F9)NJJ?[S:"9D5[X9G\F_>J(V'7V7D7RPC_R$"7VD0P[XBZ,V=BV2/2 M=(%DFYBMF4?Q9*3QH4,DV>$!?D>UKW;K\[!F!$KW[%A/.A@YZ M^T'P59;!^P_4_Q,O:>B;:E.G-:*3J>>!E,09GI,/Y')RCB2O&6Z"V2K>QYL* M3V,]-15OC<&K4S8TCBW4>9MS9)7%<:W!.6GKW[KA%G?R(J!>0+%2R"+@]8:= M$2QYE-!X_Y.L#H,TY;"1(:8^'RL[]6M"P:D" 7A7R.Z/H.^/AT'6(DWGZ!IL M/)6XHR\#[36#=,O^4:F[J-?")OD-#6E<9L]AO])%TAGV+@=Z,AGUQN,IN?9] MEIE?%,VRX!HG:A_63F[7Q99D7Y#N96\TG%Z0![K/+MR'W$TD#2_HON2XO>E8 MPQB/>XYKOP+<-+3>T#9=:=IS]B4N^6S\#I[#57DV9L2U6\8FAC"&EEM:X+]0F3O MM&RA>&+>1BNN\*5EI@$^;4%H OR_YEP5"ZV@?"PO_@)02P,$% @ T3ND M5AT31@O. @ (@8 !D !X;"]W;W)K&UL?55M M;]HP$/XKIVS:6BEJ7@BA,$ JK'O3.J&6;A^F?3#)0:(F=F8[I?S[G9V0LHWR MA9SM>YY[SKX[QELA'U2&J.&I++B:.)G6U0D['HM9%SG$A0=5ER>1NAH783IS V6_)ZXES%8QFD?&W#M]SW*H#&TPF*R$> MS.)S.G%\(P@+3+1A8/1YQ#D6A2$B&;];3J<+:8"']I[]@\V=?-E3>P\' M@$O_!4#8 D*KNPED5;YGFDW'4FQ!&F]B,X9-U:))7,[-H]QI2:"ZTS!-4\Q_1OO MD;9.8+@7. M/$MXP>0&]P(70#WLG^'I=PCW+UWN!KTT4UE*4,">MD@J#+EUG M,+?7C1)^7JV4W?]U[ (:_N@XOVFBD:I8@A.'ND2A?$1G^N95$/OO3JB/.O71 M*?;_G@MF._B(8B-9E>4)?!4),\5^3/9)XN.REQG=DRBH<7.^ 6UJ NPIUPK8 MOI%!K$&3YUR4%>.[MXI\&I6R*RJ.VH75#C;/6HM6*T60%J\SB0AE4SYHR@?H M\9.L>WU@/#5&"&UI+%GXU&ZVF1(PZ6@Z.YP&$#@QM$0ED*SXGBNQ![W MW3"(R.@3LS^ 8X_O'?0MU=W&3B<%B:BY;EJXV^T&X%73]\_NS?2D=#1R4NLF#E3-4HZ M62E=,4NN7D>FUL@*7U2)*(GC850Q+H-LXF.W.INHQ@HN\5:#::J*Z9[1?ZUM-7M2A%+Q":;B2H'$U#6:]\;SO\GW"-XX; MLV>#FV2IU*-SKHMI$#M"*#"W#H'1ZPD7*(0#(AH_MYA!U](5[ML[]"L_.\VR M9 872CSPPI;3X#R E>L$?9.;3[C=IZ!P\N5,/X)FS8W30+(&V-5M2TF!A67 M[9L];^]AK^ \?J4@V18DGG?;R+.\9)9E$ZTVH%TVH3G#C^JKB1R7[J/<6TVG MG.IL=BV?4%JE7^##%[84:$XFD25<=QKE6XQYBY&\@I'"C9*V-/!)%EC\61\1 MGXY4LB,U3XX"WC!]!FDOA"1.TB-X:3=DZO'2_PYYR4TNE&DTPO?9TEA-?\6/ M0Q.W@/W#@$XI8U.S'*_>F-XP_'J';[^CVCZ%G]Z2\HA$(:@4= M]1 6C=9D'V)[%.\PVYEQ\'33>=E=-3!9P"7F6"U1[Z))"+9$6*BJ9O+EO0'> MW>:2"29SA%R12(WUB"YWI02)GB/"&/7"U!O#B_""FAWZ5M&>EBK4:[\Q#(W82-O*JHMV2VG6:O%W M>KO1:-@UEP8$KJ@T/AL- M#MEF@=JVJOS*6RI'-OEK184;L$.E\I97>.:]"M MZNP74$L#!!0 ( -$[I%;,XLZE'@, 'L' 9 >&PO=V]R:W-H965T MDA:IR5;ICZ9&M/"E$=),O=K: M]CH(3%ECP\RE:E'2R4KIAEG:ZG5@6HVLZIP:$<1AF 4-X]*;33K=7,\F:F,% MESC78#9-P_376Q1J._4B;Z]8\'5MG2*835JVQ@]H?V_GFG;!@%+Q!J7A2H+& MU=0KHNO;U-EW!G]PW)I',KA,EDI]=)N':NJ%+B 46%J'P&CYC'*42IOO" MMK<=)1Z4&V-5LW.F"!HN^Y5]V=7AD<,X?,$AWCG$7=P]41?E/;-L-M%J"]I9 M$YH3NE0[;PJ.2_=3/EA-IYS\[.Q!6B;7?"G0^/ K70(F*WBK5+7E0L#Y;\R= M7$P"2US.(RAWN+<];OP";@+OE;2U@=>RPNJI?T Q#H'&^T!OXY. [YF^A"3R M(0[CY 1>,B2>='C)"WA#CB[A0Q6@, :M@7MN2J',1B/\72R-U71]_CE6AIXE M/<[B6NK:M*S$J4<]8U!_1F]V]BK*PIL3.:1##NDI]-E""=>76Z8K4*OG61R+ M]R3B\7@+T$^);(UPIYJ6R:\_&^ '6M87CTP[&UMK1&CZBX#N(@#]QK(>_F-7 M_">J&+@A&((0-"\,G'-),&ICR-)<7#_+$>ZQQ&:)^@!05!5W'6^@:)2V_%_6 M]?\WS$7Y:<,U150L'GXI_KI[#8LSUK0W]_ 3)+D_&H]).'LUCJ/XAJ3SR"?I MPAUF?I)G!_^'^=XQOO*S,!R<]NM./2C,Y'T85313E1 M9&,_'V7/^+/$\6>YGUXEWR]$]$.%B$\6(HW]-+EZH1 I27'^?Q0BS\-O"Y%' MCC9/_''XG+\O1![[HS2#8WT4/!J(#>IU-_8-E&HC;3\;!^WPLA3]0#V8]\\2 M56O-J80"5^0:7N8C#W0_ZON-56TW7I?*TK#NQ)I>1]3.@,Y72MG]QA$,[^WL M/U!+ P04 " #1.Z165!7;'5H# #A!@ &0 'AL+W=OJE5QG3S8- MYQ4V7-_*#ELZ*:5JN"%1[0+=*>2%\1[KV@(1C>\'3&^\ MTCJ>[H_HCRYVBF7+-=[+^F]1F&KIS3PHL.1];;[*_1<\Q)-:O%S6VJVP'VP3 MNC'OM9'-P9GD1K3#E[\=\G#B, O?<6 '!^9X#Q"_,SJ4;QA 6NMT6@??J,JN/J#;VO4UXO $+ZU"O(#UMV MQ=[!BN%9MJ;2\- 66/SL'Q"OD1P[DKMC%P&?N;J%./*!A2R^@!>/P<8.+WX' M;Z.HF)7YX<.FYJT!WA;P\+T7'569@7_66VT4E1SO,<(+F#!*X0 MM.'&:@SD4@]I*I#L<^'TO1;M#DQE#16W97]C[X$&324+WW5) =1RO<:RKZ&F MOB-@#:6L:0AHN!(MN$[*^GL.#-J)QT&MM8W31P6?4N1*=:UZJA+P:2X&. M<'8RU+XX3X)H74GV1V96P*OY>ER/&GBV>9_3WSMB^IE'IE M4W5Z'OEQ/*&5$:4GI$Q5LBY -)V2KVAM-+";*(1XZH<)TT]4 - W40C.S<$-M*0R/1;2OZ#T)E M#>B\E-(&UL?57;CMLV$/T50@V*!!!6U,62O;4- MV$F#%&C0Q6[2/A1]H*61180B%9):K_^^0TJ6G<#K%XF7,V?.D#/#Y4'I;Z8! ML.2E%=*L@L;:[CZ*3-E R\R=ZD#B3JUTRRQ.]3XRG096>:-61 FE>=0R+H/U MTJ\]Z/52]59P"0^:F+YMF3YN0:C#*HB#T\(CWS?6+43K9@<19- M+!5O01JN)-%0KX)-?+_-'-X#_N9P,!=CXB+9*?7-3?ZH5@%U@D! :1T#P]\S MO V-''1IBLB(^="4/^W>R,U9@@_UT+>6#,KC.ZHKDW M'2MA%6!5&-#/$*Q__27.Z6\W]&:3WNP6^_H)B[#J!1!5DRM7=4WN3<+K[$16:4"JO16*?&-D!J);"HN=R3MUSBBNH-6IIW]V1C' 9O MKVRFZR,?H(1V!_JTDI"KCA52Z\D]MA_-K/,!+]B)#*IX0V9YF!?4#6B8Y?%T M-"6&RTLFB-4A M; ;:40QVDXDZ#XLT(VF89K.S#-6ZW0'I0H*V$^H(@&U,,.L1QGIW\QQE)2'- MZ&2MU9$)>_2&+<=DM4K"^8CR,,YG) N+^&S"I06\33N!DC#!\\E1%26/(Y^& M9Y ]7&!R.L=OG"TF(L-\<;AK9;(X,I; RZ^MYS MP_T.7E!**8EI6.#OKQ\2YC)?XW">HM-PML@Q6>)B$5(Z[=V.C:54U+CK06JBD+8YQDJLYH$_6"]<2>SW/F-<#HN M188+=%_*6\NKL$-)9(&:I-%@,9T$E_W1;.C]:X>O$E>T,0>O9&G,@U]\2"9! MSQ-"A;'S"(*'1YRC4AZ(:?QL,8/N2!^X.5^C7]?:6(-.X:#&&^Q6^/UR2]B M!\%A1W"X"WVZ:.H!3 J+JBP5"3T;&@'*XDQ#U+&J^)YY G.C MR2B9",?K:ZF%CB6'+1QO> C:)G0GE>U"[W,$Y],#EKZ&V_J5OYB.8Q-M%-0V@FB3A"\84^7FXJ$3NA@!/>Y M17R1@,#I$^==_OA/U%X.@O4E>F32HXH0!!$RI%DZ;ET-"7R*&ULM5=M;]LV$/XKA&MT M":#4>I><)@:2M,$"M%N09!V&81]H^6P3E4B5I.)ZOWY'ZL6.K6I=@7VQ21WO MX;T\=R0O-D)^5FL 3;X6.5>7H[76Y?EDHK(U%%2]$25PE"R%+*C&J5Q-5"F! M+JQ2D4]\UXTG!65\-+NPW^[E[$)4.F<<[B5155%0N;V&7&PN1]ZH_?# 5FMM M/DQF%R5=P2/HW\I[B;-)A[)@!7#%!"<2EI>C*^_\.C7K[8)/##9J;TR,)W,A M/IO)W>)RY!J#((=,&P2*?\]P WEN@-",+PWFJ-O2*.Z/6_1;ZSOZ,J<*;D3^ M.UOH]>4H'9$%+&F5ZP>Q^1D:?R*#EXE&N#BKE!9%HXP6%(S7__1K M$X<]A=3]AH+?*/C6[GHC:^4[JNGL0HH-D68UHIF!==5JHW&,FZ0\:HE2AGIZ M]@[FFIP\T7D.ZO1BHA'2""99HWY=J_O?4 _(1\'U6I'W? &+E_H3-*6SQV_M MN?8' 3]2^88$GD-\UP\&\(+.O\#B!4/^O6,JRX6J)) _K^9*2^3"7WW.UEAA M/Y:ICW-5T@PN1U@ "N0SC&:O7WFQ^W; TK"S-!Q"GSUBO2VJ'(A8D@^"K\Z> M0!;$V-]GZ2!6OZ4&RB&Y@=8&.A-86DHKLZ%> UF*'$N4\15*BH)I+#T44BO' MM&3K+B^$\@5:ED$Q!]E^]XP6^XZ5I/?8CQX]< M,I"CJ,M1-)BC&U&4@MNXH&>66]%#0EMFM@:/Y)=W6)>FC..D3 MVY"<^$[LIJ?DJ@XWM8J3I.XKNHHP,%.;]QU[7'7 MMP<(D72$2+Z;$+9R9),[&2U)[O:!_>\I=(#1(E4<,? M/$VCFAD#V4N[[*7#V:L? B88=RT%W]<-J"]3@V#]F;H[[&M[?#M7OV'5F^4;?$Q-92M)PNT?T\^!#JZ!EG;\+"U-]4*N734H,?F%(B#[G]7 M:H-JGNM,,>,M)X:./O[-PR%TDGC'J\-S9G%\^B-M$F1BBEX^;FBY0\12$04> M64EPVN$]"6Q!#AB0(E>_;+4-N D"S9@'8*TZSX,^T!)9XLH17HD9CE7K15H#1<2="X7@2KY/8N=_?]A:\<]^9D M#2Z30JEO;O-;M0AB1P@%EM8A,/K;X3T*X8"(QK]'S& (Z1Q/USWZH\^=/2%>6SU63E MY&>7S^K A#W (Y=,EEQN8+71B"2[A:LOK!!H1O/(4B1W/RJ/J'<=:OH&:@:? ME+2U@5]DA=6/_A$Q'&BF/?C+4%B1OP03Q0[CBDLRJ-4Q69G0+*^, ^S. [C.#Y9^1)S8UI/HE3& MFA!:R1I%KO]A!5=)%H['TQ$M\C";_CSR+B$()3?7%G5#8-/9),SSS*_&X21- MX*(V##29:%3NF:YZ62Z*]>'=+$VF'\VEJ@Y*$K#WM359H.E:#%V+O9;SM>8] M^GI 9P/Z-12XX5*ZTS[2>TCR61@GX\%3XPXET=^R0^-S3 MC6#5RD.AH+^$)OCD$*,2$&OW-6<,%]$,$L M)6N5E\$PX>5@NX>AVUBU]<.X4)9&NU_6]):B M=A?(OE;T01\W+L#P.B__!U!+ P04 " #1.Z16B)K#J/X" !_!@ &0 M 'AL+W=O2( M%EX+(8'2<"5!XW8:S+KC>=_Y>X=O'/?F9 XNDXU2S\[XFDZ#CA.$ A/K&!@-+WB/ M0C@BDO&KY@R:D YX.C^R?_:Y4RX;9O!>B>\\M?DT& 60XI;MA%VJ_1>L\QDX MOD0)X[^PKWP'=P$D.V-548-)0<%E-;+7^AQ. */.&X"H!D1>=Q7(J_S$+(LG M6NU!.V]B3."[=I:RLIEU..!NOK$J>/\PIKQ3N54%W;9@_KNLUVP@T M-Y/04ACG'"8UY;RBC-Z@[,&CDC8W\"!33/_%AR2OT1@=-AUVU! MU(EZ%_AZ3<::QS7K #E9B%F=9,9NCG/V8;8S75R\]SR5?<_?/< M[@V-3BA* MH0Z(\-9]GLOD8JSSF:QSA*VBT'LN,["N1.KWS'^C 4O;+,LT9LS2AM>R\5J2 MT]K"5S='>M2)TE0CP*6')DH:)7A*X)30-+C[,"Y!A]>8NV[P@B"4,806WM&J M*A*HTK&;%BQ73P:83#WIPVJQ@'2GO6"R;:[IG(JJ1-&5*%"!)7E381Y)DZA% M(4R)OF^( UR3RH(+X6+4Y+_7\>QP%+.CJ_[%A3)"95^BJ[@MOV'7T' M[2&LJ"N1OA9D*%$SX9U92N^=NTIT F#4'A B@K6RY' %W6&[[X:H/8)SI16> M-(4"=>9;GZ&#W$E;]8=FM>FNLZJI_'6O6C/EE7%I0."6H)WV[2 7;6[RK"J M]"UFHRPU+#_-Z0^!VCG0_E8I>S1<@.:?$_\!4$L#!!0 ( -$[I%9SGMK_ MC ( *\% 9 >&PO=V]R:W-H965T3AH<3#\=JZ!RH1/3QK96@2E=Y7%W%,>8E:4,]6:/AD:9T6GK=N%5/E4!1- MD%9QFB1GL1;21-FXL=VZ;&QKKZ3!6P=4:RW_L^@HW]8P"7FX5-5]8M[ZC801Y3=[J33 ST-*T?_&\N8>=@//DE8!T M$Y VO-M$#L_0@X(UP M/1CT3R%-TL$!O$%7YZ#!&[R"-ZN)+41P:?5"&M&VA"E@2L2MOW,-\&.Z(.^X M77[NNX J+EUW#O@(.IMA?P'V)L+2*!2S-"GQHDHV*Y2\D\'QV=/X DJMG&^UQ9"BF.X'TO M'?U'6$.%+5]J]0)MMPRAWTL2N+=>J']I'4$_"<#[WB+>$9%&MVI&!7'*VOA6 M3YVUFT;35H1_W-M1QLV[DJPGA4L.37KO1A&X=CRT&V^K1I(+ZUG@S;+DB8HN M./#YTEJ_W80$W8S.?@-02P,$% @ T3ND5I$RT_WU @ ^0@ !D !X M;"]W;W)K&ULK5;1;MHP%/T5*ZNF3FJ;D(10&$0J ML&I[Z(9*NSU,>S#)A5AU[-0VT.[K9SLA QI0*_6%V,X]Y]YS+LE-?\W%@\P M%'K**9,#)U.JZ+FN3#+(L;S@!3!]9\Y%CI7>BH4K"P$XM:" N7K@=-R-@>W9)$I<^#&_0(O8 KJOI@(O7-K MEI3DP"3A# F8#YRK5F\;]BOK7:M988EC#C]15*5#9Q+!Z4PQTNJ;OGZ*U1Z MVH8OX53:7[2N8CT')4NI>%Z!=04Y8>45/U4^; $T3S/ KP#^/B \ @J0/!: M0%@!0NM,*<7Z,,8*QWW!UTB8:,UF%M9,B];R"3-MGRJA[Q*-4_%=!FC$\P*S M9X19BH98$HGX'$T$2& *V^ZO()G2#"T%W&EU+C9-]5 MNAK#Z295YF&9V3^0.4 WG*E,HB\LA707[VH5M11_(V7H'R6\P>("!:TSY'M^ MT%#/Z/5POP$^/@X?0W((OJ,FJ!L36+[@ -\/L<",_+7^G^D6,?M23Z:[*V2WXELQY>H]B4ZZLMW/7LIEXU61"]: M<=YJ=SM1N&=&0UPWC/S6;MCX:"%OE>EN#84( MY!''6\:_B TA$CRE228FSD;*_-IU1;0A*1:7+">9NK-B/,52G?*U*W).<%P: MI8F+/,]W4TPS9SHNKSWPZ9@5,J$9>>! %&F*^3^W)&';B0.=W84/=+V1^H([ M'>=X3>9$+O('KL[R8PDB2:I=GRMH4[C4QL>'N_H[\K.J\XLL2 SEOQ% M8[F9.",'Q&2%BT1^8-O?2=VA@>9%+!'E+]C6SWH.B HA65H;JQ:D-*O^\5,M MQ(%!SS]A@&H#]%*#7FW0>V: T F#?FW0?ZG!H#8HN^Y6?2^%"[#$TS%G6\#U MTXJF#TKU2VNE%\UTHLPE5W>ILI/3>94@@*W G*XSNJ(1SB2XB2)69))F:_# M$AI1(L %>(\YQSJPX'5 )*:)> -> 9J!CQM6")S%8NQ*U2B-=J.Z ;=5 ]") M!O3 /F Q#\#K M5V_42Y$SK@599%1V-=,,#4C40&&'>?!R<[1K4P'Z]6\2'!0JPP7X[YLI?UNA!R5:STB/4Y7:CX>B&YV? M*[I-6&@)UA)]T(@^,(H>D*5\"Q*6K2\DX6F7M!7 /Y06]A H#_UG,EIRVI)QU,@X^E8B[I9(+07/*BVP2@MMT=KQ M.Z@GH8WYV4PY.QXV:8%56EC3#B>S@1IC]FNJMM!H+S0R"CVK9-;5.$U5 MQ-_,%P#'+"]?CWHH4ROY[QSPS"TX.T@V:8%56FB+UH[EOGR&/Z5^AE8+:*NT MP"HMM$5KQV]?1$-S%?V"@LY,.#L65@MKJ[00'G\60 A>G1SQ]E4S-)?-BPRG M^H/$O^74LI2 "E'@+"(@8D)V?WNT61_/K-("J[2PIAVJ[L.3FN^K;6@NMP.R M(IPKP25^ @G%2YJHXI%TBVVSEIY9I056:2$\+O1A_Z38^\(X#?]X\$=P_V053-O2XWH 0HUS[5EDASM=GDNBFW=MS]X]4.V3WF M:YH)D)"5,O4NARK6O-ITJDXDR\M=E263DJ7EX8;@F'#]@+J_8DSN3K2#9NMO M^C]02P,$% @ T3ND5JZC85CN @ "0P !D !X;"]W;W)K&ULK59=;YLP%/TK%I.F3>K"5YJD'4%*TDVMM$I1HFT/TQY< MN(!5L)GM)-V_GVT(#1U)4XF7@.U[#N?8%W*"'>./(@.0Z*G(J9A:F93EM6V+ M*(,"BP$K@:J5A/$"2S7DJ2U*#C@VH"*W/<<9V04FU H#,[?D8< V,B<4EAR) M35%@_G<..=M-+=?:3ZQ(FDD]88=!B5-8@_Q>+KD:V0U+3 J@@C"*."13:^9> M+UP#,!4_".S$P3W25AX8>]2#NWAJ.5H1Y!!)38'590L+R'/-I'3\J4FMYID: M>'B_9_]JS"LS#UC @N4_22RSJ36Q4 P)WN1RQ7:W4!NZU'P1RX7Y1;NZUK%0 MM!&2%358*2@(K:[XJ=Z( X#BZ09X- ?@UP#=&*V7&U@V6. PXVR&N MJQ6;OC%[8]#*#:'Z&->2JU6B<#)<5\>'6(+6)*4D(1&F$LVBB&VH)#1%2Y:3 MB(! G]""T0BHY-BT]D+>^7 MC??+TT?<\LZ5]PM4 M=SZOO99;WBFQ@^_7G>AL[ 'P7V]M#2*T4MJ:-&ZNB\ M;IQWR3J)?>N)]$36LCEN;([[[L9QG]Y[(FMYGS3>)SUWX^2<;NPL\KJ[\:J1 M>G5>-RZZ9)W$OO5$>B)KV72=Y[]FI^]^K!E[LM\76]O_031Q>^[)FK#=;^[X M15.^5E7)M0]"E>JVU&1-@4PNJG)%,]ODV9E)<2_FYSKGFK#V3%.%9)4:4D(% MRB%1E,Y@K#[>O,J=U4"RTD2W!R95RYO;3&5UX+I K2>,R?U /Z!)_^$_4$L# M!!0 ( -$[I%9 ();R7 0 ($5 9 >&PO=V]R:W-H965T+(6,B4:;N7&5SM)26R=TL0/@Z#OIX1Q;SJV8PLY'8M,)XS3A40J M2U,BO\UH(@X3#WLO X]LL]5FP)^.=V1#EU0_[182[OP2)68IY8H)CB1=3[P[ M?#L/K8.U^)O1@SJZ1B:5E1#/YN:O>.(%)B*:T$@;" )_>SJG26*0((Y_"E"O M?*=Q/+Y^0?_#)@_)K(BB3KRAAV*Z)EFB'\7A3UHDU#-XD4B4_46' MPC;P4)0I+=+"&2)(&<__R=>B$$<.@-/L$!8.X6N'[@F'3N'0L8GFD=FT[HDF MT[$4!R2--:"9"UL;ZPW9,&YH7&H)3QGXZ>DRIP^)-5JR#6=K%A&NT5T4B8QK MQC=H(1(6,:K0-?H$;?51*(465**Y2%/@8;DEDJ(/]U03EJA+L'I:WJ,/%Y?H M OE(F:<*,8Z>.-/JZFC@\U9DBO 8!B]J]V-?0V(F/#\JDICE280GDNB@!\'U M5J'?>4SCNK\/!2FK$KY4918Z 1^(O$$=?(7"(.PTQ#-_OWOH"*=3DM2Q>)T3 M>)^RE$JBA;QMJDWNVVWV-*RCWUIK_^@OO!;TV)M0162[-; MIMEUH4]->R707DU)YIY]ZVF6IOWT&O=&@WYW[.^/XV^P&W7[(2[-:I'URLAZ M3@+N*1,V%$7Y+"^F;:;@$LHBQ OZ$,[6!U4OBRP%]?+IK+EL?2.R,*=?J?7>\5I@QD> MCL)1,Z>#,M6!D]-V4VULBT&;;=$26*U6P[)60V=;W+,D,]LM4C3*)-.P'5Q! MO3A43K-50F'C7.FWV!Y^1V/PBFB712WN41GWZ+^T,\@:I6'+,=ND MQR9]0#F_PT?OZ_ &,T>'XZ#:W /WQO&^/BU06FK4MM#J.1\)&NSD?&9GJ.$E M%DE"Y%'RC105<(/:UG*#!Z\H:C(+;H8G& JK:,.W9Q:TUAGQAN^+M\'L=+R5 M$L%.!3 M5!_HTN@9B9V9(E*E^#NS]XJL%,:G5VOEM#J]:K4 M$G9JE.;MPN9^;3ZY8K0CW^!3\,T=HWB-:\MPFM3#KS00=HN@QR6"30$]+I^: M6]OI?395+:'54T(^T]MMJR&E2#[_20]@M MB!:G>MKI=C9'+:'5O]TKU1.Z5<__T--AJXJI+;1ZO2K%%+H54UL]7;S&U=-. MDSQ\_^@P*Z5R8\_X%++G4?D)3CE:GB/>V=.S5^,S?#O/3P,KF/QP\H'(#>,* M)70-D,'- .*1^7E??J/%SAZ9K836(K676TIB*HT!/%\+H5]NS O*4]?IOU!+ M P04 " #1.Z16Y3> ;I(# ]$0 &0 'AL+W=OA@!%OML^T-+:(4*)* M4G;R]QU2BFPYLMH >DA?+)&<.9IS.&-Q--T+^: 2 $T>4YZIF9-HG5^[KHH2 M2*FZ%#EDN+(1,J4:AW+KJEP"C:U3RMW \T9N2EGFS*=V;BGG4U%HSC)82J** M-*7RZ1:XV,\N&/;1)L)=S[-Z196H._SI<216Z/$+(5,,9$1"9N9<^-? M+_R!<; 6_S/8JZ-[8JBLA7@P@W_CF>.9B(!#I T$Q)+BROV1?V7H. MB0JE15HY8P0IR\HK?:R$.') G':'H'((3AT&9QS"RB&T1,O(+*W/5-/Y5(H] MD<8:T?05/&U0)W:I2)XJI]&N5TPAF M#I:R KD#9_[/.W_D?6JCV!-8@_"@)CRPZ.$9PLT,4H<,@L>(%[C'9"-%2B*1 MYH6F5@^3FM8#%_>V*B&^H#N0^"]C#*V 9;+AWY32F&F8MFTJ#OI4L2>PAHK# M6L5A9]HLA084DG+^1'H4\Z6*Y#U[%O=#FZ)EF$,;IGEA[.;^E3\<3=W=L50M M5L-@$M16#0U&M0:C3@WNLQTH0P-CTY)%YK:L(PR=W*WN6PNI$_.U*= 36(/^ MN*8_?KN%-.Y3Q9[ &BI.:A4G?TQE=U0I<=2MP MIE ZO5Z[Q3V!-0CZWN&$X[W=4JEBZTG(OM":2AZ=%?V_HURJ.(]+833V3\JE MU>BJO5S\X*!!\)LC&[YXI&9K#M@NK/41_]9(.]%>O?\]H36Y'TZK?OB&*ZG7 M0W!?:$TE#\=@O_-\^(8J:?#RS1,.PM-7SV_-2AW)D!CD,8 US<"M:\&Y@'U%Y/Y+U!+ P04 " #1.Z16/BKSBC@' !_ M0P &0 'AL+W=O?$E76*@,56L0 L4S=I]5FPZ%BI;KB0G+; ?/TI632EDCL3XZ$OBRSFO MCEY2E!Z1UN5#DG[+-DKEY,[]\,A]ERH[9A]CK9JYW^9IVDVS#7 M;].[8;9/5;@JD[;QD(U&D^$VC':#^67YV:=T?ID<\CC:J4\IR0[;;9C^O%9Q M\G UH(-?'WR.[C9Y\<%P?KD/[]2-RK_L/Z7ZW?"DLHJV:I=%R8ZD:GTU>$O? M!&):))017R/UD-5>DV)7;I/D6_'F_>IJ,"HJ4K%:YH5$J/_=JX6*XT))U_&] M$AVF=LP4XLD_C=:Y9NKP6Q 5FH='N+\<_+PMZIV:%SH M+9,X*_^2ARIV-"#+0Y8GVRI95["-=L?_X8_*B%H"%4\DL"J!=4W@50+OFB"J M!-$U85PEE+L^/.Y[:9P,\W!^F28/)"VBM5KQHG2_S-9^1;NBH]SDJ?XVTGGY M_%T8I>1K&!\4^:C"[) JW0ORC/Q);G2?7!UB19(U681I^C/:W561X6Y%:HDZ MX&V6*9U5?/$A"F^C.,HCE9&74N5A%&>OM-Z7&TE>OGA%7I!H1_[9)(=,1V>7 MPUSO15'+<%E5?'VLF#U1\<..] 6<+M7RE,XM MTV;Z4+??T#OZ[C+QF"?<><7P\R;;ATMU-=#C2Z;2>S68__X; MG8S^Q43UQGE&DST[>*88A)3+$ 2:[@_/;D_/6>0F6*V *:8Q!0+ MD,0:+3 [M< ,[/^+9)?K"TQ][=D^S,RZ##,SZYP[%8^#I!U$V6Q"FU&!(TI< MPUV"B;W?#%).88@&26,-].C+<,SKGD*^RD1H!54VB MJ@58:LUVJ/$G13OP*ZGZD2\<%]*.L/&,6@=_%58_KB<3RAZ%!8ZPZ7@RF;D/ M?VK(C8)L,G_$U/^1SP5#I,4GMV$6N7LE*M6AJDE4M0!+K=DXANPH?R974TRR M6J"J252U $NMV02&^R@(-?KXR#;E#:5E\4)]/T3W85S M&NPX.BHN#*S! 17?L-2:5AJ HS#!=;Y106V"<]VI<(1-A74))N&JO#WL \^H MX3,* ]HBB>,PUR>GF*R3E$0[_5IE.=%G*^WJ0[AW^CFQST167UMTBI)P?=YN M]H%;U/ 6/0NX*"IQH:I)5+4 2ZW9#H:Z*(Q=[[MU8YNXN'4]M7!$T;'=C<&" MO.U#4FO:9QB.PA#7_=98)=0"K8XH![7"17E;V >',<-A#.0+K^O_2JKM^M\1 MYKK^APOSGHCH Z.8P2@&8U20Y=&V.(:3-7'/Z=F$H3\YWH6@3K/!#7K/(&&J M252U $NMV72U*;QGS^'A3N+ASN+A3N/U@7O,X!Z#9_*\6*/2:F4-1YR;->#B MO*WL ]N8P38&8UMGUF VBKE8PQ'F8@VX*F\/^^ U9GB-P;SV+-9@-I0Y6*-3 ME(3K\W:S#W)CAMS8Y!S68*CS:ZAJ$E4MP%)KMH-A/@:R3$?6J$3J'=3JPZTA M$B[%V[@^((T92&,PI'6G#&8CF&5>:XB$R_$VKP]$8P;1&(QH7GQAXY=E7VN( MA ORMJ\//.,&SSB,9V=QA7,Y [Q!W_$654VBJ@58:LVF,TC(Z3.Y@J.B':J: M1%4+L-2:36#0CK?-\7EP1:4%C3[M(1*NR-N_7M97UA988JVPM%G+\JXU1,+5 M>'O7!XAQ V*\9?[L.1#!;=JR?&P-D7!EWC[V 6/&L4>3N)M8=(N"!O^_H@,6Y(C,,D=A9*.!=*PAOT M'GM1ETJBJ@58:LV?8!@*%/!BR:=10J#2'*J:1%4+L-2:36!H3K2LD_1!"6&O M@'P\^K2'2+@B;__Z0#%A4$S *-89)40[AK6'2+@:;^_ZP#!A,$RT3(\]!R5$ M.Y*UATBX,F\?>_DE6^VG;.('ZM&TH(>ZK, MZL"M(1(NQ=NX/AA,& 83,(-UAPAA$Y9E7FN(A,OQ-J\/ A.&P 1,8#[X4$G5 M?W3@6NGD"'.M=((+\[81E<*&M6<7%(^FT.?INVB7D5BMM?SH]53WC_3XM(?C MFSS9EX\SN$WR/-F6+S&UL MS55M:]LP$/XKAU=&!UGL."_=NL30-)05VBTTM/LP]D&Q+XFH+'F2G+30'[^3 M[)BL)!D,!OMBZ^7NN>1B:=(4Y,VU5H*2= MA=(YLS35R] 4&EGFG7(1QE$T"'/&99 ,_=I4)T-56L$E3C68,L^9?AZC4)M1 MT FV"W=\N;)N(4R&!5OB#.U],=4T"QN4C./& M[(S!*9DK]>@FU]DHB!PA%)A:A\#HM\9+%,(!$8V?-6;0A'2.N^,M^I773EKF MS."E$M]X9E>CX$, &2Y8*>R=VGS&6D_?X:5*&/^%36T;!9"6QJJ\=B8&.9?5 MGSW5>=AQZ'8/.,2U0^QY5X$\RPFS+!EJM0'MK G-#;Q4[TWDN'2',K.:=CGY MV>2*<0T/3)0(M\A,J9$R;@V\AZ]S@WK-Y@+A6A:E!2Z](?/95 N8X *UQ@PN M%9U1AKK:.9V@95R8=W#B7&ZY$+1LAJ$ENBYHF-;4QA6U^ "U6Z;;T.VT(([B M+MS/)G!ZXD!#,"NF\15B2,(;]7&C/O8ANG]4WX(+8Y"$,YG!#6=S+KCE:+99 MR8"DW6%::LWETEM]45(W"V-FN('O-Q0 KBWFYL<^P16;WGXVKO[.3<%2' 54 M8"[[&"1OWW0&T:&ULS9K;;N,V$(9?A5 7Q2ZPC0X^Q$YM YN(BP9(BB!I MMA=%+VB9MHF51)>D[ 3HPY>4%4JG5A>_+9$DS(L_XBN;ZR9R+C"A]*Q:^7 E*9J51EOI1$/3]C+#< MFXS*S^[$9,0+E;*=C[TMX@:.>,2A;?&-T(W>ND1G*E//OYN9Z-O8"TR.: MTD09!-'_UO2*IJDAZ7[\54&]^IW&S)1(>L73W]E,+P$,S M.B=%JN[YYA=:#:CL8,)36?Y%FZIMX*&DD(IGE;'N0<;R[7_R5#EBQR"*WC"( M*H/H4(-.9= YU*!;&70/->A5!N70_>W82\?%1)')2/ -$J:UIIF+TONEM?87 MR\U$>5!"/V7:3DV^$B;0-Y(6%-U2(@M!]2Q0$OV$'M@B9W.6D%RAQYQ/)15K M,DTINLY7A6[!F[ =X^L@UY&.ZDA');?[!O>&KFF*.FU> M=AH:J;J0*Y+0L:>UR$P#ZDU^_"'L!S^W^1H2%D/",!#,\GZG]GZGI'?>76>? MT1LY;ZZ):?S.DU\L]30HA]%(J6_W*M= M/[]NU1N$^ZWBUZWZ_3#::X5?MSKO]?N#NI4UY%X]Y)YSR'>"3YL)JP5?%DE" M9:MT.TG'SD!(6 P)PT P*QS].AS]DQ*5/F1((6$Q) P#P:R0GMNL#*: MK>MI:Q<&.RLZ..M&>Q+BI!_K54@8!H)97AW47ATXO1J;O0]?F:UM.?<%710I M45P\ZSUU2O4N.V]WNA-[[(R'A,60, P$LV(SK&,S/"D1&T*&%!(60\(P$,P* M:1@T664 MC>J4-;F2.]G]C='[C<>ZVM0&H:BV=[>R>'#=[9EC NFGK6NK4UM M9LV+9$E%HVVM;GN\SMI:- XTTP:E82B:[>PFV0[=V?:[&H?^1F^EI_J1H_KE?O'1 MZP62%H/2,!3-#F%3/ A[IR6$H"4(4%H,2L-0-#NP31DB=*;$CJ2U,@Q#*VL- M^]U]X0.M!H#2,!3-=FY3$ C=%8%#A"]F,N&%_A[27T#T';6#3.JO0&DQ* U# MT>RX-26'<'!::@=:JP"EQ: T#$6S ]O4*T)G[NQ2NV&KVD6=?;4#+1N TC 4 MS?Z-LBD<1.["P2W+659D1M,.J=G]ZTV?NQM'_^8)6IL I6$HFAW0IC81A28*W9; RW/NI(MS?\[GY1_L6]JC ?U%9B)K* M0N2N+-R2I_]'!4&/"8#28E :AJ+9 6VJ%U'WM%00M*8!2HM!:1B*9@>VJ6E$ M[A,1#A7LM:G@\'Q?!4'+"J T#$7;^M;?.:5H#J'>$K%@N40IG6M\<':NWR:V MYSJW-XJORH.+4ZX4S\K+)24S*DP#_7S.N7JY,6&PO=V]R:W-H965T&<6+=#$(O7JK&,@#/XU+WXK;].T\OZY7*S*]R>W M577W[O2TG-^FRZ1\F]^EJ_IOKO-BF53UM\7-:7E7I,G59J/EXC08#":GRR1; MG5R<;W[VN;@XS]?5(ENEGPNO7"^72?'MQW21?WU_XI\\_N"7[.:V:GYP>G%^ ME]RD7]+JU[O/1?W=Z4ZYRI;IJLSRE5>DU^]//OCOS/2LV6#SB+]EZ=?RR==> M?Y;\XVZ>G\R:/8H7:3SJB&2^H_[]&.Z6#12O1__V*(GNS&;#9]^_:C' MFX.O#^8R*=./^>+OV55U^_YD=N)=I=?)>E']DG^5Z?: QHTWSQ?EYK_>U^UC M!R?>?%U6^7*[<;T'RVSU\&?RS^TOXLD&P=D+&P3;#8+G&_@O;##<;C!\ML%P M\L(&H^T&HT-'&&\W&!^ZP62[P>3Y!L$+&TRW&TP/W6"VW6!VZ 9GVPW.#CT& M?_#X?VYPZ!C^[G_VPY/NX5FR>8J%295;Y^EF^_J9E:V: M2'VIBOIOLWJ[ZB).LL+[6[)8I]ZG-"G715KGI2J]-]Z'JZNL>=8G"T^M'K+; M9."[,*V2;%%^[_W)RU;>7V_S=9FLKLKSTZK>G08]G6^'_O@P=/#"T+[W*5]5 MMZ47K:[2JX[M0_?V0\?VI_6O8?>["!Y_%S\&3O##^N:M-QC]X 6#P/=^_1)Z MW_WI>Z^\38JT\_ .T(;^5GM1"=W*IZ38*WK7X<,5Q@,*MA.E\=X#!XP%V,/+PWY.+48?OC>]@]&M[\^T0Q;@5 MG:P>=\:?=3/6\WRXR_QPXPY?S?P/WH>R3.NXUPGV?LJ2RVQ19SXM'_\MN/+J MQ/^2SM=%D:UN-H_Z2[XJ=C_X,2FSTON?G^H!/%6ER_)_.X[RQX>]&77O33-G M>%?>)?/T_4D]*2C3XCX]N?C/__ G@__J"AV)A206D5A,8H+$)(DI$M,D9B#, M"NAH%]"12[_X6,>K/@M[R7U]IDTN%^F;^OS[IJS_L??*)GN;C'8ES;XJLZNTV%SH=27&Z?1-#(F%D[W$3/8C0XX8DY@@,4EB MBL0TB1D(LR(SW45FZHQ,?1'T9KZ=I-6IJ>IKH>V7[@ YU;X!(K%PNC<_&\XF M>PDBAXQ)3.SO_]CWG^^_)(=4)*9)S$"8%8W9+AHS][5+OKI/BRJKKUJ\55YU M7Z5I;K9#5/O?S: M._"4VIE(M+>!:N%6\X,GJ&'5EI0+42U"-5B5!.H)E%-H9K>:M8' M*@;#T?Z%WK^CM>*WM17?^:9[<[ZZ;.>1]6FJ7,_G:77V_9),#BJJ[@ ;;"@6HAJ$:K%J"903:*:0C6-:H;2 M[+"V/9? W7/Y^V:ACSJ)23V_3&Y2[VYWFOSVRDG2+??.'=IIV6I-/>C)M=HH M>':EA@X:HYI -8EJ"M4TJAE*LP/5EE4"Y_OK%V%ZGR[RN^7F0]/U":U(;]:+ MI,J+;]XR6Z1EE:^Z+]O<;N\XH:T35(M0+48U@6H2U12J:50SE&:GKFV=!,>U MCDB %E)0+42U"-5B5!.H)E%-H9I&-4-I=EC;UDKP:FOEX(^INJG>04-;*\%^ MPV'D[W_6&QTT1C6!:A+5%*II5#.49B>H+:T$[M+*3\TDTQMV!@8MH*!:B&H1 MJL6H)E!-HII"-8UJAM+L7+4%E."X"B@!6D!!M1#5(E2+44V@FD0UA6H:U0RE MV6%M"RB!NX#2:QJ)]DI0+0SV%PP9=2Q(APX:HYK8:D\7/1K/]M<\Z3C2R:2> M,=L/4QT/FXXGDYG],(T>@J$T^\G<%CP"=\%C.Z/S?O<^9:MLN5[67QWT4F+] MN#[O;+MWHW<0T'((JD6H%J.:0#6):@K5-*H92K-#VE9(@N-:^B1 :RBH%J): MA&HQJ@E4DZBF4$VCFJ$T>V'QMH8R="^"\B^\L^V6^^8.U<*M]NR=;7_T;+:( M#AJCFD UB6H*U32J&4JS ]5618;NJLC#%#7H# Q:!4&U$-4B5(M13:":1#6% M:AK5#*79N6H;(\/C6MYDB!9-4"U$M0C58E03J"913:&:1C5#:798G]ROQKV\ M29\7'=U4[Z"QMYL9[K\4M__6-3IFC&IBJSU]S7&Z]Z$3V7&#!#M;:":>'WW)3J@0C6- M:H;2[$"T98PA5\9P4[TC@98QAOM-AJXR!CIHC&JBXQ"ZRACHH K5-*H92K.C MT58[ANYJQTO76<$?O\Y"2QRH%J):A&HQJ@E4DZBF4$VCFJ$T.XYMB6-X7"6. M(5KB0+40U2)4BU%-H)I$-85J&M4,I=DWGVY+'"-WB>/PZRPWU#=FJ!9NM5?N M"8J.&:.:Z#B"CA?;T3$5JFE4,Y1FQZ*M8HS<58P^5UMNJGOR=">!ZH)5).HIE!-HYJA M-#M";<]CY%Z[PS51/?QF-']PHHIV/E M1+4(U6)4$Z@F44VAFD8U0VEV<-O. MQ^BX%@<9HK6/VCH%HX MVB]SU#. X?Y$%2VDH)I -8EJ"M4TJAE*LR/4]E9&[M[*S]5M6C0GKN:TU;S5 M\.1,UQDCM)6":B&J1:@6HYI -8EJ"M4TJAE*L\/6ME)&Q]5*&:&M%%0+42U" MM1C5!*I)5%.HIE'-4)H5UG';2AE3K10WU#=FJ!:.]SL=P[V:<(2.&:.:0#6) M:@K5-*H92K/CT[97QN[VRH?YO%BGULGM!^_CPR2S,T1H@P750E2+4"U&-8%J M$M44JFE4,Y1FAZWMQ8R/:W61,=J%0;40U2)4BU%-H)I$-85J&M4,I=EA;;LP M8_?J(CTFEFB+!=7"\?YB&ET32[2=@FH"U22J*533J&8HS8Y/VTX9N]LI'Q8W M2;I*_[LS,&@;!=5"5(M0+48U@6H2U12J:50SE&8'J^VLC(]K;9(QVE-!M1#5 M(E2+44V@FD0UA6H:U0REV6%M>RIC]]HD7VZ3FO6RLFQ>9%G?U8'^WW[56<'_9CN%D-IM,[0EBB(X:H5J,:@+5 M)*HI5-.H9BC-#EK;,1F[.R:?\FK=G1>T4()J(:I%J!:CFD UB6H*U32J&4JS M4]763L:SXYIKHK455 M1+4*U&-4$JDE44ZBF4H<+K9ET'(0_]4?!LV.(#SU8 M@>Z>1#6%:AK5#*59B9BTW9")NQO"7WU-]GL:X^%H-IX&S^+AWK.^\4"U"-5B M5!.H)E%-H9I&-4-I=M+:&LG$72/YG%=UCK)DX=TEW_)UY=VEQ;S^27*3=L8( M;9&@6KC59D\B/G@[?O:&&3IDC&H"U22J*533J&8HS8Y06PZ9N!=-^?R0F,WM MT)+%"ZR4W:$\#U02J2513J*91S5":G9NVIS%Q]S3^LEY>ID43 MF[OUY2*;+[YY5UDY7^1E/>>[*[*\:&XR6*3W6?K5N\_7\^:3-)N$U3.]U6;C MGZ^_O)@XM-N!:N%D_ZXKP^=Y0XL=J"903:*:0C6-:H;2[+RUQ8Z)N]C19[V[ M+66UC\:#Y_6CC^X1>\<";7"@6HQJ M4DJBE4TZAF*,U.4-O@F+A7'=F\5U6? M?+ZD=8"NO&2URN[3HDR*S;UPFS-7\XKY55)U7SNA?0Q4"U$M0K48U02J2513 MJ*91S5":';VVCS$YKG5#)FA; ]5"5(M0+48U@6H2U12J:50SE&:'M>UT3-R= M#N0-+?<8O1.XOP2(/QN-AL^NNT)TU C58E03J"913:&:1C5#:7:VVF;'Q+V@ MR.,<-,Z*LNH]!45K&J@6HEJ$:C&J"523J*903:.:H30[>6U-8W)F<@J*C M1J@6HYI -8EJ"M4TJAE*L[/5=D:F[L[(XQ3TK[=9T?M54+?=.U-H@P35(E2+ M44V@FD0UA6H:U0REV@J*WT$&U&-4$JDE44ZBF4@#W?]&'8FAVP>?$2U$-4B5(M13:":1#6%:AK5#*79^6J;+M/C6JMDBG9C M4"U$M0C58E03J"913:&:1C5#:798VV[,U+U629]BIYOJ'32TU[+5GI9.?7__ M%M_HH#&J"523J*903:.:H30[06UA97K (B3U=-)UMXY79IMH6P750E2+4"U& M-8%J$M44JFE4,Y1FQZ_MM$R/:[62*5J#0;40U2)4BU%-H)I$-85J&M4,I=EA M;6LP4_=J)77>WCR>'N=]9IYHG075PJUF?=QI-MF?>:(]%503J"913:&:1C5# M:0]I.BUOT[0*DRJY.%^FQ4WZ,5TLRCHEUG3;_W8?@Y'3O MYZ'_+O:;GY^VS,7Y77*3?DJ*FVQ5>HOTNB8';YN+SR*[N=U]4^5W[T_\$^\R MKZI\N?GR-DWJ:#8/J/_^.L^KQV^: ;[FQ6^;W;[X?U!+ P04 " #1.Z16 M(LC^7= # *#P &0 'AL+W=OLW.K42MWF)P%Z@%3@5KO2]E2UV]V'TSV89 !K'9NS'=C^]V)P9[;CX*=< "OW**)-C9ZW4YL9U9;*&#,MKO@&FGRRY MR+#24[%RY48 3@NGC+J!Y\5NA@ES)J-B[5Y,1CQ7E#"X%TCF68;%\Q0HWXT= MW]DO/)#56ID%=S+:X!4\@GK:W L]EL,0Y50]\]QFJ@'H&+^%4%K]H5]EZ#DIRJ7A6.6L& M&6'E/_Y5"7'DH'&Z'8+*(7CI$)UP""N'L BT9%:$-<<*3T:"[Y PUAK-# IM M"F\=#6'F-3XJH9\2[:* ML)5^9(:2I"!P\1J^$KP@E"@"$EW,06%"Y:7V?GJ!%? .BVL4^EZ!A4Y8ZQ\6>-$)O*^P!8J"+F&LCN9XW\@-3F#LZ/,K06S!F?S^ MFQ][?W1%=2:P1HQ1'6-4H(>OYM@5^DM7ICD(LL7F^*);*?7"Q3Z+GB_W69@B MG5P/D.1"Z+Q#4RR)O$)/C"\,.[R@@+ZP3:Z,#6>)=B[S\>\'3BG2)WR'1?I/ MEZS1.64]$UA#UEXM:\^:.HV#>(46L"*,&;$6F&*60%?P)6)<()H*OYWT(\\; MN=OCH-I&?C0,_=JJP3:NV<96MK=I2@S1SAI0NO:.=GS)R6;1X-.O^?3MZJVQ MKF>F.AW2LXM:O[7Q1S]H2=9A%7C]$Q0'-<6!E>(]?BZ*<1>MP:N*V2P:=(8U MG>%[\@U8^DJR#5L,XK9R;2,_&,0GDLWW#M>:]X:ZVE7@IW;/]U: 1Q.O<&?BOI.\SZO3@>G,CZP\>$;_^: ML!;9RM=6,ZPF34Z'R]^W7H)O+K053*.&#L*V=!UFPUYT2KK#9>K;;U-;L:U< MKF;[\RWUUP*[SCFSL:#MH2MLWB6%]J+_BZ1UU%!F)5-%L2)3QG MJOS>KE?KANZV:&->K$]-HU=T*P>8LDO47]/Z4$E$8:DAO>N^UD^4C5&PO=V]R:W-H965T4( :KB7%NG\UM5R7HB)\Q;/C.&"DI]Y0^ MJ,EE,#$LQ0@2\(6"P/*RACDDB4*2//Z6H$;U3)6X.]ZB?];BI9A[S&%.DU]Q M(**),310 "N<)^*6;KY"*:BO\'R:#IF=(.8BI9H:J!KH[.EFIBH;5P* M)N_&,D],;Q@-8!'QL"LE3/%CEO5W-5X[BMXBYCC M,&00%B6DJVV5T>\K&8HN!:3\3U/="MQ>,ZYZX\]XAGV8&/*5YL#68$S?O[,] MZU.3Z([ :B7H527HM:%7MF.5[0B()L4%C*=AU%_2>NKU';LW-M>[4EY&]5W; M&E11-8[]BF._E>/=LHE0:\ZA6] 16$V>5\GSWLB%7I5[D3+:0 M2'[8)54NU&[)/BT)&JFV0AVZ/UVAU84[S\*=-W)I"=Q5&3I"JY?AN76Q6]N" M WSJOO@F.Z.1O6_3EU&VUQOMN=3V<<^ZY=N[UI)+J26\ M#'G.N=!39V-,<>&Z.MU 3O6I+$#@EY54.34X56M7%PIH5I-R[@:>%[LY9<)) M)O7:G4HFLC2<";A31)=Y3M7+%7!931W?>5VX9^N-L0MN,BGH&A9@'HH[A3.W M4\E8#D(S*8B"U=2Y]"]FL<77@!\,*MT;$YO)4LHG.[G-IHYG#0&'U%@%BJ\M MS(!S*X0V?K>:3A?2$OOC5_7K.G?,94DUS"1_9)G93)TSAV2PHB4W][*Z@3:? MR.JEDNOZ2:H&.T9P6FHC\Y:,#G(FFC=];O>A1_!''Q""EA#\*R%L"6&=:..L M3FM.#4TF2E9$632JV4&]-S4;LV'"GN+"*/S*D&>26[$%8:1Z(2=D@;](5G(@ MN 8M66$W;<-? M->&##\)_I>J4A/XQ";P@'*#/]M/GD';T8)?NXD9TNQ%TNQ'4>N%?=V/.=,JE M+A60GY=+;13^;[^&\FL$1\."M@8O=$%3F#I89!K4%ISD\R<_]KX,9?N?Q'9R M#[O[T]8BLX8>*D4#(%/>BN$8CZ<3T_CM^X&T %H]@;=A=U[J*][JZ98%B!&5E+ M.5P$T?NP<71^]L;< ,H+_/&PN;@S%^\UUROD;V"&S,7O3FSLA[VPC;GWJ/C\ MW!;=CCFWUXGL+8#UO69"$PXKY'FG8\Q.-9VUF1A9U,UI*0VVNGJXPQ9DRB'W&4B)O>6LK-=;\O%FL6^^(]W[!$?;/D:>Q+=9FN^F*3,C_(G>*H M3P8#NQ_[8=*;3O)[#^ETPK'>RXW'<+66V8W^ M=++Q5^PSDU\V#ZFZZA0CW_W*#A.R,KP%CT3^%^WVMK;50XNMD#P^.*L( MXC#9__=_'(@XU ^RU1]&RH_.;U+I)^LPJ>(B7?H=_5@^DF M/G$>[,(H0F]<)OTP$F_1%?KRV45O7KU%KU"8H#_6?"N4J9CTI8HBP^HO#B/> M[D3]\CBM\A,B!4$\^\O3O1 MN+MF=Y>W=L((,6^:0Y'CV!5Z0NRV.97#03@DF!W% L(BZV*4-?9T]" MIFJA_J/+X7Z4H7Z4;/>Z%AM_P6YZ:GL2+'UFO>GK7[ ]^*!+ "28"PGF 8%5 M4C4L4C4TH1\M/>3OL\.$#-7>QP*T%6RYC5 4+IDN.V9@3-!/YJ>ZM3DW>G9- M!228!P162855I,(R,C:+>2K#?_W\W<67:H>KI>;D\K[= ]LY#"8 M])^/63>.WI5U2# /"*S"NEVP;@.PKMO2;_? EIEUX^A=68<$\X# *JP[!>L. M .M#'>M.&]:-HW=E'1+, P*KL#XJ6!\!L&[I6!^U8=TX>E?6(<$\(+ *Z^." M]3$ Z[:.]7$;UHVC=V4=$LP# JNPC@>EJ!@8>7^I0K7J8-!@%E,;XSJWYB&Z MDGM L\^,ZD&-6B7N2(UA8_G^,4Q"R:XB)9YUY?O71ZY*>Z60=WX::.OV SY0 MX0Z*YH*B>5!HU4R1,E.D9?6N-I%5RH5>"AM!.J<#$LT]H!TO1'OD6'9]19#& MRG'H:# NS*H$ED(5&\75=!8$8;8OZWFCC=@:^P-MQ%4S<V+B&_<*F_\!D!MOB^#5/UIID]WOTV^WONH%5J6N5%;$J =:U0 'B,IJ ML*ECU^EKF@TQ(4Z=/E"Y X56I:^4.\0L=XI2X>[!4".80;IN=:!H+BB:!X56 M34:BI&, M[?IOH=Y9LRJ!I7@C9\[F3#4":>JL>HUPWL0U1]#Y@;N$J".EJ"/M3]6TE#7/ MSAJ4G35QS4%TINP2BHN4BHN8C\1:U0;-PR_-*IBW,W/- 76F[Q(RB)0RB)AE MT,/L\0[%H6)/\H3IURFH!@)%N,#"#=&[$ CU3HYHS-LY8UE FPJM MOE&?-W'-$71N-;N$@*.E@*-G!-R9LH V3X.N+%PGK861:PZD,VV7$%KTJ)W2 M?$K5IC2@S9,H;&&GSIW&RL'C.GFP[8V@VJ=_U&8[WW%Y)O\F;F M)RXEC_./:^8'+,T,U/=+SN7+139 T7$__0]02P,$% @ T3ND5ML5+4;0 M!0 ]"@ !D !X;"]W;W)K&ULM9IM;Z,X$,>_ MBI5;G5JINX -).FED;8/JUVIO:NVMW"L;9I6N@]_AE <)\19 M*O.F!>+Y,S/,P _CR9KQ[V))B 3/69J+B\%2RM6YYXG9DF18?& KDJM?YHQG M6*I=OO#$BA.<5$99ZD'?C[T,TWPPG53'[OETP@J9TIS<L2!7+/V;)G)Y,1@-0$+FN$CE5[;^3.J HE)OQE)1_07KS=@( M#<"L$))EM;'R(*/YYC]^KA.Q9:!TV@U@;0!W#<(#!J@VJ#+G;3RKPKK&$D\G MG*T!+T7D9'R17OU)E)Z>?Z#-)P$2%0+GB9AX4IVYM/=F]5DN-V>!!\Z"P!W+Y5* MFSPAB6GO*8\;M^&KVY?0*GB'^0> @C, ?8A:_+FRFU^366,.+>Z@)HNHTD,' M].ZYZBLN7\[ ?8IS"526P,V/@JY4P4OPSZT:#KY(DHE_VW*WT0[;MY(S$A#V*0AM*G7Q83K8EIP)EIK92,25R+E M;>9I&OCJ,H83[VD[DOUAXVB,XF:4X6+4N!A97;PE0IRKF\>LR(H42^5N0E0F M9A27=Y4V;S=ZT98;[T,_'HYVO&T9AL9A&+6[&S?NQATRFA/9YF&\EZAH'$7Q MCH/QGH-1'(Z#=O^&C7]#>SKQ(R"OA=[FF]6\:VT[$C,B'361CGIL\9'+-#@2 M,](P;M(PME[P&R%I5O7--T'F10INZ9R DQ>"N3AMB]PN-P2595N45L,W1AGX M^K'HN[B5U2K&O6PT'L&=WJN';3=?$(<^:F^^8.OA'=B]+'A.9<%)58YS^EQN MMSMJ%>I:@:[4S+"A#AOVV(NUN*M4.%(S4Z'!([ ^T+OWXQ$]2T/:+=\:J6:+ MP EZTNFL5 M[%R,CM3,\#6L!'&??6E%H=$HTK-3,1FFF"<9]UZXA4ZE3TP3U06*W?&NDFIV@G9V.5S]^/E3]=NFNE]R5FID(35.P3YJ"3FG* ME9J9"DU3T#%-'=&++-7?!TU!35/03E-_S.=T1NSO[G:)SI?6D9H9L$8S&/59 MY4XQS96:F0J-:= ^J=2]RNUZEG<&N^5;(]44!IU0&-RGL-%XA\'@/H-MC3'] MTP0&[01VA_-BCF?JK9WFBR/-Z!2X7*F9<6O@@GT"%W0*7*[4S \'&KB08^ Z MHF=I1KOE6R/5P(6.3%;]7#/6*L:4&D*[L]GU*&-Z:4$.:A9 5,*:W! NR M9&D":+;B[(F4!=GNIE/N<:5FAKWU^:K7[U=N/V#U 49(@Q%R,LV$]J>9T- / M=R=^T?X\DQH6'7AU1YIFT+'/6&UU:G]EMTMVODQ], S2#(/ZG&I"3J>:7*F9 MJ="0@^R0T_T)8M>#EB=('U_@D,8E9,>EPU5_^%7=+MGY4O?!34AS$^J3FY!3 M;G*E9JXTT-P4.N:F(WJ!?[CL[:9O#56#4WALIBH7DA>;=4\T!ZKT%^H\[6LK MG,Y,N5(S ]&PO=V]R:W-H965TPITBNBH* MIMZN0^X5[_KPQ]H*_F&W9,SR >=K>*3SSNR@K7D"IN2R)@O7/A\7OT+[5X%+-D&FZD^)NOS&;N33RR@C6KA+F7N]^@%50#YE+H^I?L&MLT M]DA>:2.+UAD)"EXV_^RU3<2! QUR"%N'\%R'J'6(:J$-62WKEAFVF"FY(\I: M8S1[4.>F]D8UO+2/\<$HO,O1SRRN\EQ5L")_<+;D@AL.FGR\!<.XT)_(+^3I MX99\_/")?""\)(\;66E6KO3,-[BVC>#G[3K7S3KAP#I?F;H@$?U,PB",'.XW MX^ZWD'?NX;&[CXH[V6$G.ZSC10/Q[M@;6PK4BFI(G0,F-/GG:JF-PLKZUR6P MB1B[(]K7[5)O60YS#]\G#>H%O,7//]$T^-4E]W\*=B0^ZL1'8]'M,Y=5:339 M-EFHDR#-!A2^54TY8)M0S/#RF< K=@P-SD?>+)/6R]A^\;)(TC0+9O[+H52' M51"GM+,ZTA!W&N(?::A!<[S!*TCA)W;1) M1YN<1;M5<@W:MD!D78.;,^D1T$D8AR><#JLX#B(W9]IQIF=Q&L@W35K;0L"& M.Y;:M >39E%\0MPWBJ(X<0-G'7!V7AG(PM(UI+:I*=ET;>*PB .W/23CGYR%KV2;TR8MQJ\X-B6C"RA>SU=T)-^PFF:G##W MC>*,#B!/.^3I68-^/4#HZI#KV+\HBDZO')R3FQ;)2&G"C-UH:;>@C\G :GU;P@-E MEZ/[ 4C')^ MK$$I9+=ISF5I)YTEQD/-5^\=;ZUD0:XKC\4UMW>< MBB)'0XZ"TW)WF059,%3P^W%(Q^?AGT?C6^QWCL*FDV#H"? 83<)\0TYD> ?;)_MMPON59]YJ8F M-3H&%QG&442^EP?UY?;C!3RA0U@#OKZ4T[R=VD]Y]E"W^ U!+ M P04 " #1.Z16PQ)D8$X# !?#P &0 'AL+W=O&6$2&]Y(M]TR;T13$9(8;AGB:11A M]C*!D&['AFWL&N[(:BU4@^F-$KR">Q /R2V3-;-@69 (8DYHC!@LQ\:5/?1M M#= C'@EL^5X9*2ES2I]4Y7HQ-BPU(P@A$(H"R\\&IA"&BDG.XW=.:A0Q%7"_ MO&/_JL5+,7/,84K#'V0AUF/CTD +6.(T%'=T^PUR05W%%]"0ZU^TS<9V70,% M*1636*W[O6"RETB<\&Y FL;1!?J.&<-J#="Y#P*3 MD'^2K0_W/CH_^X3.$(G1C(2A7"L^,H6,K/!FD$>99%&<(U%<-*.Q6'/T)5[ MH@+OU^-MIX; E)(+WY4Z:F'^Q <@Y?4 MN,4JNIK//;J*G .TD%[-%O*!!XPD^F#]O)%CT;6 B/^J6KB,N%--K&Z=(4]P M &-#7BL(&<'S$%"8.1I0+JK< MRU@&FD5=L1O/:MLC<[-ORAO&^+6S^4^MW4)KMU:KWC1:80LM4Y$R0$S=EA=T M>9'*'BSW5J7X[E_".DZ[>Z"^-O:I6Z(BHM7N%Q%+\GN%_%ZM_!F)291&50)K M@:>>C2;)_(;(2H;U"\/Z[W79])LTM$DROR&RDJ&7A:&7M3OP#M0#C<2K[+9! M ECE=JQGL=$+8%9E5"WN5*,:(BL9-2B,&M0?5?Q\[*C6 D_=64V2^0V1E0RS MK=?GG?5>AS5G;LC31MG\IMC*KNX]FNU&3NP_:&Q+GUF.9"'2[]M*YVI)3G:N M(;;,.7,O\XB K70&Q^5C(HU%]A@O6HLL\4KG1@?M$WLXS7*]5YHL]91/[16) MN71Z*2GEW[U\!+ LF\LJ@B8ZOYE3(;,E75S+#!B8&B#[EY2*744%*')J[P]0 M2P,$% @ T3ND5AG B%J6 @ J@8 !D !X;"]W;W)K&ULM57?3]LP$/Y7K Q-(%'RJZ6,I9%H&6+2T!",[6':@YM<$PO' MSFRG9?_]SDZ:E5*J/6POR=F^[[O[+KY+LI+J49< ACQ57.B)5QI3G_N^SDJH MJ#Z1-0@\64A548-+5?BZ5D!S!ZJX'P7!J5]1)KPT<7NW*DUD8S@3<*N(;JJ* MJE]3X'(U\4)OO7''BM+8#3]-:EK /9B'^E;ARN]9L,F5LE[^)A/O, F!!PR8QDHOI8P \XM$:;QL^/T^I 6N&FO MV:^<=M0RIQIFDG]CN2DGWIE'ELW/NIC3-F;T2LR8W$AA2DT^B!SRYW@?\^]%1&L1 MTV@OX0U5)R0.CTD41/&.?&9_#X_VI!/W-8T=7[ROIL=DAJ4DWR_FVBB\K#]V MU:GE&>[FL0U\KFN:P<3##M6@EN"E;]^$I\'[72+_$=DSR<->\G ?>WK%!!49 M$&6[9B 7@T8#H5H#7B8YQQLD(+>W!IZRDHH"",X?PFV=\)BS@MJ>WGF5VKBG M+JX=2I%O.!Z%6Z)> M.L7#<$N3O]'V%:C"34.-+=P(TS9/O]L/W LW9[;VISB(V[GYAZ:=XM@:!1,: MA2V0,C@98UZJG8SMPLC:#9>Y-#BJG%GBSP24=<#SA91FO; !^M]3^AM02P,$ M% @ T3ND5G)OC)W/ @ JPH !D !X;"]W;W)K&ULK59M;YLP$/XK%JNF5FK+.TDZ@K0FFE:IDZJFW3Y,^^# ):""S6R3 M=/]^MJ&,5!2U'5_ QO<\ON?N;"[<4_; 4P"!'HN<\+F1"E%>F":/4R@P/Z)J-J^? M31V\"U[B&.:&/%DQ N-L*=X?8M?!3E*N$"YGP/JTU M0: )U)VPBVS;=>SI-#1W71E]=H[O^%9K=^"AUWKH#7JXH&0'3&1K69N$"N@M MMD&*M^9C)+(#M7ZKUA^U$/TQA8]$=B \:(4'@VG6U\TUQ:1/90WU.Z4UF0:> MYSZKP#XS/W#L_@*(3%[G7Y_9R_Y-6_^F[X_<(/2M]3$2V8'*6:MR M-NK!F(TI?"2R ^&V]>\';;T_P0VV>^VZGC_Q_&>UUV?GS@)G]JSXS$XGH=HX M^:/>9H2C'#82:)U/9/FRNC.J)X*6NKE84R%;%3U,93<)3!G(]0V5EW8S4?U* MVY]&?P%02P,$% @ T3ND5L,A*5LY#P ><, !D !X;"]W;W)K&ULO9U=<]LV&D;_"D;;W4EG&DO\$J6L[9G:!-#LI(W' M2;H7.WO!2)#%B42J)&77._WQ2TJT((C4:\%^VEXTMD(<4.(3 #P"P/.'+/]6 MS)4JV>_+15I<].9EN7K7[Q>3N5K&Q5FV4FGU-[,L7\9E]6M^UR]6N8JGFT++ M1=\=#(;]99RDO5YMBX72:IN[F M9?U"__)\%=^I3ZK\LKK)J]_Z.\HT6:JT2+*4Y6IVT?O1>2?'@[K YHA?$_50 M[/W,ZK?R-E+?9PT^J>4-!S9MDBV+S?_;0 M'#OHL,,C!;RF@'=8(#Q2 MP&\*^(>GY!\I$#0%@E/?P[ I,#RU0-@4"#<7:_OI;BY-%)?QY7F>/;"\/KJB MU3]LKN^F='5%DK2.XJKGS_-L7<3IM#COE]4YU*3^I*GO:EN?>Z0^A_V< MI>6\8#R=JFE'>4Z7]XCR_>J][SX ]^D#N'))X,=)><8\YP?F#ER7??D4L3?? M?=]Q7MJ=_F/OSG#P3^[LH*$14@81\($$B9!,",L_BXL M/D6_O(F3Z=LD??LM2:=5 U>JJHJ23>)54L:+Y'^=#=45B;1-#!(6(6%\"QMN M8/7 YOXR\(/A>?]^/PGM@P;F$1)T3L;E#7:7-R O[^ L#/[.)EEZK_(R^;I0 MK%!IDN4LSZL6EZHK)R3(-B=;F./M MM[UG V\0#L>NV09'S:'^WJ%>U3:V#N3($Q1(F 3!C"L\VEWA$:(;87^P#^I> M+9A;_71=W5@])ND=^S5>5'__![M5DW6>UZ]4=]!)YQT4>1:V\4#"(B2,(V$" M"9,@F!&R\2YD8VB?,T:&!0F+D#".A DD3()@1EB<@=8W [)-NC[2&G6:&1)E MFQ4H+8+2>$,+]F]:AIXW.+@I$=!:)8IF1F'/Y#ED%)R3NJ>@,QDDV3H92%H$ MI7$H34!I$D4S\^/J_+C0GJ?!H4*#I$50&H?2!)0F430S--JR.J27L[GKH4G6 M>?$Z[WO<(/!&_L%]S].Q^S<^;G#6/I)#SU% :1)%,Z^T5J0.[4A/[%Y>??=# MGX9U3*!B%4KC4)J TB2*9H9-"ULGP/9%4$\+I450&H?2!)0F430S--K6.J3? ML[L7@KI:*"V"TGA#V[\7CFYFN\B--)]_W/N/4EN1<,!H<-\35=J748H!JV MH07/O [KY5Y\4Q;J^9M6]35%/<5NG\3*KAA%'IGTT MR/V3<8)6=WI-UVQ[%:$T#J4)*$VB:&8BM$1U:8EZT _\P&Y4/JD[A(^SZN5F M8M!-_!A7@\S.=&SQ(\-*!(?9@ I2*(U#:0)*DRB:F0TM2%W2I6VS4=9-_9LD M9I-G$Z6F!9OE MV9(MJJ% YVUG0S%Z,L\?M7L/Z Q2*(U#:0)*DRB:F0+M2%W:D1Z[[=S[]>.] MRM-Z?003U= QG=0N]#8N%7OSZ:.X[6Y.H$842HN@- ZE"2A-HFAFM+01=;%& MU(4:42@M@M(XE":@-(FBF:'11M2EC>ANQ'KL.[FFO.,>?HMVV!]!!2>4QJ$T M :5)%,V\_EJ#NB_3H*?W1]61O\9Y4M_N;%^^SI:K+*U;H,\/66>DH#H52HN@ M- ZE"2A-HFAF\+1.=;$ZU87J5"@M@M(XE":@-(FBF:'1.M6E=>KSO=6XL[<* MPU9W!56H4!J'T@24)E$T<\6FUK'>Z9-9CWYS2S-LFPHH+8+2.)0FH#2)HIE) MT9K6=X JE15 :A]($E"91-#,TVM]ZM'>UF1]"HZP# Y6Z#F2A",ZTS M@=TDH"V6'7\P;F<"NP$ =@> /T/>>EK>>K2\Y;.9VFR,HW< .#80I4G62?"[ MA[6#L?'?P:3F8Z6&AU<@-=YD?[!7[!5 UV:="JAR MA=(XE":@-(FBF9G2RM7#[AG@02>B0FD1E,:A- &E213-#(WVM![M:>TFDM$P MZ\B$K9%#$ :M*5T1M%8.I0DH3:)H9ABT._7H;08^KC:;])496ZWSR3PN%(NG MTZ1^L4K(T<$IU* VM/UY?IV9@*I1*$U :1)%,S.AU:A'J]&73%2DD=:):,_\ M=(*PG0BH*_7:$S\=IU6I@%8J431S)S(M07U:@OZB2K9J9A-U75:ZN.UE]=NS M68-@W%HI'T%KY5":@-(DBF9>?FTV?7H":L>"VE6>5/_HZSF'TVRQB/."K52^ MW?ZQ_GZ6W ORBJ[..BY;6KBOGMS#^:T1M$X.I0DH3:)H9EBTT?1Q1I-&60>A MPT&&U<&M=@,Z 15*$U":1-',*&BCZ3]G-.N-I^O9&].DF&3KZM:S&1W$F^%D MU60DV733BCRJJ@WIG&E(UV&=$:CAA-+X,Y]FL/V0F-O,U&9.O>UN9XB@"A1% M,T.TMPTJK4!?(<3JU?ZZR_J\G27?'3*H/(72(BB-0VD"2I,HFIDTK5Y]['16 M'^I6H;0(2N-0FH#2)(IFAD:[59^>SOIY7E'GV6+*RCR>;OJZ^+%NH[K;YBL: M9QV:]D+ZUL 7*DRA- &E213-3((6IOXS$UMW2:@ZID)-UIOO[4Y,!52?-C0R M%5!S"J4)*$VB:&8JM#GU:7.J4[%J5FUF,U:4V>1;A-7(H34!I$D4S8Z'U;D + MR=<,;6FT=2R\CJ&M(=TC-T7Z-H:+1M+(;M MYURU1C#0&CF4)J TB:*9L= 2=WBJQ+57-#3:.A;M36B=,^\P%U"C"Z4)*$VB M:&8NM-$=GCY)]VED^XIGM=&U64<%NC,!E,:A- &E213-S)36P4,/.H0=0A4P ME!9!:1Q*$U":1-',T&A7/*1=L=TJ4QIF'1FH\FUH^ZL/_(['$'!HK0)*DRB: M&08M5":BKA=(DBF9F0KO:(>UJ7[+*E$9: M)P*Z?\&P+7@=O_6H#MX<9JPR;6W)+J"G)E$T\TIKVSJD;>MSBTSIXM97%>I) MA^T-"WPO:%TP#JU50&D213,OOS:@0WJB[*UZ:O2G]2JQ==K=V$.]9T/;OVRN MV[&G +16#J4)*$VB:&8(M-$SC,^=P[S1H MI0)*DRB:F19M.T/:=MHL/:=1UDEPVAW)P/-;#0>T5@ZE"2A-HFAF%+3@#&G! M"5EZ3M=AG1&HUH32^#.?IK/YD-AXM_+[HU"T)[(>V--HZ%E"MV]#( ME>P<6J6 TB2*9N9"&]O17VMLCPQMZ;.PCA#4V4)I'$H34)I$T+':YDY] :!90F430S"EKQ MCD[=AN %B@:J>Z&T:-2>#-P>P4 E+I0F430C%F,M<<>G2EQ[14.C;6,!I44- MC5S)SJ%5"BA-HFC;7/2+N5)E%)?QY?E2Y7?J6BT6!=O,N:S'''NOLES-JMPX M[WYT>_W6ZU?.N\CI>)T[[\3F];[&7YZOXCOU&PO=V]R:W-H965T\Y/B>Y_ABMI;K72P!#'@HN]-A9&E.>NZ[.EE!0 M?29+$#@REZJ@!D.U<'6I@.8UJ.!NX'FQ6U FG'14]UVK="0KPYF :T5T5114 M_;X +M=CQW<>.V[88FELAYN.2KJ 6S!WY;7"R.U8]M<)6/'<\* @Z9L0P4'RN8 .>6"&7\:CF=;DH+W&P_ MLE_6WM'+C&J82/Z=Y68Y=A*'Y#"G%3Y,SZ^U/'WH<^JP=L;#?>RU\1/"I5B<&E!%G]>&(*X)[%:P M2GT_#/PD&;FK31M]>4$41%Z7MZ5PT"D<[%4XD6(%RK 9!R*D@=YBVTOQK]_C M0&1;;J/.;7300HP.:?Q 9%O&X\YXO/@=UW\)31!G<6)A8D>TT! M-.311O$EGOWMU.B+:5O:AYWVX8N+B#"M*RK01":UT2>D$K20*/L/Y'V"AT^4 M^&$4#7?T]F0-PN'[?KE))S?YWS6?/%G+PR0>#,(=>7UI41SX._K&ULK5==;]HP%/TK5E9-K52:D"^@@T@KT;1*G5J5MGN8]F"2 M"UAU;&8[I=VOGYVD&= TH@@>B.W<!7 +]PII12^!!C MA:.AX"LD3+1F,XW"S *MY1-F7OM$"7V7:)R*8I@JU$$3/9W2G +B,S3&0KP0 M-D:*Q_^]VT/TD1L=')^@($8;N%CR7 MF*5R:"N=JGF@G51I791IN>^D]0.+,^1U3Y'KN%X#?-P.CR&IX6X#/&Z'7R?J M/;BM_:U-=FN3W8+/:S/YDDDE';I;D9MJ&H5ROJM2JZP23M$-9Y)"S5>Y(";9I""5X2A2GY M"VF3L-Z;C'6-Z&[)>AOD=\.M>A.W)K?GR^S7TON[U4M$I,R+;3OA4LE3E#.< M<:'>D]]_HZS3]?J]<,N IC _\+;"XM8D][1@4%LPV'_+&.RV932$-6T9K8E\ M5*:]=J SIV]]'-+K4B(*,TWOG/6TZZ(\T98=Q9?%&6_*E3XQ%LV%_@@ 80+T M_1GGZK5CCHWU9T7T#U!+ P04 " #1.Z168KVVX7H" "^!@ &0 'AL M+W=OJT9 M5W.OTKJ9^;[**ZB)NA8-<+-3"ED3;:9R[:M& BE<4LU\' 2Q7Q/*O2QU:TN9 MI:+5C')82J3:NB;R[0:8V,Z]T-LO/-!UI>V"GZ4-6<,CZ.=F*S'W FL(&.3:*A#SV, M,&:% MC(T_.TVO1]K$P_%>_<[5;FI9$06W@OVBA:[FWL1#!92D9?I!;.]A5T]D]7+! ME/M%VRXV-L%YJ[2H=\G&04UY]R2ONW,X2,#X1 +>)6#GNP,YEPNB299*L472 M1ALU.W"ENFQCCG+[ISQJ:7:IR=/9 E8:?49WK6XEH*6D/*<-8>@!&O)F#E\K M)$KDHBX7H EEZ@I=(,K14R5:17BA4E\;(U;.SW?0FPZ*3T!_$'F-1N$GA ,\ M0L^/"W1YSDQL-R]C[,5$-RF'OFA5<@-^!EG=X[9D>]V=%[ZIFM?0KL"TVE*#'()/CN!1&PO=V]R:W-H965T G8 MW'M\CGWMZYO)CO%?8@T@T4.:4#&UUE)NSFU;1&M(B3AC&Z#JRY+QE$C5Y"M; M;#B0A7%*$]MU'-].24RM<&+Z;GDX89E,8@JW'(DL30E_O(2$[:86MO8==_%J M+76''4XV9 7W(+]N;KEJV27*(DZ!BIA1Q&$YM2[P^0P'VL%8?(MA)X[>D98R M9^R7;MPLII:C&4$"D=001#VV,(,DT4B*Q^\"U"K'U(['[WOT:R->B9D3 3.6 M?(\7&L&*0QS9_D MH9B((P>%T^[@%@YNW6'PA(-7.'A&:,[,R+HBDH03SG:(:VN%IE_,W!AOI2:F M>AGO)5=?8^4GPRN82_0.W5 )'(1$'QY4@ A KZ] DC@1;]3'K_=7Z/7+-^@E MBBGZLF:9('0A)K94XVL4.RK&NLS'BU\9J>[NQUTO'(N/8/G=T)K")\4 H?=*&'%RGC M,OY#S,9D2[6-U$3$0F2$1H B)F1KM.2@O@'5Q\TVQ($[F-C;8UU-HY%>K&T+ MW6%)=]A)]WY'-BJ4BXB/:<12:..7HPR/AGX7>#5Z31NGG9Q?DO,[R7UADB3% M#.XI0KXIVSCZC?'QV!N-:RR;5NYH-&PG&I1$@TZBUS$URYN .D5/XAHT6/BX MOMQ-FX'CMQ,=E41')\SH*01'S6ER'*>^Y$TKSQWC=H[CDN.XD^.,T2VH/31/ M .ECI(U=)\)SCXN>P"IBL7-(.DZO)V4!UY/VOM"JXH\R+CYYKIC^RZK*WCVP=[MW$_ 4?6*$MC+K]'WV.O6$5E5ZR.:XWW2. M>\WG?:%5Q1\R.NY.Z?\?I(-F9G+&&->CM&GV1 +%A_2.N_/['7LDB7Q$%RL. MH)>N_:[:"?+LY>H)K2KY<&G ?K^QVGD)>;;XGM"JX@\7$=Q]$_G_6 T:E\Q! MX->O)BU6]5"UCPJQ%/C*U*="\L@2],Y5?KO]2UL2GP#C!Y8:V* MEE5,A;IV+16DS>M:U?? M8'ZOF1,[AMZ@/(? M@_ O4$L#!!0 ( -$[I%;F6YZ?;00 ,87 9 >&PO=V]R:W-H965T M#ME55 M]8-)#A!M$F=M!V:D_?%K)R$A;/#.4/,%DN#SVH]]'+^<\9:RSWP-(-!3'"5\ M8JV%2"]MF_MKB GOT!02^T@0Q6$ZLJ7MYC7LJ(&_Q5PA;OG>-%,J"TL_J9A9,+$>-""+PA9(@\FL# MUQ!%2DF.XTLI:E5]JL#]ZYWZ70XO81:$PS6-_@X#L9Y80PL%L"19)![I]CRHG8"Y Z[0&X#,"' ;TC =TR MH)N#%B/+L6Z((-Z8T2UBJK544Q?YW.31DB9,U#+.!9._AC).>(_TF43B&=V% M"4G\,%FAZ8H!R(42Z!#NRH&AX\,SD7W-!%KCFZ3 ()FO"U! M*UJ\H[W"6L$_?=%!7?<]P@[&+>.YUH?/(>T@IPCO:X;3K2:_F^MUC^C=P$+( MB>6"9?F$__M1-D S 3'_KVVV"K5>NYK:\)<\)3Y,++FC.; -6-[//[D#Y]!=[3J5=9)Q,YC+.XC;404-M&*JB7T<9S.\.QO=EGT/9R(D._8NAK M&>Z/CUT;^-IU,B368!Q4C .C"3HP"6Y(K %^48%?_-\$O6A+T-%!@FI[.9%A M6#$,M0S3Q]GOTW^N;]&'B"[D&_P/:0KF)(+6%[%6ZK4K9TBL03VJJ$=&4W9D M$MR06 /<=>JCW'E1TJ; ?(DN75CKD5N(#/?RMM?I'^2MOJ=32?9,B7M:ZJ*O M:)XM.'S)U-K>;N1G*Z-6_K6K:DJM.1FXG@QL-*-+.5/PAM2:\+5#O:*KEZKS0'/V,0(+6>K1"& M3% )<0Y+Y=:>RAV:35JCQLJ46A.^ME:NUL!X#XSZ %'2T9CQ,H47NY*!ZW\ MA>)@WR7WG4.W<0[?A&O?A/6^:98(D+H"I>0YKV"T@90:?2V(OJ-306K;A/6V MZ4Y*(Q+3K/WT**-_@' .LX-KLX.U?L+["$D 3&88R$.1) $*0)Z3\)3*L[/] MGTLI.-JCZGY7*-#W>BI5[6*PWL7<+I>0URM1N,LU1D3K*[]4WBWB'1 M.>HWN#8S6&]F?O J0&17#GR/$FC/QMYWZ^;V!AU\R&G4I-A[E=(8V"HO('/D MJRU3%$VKIU61>IJ79NVZ>5'AOB=L%28<1;"4H>H@M1 KBL;%C:!I7G==4"%H MG%^N@Y&=5"5[KUO4$L#!!0 ( -$[I%;(J3D,I , ($/ M 9 >&PO=V]R:W-H965TQCV0$O7%E&*]$C*CH?]^)*40G\I;.,F+[9(\1Z> M>]HS<4760(H]%!1)L=!J=3R,@QE7D*%Y3E? M-OYEQ46.FA6(1R*0 7 MUJBB81)%65AAPH+)R,[=BLF(UXH2!K<"R;JJL-A< ^7K<1 'CQ-W9%$J,Q%. M1DN\@'M0GY:W0H]"AU*0"I@DG"$!\W%P%5].X[XQL"L^$UC+G6=DI,PX_V(& MOQ?C(#*,@$*N# 36?RN8 J4&2?/XMP4-W)[&,$A;@]0*;9A963=8X@,*'R MG;;\='^#WKYYA]X@PM"?):\E9H4)%_ C%N&GG-# MSX?NW#!W;L [83B#!6',S,XPU>^ARQ?-!IG=P"2OU23N#:.X/PI7NRJ]/$Y4 MV7?A0/#JE[29P8,T,G<>B5> ]Y+:! -S!3Z'^7?UV6Z P; M+^1S\\(+@>VIOW#J+UXQ/5Z\I!M>"&S/#7&TO::CUTZ0[0[];V5(/Y-3E>X4 M)/%W*16P J:+CB7>/!GG+=1^ZHD'AX*\&YXJ*-D*2IXK",]H]R=*CO2<)5DT M/!3DW?!40=N2)?:6 B=<8RW@7NBEA]>8?]=356TKD-A?@CSKRFNQ]@(O.SY) MKU%LQ-MJ(_:7&S]Z.\;'A47G]>BG\5R9X4XS4X%8V!Y/ZMBJF6K*?#?K^L@K MVST=S%^;_M(V25N8ICG51;S.EQ)1F&O(Z'R@!8BFWVL&BB]MRS3C2C=@]K'4 M/3((LT"_GW.N'@=F ]=U3[X"4$L#!!0 ( -$[I%:R&D*'H L *68 9 M >&PO=V]R:W-H965TM'IA0QKT$1(1%KLDW[Z2D(@%N0%)4]RD6#,_E8B M[PN+'A!7KVGV-5\((7@T$^78AEF/?3E4B*WSRGV3*4Q8_9 M?)"O,A'.JD'+>& .AZ/!,HR2WLU5==U#=G.5KF4<)>(A(_EZN0RS[Q]%G+Y> M]XS>]HK/T7PARRL&-U>K<"X>A?RR>LB*GP8[918M19)':4(R\7S=NS4N V=8 M#JAN\4 M;LYRX/[EK>Y5.U_LS%.8B[LT_G M_4U>Z]L.>V2ZSF6ZK <76[",DLV_X9_U';$WP+#?& \S# X)P[PZ@>,#IWP+@>,#YWP$4]X.+< 9-ZP.3< <9P^S]7E>1@ M\U]>U8L;RO#F*DM?25;>OO#*"U715>.+,HF2LC\>95;\-BK&R9O'19B)11K/ M1);_C=!OZTA^)[^3?X99%I:52]ZY0H91G+\OKOWRZ))WO[TGOY$!R,;?WS$=3"]ZNYWTRM#\0'>^_K1#N\7382ZR%]&[^>M?C-'P[VTEBL1<)$:1F(?$?"3& MD!A'8@$(4UK"WK6$K=-O[M+ELE@;Y65#?"#A6B[2+/J?F&V?5-X5SR2;B^_; M6D2+=VT1).8B,8K$/"3F(S&&Q/@&U0[[0^.@M$_<2*GJT:ZJ1QVJ.LKS]=D/UUJX:SDC,1>)423F(3$?B3$D MQD='#\*&-;+-B6F,#FJZ[9;.R+'&UAN%/=X5]KA#8:=KF5#%R!D] M).:W;/ZX?UC'R!DY$@M F%+'QK Y]#[45W(FBD?GK%Q('QT).;'JT,M=*QJJ MN5"-0C4/JOE0C4$U7FN.\NS8?B@$-;':!GL)E-&M#7[DF(E^CLX-@=1!RZEE!BW=N J3F0C4*U3RH MYD,U!M5XK>T_*QP]&X F5#N@24L-;?+T9@?L'YDYU0;0#!6JN5"-0C4/JOE0 MC4$U7FO:-O@5 :G1)*2&/B*]3^6Z]:6L?ESGXH;&GU"-0C4/JOE0C4$U#M4" ME*;V01.F&@[RW3,&-#N%:BY4HU#-@VH^5&-0C4.U *6IW=&$LL;YJ>QVH53/ M,R//:=8<&CVU9(*&M%#-A6H4JGE0S8=J#*IQXSB!G=C#D6&8APLGT+1J2S1Q MKJ'/, ML6&;!_O@G;NS/G3S&%3C4"U :6KI-EFMH0]K[])$%B]O12+)-$WR:";*]^"G M26NI'N>'EG-8I="T%:I1J.9!-1^J,:C&H5J TM2";Y)<0Q_EUH_5>1I7C]3I M]LT*IQZFH7$N5'.A&JTUY;'; M!O*(CPD-?J&:"]4H5/.@F@_5&%3C4"U :6IW- &QJ0^(84=\]/-T[IOC7-%Q MCM]JXD)GI5#-@VH^5&-0C4.U *6I'=$$QJ8^,/Z9 SYZNG,3'*>*3LO[K5SH MK!2J>5#-AVH,JG&H%J TM0F:N-C4Q\5\^ZA?K)NF^T\1Y5/"TSHO;EXLJKIT M!C1FKK73G0$-D*&:!]5\J,:@&H=J 4I3.Z,)D,U3'\<]_Z"JGNI<]-#T&*I1 MJ.9!-1^J,:C&:VW_L/OA.TA1$ZKUWD3"ICX2?E@_Q=&T?O&\_?A7:[%#(U^H MYD(U"M4\J.9#-0;5.%0+4)K:%TTN;(ZAAY6@G^N%:BY4HU#-@VH^5&-0C4.U M *6IW=%$SZ8^>O[!)$ZO=NX2:%Y=:^J'JLV&TO79BT'DY M5 M0FEK=3-@W#LL;FB)#M0"EJ><7;%)D2Y\B?WH1V>^W M<9S*\H/QY-/JK=>W>J=K)4,U%ZI1J.9!-1^J,:C&H5J TM2^:))D"YHD6] D M&:JY4(U"-0^J^5"-034.U0*4IG9'DR1;^B3Y!Y?\>K5SET _8PS5*%3SH)IO M'>?M[:\*H--RJ!:@-+4!]L[+K ^.;_]U3QZR=)Z%R]9"QYZ)&7LJ9NRYF+$G M8\:>C1E[.F;L^9BQ)V3^%0FRU23(E@U=+$'S8:CF0C4*U3RHYD,U!M4X5 M0 MFMH=38ILZ5-DP'D4]3-T[AAHN S5*%3SH)H/U1A4X];QB9O-47]T<# O0$VJ MMD(3,%OZ@/GG#J;J\J4:CF M034?JK%:4\_R>_ 2G4.G#%":VAA-D&SI@^3/HOQ2OKW3IU?'EU)E^=1:_= D M&:JY4(U"-0^J^5"-035>:TI.:#C]PU.IHR95Z[^)FBU]U'R7)B\BD]%3+,A, M/$F2B^DZBV0D6L_FI=(@\R MV="\&JJY4(U"-0^J^5"-034.U0*4IG9'DU?;^A-APS[;J9^G<]] DVRH1J&: M!]5\J,:@&J\UY>1/EFU=V-;1]^3]BI3:;E)J^\0)L1^_M"Z<],,ZES@TAH9J M%*IY4,V':@RJ<:@6H#2U#9JLVH9^B; -S:ZAF@O5*%3SH)H/U1A4XU M0&EJ M=^Q]G; V_0,NG*"I-E1SH1J%:AY4\Z$:@VJ\UO873J.Q<7P65-2L:D;5] M_I<0D[1Z0WC[,@H:2D,U%ZI1J.9!-1^J,:C&H5J TM2V:+)K>P1=1D'#:JCF M0C4*U3RHYD,U!M4X5 M0FMH=3:AM=PBU?VH9!8VRH9H+U2A4\Z":#]485.-V MRTG*)X;C.(=GM@U0\ZH]T>39MC[/_I*\B%P6]5_@,HNFG MH&DV5'.A&H5J'E3SH1J#:ARJ!2A-;9(F]+8GT&45-/2&:BY4HU#-@VH^5&-0 MC4.U *4IW>$TH;>C_W@V;%FEGZ=KWT U%ZI1J.9!-1^J,:C&G;8O?7;&H\G! MVXX#U+2;EACD"R&D&\KPYFHILKFX$W&FKW! MT?5WQJ5KM%Q/C4M673]H^)NK53@7]V$VCY*X'F:ZN M>T://*52ILOJXD*$,Y&5-RA^_YRF\+AYL' 74@ &0 'AL+W=O=7D67SWGQO5P)(N%;O%Q)?:$_NUSSI;@3\GX]+]19?TN)XE1D99QGI!"/ M5[UKYR+T/!U0W?%7+)[+G6.BW\I#GG_7)Y^CJ]Y ET@D8B$U@JL_3^)6)(DF MJ7+\TT![VYPZS ,OQ6V>_!U'L;EYL2IFG3; J01IG]5_^H_D@=@(<[YT MPEPCPWPF@#O MV(!A$S \-F#4!(SV T;O!(R;@/%^P/"=@$D3,#FV2-,F8%H]W?IQ5,_2YY+/ M+HO\F13Z;D73!Y4@JFCU".-,:_=.%NK56,7)V9W,%]\_W:BG'Y';/%7_$B6O M1/6)?.5%P;6RR =?2!XGY>_JZOV=3S[\^OME7ZKLFM%?-)E8GUT1/M'1P\Z MHND1T2,=[4R[/LA#T<49\>HW[G6$!\>'=WUNX1%E'U=E/[<\1&^K/Z_">2?J MKZ-@-S5IV$W2E?Q%N>8+<=53M7@IBB?1F_WVBS,>_-&E#B3,1\(H$L:0L ) M"T$P0W7#K>J&-OKLDZR5^$ M*,F'."/EBJNB=%5]-]9TITH3"?.1,(J$L1HVJF"ZB_4T&TZ'WKFJ3Y]V18?, M&8)@ANA&6]&-K*)3U5NJ&E9#<%U:LE).U1(2YB-A% EC2%B A(4@F*&X\59Q M8UCC.D:J#@GSD3"*A#$D+$#"0A#,4-UDJ[J)M9Z[SPJQR)=9_*^2W6)W3"%^ MZ&.AQKP);UK93?8D2GU\L%JT)CU5H$B8CX11)(S5L/%.$^LXX]% _^RULLBT M(0AFJ&^Z5=_4JKX_FYY%":#Z51*(U!:0&4%J)HIOQVYHF=G]"K M4Q4CX<^\B#JK1WO*DV6*I/E0&H726$/;[==Y(Z^K6P?-&Z)HI@3=5H*N58)S M451F7;80MH&"G7*RJI T'TJC4!J#T@(H+4313.6U)H6#2Y')F"?U>("L^8NJSCJ%!;4BH#0?2J-0&FMHTUUA[2L*:C*@:*:B6IO! ML?L,UTF2+ZH19]4.?GJHNF='5U]0/P%*\Z$T"J4QYZVG\*;>.GA+B"J3*9W6 M(W#L)H%>O$0^JW%D5JUOFR>\NRL/=0:@-!]*HU :@]("*"U$T4SEM3:"5.. Q[P@<5ENJNFV Z-->]93E0JE^5 :A=(8E!9 :6%#VQT)>WO# M%%.$K97@VJV$KYOT011:A#R*8EW[J5%!K:Y= 1[2G/.V?(..8=2MO30GR^EM MVF'7Z(U"TS(H+8#20A3-E%-K"[AV6Z"IT_@3CQ/^D(BJYJH6\AZ4$-0I@-)\ M*(U"::RA&9-DP]%D>KXW$(!F#5$T4V:M!^!:)WF[Q@P?R9U8Y%E$KE.117HY M>:?*H(8 E.9#:11*8U!: *6%*)JIQ=80<(>P480+=0*@-!]*HU :@]("*"U$ MT4SYM7Z!:_<+0!TXJ('0T(PV:3)ZVR_SH6DIE,:@M !*"U$T4W.M?^#:_0/] M74E"[^;S3BE!+0,HS8?2*)3&H+0 2@M1-%-OK;O@3G!-+-1+@-)\*(U":0Q* M"Z"T$$4SY=HA!TP906HBBF2)LS0K7 M_J4'4#\/:F- :3Z41AN:H3FW4W-0AP)*"U$T+-4X=9/)>O>V[=7M[H;7U9Y^>]>9Q2V MF'K+Q"^\6,9921+QJ)"#LXF26E'O0EB?R'Q=[6GWD$N9I]7A2O!(%/H&]?IC MGLO7$YU@NQ?D[#]02P,$% @ T3ND5F>YO@<, P 3@L !D !X;"]W M;W)K&ULM59=;YLP%/TK%JNF5FJ!0#Z[!*E)-VT/ ME:I&V9X=N E6#6:VDW3_?M>&T"2CT2K1%_#'/8=S[(M]QSLAGU4*H,E+QG,U M<5*MBUO/4W$*&56N*"#'F960&=78E6M/%1)H8D$9]P+?[WL99;D3C>W8HXS& M8J,YR^%1$K7),BK_3(&+W<3I./N!)[9.M1GPHG%!US 'O2@>)?:\FB5A&>2* MB9Q(6$V6"/%E>1I*3EX0W)('D2N4T6^Y@DDQW@/[==K$.S78!J< M)7R@TB5AYYH$?A VZ)G]/SPX(R>LMR2T?.$[MZ1II4JF;C.3.0)N54%CF#CX MCRN06W"BSY\Z??]+D\V6R(Y,=VO3W7/LT1WG(J8FK51*)=PLK?WX,"/AQ;2A M:1E*[I'E-@?7-NKTW>[8VQ[::P@*W&$=="2[5\ONG96-OP-0&:97KO7K5$=F2Z7YONMY:@_39-MT1V9'I0FQY\8(*6W.82J)-OX(Y. M$K0AJ.?VFQ-T6,L>GI4]QPN2Y>MKLH8<).4V46F"-PG#@YR:.[1)[UG2]VY; M2V1'_D>U_U%KN3IJTW1+9$>F._[KK>Y_8+96Y(='Y=#MG61K0]# #4ZRU3NH M3#*0:UNP*12RR75Y0=>C=5%X9TNAD_&I*19MQ?-*4U::>/VN&18:'%9(Z;L# M_']D6;R5'2T*6_\LA<9JRC93+'A!F@"<7PFA]QWS@;J$COX"4$L#!!0 ( M -$[I%:3EB1/H@( $H' 9 >&PO=V]R:W-H965TQ#>P%_W'-\SH5['>V$?% Y@":/9<'5U,FUKBY=5R4YE%2=BPHX[F1" MEE3C5*Y=54F@J065A>M[7NB6E'$GCNS:4L:1V.B"<5A*HC9E2>7W&11B-W5& MSG[AEJUS;1;<.*KH&NY WU=+B3.W94E9"5PQP8F$;.IB,$0HXUO#Z;1'&F!WO&=_;[VCEQ55 M,!?%9Y;J?.I<."2%C&X*?2MV'Z#Q,S%\B2B4?9)='3O!X&2CM"@;,"HH&:_? M]+')0P> //T OP'XQX#Q,X"@ 036:*W,VEI03>-(BAV1)AK9S,#FQJ+1#>/F M*]YIB;L,<3J^YHDH@7RDCZ#(R0(T984Z):_)_=V"G+P\C5R-IYA8-VD89S6C M_PQC0&X$U[DB[W@*Z2'>176M1'\O<>8/$MY0>4Z"T1GQ/3_HT3/_<[@_("=H M,Q98ON"W&2,+II)"J(T$\N5JI;3$G_)K7\9JQG$_HRG42U71!*8.5J("N04G M?O5B%'IO^^S^)[(#\^/6_'B(/5Y*L66V@K&!$%:G0IN?I\]VS15:+M-.MO'X M(O \+W*W74-/PX*+23?L0.JDE3H9E+J #*2$U,@C*^"0,=TGLF:9=$X_UC=X MSC\F/&Q=A(,N[KF$1*PY^W'H1)UA]C7@@9I0GA+LZK30#(N8)HG<'!=>;35\ MDNACJX-B_M:JVVE+)\VX(@5D2.F=O\%O)>O.74^TJ&SS6PF-K=0.<[SL0)H W,^$T/N).:"]/N.? M4$L#!!0 ( -$[I%9[R+D5; ( -<% 9 >&PO=V]R:W-H965TBF;D*(E\2^ON?<#_N>\4Z;.ULC.KB70ME)4CO77*2I+6N4 MS/9T@XI.5MI(YFAKUJEM#+(J@*1(LWY_E$K&55*,@^W:%&.]<8(KO#9@-U(R M\VN*0N\FR2#9&Q9\73MO2(MQP]9X@^ZVN3:T2SN6BDM4EFL%!E>3Y')P,1MZ M_^#PE>/.'JS!5[+4^LYO/E>3I.\30H&E\PR,?ENB-+XV7(F74@//%SO MV3^&VJF6);,XT^(;KUP]2=XF4.&*;81;Z-TG;.MYX_E*+6SXPB[ZGH\2*#?6 M:=F"*0/)5?RS^[8/!P#B.0[(6D#V&#!\ I"W@#P4&C,+9")[#%86K+7Q0 M%58/\2D5TE63[:N99L\27C'3@WSP"K)^EA_)9_;W\.R9=/*NN7G@R_^IN7-N M2Z'MQB!\OUQ:9^A)_SC6Q!AD>#R('_,+V[ 2)PG-L46SQ:1X^6(PZK\_UH'_ M1/:@'\.N'\/GV(L%=0+PGA3((I0U,VNLP&D@3?*/[(DW%#G?!4XO2MLBZ]'M M; ^KBCZC0Y_.(Z::'LR(1(KLI<-"J3?*Q0?663MUN@Q#^<@^)=6*(O.')DH> M/9\U5Q8$KHBRWSNGF3=11N+&Z29,XE([FNNPK$EYT7@'.E]I[?8;'Z#3\N(W M4$L#!!0 ( -$[I%;)*VC8PP@ $!I 9 >&PO=V]R:W-H965T(O%#-"-+4H^)$T")!$/4S2+0;/M%ECL M!<=F;*&RY(IRT@'ZXZM3+-.1Z:AXTUYT8L5\*-EO1(F?95T^I]FO9J5U3GY? MQXFY&JSR?',Q')KY2J^5.4LW.BE^\YAF:Y47#[/ET&PRK195HW4\I*/19+A6 M43*XOJR6?)_IP1LUVO5?;U5L?I\]7 &[PL^#%:KO)RP?#ZL;/D7XV>S^3MY7A*J^.=)W^DX+J5B/7YKT,&NS[+A_L\O.J\VOMB8+\KH MNS3^;[3(5U>#V8 L]*/:QOF/Z;/4S0:-2V^>QJ;Z/WENGCL:D/G6Y.FZ:5RL MP3I*ZG_5[\T+L=> GA]I0)L&]*"!-SO2P&\:^ <-@F.K%#0-@K NCI,SN0YX5OXV*=OGUS?RW;62B,D>&_(O\6V69*M-$/H0Z5U%L/EX. M\Z*?\MG#>6.&M4F/F!ZY3Y-\90A+%GK1T9Z[V_N.]L-B^W8;25\V\I8ZP9OM M\HR,@F\)'5&/_/00D@_??"1FI3)M.E;OSJW=JZ^$OF +];6+"-W$]RHY([Y7 M&?YNA;XAPV:ECJ\;>\.6-K#7"^9N^$%O"GA4P?2X(MZN>,<5>>H-R%Z_>HZ8 M^+N_!;]R_2/N[=842XPA>W\4Y'\_%,O(IUROS?\[5O6V)H-NLAQY+LQ&S?75 MH!A:C,Z>].#ZG__P)J/ONH*'Q$(DQI 81V("B4D09L4OV,4O<.G7=\4N6,^W MU=XWS]0B2I;E[H5L=!:E"_+'L7W-K9/M&\$:&U=8>>#S=!V,+X=/^\%"]L>0 M&$=B HE)$&8%:[P+UM@9K/LTWQJBD@6YB9=*)_J7KA0YC;XI0F(A$F-(C",Q M@<0D"+/R-MGE;8(?1R?(^"&Q$(DQ),:1F$!B$H19\9ONXC=U[NYNELM,+U6N MR9.*M[HK;$Z@;]B06(C$6(U-]L9R;S(>C\K_["&=([L52$R","M)LUV29J<' MSJ[\.)OUS0\2"Y$80V(ZGFAR)BM7I"HG$UN@_BA>%S/TGPLSC^/SM?<-GWLGS72 MV>S;.O3)]TP;5&%3C'2^)-_4">O"*B+>^=!*U>G9.]N:)O5.S$WF4 M+'62DWF:F&BARXGB-.F,@_?JP,.O#SM&AWEP=MH[#TB-034.U014DRC-CA9M MHT5[[(*VFV+'LXYB;?*T& 75?!7I)[TN@F?>OC^BK_ZHQGXP&T_I8?Z<:]8[ M?TB-034.U014DRC-SE\[[>\YIW7K_)%-%LTUV9HB@GE*YBJ>;^/R)+*,I?H2 MZY<*2IG!11K'*C/EU&R]N(QC6V7IC"2T4 #50JC&&FVZ/Z)-SSSOX)03VJF M:A*EV8%L"P&>NQ)03]C^07B4F9RH)(F>=&94]I6DCV0>IZ8N#>2=@L"'S_<"2&UA&@FD1I=N+:4H+GKB6\C,0/NCCI M7?0>BJ%U!J@60C4&U3A4$U!-HC0[D&U%PIN]PU ,K5= M1"J,:C&H9J :A*E MV3ELRQ:>6P+(M3#C\04.6]_!]5"J,:@&H=J JI) ME&;GL*V>T#[5D[\X$KO[Z)U+:%4%JC'ZNC34.1)#>Q503:(T.W%MO82ZZR6N M3Q&[F_8.$K3, =485.-034 UB=+LN+75$!J\PT +K8) M1"J,:C&H9J :A*E MV3ELJR#4?1D%_F,*[@Y[AQ1:(H%JK-'V1UU_,IL=?LB)0WL54$VB-#M^;?&# MNHL?=\JLR$9%A\=XG<&"UCB@6@C56*-9GW'O_(0[M%L!U21*LY/5%CFHN\CQ MMWS^Q;T.O2,)K85 -=9HIS[_ NU40#6)TNQ MD4.ZK[NXF>=Y<7NC=Q&Z;?D M4S(_ZPP4M*@!U4*HQJ :AVH"JDF49N>N+6K0=[@8@T*+&% MA&H,JG&H)J": M1&GVUU"TI0[_;[@FP]U'WUQ"M=!_?=%#UT$;@_;*H9J :A*EV8EKBQG^B:L[ MFOJ9V3L4_(L'>NZ>>N<.6N)HM/U#,V]V-CY,';1T =4$5),HS4Y=6[KPW:6+ M/M<4N:G>L8)6** :@VH-SF=*%&<_@X M] [4-BO M;O([7A@Z[AHAL5_,A/UF)NQ7,[U'%<)OJQ"^[Z9_V5.Y$_,Z M?X#5J2@&JAWW&A1-?EZ@S:+8=J JI)E&8GJRU)^.Z2Q%M&6]H9 M,VB9 :J%4(U!-0[5!%23*,W.8EN-\-_AD@L?6IV :B%48U"-0S4!U21*LW/8 M5B=\]R47O49;:%$"JH7^ZVLAJ-\]W$(+#E!-0#6)TNPO'FX+#H&[X/"6X=;O MRIG;[9LSJ!9"-0;5.%034$VB-#N+;2DB>(?K*@)HT0&JA5"-034.U014DRC- MSF%;G APQ0DWU3M^T.)$\'J2?>+/NH9;:+\WWUBMW1WNY^;ZB8W!\M#[X)Y'&PO=V]R:W-H965T MLFHK4D1#>.X@$=-.H5JDJ:_=AV@>3 M',&J$V>V ZVT'S^_0,94R*1IT_A [,O=<\^]V)?1EHM'N494\)2Q7(Z]M5+% MI>_+>(T9D4U>8*[?K+C(B-);D?JR$$@2:Y0Q/PR"GI\1FGO1R,IN133BI6(T MQUL!LLPR(IZGR/AV[+6\O>".IFME!'XT*DB*"U3WQ:W0.[]"26B&N:0\!X&K ML3=I74Z'1M\J/%#X$AA QC91"(?FQPAHP9($WCVP[3 MJUP:P\/U'OV]C5W'LB029YQ]IHE:C[V!!PFN2,G4'=]^P%T\78,749@Z"N$)"BVXX;E:2WB7 M)YC\:N_K<*J8PGU,T[ 6\)KD36BW+B ,PC;<+Z[@_*P![4H4<+&[FIZ3R7F2Y@S+-,<];-%3\"E;(D2X:@)=P:7N Z< MTWR7M 9\/YH^%YISWK7.S1VPB;J!^8W\S1'2W8ITMY;T)$T%ID0A; @K43,X M.^;<@?0.G+>"L'O:?:]RWZMU/W,I6I@4'?-;:_V']>Q7W/I_OP'[_X#PH"(\ M^'T#0B%HC%!*W8"*0TQ87#)3WZH!78O9ODLX8T1(*% X<>-4 PQ>-,"PKO[# MBO+P?YZ9X8LSTPJ.'1K_X&;/4*1V?DE-ILR5N^0K:34B)VXR_%1W\_6&B)3J M2Y[A2IL&S;[V+MS,6QEJ+LJ)"(WDI M"Z)T5LW*3,Z,B_/WO_:UFJJW>>O9Y\.#D)[\^O]MO/#'#N!T[1RV>(7H2XKL8P MZ617VG0_U4*6>(K1^L]R](0A3'C@\*/MAZTEJ&#DU$T^[9*Q(?5#)'*X'SW$ M'?0C3&17 :/WG/0.UQ"#)A7'P[P4VXR,?=N@E4E!O0?"1_Z$<#:5#%@Y*1A? MV^8>-,Q*7DI/Z:V@0T704O^Q<&1KL$L:G8*)4IK8-H+]G3;=]X!-#0PRSEN# M/=\VC(<548I*<:TKIK-I? 1Y3?EN76F'_2WQ+,10>9EC*CL@T3^9NF M\9#3'.Q(-E_ 5955 *!29:$+&2/S4A#C8<-H"EIV1CF_A5O(SWQ'>Y5WULQD MC6B+VE!3M#*V OI=-:O=E4U>I>M5[*%47Y9Z.,+488O1&TESMC+U5=X:P-0C M7)U4%5]_YFPN"FH'_^R XR'9\+Q%*=D?'0U29:8;J/2]!RH5FW5;?DM2W=&5 MVJ33*L<]]X[0\[^=YSD55!+>-:US_Y!G^=6.X_Y;639WE7W#3H_-N>#035X> M@\GD&$P>04[&Z>%[;,Z#AV[R&&:R_V9W]I>8C([!9.\@30;-F;)S<-TYMK:M M'KP>C/P?\*+!MT&]Z9)QQ4136[ LH^+1Z57+*S+5K]4[^KI_1G.RY.JN!4?^ MMOR=9FQ9I&VO&YB(IM>V_ V&IX_"FW<3'8N)C*YH-FFJ,DP69T,G$ZF&#SEB3PYU;#O $#BP.17C;7^&KC&?)T'F!K^E2& M8"/%,Q$;*3[7@+CG#1AIZEYM+ XPL%7 <@?BN^- 3KDY<0RKBGG#=C".I"F& M0"ZZ'VR7Q'&:NA' W [B&$-@-^((Y@ \8$@-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J. MW&,EC'%BM/XU@LD/['X 4$L#!!0 ( -$[I%95O!2S1@4 !XL / M>&PO=V]R:V)O;VLN>&ULQ9I;3^,X%(#_BM679:7IEN;&# (D%H99))9!%/$Z M,HG;6B1VUW: SJ_?X[1E3J$]NR^'/K5UTN2+;]\Y=HZ>K7M\L/91O#2U\<>] M:0BSP\' EU/52/^'G2D#1\;6-3+ 3S<9^)E3LO)3I4)3#Y+]_6+02&UZ)T>K M:]VX ?YA@RJ#M@8*8\&]5L_^U_'X4SQIKQ]TK\/%@7OE@B[?%8\BY)U\\%U)D ^W$D".>\4^ M7'"LG0_=&=WU)3 ^*3AY\:L-]D+70;ES&=0W9]N9-I-X&7B* 7J,KAY6GXM* M/'3_IQKM>*Q+=6[+ME$F+.K1J3H"&C_5,]\31C;JN'=FGY03-W*BXD/!72ZK MQ0,&($/5Y0XU''"75/ !,",-D9H-B[D0@R M)2#3#X0<18CX!R_L6)S99H8@,P(RVQGD:"H=@LP)R'QW-2G]%$$6!&3!"WDW M55V[2C,7TL1NZ76'>..45P9!'A"0![R0H[9II)MWS:LG1L/?I GBM"QM:X)& MD)\)R,^\D!=2.W$OZU:)OY7TK5LT-X+[0L!]X84#V55M&<2M>E*F5?Z3N%8! M3]O[U+R]SPMW:0 J6#?'0*1(F$UR"28WDWC3145U(^.;M=6SKFL,2X=$ZI!0R9';(%0Q2 MA8?GD'+%D%D6Y^IAK0$I)0R9G7!KY[(.O^":6 A%D!4$^-#HOX*$X7$#L%Z'@*NM\Z)*6%A%D+IR7T,Z^[ MP[J-9)0]$F9[D/&=V,.8E$@2[HSB;82WL2(IE23,*OD5 MU.,2FCI-RI"8E98$Q**RFS5FC, [P&39DE8S;+MFBQ+T9P]0IC4J;)F$VS M'?/[@U=XL3RCW)-QKV=MK\W8!S FY9Z,V3W;,4^K2N,%DHS<(-E1)M,7YVJ\ MWNB4A;*=9#)]L2S'F)2%L@]+999CNZU5G)V6Y1B3LE"VR[QFS>D99:'LX_.: MBHXPR4+:+Q&8#9$[Y)_^8S*8OKJ5S,KXEL)F1DD_.+)]7QN[+)U%: M'[94)26?G%D^73:V/K:OK)GT[Y1K8,;$F)1\R9F]L\2\: ,('*2H(2F? MR1IT.9/S9JU;4M[)F;VSQ 3]*$@>@_CZ$E/RU]Z),2GOY,S>H58W('S#F)1[ M8E'P*9OFLK0N^MSG&)-\,8Y;/&TRT M*!/?;%O#I.13=/(9="?[DZ-*C;51U37ORQHGXL7BC)LOCYOBXK>LS M*/MNKJRL5J^WKE[-/?D74$L#!!0 ( -$[I%;(7,%2( ( - G : M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VCMNVT 4A>&M"%R 1_0"^D0*=(8/!4Q)'CY5Q^((9]^E4,[[KM3W>W[ MNO@X'DYUU>S&L?^14EWORK&M=UU?3N]V5,C:+UW;8EG'5I(_# M]71-EX/W53.\O$F3Y@Y2"-+Y@PR";/X@AR"?/R@@*.8/RA"4YP^Z MAZ#[^8,>(.AA_J!'"'J"8 N!V()D"X'9@F@+ M@=J"; N!VX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK@=XZ>=DFT%M1;R706U%O M)=!;46\ET%M1;R706U%O)=!;46\ET%M1;R70VU!O(]#;4&\CT-M0;R/0VR:; M)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ M[01Z.^KM!'K[9+.;0&]'O9U ;T>]G4!O1[V=0&]'O9U ;T>]G4#O0+V#0.] MO8- [T"]@T#O0+V#0.] O8- [YA\K"30.U#O(- [4.\@T#M0[R#0.U#O(- [ MH]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.^,>F<"O?/D9Q,"O3/JG;]3[SI^ M'DJ]]GRM\?G?2?5XOK=<'W]9?IV_4$L#!!0 ( -$[I%;B M(3)"\0$ !DG 3 6T-O;G1E;G1?5'EP97-=+GAM;,W:RT[#,! %T%^I MLD6-ZR7M+2;-DVNMOGGV+A^7@1J8S&YV&T$ M,I\<]\15X^-1WE"P+Q.&E>\#7L_=/%((34V36QO2M>WR+K9M64S/+<5R?XDO M>G3+95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T^^0'YX]E]@7FG;?!^9@G M%NCW<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S\_4^N; >YQ'9^#C\CC_. M^+W^+_L0('U(D#X42!\:I \#TL&PO=&AE;64O=&AE;64Q+GAM M;%!+ 0(4 Q0 ( -$[I%;A)H.?UP4 -0> 8 " @0T( M !X;"]W;W)K&P & @($:#@ >&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5C"^!J>@ @ :@< !@ M ("!X!0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ T3ND5GY*D1*=!P 3B$ !@ ("!OR8 'AL+W=O*_B1A0L PA 9 " @09C M !X;"]W;W)K&UL4$L! A0#% @ T3ND5ND@ M;XWV @ 5 8 !D ("!PFX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5NL"O-%\ P ^ < !D M ("!-7H 'AL+W=O$7,DD' #0( &0 @('H?0 >&PO M=V]R:W-H965TI[! M (HV 9 " @6B% !X;"]W;W)K&UL4$L! A0#% @ T3ND5FN?-.)(!@ 7@\ !D ("! MBY8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ T3ND5K&PTV;E! "@P !D ("!N*P 'AL+W=O&PO=V]R:W-H965TJ0D %P> 9 " @3JU !X M;"]W;W)K&UL4$L! A0#% @ T3ND5@G&+,&D M&P T%H !D ("!&K\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5AT31@O. @ (@8 !D M ("!*^4 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ T3ND5E05VQU: P X08 !D ("!7>X M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MT3ND5H$4BG!T!0 PP\ !D ("!I?@ 'AL+W=O\! 0!X;"]W M;W)K&UL4$L! A0#% @ T3ND5G.>VO^, @ MKP4 !D ("!) 4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5JZC85CN @ "0P !D M ("!'A ! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ T3ND5CXJ\XHX!P ?T, !D ("!GQL! 'AL M+W=O&PO=V]R:W-H965TTE 0!X;"]W;W)K&UL4$L! A0#% @ T3ND M5K\GP8/1$ ^@\! !D ("!4BL! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5D8&L1"7 @ Z@8 M !D ("!V4,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5@/Q]1 %! H T !D M ("!#U,! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ T3ND5G)OC)W/ @ JPH !D ("!G5T! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5H"/ M07LK P 8@P !D ("!%7,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T3ND5N9;GI]M! QA< !D M ("!&WT! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ T3ND5IWO"X>;!P %U( !D ("! M<9$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ T3ND5GO(N15L @ UP4 !D ("!7Y\! 'AL+W=O6QE+ #P M@ &7L@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#% @ T3ND5LA XML 83 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 240 305 1 false 84 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.insmed.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.insmed.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited Consolidated Statements of Comprehensive Loss (unaudited) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited) Sheet http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited Consolidated Statements of Shareholders' Equity (unaudited) Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Cash Flows (unaudited) Sheet http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - The Company and Basis of Presentation Sheet http://www.insmed.com/role/TheCompanyandBasisofPresentation The Company and Basis of Presentation Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Fair Value Measurements Sheet http://www.insmed.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 0000010 - Disclosure - Product Revenues, Net Sheet http://www.insmed.com/role/ProductRevenuesNet Product Revenues, Net Notes 10 false false R11.htm 0000011 - Disclosure - Inventory Sheet http://www.insmed.com/role/Inventory Inventory Notes 11 false false R12.htm 0000012 - Disclosure - Intangibles, Net and Goodwill Sheet http://www.insmed.com/role/IntangiblesNetandGoodwill Intangibles, Net and Goodwill Notes 12 false false R13.htm 0000013 - Disclosure - Fixed Assets, Net Sheet http://www.insmed.com/role/FixedAssetsNet Fixed Assets, Net Notes 13 false false R14.htm 0000014 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.insmed.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Leases Sheet http://www.insmed.com/role/Leases Leases Notes 15 false false R16.htm 0000016 - Disclosure - Debt Sheet http://www.insmed.com/role/Debt Debt Notes 16 false false R17.htm 0000017 - Disclosure - Royalty Financing Agreement Sheet http://www.insmed.com/role/RoyaltyFinancingAgreement Royalty Financing Agreement Notes 17 false false R18.htm 0000018 - Disclosure - Shareholders' Equity Sheet http://www.insmed.com/role/ShareholdersEquity Shareholders' Equity Notes 18 false false R19.htm 0000019 - Disclosure - Stock-Based Compensation Sheet http://www.insmed.com/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Income Taxes Sheet http://www.insmed.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 0000021 - Disclosure - Commitments and Contingencies Sheet http://www.insmed.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 0000022 - Disclosure - Acquisitions Sheet http://www.insmed.com/role/Acquisitions Acquisitions Notes 22 false false R23.htm 0000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.insmed.com/role/SummaryofSignificantAccountingPolicies 23 false false R24.htm 0000024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.insmed.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 0000025 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.insmed.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.insmed.com/role/FairValueMeasurements 25 false false R26.htm 0000026 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.insmed.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) Tables http://www.insmed.com/role/ProductRevenuesNet 26 false false R27.htm 0000027 - Disclosure - Inventory (Tables) Sheet http://www.insmed.com/role/InventoryTables Inventory (Tables) Tables http://www.insmed.com/role/Inventory 27 false false R28.htm 0000028 - Disclosure - Intangibles, Net and Goodwill (Tables) Sheet http://www.insmed.com/role/IntangiblesNetandGoodwillTables Intangibles, Net and Goodwill (Tables) Tables http://www.insmed.com/role/IntangiblesNetandGoodwill 28 false false R29.htm 0000029 - Disclosure - Fixed Assets, Net (Tables) Sheet http://www.insmed.com/role/FixedAssetsNetTables Fixed Assets, Net (Tables) Tables http://www.insmed.com/role/FixedAssetsNet 29 false false R30.htm 0000030 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.insmed.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables 30 false false R31.htm 0000031 - Disclosure - Leases (Tables) Sheet http://www.insmed.com/role/LeasesTables Leases (Tables) Tables http://www.insmed.com/role/Leases 31 false false R32.htm 0000032 - Disclosure - Debt (Tables) Sheet http://www.insmed.com/role/DebtTables Debt (Tables) Tables http://www.insmed.com/role/Debt 32 false false R33.htm 0000033 - Disclosure - Royalty Financing Agreement (Tables) Sheet http://www.insmed.com/role/RoyaltyFinancingAgreementTables Royalty Financing Agreement (Tables) Tables http://www.insmed.com/role/RoyaltyFinancingAgreement 33 false false R34.htm 0000034 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.insmed.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.insmed.com/role/StockBasedCompensation 34 false false R35.htm 0000035 - Disclosure - Acquisitions (Tables) Sheet http://www.insmed.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.insmed.com/role/Acquisitions 35 false false R36.htm 0000036 - Disclosure - The Company and Basis of Presentation (Details) Sheet http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails The Company and Basis of Presentation (Details) Details http://www.insmed.com/role/TheCompanyandBasisofPresentation 36 false false R37.htm 0000037 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 37 false false R38.htm 0000038 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails Summary of Significant Accounting Policies - Concentration Risk (Details) Details 38 false false R39.htm 0000039 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Details 39 false false R40.htm 0000040 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 40 false false R41.htm 0000041 - Disclosure - Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details) Details 41 false false R42.htm 0000042 - Disclosure - Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details) Details 42 false false R43.htm 0000043 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details) Details 43 false false R44.htm 0000044 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 44 false false R45.htm 0000045 - Disclosure - Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) Sheet http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details) Details 45 false false R46.htm 0000046 - Disclosure - Product Revenues, Net - Product Revenues By Geographic Location (Details) Sheet http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails Product Revenues, Net - Product Revenues By Geographic Location (Details) Details 46 false false R47.htm 0000047 - Disclosure - Inventory - Schedule of Inventory, Current (Details) Sheet http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails Inventory - Schedule of Inventory, Current (Details) Details 47 false false R48.htm 0000048 - Disclosure - Intangibles, Net and Goodwill (Details) Sheet http://www.insmed.com/role/IntangiblesNetandGoodwillDetails Intangibles, Net and Goodwill (Details) Details http://www.insmed.com/role/IntangiblesNetandGoodwillTables 48 false false R49.htm 0000049 - Disclosure - Fixed Assets, Net (Details) Sheet http://www.insmed.com/role/FixedAssetsNetDetails Fixed Assets, Net (Details) Details http://www.insmed.com/role/FixedAssetsNetTables 49 false false R50.htm 0000050 - Disclosure - Accrued Liabilities (Details) Sheet http://www.insmed.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.insmed.com/role/AccruedLiabilitiesTables 50 false false R51.htm 0000051 - Disclosure - Leases - Narrative (Details) Sheet http://www.insmed.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - Leases - Lease, costs (Details) (Details) Sheet http://www.insmed.com/role/LeasesLeasecostsDetailsDetails Leases - Lease, costs (Details) (Details) Details 52 false false R53.htm 0000053 - Disclosure - Debt - Schedule of Long-Term Debt (Details) Sheet http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails Debt - Schedule of Long-Term Debt (Details) Details 53 false false R54.htm 0000054 - Disclosure - Debt - Narrative (Details) Sheet http://www.insmed.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 54 false false R55.htm 0000055 - Disclosure - Debt - Components of Debt (Details) Sheet http://www.insmed.com/role/DebtComponentsofDebtDetails Debt - Components of Debt (Details) Details 55 false false R56.htm 0000056 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details) Sheet http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails Debt - Schedule of Carrying Value of Term Loan Balance (Details) Details 56 false false R57.htm 0000057 - Disclosure - Debt - Future Principal Repayments of Debt (Details) Sheet http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails Debt - Future Principal Repayments of Debt (Details) Details 57 false false R58.htm 0000058 - Disclosure - Debt - Interest Expense (Details) Sheet http://www.insmed.com/role/DebtInterestExpenseDetails Debt - Interest Expense (Details) Details 58 false false R59.htm 0000059 - Disclosure - Royalty Financing Agreement - Additional Information (Details) Sheet http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails Royalty Financing Agreement - Additional Information (Details) Details 59 false false R60.htm 0000060 - Disclosure - Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) Sheet http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details) Details 60 false false R61.htm 0000061 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://www.insmed.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 61 false false R62.htm 0000062 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.insmed.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 62 false false R63.htm 0000063 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) Sheet http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) Details 63 false false R64.htm 0000064 - Disclosure - Income Taxes (Details) Sheet http://www.insmed.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.insmed.com/role/IncomeTaxes 64 false false R65.htm 0000065 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 65 false false R66.htm 0000066 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.insmed.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 66 false false R67.htm 0000067 - Disclosure - Acquisitions - Summary of Consideration Transferred (Details) Sheet http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails Acquisitions - Summary of Consideration Transferred (Details) Details 67 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1 - insm-20230331.htm 4 insm-20230331.htm insm-20230321ex102.htm insm-20230331.xsd insm-20230331_cal.xml insm-20230331_def.xml insm-20230331_lab.xml insm-20230331_pre.xml insm-20230331ex101.htm insm-20230331ex311.htm insm-20230331ex312.htm insm-20230331ex321.htm insm-20230331ex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "insm-20230331.htm": { "axisCustom": 3, "axisStandard": 30, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 686, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 240, "dts": { "calculationLink": { "local": [ "insm-20230331_cal.xml" ] }, "definitionLink": { "local": [ "insm-20230331_def.xml" ] }, "inline": { "local": [ "insm-20230331.htm" ] }, "labelLink": { "local": [ "insm-20230331_lab.xml" ] }, "presentationLink": { "local": [ "insm-20230331_pre.xml" ] }, "schema": { "local": [ "insm-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 525, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 14, "http://xbrl.sec.gov/dei/2022": 5, "total": 19 }, "keyCustom": 32, "keyStandard": 273, "memberCustom": 36, "memberStandard": 43, "nsprefix": "insm", "nsuri": "http://www.insmed.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.insmed.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Product Revenues, Net", "menuCat": "Notes", "order": "10", "role": "http://www.insmed.com/role/ProductRevenuesNet", "shortName": "Product Revenues, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Inventory", "menuCat": "Notes", "order": "11", "role": "http://www.insmed.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Intangibles, Net and Goodwill", "menuCat": "Notes", "order": "12", "role": "http://www.insmed.com/role/IntangiblesNetandGoodwill", "shortName": "Intangibles, Net and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fixed Assets, Net", "menuCat": "Notes", "order": "13", "role": "http://www.insmed.com/role/FixedAssetsNet", "shortName": "Fixed Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Accounts Payable and Accrued Liabilities", "menuCat": "Notes", "order": "14", "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Leases", "menuCat": "Notes", "order": "15", "role": "http://www.insmed.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Debt", "menuCat": "Notes", "order": "16", "role": "http://www.insmed.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Royalty Financing Agreement", "menuCat": "Notes", "order": "17", "role": "http://www.insmed.com/role/RoyaltyFinancingAgreement", "shortName": "Royalty Financing Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Shareholders' Equity", "menuCat": "Notes", "order": "18", "role": "http://www.insmed.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "19", "role": "http://www.insmed.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.insmed.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://www.insmed.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "21", "role": "http://www.insmed.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "22", "role": "http://www.insmed.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.insmed.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Product Revenues, Net (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.insmed.com/role/ProductRevenuesNetTables", "shortName": "Product Revenues, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.insmed.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Intangibles, Net and Goodwill (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillTables", "shortName": "Intangibles, Net and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Fixed Assets, Net (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.insmed.com/role/FixedAssetsNetTables", "shortName": "Fixed Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Accrued Liabilities (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.insmed.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.insmed.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Debt (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.insmed.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Royalty Financing Agreement (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementTables", "shortName": "Royalty Financing Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.insmed.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Acquisitions (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.insmed.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - The Company and Basis of Presentation (Details)", "menuCat": "Details", "order": "36", "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails", "shortName": "The Company and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "reportingunit", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "37", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "reportingunit", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i6da0c68d51f5413ebe76c39ed1aca455_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)", "menuCat": "Details", "order": "38", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails", "shortName": "Summary of Significant Accounting Policies - Concentration Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i6da0c68d51f5413ebe76c39ed1aca455_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)", "menuCat": "Details", "order": "39", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "id93cc85a332446bc823faa43c535e319_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "menuCat": "Details", "order": "40", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "shortName": "Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "id93cc85a332446bc823faa43c535e319_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details)", "menuCat": "Details", "order": "41", "role": "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "shortName": "Fair Value Measurements - Schedule of Carrying Value and Fair Value of Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i8a399a3492df447fbca79a7d265a693e_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "insm:BusinessCombinationDeferredLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details)", "menuCat": "Details", "order": "42", "role": "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "shortName": "Fair Value Measurements - Observable Input in Valuation of Deferred Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ifb2e5e0c82d241d394e098946a683e96_I20230331", "decimals": "2", "lang": "en-US", "name": "insm:BusinessCombinationDeferredConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "id425f4b5e89345349bcb65aa97a067b5_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details)", "menuCat": "Details", "order": "43", "role": "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Significant Unobservable Inputs in the Valuation of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i3f21899b85e5435289864b6cb90b1c56_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Fair Value Measurements - Additional Information (Details)", "menuCat": "Details", "order": "44", "role": "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ifdded2cebd3845858315ea5c08083968_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details)", "menuCat": "Details", "order": "45", "role": "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Deferred and Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i963da8b4cdb641498da799b782807752_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LiabilitiesFairValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Product Revenues, Net - Product Revenues By Geographic Location (Details)", "menuCat": "Details", "order": "46", "role": "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails", "shortName": "Product Revenues, Net - Product Revenues By Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "if35c7fe1255a4a45b5d7b75c1358a82a_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Inventory - Schedule of Inventory, Current (Details)", "menuCat": "Details", "order": "47", "role": "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails", "shortName": "Inventory - Schedule of Inventory, Current (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Intangibles, Net and Goodwill (Details)", "menuCat": "Details", "order": "48", "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails", "shortName": "Intangibles, Net and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Fixed Assets, Net (Details)", "menuCat": "Details", "order": "49", "role": "http://www.insmed.com/role/FixedAssetsNetDetails", "shortName": "Fixed Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "iafe19536aacb435796e6109f58e77e7f_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Shareholders' Equity (unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "shortName": "Consolidated Statements of Shareholders' Equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "iafe19536aacb435796e6109f58e77e7f_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Accrued Liabilities (Details)", "menuCat": "Details", "order": "50", "role": "http://www.insmed.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "51", "role": "http://www.insmed.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Leases - Lease, costs (Details) (Details)", "menuCat": "Details", "order": "52", "role": "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails", "shortName": "Leases - Lease, costs (Details) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Debt - Schedule of Long-Term Debt (Details)", "menuCat": "Details", "order": "53", "role": "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "shortName": "Debt - Schedule of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ie9febab1186a402ca561e7ee81a48013_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaidInKindInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Debt - Narrative (Details)", "menuCat": "Details", "order": "54", "role": "http://www.insmed.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i7820cfc38bfd48a28cfa272979fcb910_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Debt - Components of Debt (Details)", "menuCat": "Details", "order": "55", "role": "http://www.insmed.com/role/DebtComponentsofDebtDetails", "shortName": "Debt - Components of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ie9febab1186a402ca561e7ee81a48013_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:SecuredDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i98586b1bfb0049729946247764555270_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details)", "menuCat": "Details", "order": "56", "role": "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "shortName": "Debt - Schedule of Carrying Value of Term Loan Balance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i821dc505cb9e4e889a3f4a3ed54052e7_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccumulatedCapitalizedInterestCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Debt - Future Principal Repayments of Debt (Details)", "menuCat": "Details", "order": "57", "role": "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails", "shortName": "Debt - Future Principal Repayments of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Debt - Interest Expense (Details)", "menuCat": "Details", "order": "58", "role": "http://www.insmed.com/role/DebtInterestExpenseDetails", "shortName": "Debt - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestExpenseOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "idb1c01b6a28046e8946dda809bad3a51_I20221031", "decimals": "INF", "first": true, "lang": "en-US", "name": "insm:DebtInstrumentRoyaltyPayableMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Royalty Financing Agreement - Additional Information (Details)", "menuCat": "Details", "order": "59", "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "shortName": "Royalty Financing Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "idb1c01b6a28046e8946dda809bad3a51_I20221031", "decimals": "INF", "first": true, "lang": "en-US", "name": "insm:DebtInstrumentRoyaltyPayableMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows (unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "shortName": "Consolidated Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i1a8cb77fb5934bc281468d7a4c6936a3_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details)", "menuCat": "Details", "order": "60", "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails", "shortName": "Royalty Financing Agreement - Carrying Value of Royalty Financing Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i239da0a09e6241a38a2d7f80b458bd21_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "ic6240a44458b48be9485ff21b003473a_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Shareholders' Equity - Narrative (Details)", "menuCat": "Details", "order": "61", "role": "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i176611a1ad64427391c1391c63577377_I20221031", "decimals": "2", "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Stock-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "62", "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i64efa3fcd7024da49d1f4c2a0a719d8f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)", "menuCat": "Details", "order": "63", "role": "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "shortName": "Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i64efa3fcd7024da49d1f4c2a0a719d8f_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "64", "role": "http://www.insmed.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Commitments and Contingencies - Narrative (Details)", "menuCat": "Details", "order": "65", "role": "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i870bc34d6bd94a17bd4e002b9c7710a7_D20210524-20210524", "decimals": "INF", "first": true, "lang": "en-US", "name": "insm:BusinessAcquisitionConsecutiveTradingDayPeriod", "reportCount": 1, "unique": true, "unitRef": "days", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Acquisitions - Narrative (Details)", "menuCat": "Details", "order": "66", "role": "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i870bc34d6bd94a17bd4e002b9c7710a7_D20210524-20210524", "decimals": "INF", "first": true, "lang": "en-US", "name": "insm:BusinessAcquisitionConsecutiveTradingDayPeriod", "reportCount": 1, "unique": true, "unitRef": "days", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "id64e661ae7a8448bbc871bb3e493ab63_D20230101-20230131", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Acquisitions - Summary of Consideration Transferred (Details)", "menuCat": "Details", "order": "67", "role": "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails", "shortName": "Acquisitions - Summary of Consideration Transferred (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i5057c0f6ccce428eb170a1d39536f985_D20230101-20230131", "decimals": "-2", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - The Company and Basis of Presentation", "menuCat": "Notes", "order": "7", "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentation", "shortName": "The Company and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "9", "role": "http://www.insmed.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "insm-20230331.htm", "contextRef": "i13c4a95f65e1453a93891820c52281db_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 84, "tag": { "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "verboseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "verboseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "verboseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "verboseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "verboseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "verboseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "verboseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "verboseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "verboseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.insmed.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "insm_A2019IncentivePlanSecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Incentive Plan, Second Amendment", "label": "2019 Incentive Plan, Second Amendment [Member]", "terseLabel": "2019 Incentive Plan, Second Amendment" } } }, "localname": "A2019IncentivePlanSecondAmendmentMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_A2019IncentivePlanThirdAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Incentive Plan, Third Amendment", "label": "2019 Incentive Plan, Third Amendment [Member]", "terseLabel": "2019 Incentive Plan" } } }, "localname": "A2019IncentivePlanThirdAmendmentMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_ARIKAYCEGlobalNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ARIKAYCE Global Net Sales", "label": "ARIKAYCE Global Net Sales [Member]", "terseLabel": "ARIKAYCE Global Net Sales" } } }, "localname": "ARIKAYCEGlobalNetSalesMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "insm_AccruedClinicalTrialExpenses": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.", "label": "Accrued Clinical Trial Expenses", "terseLabel": "Accrued clinical trial expenses" } } }, "localname": "AccruedClinicalTrialExpenses", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_AccruedLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities, Current", "label": "Accrued Liabilities, Current [Member]", "terseLabel": "Accrued Liabilities, Current" } } }, "localname": "AccruedLiabilitiesCurrentMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "insm_AccruedSalesAllowancesandRelatedCosts": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Sales Allowances and Related Costs", "label": "Accrued Sales Allowances and Related Costs", "terseLabel": "Accrued sales allowances and related costs" } } }, "localname": "AccruedSalesAllowancesandRelatedCosts", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_AccruedTechnicalOperationExpenses": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.", "label": "Accrued Technical Operation Expenses", "terseLabel": "Accrued technical operation expenses" } } }, "localname": "AccruedTechnicalOperationExpenses", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_AcquiredResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired Research And Development", "label": "Acquired Research And Development [Member]", "terseLabel": "Acquired ARIKAYCE R&D" } } }, "localname": "AcquiredResearchAndDevelopmentMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "domainItemType" }, "insm_AlgaeneXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AlgaeneX, Inc.", "label": "AlgaeneX, Inc. [Member]", "terseLabel": "AlgaeneX" } } }, "localname": "AlgaeneXIncMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "insm_AmendedAndRestatedPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Plan", "label": "Amended and Restated Plan [Member]", "terseLabel": "Amended and Restated Plan" } } }, "localname": "AmendedAndRestatedPlanMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_AtTheMarketAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At The Market Agreement", "label": "At The Market Agreement [Member]", "terseLabel": "ATM Program" } } }, "localname": "AtTheMarketAgreementMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_BrensocatibGlobalNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brensocatib Global Net Sales", "label": "Brensocatib Global Net Sales [Member]", "terseLabel": "Brensocatib Global Net Sales" } } }, "localname": "BrensocatibGlobalNetSalesMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "insm_BusinessAcquisitionConsecutiveTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Consecutive Trading Day Period", "label": "Business Acquisition, Consecutive Trading Day Period", "terseLabel": "Consecutive trading day period" } } }, "localname": "BusinessAcquisitionConsecutiveTradingDayPeriod", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "insm_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share", "terseLabel": "Closing share price (in dollars per share)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares", "label": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares", "terseLabel": "Shares issued upon milestone achievements (in shares)" } } }, "localname": "BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Deferred Consideration Liability, Measurement Input", "label": "Business Combination, Deferred Consideration Liability, Measurement Input", "terseLabel": "Business Combination, Deferred Consideration Liability, Measurement Input" } } }, "localname": "BusinessCombinationDeferredConsiderationLiabilityMeasurementInput", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails" ], "xbrltype": "decimalItemType" }, "insm_BusinessCombinationDeferredLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Deferred Liability", "label": "Business Combination, Deferred Liability", "terseLabel": "Deferred consideration" } } }, "localname": "BusinessCombinationDeferredLiability", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_BusinessCombinationDeferredPaymentsCurrent": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Deferred Payments, Current", "label": "Business Combination, Deferred Payments, Current", "terseLabel": "Deferred and contingent consideration from Business Acquisition" } } }, "localname": "BusinessCombinationDeferredPaymentsCurrent", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_CommonStockAuthorizedAggregateGrossSalesProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common Stock Authorized, Aggregate Gross Sales Proceeds", "label": "Common Stock Authorized, Aggregate Gross Sales Proceeds", "terseLabel": "Common stock authorized, aggregate gross sales proceeds (up to)" } } }, "localname": "CommonStockAuthorizedAggregateGrossSalesProceeds", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "insm_ComputerHardwareAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Hardware And Software", "label": "Computer Hardware And Software [Member]", "terseLabel": "Computer hardware and software" } } }, "localname": "ComputerHardwareAndSoftwareMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Debt Instrument, Discount Amortization Period, Remaining", "label": "Convertible Debt Instrument, Discount Amortization Period, Remaining", "terseLabel": "Remaining discount amortization period (in years)" } } }, "localname": "ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "insm_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "insm_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "insm_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerCMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "insm_DebtInstrumentConversionTermAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Conversion Term [Axis]", "label": "Debt Instrument Conversion Term [Axis]", "terseLabel": "Debt Instrument Conversion Term [Axis]" } } }, "localname": "DebtInstrumentConversionTermAxis", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "insm_DebtInstrumentConversionTermDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]", "label": "Debt Instrument Conversion Term [Domain]", "terseLabel": "Debt Instrument Conversion Term [Domain]" } } }, "localname": "DebtInstrumentConversionTermDomain", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_DebtInstrumentConversionTermFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion Term Four [Member]", "label": "Debt Instrument, Conversion Term Four [Member]", "terseLabel": "Conversion Term (iv)" } } }, "localname": "DebtInstrumentConversionTermFourMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_DebtInstrumentConversionTermOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion Term One [Member]", "label": "Debt Instrument, Conversion Term One [Member]", "terseLabel": "Conversion Term (i)" } } }, "localname": "DebtInstrumentConversionTermOneMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_DebtInstrumentConversionTermThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion Term Three [Member]", "label": "Debt Instrument, Conversion Term Three [Member]", "terseLabel": "Conversion Term (iii)" } } }, "localname": "DebtInstrumentConversionTermThreeMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_DebtInstrumentConversionTermTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Conversion Term Two [Member]", "label": "Debt Instrument, Conversion Term Two [Member]", "terseLabel": "Conversion Term (ii)" } } }, "localname": "DebtInstrumentConversionTermTwoMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change", "label": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change", "terseLabel": "Threshold trading days following fundamental change" } } }, "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Option To Purchase Additional Debt", "label": "Debt Instrument, Option To Purchase Additional Debt", "terseLabel": "Option to purchase additional debt" } } }, "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "insm_DebtInstrumentPercentOfInterestPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Percent Of Interest Payable", "label": "Debt Instrument, Percent Of Interest Payable", "terseLabel": "Debt Instrument, Percent Of Interest Payable" } } }, "localname": "DebtInstrumentPercentOfInterestPayable", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "insm_DebtInstrumentRoyaltyPayableMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Royalty Payable, Maximum", "label": "Debt Instrument, Royalty Payable, Maximum", "terseLabel": "Royalty maximum" } } }, "localname": "DebtInstrumentRoyaltyPayableMaximum", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "insm_DebtInstrumentRoyaltyStatedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Royalty, Stated Percentage", "label": "Debt Instrument, Royalty, Stated Percentage", "terseLabel": "Royalty percentage" } } }, "localname": "DebtInstrumentRoyaltyStatedPercentage", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "insm_DerivativeLiabilityCollateralFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative Liability, Collateral, Fair Value", "label": "Derivative Liability, Collateral, Fair Value", "terseLabel": "Collateral for interest rate swap" } } }, "localname": "DerivativeLiabilityCollateralFairValue", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_DevelopmentAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development And Regulatory Milestones", "label": "Development And Regulatory Milestones [Member]", "terseLabel": "Development and regulatory milestones" } } }, "localname": "DevelopmentAndRegulatoryMilestonesMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "insm_EmployeeStockPurchasePlan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan 2018 [Member]", "label": "Employee Stock Purchase Plan 2018 [Member]", "terseLabel": "2018 ESPP" } } }, "localname": "EmployeeStockPurchasePlan2018Member", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_EuropeAndTheRestOfTheWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Europe And The Rest Of The World", "label": "Europe And The Rest Of The World [Member]", "terseLabel": "Europe and rest of world" } } }, "localname": "EuropeAndTheRestOfTheWorldMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "insm_InterestExpenseExcludingFinanceLeaseInterestExpense": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest Expense, Excluding Finance Lease Interest Expense", "label": "Interest Expense, Excluding Finance Lease Interest Expense", "totalLabel": "Total debt interest expense" } } }, "localname": "InterestExpenseExcludingFinanceLeaseInterestExpense", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets)", "label": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]", "terseLabel": "Inventory and Cost of Product Revenues (excluding amortization of intangible assets)" } } }, "localname": "InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "insm_LeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Remaining Lease Term", "label": "Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LeaseRemainingLeaseTerm", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount", "terseLabel": "Lease cost, future right-of-use asset" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "insm_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, after Year Four", "label": "Long-Term Debt, Maturity, after Year Four", "terseLabel": "2028 and thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "insm_ManufacturingEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Equipment", "label": "Manufacturing Equipment [Member]", "terseLabel": "Manufacturing equipment" } } }, "localname": "ManufacturingEquipmentMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "insm_MeasurementInputProbabilityOfSuccessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Probability Of Success", "label": "Measurement Input, Probability Of Success [Member]", "terseLabel": "Probabilities of success" } } }, "localname": "MeasurementInputProbabilityOfSuccessMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "insm_MilestoneEvent1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Event 1", "label": "Milestone Event 1 [Member]", "terseLabel": "Milestone Event 1" } } }, "localname": "MilestoneEvent1Member", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_MilestoneEvent2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Event 2", "label": "Milestone Event 2 [Member]", "terseLabel": "Milestone Event 2" } } }, "localname": "MilestoneEvent2Member", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_MilestoneEvent3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Event 3", "label": "Milestone Event 3 [Member]", "terseLabel": "Milestone Event 3" } } }, "localname": "MilestoneEvent3Member", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_MotusBiosciencesIncAndAlgaeneXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Motus Biosciences, Inc. And AlgaeneX, Inc.", "label": "Motus Biosciences, Inc. And AlgaeneX, Inc. [Member]", "terseLabel": "Motus and AlgaeneX" } } }, "localname": "MotusBiosciencesIncAndAlgaeneXIncMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_MotusBiosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Motus Biosciences, Inc.", "label": "Motus Biosciences, Inc. [Member]", "terseLabel": "Motus" } } }, "localname": "MotusBiosciencesIncMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_NoncashAcquisitionRelatedExpense": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Acquisition Related Expense", "label": "Noncash Acquisition Related Expense", "terseLabel": "Vertuis acquisition" } } }, "localname": "NoncashAcquisitionRelatedExpense", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "insm_NoncashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Operating Lease Expense", "label": "Noncash Operating Lease Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "NoncashOperatingLeaseExpense", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "insm_NumberOfPubliclyDisclosedPriorityReviewVoucherSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Publicly Disclosed Priority Review Voucher Sales", "label": "Number of Publicly Disclosed Priority Review Voucher Sales", "terseLabel": "Number of publicly disclosed priority review voucher sales" } } }, "localname": "NumberOfPubliclyDisclosedPriorityReviewVoucherSales", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]", "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]", "terseLabel": "1.75% convertible senior notes due 2025" } } }, "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "insm_PercentOfSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent Of Sales", "label": "Percent Of Sales", "terseLabel": "Percent of sales" } } }, "localname": "PercentOfSales", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "insm_PotentialPayoutPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Potential Payout Percentage", "label": "Potential Payout Percentage", "terseLabel": "Potential payout percentage" } } }, "localname": "PotentialPayoutPercentage", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "insm_PriorityReviewVoucherMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Priority Review Voucher Milestone", "label": "Priority Review Voucher Milestone [Member]", "terseLabel": "Priority review voucher milestone" } } }, "localname": "PriorityReviewVoucherMilestoneMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "insm_ProceedsFromRoyaltyFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Royalty Financing", "label": "Proceeds From Royalty Financing", "terseLabel": "Proceeds from royalty financing" } } }, "localname": "ProceedsFromRoyaltyFinancing", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "insm_ProceedsFromRoyaltyFinancingAgreementNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Royalty Financing Agreement, Net", "label": "Proceeds From Royalty Financing Agreement, Net", "terseLabel": "Proceeds from royalty financing agreement, net" } } }, "localname": "ProceedsFromRoyaltyFinancingAgreementNet", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "insm_PublicStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering", "label": "Public Stock Offering [Member]", "terseLabel": "Public Stock Offering" } } }, "localname": "PublicStockOfferingMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_RoyaltyFinancingAgreementRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Financing Agreement", "label": "Royalty Financing Agreement [Roll Forward]", "terseLabel": "Royalty Financing Agreement [Roll Forward]" } } }, "localname": "RoyaltyFinancingAgreementRollForward", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "stringItemType" }, "insm_RoyaltyRevenuePayable": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty Revenue Payable", "label": "Royalty Revenue Payable", "terseLabel": "Royalty revenue payable" } } }, "localname": "RoyaltyRevenuePayable", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "insm_SaleOfStockRemainingAuthorizedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Remaining Authorized Amount", "label": "Sale Of Stock, Remaining Authorized Amount", "terseLabel": "Remaining shares sold offering price" } } }, "localname": "SaleOfStockRemainingAuthorizedAmount", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]" } } }, "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "insm_ScheduleofEarningsPerShareBasicandDilutedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]" } } }, "localname": "ScheduleofEarningsPerShareBasicandDilutedTable", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "insm_SecuredOvernightFinancingRateSOFRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR)" } } }, "localname": "SecuredOvernightFinancingRateSOFRMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of inducement share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross", "terseLabel": "Inducement stock options granted to new employees (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "insm_StockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.", "label": "Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock options and RSUs" } } }, "localname": "StockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "insm_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "insm_TriggeringEventAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triggering Event", "label": "Triggering Event [Axis]", "terseLabel": "Triggering Event [Axis]" } } }, "localname": "TriggeringEventAxis", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "insm_TriggeringEventDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triggering Event [Domain]", "label": "Triggering Event [Domain]", "terseLabel": "Triggering Event [Domain]" } } }, "localname": "TriggeringEventDomain", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_VariableRateComponentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component", "label": "Variable Rate Component [Axis]", "terseLabel": "Variable Rate Component [Axis]" } } }, "localname": "VariableRateComponentAxis", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "insm_VariableRateComponentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component [Domain]", "label": "Variable Rate Component [Domain]", "terseLabel": "Variable Rate Component [Domain]" } } }, "localname": "VariableRateComponentDomain", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_VariableRateComponentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component Two", "label": "Variable Rate Component Two [Member]", "terseLabel": "Variable Rate Component Two" } } }, "localname": "VariableRateComponentTwoMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_VertuisBioIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vertuis Bio, Inc.", "label": "Vertuis Bio, Inc. [Member]", "terseLabel": "Vertuis Bio, Inc." } } }, "localname": "VertuisBioIncMember", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zero Point Seven Five Percent Convertible Senior Note Due 2028", "label": "Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member]", "terseLabel": "0.75% convertible senior notes due 2028" } } }, "localname": "ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member", "nsuri": "http://www.insmed.com/20230331", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r192", "r238", "r245", "r251", "r310", "r463", "r464", "r465", "r476", "r477", "r503", "r506", "r508", "r509", "r563" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative impact of ASU adoption 2020-06" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r192", "r238", "r245", "r251", "r310", "r463", "r464", "r465", "r476", "r477", "r503", "r506", "r508", "r509", "r563" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r192", "r238", "r245", "r251", "r310", "r463", "r464", "r465", "r476", "r477", "r503", "r506", "r508", "r509", "r563" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r301", "r637", "r686", "r732" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r338", "r339", "r340", "r341", "r426", "r571", "r587", "r616", "r617", "r634", "r647", "r653", "r684", "r724", "r725", "r726", "r727", "r728", "r729" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r338", "r339", "r340", "r341", "r426", "r571", "r587", "r616", "r617", "r634", "r647", "r653", "r684", "r724", "r725", "r726", "r727", "r728", "r729" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r301", "r637", "r686", "r732" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r338", "r339", "r340", "r341", "r419", "r426", "r454", "r455", "r456", "r570", "r571", "r587", "r616", "r617", "r634", "r647", "r653", "r680", "r684", "r725", "r726", "r727", "r728", "r729" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r338", "r339", "r340", "r341", "r419", "r426", "r454", "r455", "r456", "r570", "r571", "r587", "r616", "r617", "r634", "r647", "r653", "r680", "r684", "r725", "r726", "r727", "r728", "r729" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FixedAssetsNetDetails", "http://www.insmed.com/role/LeasesNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r299", "r300", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r636", "r652", "r686" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r299", "r300", "r601", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r636", "r652", "r686" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r239", "r240", "r241", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r463", "r464", "r465", "r476", "r477", "r489", "r490", "r491", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r540", "r541", "r545", "r546", "r547", "r560", "r561", "r562", "r563", "r564", "r565", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r675" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccountsPayableandAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r17", "r651" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 12.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable and other accrued operating expenses" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r302", "r303" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r170", "r185" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r21", "r620" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalty and milestones payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r170", "r185" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued Royalties", "periodEndLabel": "Royalty financing agreement - ending balance", "periodStartLabel": "Royalty financing agreement - beginning balance", "terseLabel": "Royalty financing agreement" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.", "label": "Accumulated Capitalized Interest Costs", "terseLabel": "Paid-in-kind interest capitalized" } } }, "localname": "AccumulatedCapitalizedInterestCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r89", "r201" ], "calculation": { "http://www.insmed.com/role/FixedAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r32", "r33", "r209", "r583", "r595", "r599" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r30", "r33", "r137", "r565", "r590", "r591", "r662", "r663", "r664", "r672", "r673", "r674" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r9", "r651" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r463", "r464", "r465", "r672", "r673", "r674", "r717" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r239", "r240", "r241", "r242", "r251", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r463", "r464", "r465", "r474", "r475", "r476", "r477", "r489", "r490", "r491", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r540", "r541", "r545", "r546", "r547", "r548", "r560", "r561", "r562", "r563", "r564", "r565", "r574", "r575", "r576", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r118", "r119", "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r458" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Allocated share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r38", "r373", "r543", "r666" ], "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "order": 2.0, "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs", "verboseLabel": "Amortization of issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r373", "r543", "r632", "r633", "r666" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r57", "r80", "r85" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Amortization", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.", "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "negatedTerseLabel": "Change in Fair Value" } } }, "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r165", "r180", "r204", "r230", "r285", "r290", "r296", "r306", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r495", "r497", "r522", "r651", "r682", "r683", "r722" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r197", "r211", "r230", "r306", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r495", "r497", "r522", "r651", "r682", "r683", "r722" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "terseLabel": "Unrealized loss" } } }, "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r77", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Current available-for-sale securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r487", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r123", "r124", "r487", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Shares issued in acquisition (in shares)", "verboseLabel": "Shares of Insmed common stock issuable on July 1, 2024 (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price used to calculate issuable shares (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r127", "r128", "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate value" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r127", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Share price used to calculate issuable shares (in dollars per share)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r494", "r665" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of deferred and contingent consideration liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r126", "r129", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Consideration, ending balance", "periodStartLabel": "Consideration, beginning balance", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Values", "verboseLabel": "Weighted average probability of success" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r126", "r130" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration", "verboseLabel": "Non-current contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r133", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r59", "r199", "r618" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r52", "r59", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r52", "r157" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r92", "r336", "r337", "r603", "r681" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock shares reserved for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r672", "r673", "r717" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r104" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding shares (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r651" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 136,429,216 and 135,653,731 issued and outstanding shares at March\u00a031, 2023 and December\u00a031, 2022,\u00a0respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r34", "r214", "r216", "r221", "r579", "r584" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r68", "r69", "r154", "r155", "r301", "r602" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r68", "r69", "r154", "r155", "r301", "r600", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r68", "r69", "r154", "r155", "r301", "r602", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r176", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r68", "r69", "r154", "r155", "r301" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r66", "r68", "r69", "r70", "r154", "r156", "r602" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r68", "r69", "r154", "r155", "r301", "r602" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerRefundLiabilityCurrent": { "auth_ref": [ "r687" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.", "label": "Contract with Customer, Refund Liability, Current", "terseLabel": "Accrued France ATU reimbursement payable" } } }, "localname": "ContractWithCustomerRefundLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Convertible senior notes" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r95", "r351", "r352", "r363", "r364", "r365", "r369", "r370", "r371", "r372", "r373", "r629", "r630", "r631", "r632", "r633" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r689" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible debt securities" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r2", "r166", "r178", "r188" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible notes", "verboseLabel": "Convertible debt securities" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r40", "r572" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product revenues (excluding amortization of intangible assets)" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r39" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r67", "r301" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r100", "r228", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r367", "r374", "r375", "r377" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r166", "r168", "r178", "r234", "r351", "r352", "r353", "r354", "r355", "r357", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r544", "r629", "r630", "r631", "r632", "r633", "r668" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r4", "r168", "r178", "r378" ], "calculation": { "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Term Loan" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Residual equity component of debt" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r97", "r353" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r24", "r105", "r108", "r110", "r353" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Initial conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Threshold percent of stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r159", "r161", "r351", "r544", "r630", "r631" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Original Term Loan balance", "verboseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Lenders fees and deal expenses" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r23", "r159", "r380", "r544" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r23", "r352" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Proceeds from issuance of 0.75% convertible senior notes due 2028" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r26", "r234", "r351", "r352", "r353", "r354", "r355", "r357", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r544", "r629", "r630", "r631", "r632", "r633", "r668" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to interest.", "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Interest payments" } } }, "localname": "DebtInstrumentPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Repurchased amount" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r26", "r105", "r109", "r110", "r111", "r158", "r159", "r161", "r175", "r234", "r351", "r352", "r353", "r354", "r355", "r357", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r376", "r544", "r629", "r630", "r631", "r632", "r633", "r668" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt term (in months)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r160", "r685" ], "calculation": { "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, unamortized", "verboseLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r57", "r121", "r473", "r480", "r481", "r670" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r5", "r6", "r167", "r177", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTerseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r57", "r87" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r139", "r140", "r141", "r142", "r145", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Weighted average common shares used in calculation of basic net loss per share:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r416", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r431", "r459", "r460", "r462", "r466", "r648" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r222", "r243", "r244", "r245", "r246", "r247", "r252", "r255", "r263", "r264", "r265", "r267", "r509", "r510", "r580", "r585", "r625" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r222", "r243", "r244", "r245", "r246", "r247", "r255", "r263", "r264", "r265", "r267", "r509", "r510", "r580", "r585", "r625" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r63", "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r531" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and employee related costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r461" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r716" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to unvested RSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r716" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Common stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Lab equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r104", "r192", "r217", "r218", "r219", "r235", "r236", "r237", "r240", "r248", "r250", "r268", "r310", "r398", "r463", "r464", "r465", "r476", "r477", "r508", "r532", "r533", "r534", "r535", "r536", "r537", "r565", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of equity interests that are issued or issuable in a business combination.", "label": "Equity Interest Type [Axis]", "terseLabel": "Equity Interest Type [Axis]" } } }, "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.", "label": "Equity Interest Issued or Issuable, Type [Domain]", "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]" } } }, "localname": "EquityInterestIssuedOrIssuableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r365", "r521", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value Measurement" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r512", "r513", "r518" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Observable Inputs in Valuation of Deferred Consideration" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r365", "r420", "r421", "r422", "r423", "r424", "r425", "r513", "r567", "r568", "r569", "r630", "r631", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r149", "r150" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r146", "r151", "r365", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r512", "r513", "r515", "r516", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r365", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r365", "r420", "r425", "r513", "r567", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r365", "r420", "r425", "r513", "r568", "r630", "r631", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r365", "r420", "r421", "r422", "r423", "r424", "r425", "r513", "r569", "r630", "r631", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r365", "r420", "r421", "r422", "r423", "r424", "r425", "r567", "r568", "r569", "r630", "r631", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r517", "r519" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r551", "r555", "r650" ], "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities, long-term" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r552", "r557" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments of finance lease principal" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r549" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r551", "r555", "r650" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance lease amortization expense" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible assets estimated useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Amortization of intangible assets, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Amortization of intangible assets, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Amortization of intangible assets, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Amortization of intangible assets, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Amortization of intangible assets, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r325", "r327", "r328", "r329", "r573", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r84", "r577" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangibles, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r81", "r83" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r84", "r573" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangibles, net", "verboseLabel": "Intangibles, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Finite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Finite-lived Intangible Assets [Roll Forward]" } } }, "localname": "FiniteLivedIntangibleAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Additions" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r57", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r202", "r315", "r578", "r628", "r651", "r678", "r679" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Indefinite-lived intangible assets, Finite-lived Intangible Assets, Impairment Assessment, and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Acquired IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r35", "r163", "r172", "r187", "r285", "r289", "r295", "r297", "r581", "r627" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r231", "r468", "r470", "r472", "r478", "r482", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r232", "r249", "r250", "r283", "r467", "r479", "r483", "r586" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "verboseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r56" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r56" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r665" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r56" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRoyaltiesPayable": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.", "label": "Increase (Decrease) in Royalties Payable", "terseLabel": "Royalty revenue payable" } } }, "localname": "IncreaseDecreaseInRoyaltiesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r259", "r260", "r265" ], "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Dilutive securities, convertible debt (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r256", "r257", "r258", "r265", "r430" ], "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive securities, share-based payment (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangibles, Net and Goodwill" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r160", "r174", "r220", "r279", "r542" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.insmed.com/role/DebtInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Non-cash interest expense", "totalLabel": "Total interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r43", "r371", "r381", "r632", "r633" ], "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "order": 1.0, "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Convertible debt contractual interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/DebtInterestExpenseDetails": { "order": 3.0, "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedTerseLabel": "Swap interest income" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Summary of Interest Expense" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r223", "r225", "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest rate swap" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r79", "r621" ], "calculation": { "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r210", "r619", "r651" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Inventory, Net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r79", "r623" ], "calculation": { "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r79", "r622" ], "calculation": { "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r42" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Supplemental Noncash Disclosures included in Consolidated Financial Statements" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r230", "r306", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r496", "r497", "r498", "r522", "r626", "r682", "r722", "r723" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r169", "r183", "r651", "r669", "r677", "r719" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r198", "r230", "r306", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r496", "r497", "r498", "r522", "r651", "r682", "r722", "r723" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "Liabilities, Fair Value Adjustment", "terseLabel": "Additions" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "PARI milestones" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r4", "r168", "r181", "r364", "r379", "r630", "r631" ], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Year Ending December\u00a031:" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r93", "r234", "r369" ], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r93", "r234", "r369" ], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r93", "r234", "r369" ], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r93", "r234", "r369" ], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r671" ], "calculation": { "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r205" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Debt, long-term", "totalLabel": "Debt, long-term" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/DebtComponentsofDebtDetails", "http://www.insmed.com/role/DebtScheduleofLongTermDebtDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r26", "r94" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails", "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Share Price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsObservableInputinValuationofDeferredConsiderationDetails", "http://www.insmed.com/role/FairValueMeasurementsSignificantUnobservableInputsintheValuationofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r224" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r224" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r52", "r55", "r58" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r36", "r58", "r173", "r186", "r196", "r212", "r215", "r219", "r230", "r239", "r243", "r244", "r245", "r246", "r249", "r250", "r261", "r285", "r289", "r295", "r297", "r306", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r510", "r522", "r627", "r682" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails", "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r243", "r244", "r245", "r246", "r252", "r253", "r262", "r265", "r285", "r289", "r295", "r297", "r627" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and New Accounting Pronouncements (Not Yet Adopted)" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r285", "r289", "r295", "r297", "r627" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r720" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense charged to operations" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r549" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "The Company and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/TheCompanyandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.insmed.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r164", "r179", "r203" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r134", "r135", "r136" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r134", "r135", "r136" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r134", "r135", "r136", "r213", "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Royalty financing non-cash interest expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r57" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Paid-in-kind interest capitalized" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "terseLabel": "Payments" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsDeferredandContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "terseLabel": "Royalty revenue payments" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r49" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r45", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid in acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r76" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r46" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PSUs", "verboseLabel": "Performance options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.insmed.com/role/FairValueMeasurementsScheduleofCarryingValueandFairValueofAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r382" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r7", "r382" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r661" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "verboseLabel": "Net proceeds" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r47", "r117" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options and ESPP" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r91", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Fixed Assets, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r88", "r200" ], "calculation": { "http://www.insmed.com/role/FixedAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Fixed assets, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r90", "r184", "r582", "r651" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.insmed.com/role/FixedAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net", "totalLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life (years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for repurchase agreements (also known as repos), resale agreements (also known as reverse repurchase agreements or reverse repos), securities borrowed transactions, and securities loaned transactions.", "label": "Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block]", "terseLabel": "Royalty Financing Agreement" } } }, "localname": "RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r120", "r189", "r730" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted stock and RSUs", "verboseLabel": "RS and RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r112", "r182", "r594", "r599", "r651" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r192", "r235", "r236", "r237", "r240", "r248", "r250", "r310", "r463", "r464", "r465", "r476", "r477", "r508", "r590", "r592" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r276", "r277", "r288", "r293", "r294", "r298", "r299", "r301", "r415", "r416", "r572" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/ProductRevenuesNetProductRevenuesByGeographicLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r418", "r624" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Product Revenues, Net" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Product Revenues By Geographic Location" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ProductRevenuesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r558", "r650" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r558", "r650" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesLeasecostsDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyAgreementsMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Agreements [Member]", "terseLabel": "Royalty Agreements" } } }, "localname": "RoyaltyAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtInterestExpenseDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Aggregate net proceeds from stock offering" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares sold in offering (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Offering price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueProductLineMember": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service Benchmark [Member]", "terseLabel": "Sales Revenue, Product Line" } } }, "localname": "SalesRevenueProductLineMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r123", "r124", "r487" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/AcquisitionsSummaryofConsiderationTransferredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Carrying Value of Term Loan Balance" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r26", "r105", "r109", "r110", "r111", "r158", "r159", "r161", "r175", "r630", "r632", "r671" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Components of Debt Balance", "verboseLabel": "Carrying Value of Royalty Financing Agreement" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtTables", "http://www.insmed.com/role/RoyaltyFinancingAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Allocation of Employee Stock-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Carrying Value and Fair Value of Assets and Liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r81", "r83", "r573" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r81", "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Rollforward of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IntangiblesNetandGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r14", "r15", "r16" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Future Principal Repayments of Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/FixedAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r427", "r429", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r101", "r102", "r103", "r105", "r106", "r107", "r109", "r110", "r111", "r112", "r206", "r207", "r208", "r269", "r382", "r383", "r384", "r386", "r390", "r395", "r397", "r634", "r660", "r667" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r66", "r68", "r69", "r70", "r154", "r156" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Percentage of Total Gross Product Revenue Represented by the Three Largest Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r4", "r168", "r181" ], "calculation": { "http://www.insmed.com/role/DebtComponentsofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "terseLabel": "Face value of outstanding convertible notes" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtComponentsofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails", "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails", "http://www.insmed.com/role/RoyaltyFinancingAgreementCarryingValueofRoyaltyFinancingAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r301", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r334", "r335", "r628", "r731" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r56" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r649" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage of outstanding shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails", "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "First anniversary of closing date" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Third anniversary of closing date" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Second anniversary of closing date" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Potential award payout" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r62", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r195", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r301", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r332", "r334", "r335", "r628", "r731" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r29", "r104", "r192", "r217", "r218", "r219", "r235", "r236", "r237", "r240", "r248", "r250", "r268", "r310", "r398", "r463", "r464", "r465", "r476", "r477", "r508", "r532", "r533", "r534", "r535", "r536", "r537", "r565", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r235", "r236", "r237", "r268", "r572" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r7", "r8", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock for business acquisition (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited", "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r7", "r8", "r104", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock for vesting of RSUs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r104", "r112" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Exercise of stock options and ESPP shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r29", "r104", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock for asset acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r104", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock for vesting of RSUs" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r112", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Exercise of stock options and ESPP shares" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r75", "r651", "r669", "r677", "r719" ], "calculation": { "http://www.insmed.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 (deficit) equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets", "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r113", "r229", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r398", "r499" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r538", "r566" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r538", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r538", "r566" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/RoyaltyFinancingAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r239", "r240", "r241", "r242", "r251", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r463", "r464", "r465", "r474", "r475", "r476", "r477", "r489", "r490", "r491", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r540", "r541", "r545", "r546", "r547", "r548", "r560", "r561", "r562", "r563", "r564", "r565", "r574", "r575", "r576", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r688" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedTerseLabel": "Term Loan issuance costs, unamortized" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r57" ], "calculation": { "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedTerseLabel": "Change in fair value of interest rate swap", "terseLabel": "Change in fair value of interest rate swap" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited", "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r71", "r72", "r73", "r270", "r271", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r556", "r650" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease, cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/AcquisitionsNarrativeDetails", "http://www.insmed.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r254", "r265" ], "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average diluted common shares outstanding (in shares)", "totalLabel": "Weighted average common shares outstanding used\u00a0in calculation of diluted net loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r252", "r265" ], "calculation": { "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)", "verboseLabel": "Weighted average basic common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited", "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "860", "URI": "https://asc.fasb.org/topic&trid=2197590", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r655": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r656": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r657": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r658": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r659": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130611-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 89 0001104506-23-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104506-23-000012-xbrl.zip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